The functions of ICT1 and mtRbfA in the human mitochondrial ribosome by Richter  Ricarda
 
 
 
 
 
 
 
The functions of ICT1 and mtRbfA  
in the  
human mitochondrial ribosome 
 
 
Ricarda Richter B.Sc. 
 
 
 
 
 
 
Thesis submitted to Newcastle University in candidature for  
the degree of Doctor of Philosophy 
 
 
 
Newcastle University 
Faculty of Medical Sciences  
Institute for Ageing and Health 
Mitochondrial Research Group 
November 2010 
 
 
i 
Abstract 
 
During the last decades our knowledge about the human mitochondrial translation 
system has been expanded. However, our understanding of this unique system is far 
from complete. Mitochondria contain a minimal genome, whose expression is 
dependent on factors encoded by the nuclear genome. Derived from a bacterial 
ancestor it is very close to the translation system found in bacteria, but there are also a 
lot of differences especially the translating ribosome, which differs in a number of 
features including the sedimentation coefficient, protein-RNA ratio and number of tRNA 
sites. Available cryo-EM structures of the mitochondrial ribosome are limited, making it 
difficult to understand the system completely. There are still a lot of open questions 
concerning the composition, assembly, translation initiation or the recycling of stalled 
ribosomes in mammalian mitochondria. The study presented in this thesis contributes 
to our understanding of this unique system by the characterisation of two mitochondrial 
proteins, found in association with the mitochondrial ribosome, ICT1 and mtRbfA. 
These proteins are found in association with the mitochondrial ribosome, and were 
immunoprecipitated together with the mitochondrial ribosome recycling factor (mtRRF).  
ICT1 as a member of the mitochondrial release factor family has been identified as a 
peptidyl-tRNA hydrolase. Data shown here indicates that ICT1 has been recruited into 
the mitochondrial ribosome and further, suggests the involvement of ICT1 in the rescue 
of stalled ribosomal complexes with immobilised peptidyl-tRNA. 
In contrast mtRbfA was identified as a potential ribosome assembly factor rather than a 
permanent component. The function of this protein is still elusive, but data generated 
for this thesis shows that this protein is preferentially associated with the mitochondrial 
ribosomal small subunit at a late assembly point, suggesting possible roles of mtRbfA 
in quality control or in translation initiation.  
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Triton X-100 polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether  
T. thermophilus Thermus thermophilus 
Tween-20 polyoxyethylene sorbitanmonolaurate 
U unit (enzyme activity; 1U = 1µmol/ min) 
UCP uncoupling proteins 
UTR untranslated region  
UV ultra-violet 
vol volume 
v/v volume/ volume 
WT wildtype 
w/v weight/ volume 
xg relative centrifugal force 
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1.1 
 
Mitochondria - general aspects 
Approximately 1-2 billion years ago an α-proteobacterium (symbiont) was annexed into 
a primitive eukaryotic cell (host) by endocytosis [Gray et al., 1999; De Duve, 2007]. 
This endosymbiosis theory is widely accepted as the origin of mitochondria, which are 
ubiquitous organelles within the vast majority of eukaryotes. Over evolution a 
fascinating kind of symbiosis between the host cell and the symbiont has developed 
whose communication is in such a perfection of nature that our understanding of this 
complicated system is very far from complete.  
The present day mitochondria are no longer autonomous, because they have 
transferred most of their genetic information to the nucleus of the host and therefore 
they are totally dependent on the host cell. The host in turn also depends on its 
symbiotic partner that performs many important, and for the host essential, tasks. 
Mitochondria are often called the power-plant of the cell as they produce the majority of 
cellular ATP. This is done through oxidative phosphorylation (OXPHOS), a process that 
includes electron transport and proton pumping by the organelle to generate an 
electrochemical gradient as energy force. ATP production is by far not the only function 
of mitochondria even if it is the most widely described. Mitochondria are also the 
location of many metabolic pathways such as tricarboxylic acid (TCA) cycle, β-
oxidation, urea cycle or amino acid synthesis. Furthermore they are absolutely crucial 
for iron-sulphur biogenesis, probably the essential task of mitochondria within the 
eukaryotic cell [Lill, 2009]. In addition mitochondria are further involved in many cellular 
processes such as calcium and iron homoeostasis, ROS (reactive oxidative stress) 
production and apoptosis.  
Human mitochondria have been studied intensively during the last decades since a 
dysfunction of those organelles leads to many human diseases, which are currently 
untreatable. Therefore it is absolutely crucial that we understand those little task-rich 
organelles, most of which have still their own genome, and in humans is a small 
minimised DNA molecule (mtDNA). The expression of mtDNA encoded proteins is 
dependent on nuclear encoded factors, which are synthesised in the cytosol and 
transported into the mitochondria. The reason for the transfer of the vast majority of 
genetic material (~99%) from the α-proteobacterium to the host genome is probably 
due to selective pressure to protect the DNA from mutagenesis within the organelle 
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since the uncorrected mutation rate of human mtDNA is 10- to 17-fold higher compared 
to the nDNA [Wallace, 2007, Tuppen et al., 2010]. The reason why mitochondria 
continue to maintain a small genome that encodes only a limited subset of components 
of the OXPHOS complexes and whose expression requires a complicated coordinated 
expression machinery imported into the mitochondria is not clear. Strikingly all the 
proteins that are encoded by the human mtDNA are hydrophobic components of the 
OXPHOS complexes and COX1 and cytochrome b, which are the most hydrophobic 
ones, are present in every sequenced mitochondrial genome [Wallace, 2007]. 
Therefore it is often proposed that the difficulty in import of those hydrophobic proteins 
across the membrane might be the reason for maintaining the expression of those 
components within the organelle. 
 
1.2 
 
Origin of mitochondria  
Although the endosymbiosis theory is widely accepted as the origin of mitochondria, 
there remain some controversial discussions about the host. Some groups argue that it 
was a amitochondriate primitive eukaryote containing already the nucleus and having 
the ability for phagocytosis. Others believe that it was an archaebacterium, meaning 
that the nucleus and mitochondria developed more or less at the same time from one 
event [Gray et al., 1999]. De Duve (2007) argued that the host was more likely to be a 
eukaryotic cell with a cytomembrane and cytoskeletal machineries that were involved in 
the endocytic uptake of extra-cellular materials. Thus the ability of phagocytosis and 
the development of a nucleus, which is required for the transfer of genetic material from 
the symbiont to the host, must have been present before the α-proteobacterium was 
annexed by the host. This hypothesis was also argued for a long time with the fact that 
there are anaerobic eukaryotes, called Archezoa that lack mitochondria (“Archezoa 
model”). However, it was shown that the nucleus of those Archezoa encodes typical 
mitochondrial proteins (e.g. chaperones, with rickettsia like ancestry), which are then 
imported into an organelle. This organelle is called the “hydrogenosome” that 
generates ATP anaerobically, producing hydrogen as the reduced end product. Thus 
Martin and Müller (1998) proposed the “hydrogen hypothesis” where a common 
ancestor of living eukaryotes had an endosymbiont. They further described that it is 
very common that bacteria and archea depend on each other, where one of them is 
producing the waste that the other one is using as food. Furthermore it was shown that 
one prokaryote could live inside another, non-phagocytotic prokaryote [von Dohlen et 
al., 2001]. Davidov and Jurkevitch (2009) suggested that since bacteria are not able to 
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undergo phagocytosis, a predatory interaction between the two prokaryotes might be 
the origin of the eukaryotic cell. Thus the predator, a small (facultative) aerobic α-
proteobacterium penetrated and replicated with an archeal host periplasm (-like) space 
and later developed to the current mitochondrion. In addition to the hydrogenosome 
there are also small organelles with a double membrane called “mitosomes”, present in 
Archezoa such as Giardia. The real function of those mitosomes is not clear as they 
probably do not play any role in ATP synthesis. However, since they contain 
mitochondrial proteins required for the Fe-S cluster assembly [reviewed in Embley and 
Martin, 2006] it might be that the iron-sulphur biogenesis is the essential task of all 
mitochondria or mitochondria-like organelles. Therefore it was proposed that all 
eukaryotes contain mitochondria or mitochondria-like organelles (hydrogenosomes or 
mitosomes). It is possible that both the origin of the eukaryotic nucleus and the origin of 
anaerobic (hydrogenosome) and aerobic (mitochondria) energy metabolism arise from 
the same event [reviewed in Gray et al., 1999; Davidov and Jurkevitch, 2009]. 
However, it is quite difficult to show clear evidence for an event that happened a billion 
years ago and therefore it is plausible that there is more than one accurate hypothesis.  
What is probably in agreement of all studies is that mitochondria are from monophyletic 
origin and that they are closely related to the members of the rickettsial subdivision of 
the α-proteobacteria [Gray et al., 1999]. Rickettsiales are obligate intracellular parasites 
of eukaryotes and their genome, which was sequenced by Andersson et al. in 1998, 
shows a great deal of reduction as does the human mitochondrial DNA [Anderson et 
al., 1981].  
 
1.3 
 
Structure of mitochondria 
Mitochondria were first described in 1857 as granule-like structures in muscle cells by 
Albert von Kolliker. In 1898 Carl Benda gave those organelles the name 
“mitochondria”, derived from the Greek words “mitos” (thread) and “chondros” 
(granules). Mitochondria are relatively large organelles in the eukaryotic cytoplasm with 
a diameter of 0.2 µm to 1 µm. The length can vary, but usually a single mitochondrion 
has a length from approximately 1 µm to 2 µm. The actual number, size and also 
positioning of mitochondria within the cell depends on the particular tissue, where 
heart, brain, skeletal muscle, kidney and liver are relatively mitochondria rich, due to 
the high necessity on energy production within those tissues. Mitochondria are dynamic 
organelles with morphological variations, but often are present as a branched reticular 
network that is regulated by fission and fusion events of the mitochondria. The 
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movement of mitochondria within the cell is strongly associated with components of the 
cytoskeleton, the microtubules. The cytosolic dynein is the motor protein that transports 
mitochondria along the microtubules in the cell.  
The development of electron microscopy allowed that the structure of the 
mitochondrion could be more thoroughly investigated. Palade (1952) and Sjöstrand 
(1956) were the pioneers in electron microscopy of mitochondria. Mitochondria are 
usually described with four compartments: the mitochondrial outer membrane (OMM), 
the intermembrane space (IMS), the inner membrane (IMM), whose surface is 
increased by forming cristae, and the matrix. Palade developed a mitochondrial model, 
called “baffle model” that is actually the popular presentation of mitochondria in text 
books, where cristae have broad openings to the intermembrane space.  
A new technique, the electron microscopic (EM) tomography shows the actual internal 
organisation of mitochondria in a different way. This reveals them to have extensively 
tubular cristae, which can merge to flattened lamellar compartments (Figure 1.1). The 
form and size of cristae depend on the tissue according to Frey and Mannella (2000).  
 
 
Figure 1.1: Structure of mitochondria. A) Section through a 3D tomogram of a chick 
cerebellum mitochondrion shows the organelle with the outer mitochondrial membrane (OMM), 
the inner mitochondrial membrane (IMM), the intermembrane space in between (IMS), the 
cristae and the matrix. The cristae are connected to the inner boundary membrane through 
tubular crista junctions. Image shows further an endoplasmatic reticulum (ER) vesicle in very 
close proximity to the outer mitochondrial membrane. B) Computer model generated from 
segmented 3D tomograms of the chick brain mitochondrion showed in (A). The model shows 
the outer membrane in dark blue, the inner boundary membrane in light blue and the cristae in 
yellow. (Images were adapted from Frey and Mannella, 2000) 
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What they have in common is the connection to the inner boundary membrane via 
tubular cristae junctions, which have a diameter of 28 nm (Figure 1.1 A). The outer 
membrane contains an abundance of the transport protein - porin, which forms 
channels through this lipid bilayer. A number of ions and small molecules can pass this 
permeable outer membrane and enter the intermembrane space, but they can not pass 
the impermeable inner membrane. The intermembrane space contains a number of 
proteins with cytochrome c as the most prominent one, which transfers electrons from 
Complex III to Complex IV. Additionally cytochrome c is also involved in apoptosis and 
its release from the IMS to the cytosol induces caspases-dependent apoptosis (see 
1.4.3). The inner membrane is very protein rich with approximately 75% protein content 
(compared with most others with ~50%) [Liu and Spremulli, 2000]. It contains the 
abundant enzymatic complexes for oxidative phosphorylation and further channel-
forming proteins and metabolite transporter proteins. The matrix harbours the majority 
of mitochondrial proteins that are involved in metabolic processes such as TCA cycle 
or β-oxidation, and iron-sulphur biogenesis. Furthermore it contains multiple copies of 
mtDNA, proteins that are involved in the maintenance of the mitochondrial genome, 
and also the mitochondrial gene expression machinery. Since the human 
mitochondrion comprises 1,100-1,400 proteins [Calvo and Mootha, 2010] of which only 
13 are mitochondrial encoded, the majority are nuclear encoded. These are 
synthesised by the ribosomes in the cytosol as a precursors with a mitochondrial 
targeting peptides and then transported by the TOM complex through the outer 
membrane. In most cases they are further transported by the TIM23 through the inner 
membrane towards the matrix. The majority of proteins are processed by the 
mitochondrial processing peptidase (MPP) and folded by mitochondrial chaperones 
[reviewed in Neupert and Herrmann, 2007].  
 
1.4 
 
Functions of mitochondria 
1.4.1 Oxidative phosphorylation (OXPHOS) 
A major function of mitochondria is the transduction of energy into the form of ATP via 
oxidative phosphorylation (OXPHOS). There are five enzymatic complexes (OXPHOS 
complexes) in the mitochondrial inner membrane whose interplay is crucial for this 
task: the NADH:ubiquinone oxidoreductase (Complex I), the succinate:ubiquinone 
oxidoreductase (Complex II), the ubiquinol:cytochrome c reductase (Complex III), the 
cytochrome c oxidase (Complex IV) and the ATP synthetase (Complex V) (Figure 1.2).  
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Figure 1.2: Mitochondrial oxidative phosphorylation (OXPHOS). The OXPHOS Complexes I 
to V are shown randomly distributed within the inner mitochondrial membrane. The mobile 
electron carrier ubiquinone and cytrochrome c are labelled as circles with single letter (Q and C, 
respectively). Proton pumping across the membrane into the intermembrane space by Complex 
I, III and IV is indicated as thick red arrows. Arrow in opposite direction reflects the force of the 
electrochemical gradient, used by Complex V for ATP production. (Image taken from 
Lightowlers et al., 2001) 
FAD: flavin-adenine dinucleotide; NAD: nicotinamide-adenine dinucleotide; ADP: adenosine 
diphosphate; Pi: inorganic phosphate; ATP: adenosine triphosphate.  
 
 
The reduced co-factors NADH+H+ and FADH2, which are products from different 
pathways such as TCA cycle or β-oxidation, are oxidised by Complex I and II. Collected 
electrons are transferred to the lipid-soluble, electron-shuttle ubiquinone (Coenzyme Q, 
CoQ, Q), which is then reduced to ubiquinol (QH2). With the transport of electrons, 
protons are pumped into the intermembrane space by Complex I. Ubiquinol further 
transfers the electrons to Complex III followed by a difficult mechanism, the Q cycle, 
where ubiquinol is oxidised to ubiquinone. The water soluble cytochrome c (cyt c, c) 
then transfers the electrons from Complex III to Complex IV. Both Complex III and 
Complex IV have also the ability to pump protons into the intermembrane space. 
Finally the electrons that are delivered by the reduced cyt c, are transferred to ½ O2 
and 2H+ by Complex IV with H2O as endproduct. The protons that are pumped into the 
intermembrane space by Complex I, III and IV generate a pH- and thus an 
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electrochemical gradient that is further used as a proton motive force by Complex V to 
generate ATP.   
 
Complex I 
This complex is the largest of all the OXPHOS complexes with a molecular weight of 
approximately 980 kDa. So far there is no crystallisation of mammalian Complex I, but 
low-resolution three-dimensional electron microscopy shows its overall structure with a 
L-shape with two perpendicular arms: a hydrophobic membrane arm, which contains 
the mitochondrial encoded subunits and a hydrophilic matrix arm [reviewed in Vogel et 
al., 2007]. Human Complex I contains 45 subunits, of which 38 components are 
nuclear encoded and the remaining 7 mitochondrial encoded (ND1, ND2, ND3, ND4, 
ND4L, ND5 and ND6). It further contains a non-covalently bound flavine 
mononucleotide (FMN) and eight iron-sulphur clusters, essential for the electron 
conduction. Mitochondrial disorders caused by Complex I dysfunction is very common, 
probably due to the large number of components that can go wrong. Pathogenic 
mutations have been described in every single mitochondrial encoded subunit 
[reviewed in Fernández-Vizarra et al., 2009]. Additionally also pathogenic mutations 
within nuclear encoded structural subunits and further assembly factors have been 
reported associated with Complex I deficiency. The overall assembly of this large 
complex is quite complicated and even if it was intensively studied in the past few 
years, it is still not completely understood [Vogel et al., 2007; Lazarou et al., 2009].  
 
Complex II 
The Succinate:Ubiquinone oxidoreductase is the simplest of all the complexes in the 
respiratory chain. It is an iron-sulphur flavoenzyme that catalyses as part of the TCA 
cycle the oxidation of succinate to fumarate. Complex II contains four subunits, which 
are all nuclear encoded: SDHA, harbouring a covalently bound flavin-adenine 
dinucleotide (FAD) , SDHB with three iron-sulphur centres, SDHC and SDHD, which 
together contain a cytochrome b560 [reviewed in Rutter et al., 2010]. SDHA (70 kDa) 
and SDHB (27 kDa) form together the hydrophilic catalytical unit, the succinate 
dehydrogenase, which is located towards the matrix. However, the membrane anchor, 
composed by SDHC (15 kDa) and SDHD (13 kDa) is crucial for the ubiquinone binding. 
Complex II is only involved in the delivery of electrons to ubiquinone, but does not 
translocate protons into the intermembrane space.  
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Complex III 
In 1998 the crystal structure of bovine Complex III, also called cytochrome bc1 was 
published by Iwata et al. The mammalian Complex III is a stable dimer, of which each 
monomer harbours 11 subunits with an overall molecular weight of approximately 240 
kDa [reviewed in Saraste, 1999]. Cytochrome b (cyt b) is the only subunit of Complex 
III that is mitochondrial encoded. It is one of the key elements, forming the redox centre 
of Complex III. Cyt b is very hydrophobic, containing eight transmembrane helices with 
two b-type haems (cytochrome bL and bH). The other two components of the redox 
centre are a membrane-anchored iron-sulphur protein with a Rieske Fe-S centre and 
cytochrome c1.  The function of Complex III requires the interaction with the electron 
carrier, ubiquinone/ ubiquinol at two sites: the Qo (between the iron-sulphur protein and 
cyt b, close to the intermembrane space) and the Qi (in cyt b, close to the matrix side). 
One ubiquinol can deliver two electrons: one of them is transferred to the Rieske Fe-S 
centre, further to cyt c1 and finally to the water soluble cyt c in the intermembrane 
space. The second electron is transferred by haem bL and bH to Qi. Thus after oxidation 
of two ubiquinols, two electrons can be delivered to Qi and finally reduce one 
ubiquinone. The differences in the redox potential of the two haems are crucial for the 
proton motive force. Finally with each electron that is transferred to cyt c, two protons 
are pumped into the intermembrane space.   
 
Complex IV 
The X-ray crystal structure from bovine cytochrome-c oxidase (Complex IV, COX), 
which was published in 1996 by Tsukihara et al., shows the enzyme as a dimer. Each 
monomer has a molecular weight of 204 kDa, composed by 13 subunits. The catalytic 
core contains the two of the three mitochondrial encoded subunits COX1 (57 kDa) and 
COX2 (25 kDa), which contain two type a haems (cytochrome a and a3) and further the 
copper centres (CuA and CuB), essential for the electron transfer. The third 
mitochondrial encoded protein of Complex IV is COX3 and is part of the structural core. 
The other 10 subunits are nuclear encoded. Cytochrome-c oxidase is the terminal 
electron accepter of the respiratory chain and reduces oxygen to water. The electrons, 
delivered by cyt c, are first transferred to cytochrome a in COX1 and then to 
cytochrome a3 and CuB, which forms a binuclear centre and is crucial for oxygen 
binding and reduction [reviewed in Saraste, 1999].  
One of the most common defects in the respiratory chain in human pathology is COX 
deficiency. Quite often the reason for those defects are mutations in nuclear encoded 
proteins, crucial for the assembly and maturation of Complex IV (e.g. SURF1, COX10 
and COX15 [Zhu et al., 1998; Fernández-Vizarra et al., 2009]) or for the expression of 
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the mitochondrial encoded ones (e.g. TACO1 and LRPPRC [Weraarpachai et al., 2009, 
Mootha et al., 2003, Sasarman et al., 2010]).  
 
Complex V 
The ATP synthetase (FoF1-ATP synthetase, FoF1-ATPase) is a large complex with a 
molecular weight of approximately 500 kDa, composed by a water-soluble “head” 
complex with ~380 kDa (F1) and the hydrophobic transmembrane portion (Fo) 
[reviewed in Yoshida et al., 2001]. Two protein stalks connect F1 and Fo to each other. 
The F1 ATPase is composed of 5 different subunits (α, β, γ, δ and ε), where 3α and 3β 
subunits, arranged alternately, form a cylinder around the γ subunit [Gibbons et al., 
2000]. Both α and β subunits can bind nucleotides, but it is the β subunit that has the 
catalytic activity. This catalytic component in F1 has three active sites and each site 
passes three different states: 1) “open”, an empty state, 2) “loose”, a state with bound 
ADP and Pi and 3) “tight”, a state with tightly bound ATP. The Fo part of Complex V 
contains 8 subunits (a, b, c, d, e, f, g and A6L), where subunits a and A6L are encoded 
by the mitochondrial genes MT-ATP6 and MT-ATP8, respectively. The proton 
translocation through the Fo particle causes the rotation of the γ subunit within F1. This 
leads to the described conformational changes within the β subunits and therefore to 
ATP synthesis in F1. 
 
Supercomplexes 
There have been a lot of investigations into how the OXPHOS complexes are 
organised within the inner membrane during the last decade. Usually the complexes 
are shown individually, randomly moving within the inner membrane, connected 
through the electron transfer by the mobile carriers ubiquinone and cytochrome c. This 
model is the favourite version in text books and is also called “fluid model”. Following 
from the work of Schägger and Pfeiffer in 2000, however, there have been a lot of 
reports indicating that the individual complexes are assembled in larger 
supercomplexes [reviewed in Vonck and Schäfer, 2009], also called “respirasomes”. 
This high degree of organisation of the complexes is also known as the “solid model”. 
The most abundant supercomplex in bovine mitochondria was shown to be an 
association of one copy of Complex I, dimeric Complex III and one Complex IV 
(I1III2IV1) [Schäfer et al., 2007]. Furthermore the ATPase was shown in a higher 
organisation, usually as a dimer. In 2008 Acín-Pérez et al. proposed a third model 
called “plasticity model”, which suggests that most Complex IV and Complex II and 
some of Complex III are not within supercomplexes and that those individual 
complexes are likely to move freely within the mitochondrial inner membrane. In 
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contrast Complex I always seems to be in association either with Complex III, with 
Complexes III and V, with Complexes II, III, and IV, or with Complexes III and IV. 
Interestingly the same authors have shown for the first time that some of those 
supercomplexes contain ubiquinone and cytochrome c and further they demonstrated 
that those isolated supercomplexes containing Complex I, III and IV are able to transfer 
electrons from NADH to oxygen and therefore can be really considered as 
respirasome.  
 
1.4.2 Mitochondrial Reactive Oxygen Species (ROS) production 
The respiratory chain performs one of the major functions of mitochondria, where 
electron transfer along the complexes leads to a proton motive force that generates a 
membrane potential used by Complex V to produce ATP. The final electron acceptor in 
the respiratory chain is Complex IV, which reduces O2 to H2O. But electrons may leak 
from the respiratory chain, reacting with oxygen to form superoxide (O2·-). The major 
sources producing superoxide within mitochondria are Complex I and Complex III. 
There are two known mechanisms of how superoxide occurs via Complex I: first, a high 
NADH/NAD+ ratio leads to fully reduced FMN of Complex I and reacts with O2 
producing O2·-. Thus a dysfunction within the respiratory chain can lead to increased 
NADH/NAD+ ratio and therefore to higher superoxide production [Murphy, 2009]. The 
second mechanism is the reverse electron transport (RET), where electrons enter 
Complex I through the ubiquinone binding site [Lambert and Brand, 2004], caused by 
high ∆p, leading to reduction of NAD+ to NADH at FMN site. Furthermore Lambert and 
Brand (2004) showed that superoxide production by Complex I is dependent on the pH 
gradient rather than the membrane potential and that mild uncoupling which reduces 
the pH gradient leads to a decrease of superoxide production by Complex I during 
reverse electron transport. The main source of superoxide production within Complex 
III is probably the auto-oxidation of semiubiquinone in the Q cycle at both sites of the 
inner membrane (Qo and Qi). Superoxide is not a strong oxidant, but it is the precursor 
for most reactive oxygen species and therefore it needs to be eliminated [Turrens, 
2003]. There are two superoxide dismutases (SOD) that can invert O2·- to H2O2, which 
can be further degraded by the catalase in the peroxisome [Fritz et al., 2007]. The 
mitochondrial matrix contains a manganese-dependent SOD (MnSOD) that reacts on 
O2·- that is formed in the matrix or in the inner side of the inner mitochondrial 
membrane [Fridovich, 1995, Abreu and Cabelli, 2010]. The intermembrane space 
harbours the second SOD, which contains copper and zinc instead of manganese 
(CuZnSOD) [Okado-Matsumoto and Fridovich, 2001]. This enzyme is also found in the 
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cytosol. In addition to the CuZnSOD the reduction of cytochrome c by O2·- may also 
contribute to the elimination of superoxide. The reduced cytochrome c can then deliver 
the electrons further to Complex IV [Turrens, 2003]. Furthermore since a mild 
uncoupling of the pH gradient reduces the superoxide production by Complex I it has 
been proposed that uncoupling proteins (UCP) “leaking” protons across the inner 
membrane are important for the reduction of ROS [Brand et al., 2004]. However, some 
superoxide can lead to the inactivation of iron-sulphur centre containing enzymes, 
which leads to the release of the ferrous iron that catalyses the production of hydroxyl 
radical (·OH) from H2O2. Those hydroxyl radicals can cause damage on cellular 
proteins, lipids and DNA. 
The overall rate of ROS generation was suggested to be ~2% of the total oxygen 
consumption within the mitochondria, however, this number was seen to be 
overestimated caused by experiments under unphysiological conditions. Therefore the 
rate of ROS production has been reduced to less than 0.2% of the oxygen 
consumption within mitochondria. However, mitochondria are still with approximately 
90% the main source of cellular ROS production [Balaban et al., 2005, Murphy, 2009]. 
Certain amounts of ROS are important for cellular signalling pathways like the initiation 
of apoptosis [reviewed in Circu and Aw, 2010].  
 
1.4.3 Mitochondria and apoptosis 
In multicellular organisms programmed cell death, also called apoptosis, is essential to 
eliminate damaged cells to inhibit further harm on other cells and therefore to lead to 
their survival. In addition apoptosis is very important in development to reduce cell 
numbers in certain tissues and to generate fully formed organs (e.g. the loss of the 
tissue between fingers to separate them). The intrinsic, or mitochondrial pathway of 
apoptosis is initiated by several apoptotic stimuli (e.g. ROS, UV radiation, DNA 
damage) causing the activation of caspases (cystein aspartic acid proteases) [Wang 
and Youle, 2009]. Apoptotic stimuli trigger the release of certain apoptogenic proteins 
such as cytochrome c, Smac/DIABLO, Omi/HtrA2, AIF and Endonuclease G (Endo G) 
from the mitochondria to the cytosol (Figure 1.3).  
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Figure 1.3: Mitochondrial pathway of apoptosis. Apoptotic stimuli induce the release of 
apoptotic factors over BH3-only proteins. This can cause oligomerisation of Bax or Bak and 
therefore changes in the outer membrane of the mitochondrion, which is shown in the centre of 
this image. Thus apoptotic factors such as cytochrome c, Smac/DIABLO, Omi/HtrA2, 
Endonuclease G and AIF can leave the mitochondrion, which is indicated as arrows leaving the 
organelle, and induce apoptosis. Cyt c interacts with Apaf-1 forming the apoptosome, followed 
by the caspase-cascade. IAP molecules (inhibitor of apoptosis protein) can inhibit this caspase 
pathway, however, the release of Smac/DIABLO and Omi/HtrA2 leads to inactivation of IAP 
molecules and therefore to enhance caspase-dependent apoptosis pathway. Endonuclease G 
and AIF, released to the nucleus cause DNA fragmentation. (Image was changed after Wang, 
2001)  
 
When cytochrome c is released from the mitochondrial intermembrane space it can 
initiate caspase activation [Liu et al., 1996]. Together with Apaf-1, a cytosolic protein 
containing a caspase-recruitment domain (CARD), cytochrome c forms a multimeric 
complex, the apoptosome [Zou et al., 1999]. The CARD domain of Apaf-1 recruits then 
procaspase 9, whose autoactivation leads to the caspase-9 holoenzyme that can then 
cleave further caspase such as procaspase 3 [Rodriguez and Lazebnik, 1999]. There 
are certain IAP molecules (inhibitor of apoptosis protein) that can bind and inhibit active 
caspase-9 and -3 via their BIR (baculovirus IAP repeat) domains. The release of 
matured Smac/DIABLO from the mitochondrial intermembrane space leads to 
enhanced caspase activation since this protein can competitively bind to the BIR 
domain of IAP [Du et al., 2000, Verhagen et al., 2000]. Omi/HtrA2, a serine protease, 
was identified as another IAP binding protein that can degrade IAP [reviewed in Wang 
and Youle, 2009]. The release of matured AIF from the intermembrane space and its 
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location to the nucleus causes chromatin condensation and DNA fragmentation [Susin 
et al., 1999]. Endo G has nuclease activity and once released from the mitochondria it 
can induce nucleosomal DNA fragmentation [Li et al., 2001]. How the release of certain 
apoptogenic factor occurs is not completely understood. However, it is believed that the 
mitochondrial permeability transition pore (mtPTP), a megapore spanning the outer and 
inner mitochondrial membranes, plays a certain role in apoptosis initiation. An opening 
of the mtPTP, caused by e.g. increased oxidative stress, will lead to matrix swelling, 
depolarization of the membrane potential, disruption of the outer membrane and 
therefore to the release of proteins of the intermembrane space [Wallace, 2005]. In 
contrast, Wang and Youle (2009) suggested that the opening of the mtPTP is more a 
consequence of apoptosis. Furthermore the release of all those apoptogenic proteins 
from the mitochondria is highly regulated by Bcl-2 (B cell lymphoma-2) family proteins 
[reviewed in Wang, 2001]. BH3-only proteins in the cytosol (e.g. tBid) transduce 
apoptotic stimuli to the mitochondria, which can be either neutralised by certain 
antiapoptotic proteins such as Bcl-2 and Bcl-xL, or which further induce conformational 
changes and oligomerisation of Bax and Bak [Eskes et al., 2000] that may form a 
megapore, which is required for the release of apoptotic proteins [Wang and Youle, 
2009]. 
Thus in addition to oxidative phosphorylation, the induction of apoptosis in damaged 
cells is one of the critical tasks of mitochondria in multicellular organism.  
 
1.5 
 
The structure, maintenance and replication of the 
mitochondrial genome 
1.5.1 General aspects of the mtDNA 
The size (from ~ 6 to 400 kbp), shape (linear or circular) and composition of the 
mitochondrial genome vary between different organisms [Lang et al., 1999]. This 
section will describe the organisation of the human mitochondrial genome (mtDNA), 
which is a small double stranded, closed-circular DNA molecule of 16,569 bp (Figure 
1.4). It encodes only approximately 1% of the approximately 1,400 mitochondrial 
proteins, of which the majority is nuclear encoded. The mtDNA is maternally inherited 
and its copy number varies between cell types from 1,000-10,000 in somatic cells with 
2-10 copies per organelle [Satoh and Koroiwa, 1991] up to 100,000 in a mature oocyte 
[Shoubridge, 2000]. 
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Figure 1.4: The human mitochondrial genome (mtDNA). The human mtDNA (16,569 bp) is 
portrayed above as a circle. The 2 ribosomal RNAs (MT-RNR1 and MT-RNR2) and the open 
reading frames are shown as bold lines. The 22 tRNAs (grey circles) are labelled by their single 
letter code. There is only one non-coding region (NCR), also called D-loop. The heavy and light 
strand promotors are indicated as H1, H2 and LSP. (Image was kindly provided by Dr. Z. M. A. 
Chrzanowska-Lightowlers) 
 
The two strands of the mtDNA differ in their density in caesium chloride gradient 
leading to their names [Clayton, 1982]: heavy strand (H-strand), which is guanine rich 
and the light strand (L-strand), which is guanine poor. The H-strand contains most of 
gene encoding material and codes for the two ribosomal RNAs (MT-RNR1 (12S rRNA) 
and MT-RNR2 (16S rRNA)), 14 tRNAs and 12 open reading frames [Anderson et al., 
1981]. The L-strand harbours the sequences for 8 tRNAs and one open reading frame. 
The mitochondrial genome is quite compact, lacking introns and the only non-coding 
region is located between tRNAPhe (F) and tRNAPro (P) [Walberg and Clayton, 1981]. 
This approximately 1.1 kb large region is called displacement loop (D-loop, 7S DNA), a 
triple-stranded regulatory region that contains the origin of the H-strand (OriH) and the 
promotors for bi-directional transcription of the two strands (HSP1 and LSP). A second 
promotor for the H-strand transcription (HSP2) is located close to the 5’-end of the 12S 
rRNA [Montoya et al., 1982]. The origin of the L-strand (OriL) is displaced by 
approximately two thirds of the genome within in cluster of five tRNAs (W, A, N, C, Y).  
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1.5.2 The genetic code of human mtDNA 
The genetic code of mtDNA from many organisms differs from the universal code 
[http://www.ncbi.nlm.nih.gov/Taxonomy/Utils/wprintgc.cgi?mode=t#SG3]. Here the 
changes seen in the human mtDNA only are described [Anderson et al., 1981]: i) there 
are only two codons representing stop codons (UAA and UAG) in human mitochondria. 
The third, present in the universal code, UGA, encodes tryptophan. ii) AUA codes for 
methionine instead of isoleucine and AUU codes for isoleucine during elongation but 
can code for methionine for initiation (MT-ND2). iii) AGA and AGG were presumed to 
be termination codons for MT-CO1 and MT-ND6 rather than not encoding arginine. It 
was shown recently, however, that those codons are not recognised by either a tRNA 
or a protein release factor and therefore do not represent stop codons [Temperley et 
al., 2010a]. They are still important in acting as “hungry codons”, a feature that 
promotes -1 frameshifting. This permits the use of UAG as a stop codon in MT-CO1 
and MT-ND6 transcripts within the human mitochondrial ribosome.  
 
1.5.3 The key factors of mtDNA replication  
The key factors for mammalian mtDNA replication are mtPolγ, TWINKLE and mtSSB 
[reviewed in Wanrooij and Falkenberg, 2010]. The mitochondrial DNA polymerase γ is 
a heterotrimer, harbouring the catalytic subunit PolγA with polymerase, 3’-5’ 
exonuclease and 5’-deoxyribose phosphate (dRP) lyase activities, and two copies of 
the accessory subunit PolγB. TWINKLE is a 5’-3’ DNA helicase, which forms an 
hexamer in solution and is crucial for the unwinding of double stranded DNA. The 
mitochondrial single-stranded DNA-binding protein prevents single stranded DNA from 
refolding and protect against degradation. In vitro studies showed that mtPolγ and 
TWINKLE can synthesise ssDNA of ~ 2 kb length from a dsDNA template. The addition 
of mtSSB results in an increase of replication, generating a 16 kb DNA product 
[Korhonen et al., 2004]. Additionally POLRMT is required for the synthesis of RNA 
primers, which are used for the initiation of leading-strand mtDNA synthesis at the OriH 
[Wanrooij et al., 2008]. 
 
1.5.4 Organisation of mtDNA in nucleoids 
The mitochondrial genome is usually clustered within a protein-DNA network called 
nucleoid, with 2-10 mtDNA copies per nucleoid [Spelbrink, 2010], where the mtDNA is 
protected by DNA-binding proteins. Mammalian nucleoids are dynamic structures, able 
to divide and to redistribute within the mitochondrial network. The most abundant 
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proteins within the nucleoids are TFAM and mtSSB. It has been suggested that TFAM 
protein level correlates to the relative mtDNA copy number and is therefore an 
important regulator of gene expression and possibly nucleoid packaging [Shen and 
Bogenhagen, 2001; Pohjoismaki et al., 2006]. Other components of nucleoids are also 
key factors of the mitochondrial replication and transcription machinery. These are 
proteins that are permanently or temporarily directly associated with the mtDNA or with 
other nucleoid proteins. Bogenhagen et al. (2008) suggested a model of mtDNA 
nucleoid structure with a nucleoid core (containing 31 proteins) and a surrounding 
peripheral zone according to subdivision of nucleoid proteins in three classes derived 
from native and cross-linked preparations. However, depending on the preparation 
method used the resulting composition of nucleoids can be different as He et al. (2007) 
reported a more restricted set with only 6 components.  
There is evidence that mtDNA/ nucleoids are bound to the inner mitochondrial 
membrane in close proximity of ER-mitochondrial junctions [reviewed in Spelbrink, 
2010] and transcripts derived from the nucleoid are processed and translated within the 
peripheral zone in close vicinity to their assembly point, where also nuclear encoded 
proteins get coordinated imported after being translated on ER-bound cytosolic 
ribosomes. This model is in agreement with the fact that mitochondrial ribosomal 
proteins and translation factors were found in association with nucleoids [Bogenhagen 
et al., 2008, Rorbach et al., 2008]. Therefore it was proposed that there is a coupling 
between mtDNA maintenance and mitochondrial transcription to mitochondrial 
translation, cytoplasmic translation, protein import and complex assembly through the 
peripheral nucleoid proteins [Iborra et al., 2004, Bogenhagen et al., 2008, Spelbrink 
2010].  
 
1.6 
 
Mitochondrial Transcription and mt-RNA processing 
1.6.1 The mitochondrial transcription machinery 
The key components of the human mitochondrial transcription machinery are the 
human mitochondrial RNA polymerase (POLRMT), the mitochondrial transcription 
factor A (TFAM) and the mitochondrial transcription factor B2. 
POLRMT is a single-subunit protein of approximately 140 kDa, containing two domains 
[Tiranti et al., 1997]: a C-terminal domain that contains conserved motifs for catalytic 
activity as they are found in bacteriophage polymerase, and a relatively large N-
terminal domain, which harbours two putative pentatricopeptide repeat (PPR) motifs. 
Proteins with PPR motifs are usually involved in RNA-processing. However, it is not 
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known, whether the PPR motifs within the POLRMT are responsible for RNA binding. 
POLRMT can not initiate transcription on its own, it needs therefore the assistance of 
TFB2M and TFAM, where POLRMT and TFB2M forms a heterodimeric complex. Two 
mitochondrial transcription factors B exist, TFB1M and TFB2M. Both proteins are 
related to rRNA methyltransferases and were shown to be active transcription factors in 
vitro [Falkenberg et al., 2002]. However, it has been demonstrated that TFB2M was the 
more active one. Since TFB1M was shown to be essential for the methylation of two 
adenines at the 3’-end of the mammalian 12S ribosomal RNA [Metodiev et al., 2009], 
whereas the methyltransferase activity of TFB2M was less efficient [Cotney and 
Shadel, 2006], it has been proposed that TFB1M functions more as a ribosomal 
methyltransferase rather than a transcription factor. TFAM can bind and unwind DNA in 
a sequence independent manner. It has been therefore suggested that the binding of 
TFAM causes structural changes in the mtDNA such as unwinding of the promoter 
region for facilitating transcription initiation [Falkenberg et al., 2007]. Four further 
transcription termination factors have been identified (MTERF, MTERFD1, -D2 and -
D3), however the functions of those proteins is not completely understood [Roberti et 
al., 2009, Hyvärinen et al., 2010]. Initially MTERF was shown to bind sequence 
specifically to the termination site within the tRNALeu(UUR) of the shorter polycistronic 
transcript initiated at HSP1 [Kruse et al., 1989].  
 
1.6.2 Mitochondrial RNA processing 
As already described there are three promotors in human mtDNA, the initiation points 
of RNA synthesis. From the HSP1 promotor, located within the D-loop, a transcript 
containing the two ribosomal RNAs (MT-RNR1 or 12S rRNA and MT-RNR2 or 16S 
rRNA) and further tRNAPhe and tRNAVal is generated (Figure 1.5), terminating at a 
specific site in the tRNALeu(UUR) downstream of the 16S rRNA mediated by the binding 
of MTERF [Montoya et al., 1983, Kruse et al., 1989]. The HSP2 promotor results in a 
polycistronic transcript that corresponds to almost the entire H-strand. The L-strand is 
also transcribed into a polycistronic RNA molecule starting at the LSP. It has been 
proposed in the so called “tRNA punctuation model” [Ojala et al., 1981] that the 
structures of the tRNA within the polycistronic transcripts provide signals for 
endonucleolytic excision of the tRNA leading to most of the rRNA, tRNA and mRNA 
species. The processing of the polycistronic transcripts requires the mitochondrial 
RNase P [Holzmann et al., 2008], which performs the 5’-endonucleolytic cleavage, and 
a tRNase Z [Levinger et al., 2001, Dubrovsky et al., 2004], which cleaves at the 3’-end 
of the tRNA.  
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Figure 1.5: Transcription map of the human mitochondrial genome. The transcription of the 
human mtDNA is initiated from three promotors, leading to three polycistronic transcripts 
depicted above. The transcript from HSP1 (H1) is shown at the top with two ribosomal RNAs 
(hashed boxes) and tRNAPhe and tRNAVal as circles. The longer transcripts from HSP2 (H2) and 
LSP are also shown, where black boxes represent the mt-mRNAs. RNA7 and RNA14 indicate 
the two bicistrons, encoding the proteins ND4L/ND4 and ATPase8/-6. (Image was kindly 
provided by Dr. Z. M. A. Chrzanowska-Lightowlers) 
 
Finally the 3’-end of each tRNA is modified by the addition of the CCA triplet, catalysed 
by an ATP(CTP):tRNA nucleotidyltransferase [Nagaike et al., 2001]. After folding and 
modification of the tRNA the specific amino acid can be attached to the CCA triplet at 
the 3’-end by the corresponding aminoacyl-tRNA synthetase. The mitochondrial 
mRNAs are usually either oligo- or polyadenylated at the 3’-end, which is for some 
transcripts also essential to complete the stop codon (UAA), whereas the 
polyadenylation of mt-rRNA was suggested to be not common in cultured cells 
[reviewed in Temperley et al., 2010b]. Finally 9 different monocistronic and 2 bicistronic 
(RNA7: MT-ND4L/ND4, RNA14: MT-ATP8/-6) mt-mRNAs are formed within human 
mitochondria, which are usually described as leaderless, meaning they either lack 
completely a 5’-UTR or there are only 1, 2 or 3 nucleotides upstream the start codon. 
The exception represents the two bicistrons, since MT-ND4 and MT-ATP6 harbours as 
5’-UTR the out of frame sequence of MT-ND4L and MT-ATP8, respectively. However, 
the mt-mRNAs do not contain a sequence similar to the bacterial Shine-Dalgarno 
sequence at the 5’-end, which could be utilised for promoting translation initiation 
[Montoya et al., 1981]. Furthermore there is no 5’ 7-methylguanosine cap as there are 
in the eukaryotic cytosolic mRNAs. Therefore human mitochondrial mRNAs are unique 
in many aspects.  
 
1.6.3 RNA binding proteins in human mitochondria 
Yeast mitochondria contain a number of translation activators that bind the 5’-UTR of 
mitochondrial mRNA in yeast [Towpik, 2005]. In human mitochondria there is not much 
known about proteins that act as translation activators, which could be due to the 
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absence of specific 5’-UTRs, suggesting that there are other mechanisms that promote 
translation. However, TACO1 was reported to be a specific translation activator for 
COX1 [Weraarpachai et al., 2009]. This was identified through a patient sample where 
a mutation in this gene caused a substantial decrease exclusively in COX1 protein 
level. Furthermore there have been several reports about mammalian mitochondrial 
PPR (pentatricopeptide repeat) proteins, which are found extensively in mitochondria 
and chloroplasts of land plants [Schmitz-Linneweber and Small, 2008]. Those PPR 
proteins have roles in RNA stability, editing, splicing, processing and possibly 
translational control. Because of the unique characteristics of mammalian mitochondrial 
transcripts as described above the function of those PPR proteins might be relatively 
limited. Examples for those PPR proteins in mammalian mitochondria are: POLRMT 
(described in 1.6.1), MRPS27 (a component of the mitochondrial ribosomal small 
subunit), mitochondrial RNase P protein 3 (MRPP3), LRPPRC (leucine-rich 
pentatricopeptide repeat cassette), PTCD1, PTCD2 and PTCD3. Patients with 
mutations in LRPPRC showed COX deficiency and a reduced level in mitochondrial 
encoded transcripts for cytochrome c oxidase [Xu et al., 2004]. However, further 
studies demonstrated that all mt-mRNA were reduced in the absence of LRPPRC 
except MT-ND3 and MT-ND6 [Sarsarman et al., 2010]. Additionally it has been shown 
that LRPPRC and SLIRP, a stem-loop RNA-binding protein, interact in a 
ribonucleoprotein (RNP) complex in mammalian mitochondria. The stability of both 
proteins was shown to be dependent on the presence of mt-mRNA, where the protein 
steady state level especially of SLIRP was dramatically reduced in the absence of 
mitochondrial transcripts [Baughman et al., 2009, Sarsarman et al., 2010]. Sarsarman 
et al. (2010) suggested that LRPPRC and SLIRP within the RNP complex are crucial 
for regulating the stability and handling of mature mt-mRNA. PTCD1 has been 
demonstrated to reduce the abundance of tRNALeu and was therefore suggested to be 
a negative translation modulator [Rackham et al., 2009]. Xu et al. (2008) have shown 
that a disruption in murine PTCD2 causes a decreased level in Complex III, caused by 
the depletion of MT-CYB transcript and further accumulation of unprocessed precursor, 
which included MT-ND5. PTCD3 was shown to interact with the 12S ribosomal RNA, 
crucial for mitochondrial protein synthesis [Davies et al., 2009]. Just recently ERAL1, a 
human mitochondrial protein that contains a type-II KH-domain, was shown to bind the 
3’-end of the 12S rRNA and to be absolutely crucial for the stability of 12S rRNA 
[Dennerlein et al., 2010]. 
Thus there are some RNA binding proteins in mammalian mitochondria, which are 
involved in RNA stability or processing and thus crucial for mitochondrial translation, 
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however, the list of those proteins is far from complete and needs further investigations 
in the future.  
 
1.7 
 
Mitochondrial Translation 
The translation of a messenger RNA into a protein requires a machinery comprising a 
substantial number of factors: i) the ribosome, a ~2.65 MDa compound complex of 
rRNA and proteins, ii) the mRNA, iii) amino-acylated tRNAs and their cognate 
synthetases, and iv) translation factors. In human and also in other mammals all 
protein components within the mitochondrial translation machinery are nuclear 
encoded and therefore they need to be translated in the cytosol and then imported into 
the mitochondria.  
Since mitochondria have developed from a bacterial ancestor it has been expected that 
its translation machinery should be relatively similar to the bacterial one. There are 
indeed some similarities between the mitochondrial and the bacterial protein synthesis, 
however, there are also substantial differences between these two systems. 
Furthermore the mitochondrial translation machinery between different organisms is 
not the same. In the following section the current knowledge about mammalian 
mitochondrial protein synthesis will be described and further differences to other 
systems will be pointed out.  
 
1.7.1 The mammalian mitochondrial ribosome 
The mammalian mitochondrial ribosome has a low sedimentation coefficient of 
approximately 55S, comprising a 28S small subunit (28S mt-SSU) and a 39S large 
subunit (39 mt-LSU) [O’Brien, 1971]. In contrast i) the eukaryotic cytosol contains a 
80S ribosome with a 40S SSU and a 60S LSU ii) a bacterial ribosome is a 70S particle 
with a 30S SSU and a 50S LSU and iii) yeast mitochondria harbour a 70S ribosome 
with a 37S mt-SSU and a 54S mt-LSU. The 55S mammalian mitochondrial ribosome 
has a slightly higher molecular weight of approximately 2.65 MDa in comparison to the 
bacterial 70S ribosome with 2.3 MDa. A substantial difference between the mammalian 
mitochondrial ribosome and other ribosomes is the ratio of RNA:protein content, where 
the usual 70%:30% ratio as found in bacteria is reversed in the mammalian 
mitochondrial ribosome. The ribosomal RNAs, encoded by the human mitochondrial 
genome, are much smaller than the bacterial ones: i) the 12S mt-rRNA is with 954 nt 
approximately 40% shorter than the 16S rRNA of the bacterial SSU and ii) the 16S mt-
rRNA with 1558 nt is only a half of the length of the 23S rRNA in the bacterial LSU 
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[O’Brien, 2002]. Further, it has not unequivocally confirmed whether there is a 5S rRNA 
present in the mammalian mitochondrial ribosome. It has been shown, however, that 
5S rRNA is imported into mitochondria, but its function within the organelle is still 
elusive [Entelis et al., 2001, Smirnov et al., 2008]. Thus the RNA content within the 
mammalian mitochondrial ribosome is relatively low. In contrast the protein content is 
much higher in the 55S particle than in its bacterial counterpart or in yeast 
mitochondrial ribosome. Since the pioneering work of O’Brien and colleagues in 1982 
[Matthews et al., 1982] the list of identified mammalian mitochondrial proteins is 
growing [Koc et al., 2010]. The more porous structure with visible voids in the cryo-EM 
structure of the bovine mitochondrial ribosome (Figure 1.6) [Sharma et al., 2003] make 
it tempting to speculate that there are maybe still some proteins missing. Currently 31 
proteins are known to be components of the mammalian 28S SSU, which includes 3 
isoforms of MRPS18 [Koc et al., 2001b]. It is still unknown whether a single ribosome 
contains all three isoforms of MRPS18 at the same time or only a one. However, only 
14 proteins find homologues in bacteria and the others are unique for the mitochondrial 
28S SSU. The 39S LSU consists 51 subunits of which 28 proteins represent 
homologues to components of the bacterial 50S LSU. The remainder are again unique 
to the mammalian mitochondrial ribosome [Koc et al., 2001c; Koc et al., 2010]. Most of 
the homologous proteins found in mammalian mitochondrial ribosomes are also 
present in yeast mitochondrial ribosomes, as might be predicted from a common 
bacterial ancestor. However, a number of the additional proteins found in the 
mammalian mitochondrial ribosome are absent from the yeast. This is in agreement 
with the hypothesis that those additional proteins within the mammalian mitochondrial 
ribosome replace the loss of ribosomal RNA and since yeast mitochondrial ribosomes 
do not show the truncated rRNAs there is no requirement for additional proteins 
[O’Brien, 2002]. However, Sharma et al. (2003) showed that only ~ 19% of the missing 
ribosomal RNA segments are replaced by proteins within the 28S SSU and ~ 28% 
within the 39S LSU. Approximately 50% of the 5S rRNA are replaced by protein mass, 
but as already said, the structure is relatively porous and has some open empty voids 
(Figure 1.6), which leads to speculations that potentially there are some proteins 
missing from the current structure.  
These additional proteins quite often seem to be recruited pre-existing or bi-functional 
proteins. Examples are MRPL39, which is similar to the N-terminal region of the 
mitochondrial threonyl-tRNA synthetase [Spirina et al., 2000], or MRPS29 (DAP3) and 
MRPS30 (PDCD9), which were both suggested to be involved in apoptosis [Koc et al., 
2001a]. Furthermore the homologous proteins present in the mammalian mitochondrial 
ribosome are in most cases larger than their bacterial counterparts, which also leads to 
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the higher protein content. This perhaps explains in part why the mammalian 
mitochondrial ribosome has a RNA:protein ratio of ~31%:~69%, where the bacterial 
ribosome shows the inverse ratio with ~67%:~33%.  
Sharma et al. (2003) showed a cryo-EM structure of the bovine mitochondrial ribosome 
with a relatively porous structure. The core is relatively compact and the rRNA 
components within the core are surrounded by peripheral proteins (Figure 1.6). The 
authors have also analysed the intersubunit bridges, which hold the two subunits 
together. Six bridges are conserved and show similarities to the bacterial ones (Figure 
1.6 C/D, green ellipses).  
 
 
Figure 1.6: Cryo-EM structures of bovine mitochondrial ribosome. A) and B) The 55S 
ribosome is shown with the 28S SSU (protein content in yellow and RNA in orange) and the 
39S LSU (protein content in blue and RNA in purple). P-site bound tRNA is shown in red. The 
mRNA entrance is indicated by an arrow. C) and D) The subunits are shown from the interface 
side with indicated locations of the intersubunit bridges, where green ellipses represent 
conserved bridges and dark blue ones the mitochondrial ribosome specific bridges. bc: body 
channel, bl: beak lobe, CP: central protuberance, G: gap, h44: rRNA helix 44, hc: head channel, 
hd: head, Ibf: lower-body finger, lbl: lower-body lobe, LH: LSU handle, mgt: mRNA-entry gate, 
PSF: P-site finger, pt: platform, Sb: stalk base, sh: shoulder, SRL: α-sarcin-ricin loop (Images 
were taken from Sharma et al., 2003) 
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A further nine bridges differ from the bacterial system and involve proteins. Since the 
mammalian mitochondrial ribosome is very protein rich its ribosomal subunits are held 
together by mainly protein-protein bridges. In addition to the seven protein-protein 
bridges there are five RNA-RNA bridges, two RNA-protein bridges and one bridge 
involving protein components and RNA from both subunits. The presented structure of 
bovine mitochondrial ribosome indicates certain unusual characteristics that may help 
in understanding the translation process in mammalian mitochondria in more detail. 
One of these particular features is a triangular gate-like structure (mRNA gate), which 
partially covers the mRNA entry site (Figure 1.6 A/B). Sharma et al. (2003) suggested 
since mammalian mitochondrial mRNA lack specific 5’-UTRs that when usually may 
facilitate translation initiation, this gate may be involved in the recruitment of mt-mRNA 
into the 28S SSU. 
Another special feature is the “polypeptide-accessible site” (PAS) a wide opening 
structure just before the polypeptide exit site (PES). The authors suggested therefore 
that there are possibly two pathways, through which the nascent peptide chain can 
leave the ribosome. Furthermore an interesting characteristic of the mammalian 
mitochondrial ribosome is a very strongly retained tRNA in the P-site (peptidyl-tRNA 
site) (Figure 1.6 A/B), whereas purified bacterial ribosomes show usually a strongly 
bound tRNA within the E-site (exit site), a feature essentially lacking in the 55S particle. 
Sharma et al. (2003) have shown that the 39S LSU has a unique finger-like structure 
(P-site finger, PSF) that interacts with the P-site tRNA. This could allow a stabilisation 
of the bound tRNA within the P-site. Importantly most of the rRNA regions, which are 
crucial for the interaction of the tRNA with the E-site, are absent in the mammalian 
mitochondrial ribosome, suggesting that there is a rather weak E-site or even a 
complete loss of this site [Mears et al., 2006].  
To date not much is know about the assembly of the mammalian mitochondrial 
ribosome and the factors that may be involved in this process. So far only two 
polypeptides of the 28S SSU (MRPS16 and MRPS22) have been reported with 
mutations in patients associated with mitochondrial disorders and assembly defects of 
the 28S SSU [Miller et al., 2004, Haque et al., 2008]. Additionally two proteins have 
been shown to be important for the maturation or stability of the 12S rRNA and 
therefore for the assembly for the 28S SSU: TFB1M, which is responsible for the 
conserved di-methylation of the 12S rRNA [Metodiev et al., 2009], and ERAL1, a 12S 
rRNA chaperone, which binds to the 3’-stem-loop region of the 12S rRNA [Uchiumi et 
al., 2010, Dennerlein et al., 2010]. Just recently NOA1, a mitochondrial GTPase has 
been demonstrated to be important for 39S LSU assembly and a loss of NOA1 leads to 
a substantial decrease in mitochondrial protein synthesis [Kolanczyk et al., 2011]. 
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Further for the assembly of the large subunit, MRPL32 needs to be processed by the 
m-AAA protease to become recruited into the 39S LSU as reported by Nolden et al. 
(2005). The same authors showed like other studies [Liu and Spremulli, 2000] that the 
mitochondrial ribosome is associated with the mitochondrial inner membrane and only 
membrane bound ribosomes are translational active. How the ribosome is bound to the 
inner membrane is not known. However, it has been shown that the inner membrane 
protein Oxa1 (human OXA1L), which is crucial for co-translational insertion of 
mitochondrial encoded proteins, interacts with the mitochondrial ribosome via proteins 
of the large ribosomal subunit, closely localised to the polypeptide exit tunnel [Jia et al., 
2003, Jia et al., 2009]. Additionally, Mba1 (human MRPL45) has been shown to be a 
membrane-associated ribosome receptor in yeast mitochondria [Ott et al., 2006], and 
Mdm38 also contributes to the ribosome binding at the inner mitochondrial membrane 
[Frazier et al., 2006]. The mammalian othologue of Mdm38, LETM1 (Leucine zipper 
EF-hand-containing transmembrane protein 1) has been shown to interact with 
MRPL36 [Piao et al., 2009]. 
 
1.7.2 Initiation of mitochondrial protein synthesis 
The identification and characterisation of the mammalian mitochondrial initiation factors 
(mtIF) was predominantly done by Spremulli and colleagues. Translation initiation 
needs a free 28S SSU. By binding to the 28S SSU mtIF3 inhibits the association with 
the 39S LSU and provide therefore a pool of free 28S SSU (Figure 1.7). It has been 
suggested that the role of mtIF3 in translation initiation is an active one rather than a 
passive one, meaning that mtIF3 is directly involved in the dissociation of 55S 
monosome into the 28S SSU and 39S LSU and not just being an anti-association 
factor, bound to the 28S SSU [Christian and Spremulli, 2009]. Furthermore Bhargava 
and Spremulli (2005) demonstrated that mtIF3 reduces the binding of fmet-tRNAMet to 
the 28S SSU mediated by mtIF2-GTP if there is no mt-mRNA present, which is an 
additional role not found in the bacterial counterpart. 
As already described the mitochondrial messenger RNA does not contain a m7G-cap 
structure at the 5’-end, or shine dalgarno sequence or other specific long UTRs that 
would promote translation initiation. Therefore mammalian mitochondrial ribosomes 
must have found another mechanism to recognise the mt-mRNA 5’-end and the start 
codon. One of those specific features could be the mRNA gate at the mRNA entry site 
[Sharma et al., 2003]. Liao and Spremulli (1989) have shown that the 28S SSU is able 
to bind mt-mRNA in the absence of initiation factors or fmet-tRNAMet, but neither the 
39S LSU nor the 55S monosome showed mt-mRNA binding activity. Thus the mRNA is 
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at first loaded onto the 28S SSU in a sequence-independent manner. It was further 
suggested that the mt-mRNA is fed into the mRNA entrance gate starting with the 5’-
end. After the first 17 nt have entered the ribosomal subunit there is an inspection for 
the start codon [Christian and Spremulli, 2010]. During this time mtIF2-GTP promotes 
binding of the fmet-tRNAMet to the ribosome in a codon-anticodon dependent manner 
(Figure 1.7 (1)) [Liao and Spremulli, 1990, Ma and Spremulli, 1995, Spencer and 
Spremulli, 2004]. The presence of a start codon will lead to a stable initiation complex, 
whereas in the absence of a start codon the mRNA will pull through and possibly 
dissociate from the SSU [Christian and Spremulli, 2010]. Christian and Spremulli 
(2010) demonstrated that mt-mRNAs with more than 3-6 nt prior the start codon are 
very inefficiently translated by the mammalian mitochondrial ribosome and therefore 
the accurate processing of the mt-mRNA prior to translation initiation is crucial. After 
forming a stable initiation complex the 39S LSU joins the 28S SSU, forming the 55S 
monosome and mtIF2 can then hydrolyse GTP followed by the release of the initiation 
factors from the ribosome. Bacteria contain an additional initiation factor IF1 that 
stabilises the binding of initiator tRNA to the SSU in the presence of IF2 and 
furthermore it has been suggested that it blocks the ribosomal A-site during translation 
initiation [Carter et al., 2001]. Human mitochondria do not contain a third IF, however, 
Gaur et al. (2006) have shown that an insertion of 37 residues into mtIF2 substitutes for 
the function of an IF1, suggesting that mtIF2 has functionally replaced the two bacterial 
IFs. 
 
1.7.3 Translation elongation 
For translation elongation in mammalian mitochondria three factors are required: 
mtEFTu, mtEFTs and mtEFG1 (Figure 1.7 (2)). All these factors have been identified in 
human and also mutations in each of these genes have been described in association 
with human diseases [reviewed in Smits et al., 2010].  
Many investigations analysing translation elongation were also performed by Spremulli 
and colleagues [Spremulli et al., 2004]. For the elongation process the aminoacyl-tRNA 
(aa-tRNA) is delivered to the A-site by mtEFTu-GTP. An accurate recognition and 
codon-anticodon interaction between the aa-tRNA and the mRNA will lead to GTP 
hydrolysis and therefore to the release of mtEFTu-GDP. For the exchange of the GDP 
for a GTP mtEFTu-GDP interacts with mtEFTs, a guanine nucleotide exchange factor. 
The fmet (peptide chain) from the tRNAMet (peptidyl-tRNA) within the P-site is then 
transferred to the aa-tRNA within the A-site through a catalytical action of the peptidyl-
transferase centre within the 39S LSU leading to peptide bond formation.      
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Figure 1.7: Human mitochondrial translation. (See figure legend on following page)  
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Legend for figure 1.7: Human mitochondrial translation. (1) Initiation: mtIF3 (orange) 
provides a pool of free 28S SSU (yellow). The mt-mRNA binds to the 28S SSU, where a start 
codon within the P-site is recognised by the cognate tRNAMet, which carries formyl-methionine 
(M). For the delivery of the fmet-tRNAMet another initiation factor is required: mtIF2-GTP. After 
GTP hydrolysis the initiation factors leave the 28S SSU and the 39S LSU can associate with the 
28S SSU, forming the 55S monosome. (2) Elongation: mtEFTu-GTP delivers the aa-tRNA to the 
A-site and leaves the ribosome upon GTP hydrolysis. The exchange of GDP to GTP needs the 
interaction with another elongation factor, mtEFTs. Then mtEFTu-GTP can interact with the next 
aa-tRNA and is ready for the next elongation round. The fmet of the P-site tRNA is transferred 
to the aa-tRNA in the A-site and after peptide bound formation mtEFG1-GTP interacts with the 
ribosome and causes the translocation of the peptidyl-tRNA from the A- to the P-site. The de-
aminoacylated tRNA from the P-site leaves probably the ribosome immediately since the 
mammalian ribosome probably lacks the E-site. Then the next aa-tRNA can be delivered to the 
A-site and elongation carries on until a stop codon reaches the A-site. (3) Termination: a stop 
codon in the ribosomal A-site will be sequence specific recognised by mtRF1a (green), which 
will facilitate the catalysis of the hydrolysis of the ester bond between the peptide chain and P-
site tRNA, leaving the post-termination complex. (4) Ribosome Recycling: mtRRF (red) and 
EFG2-GTP causing the release of the tRNA and the mRNA from the ribosome, exposing the 
binding site of mtIF3, which is required for complete dissociation of the 55S monosome into its 
subunits. GTP hydrolysis is required to release mtEFG2 and mtRRF from the 39S LSU.  
 
The translocation of the peptidyl-tRNA from the A-site to the P-site is catalysed by 
mtEFG1-GTP. The deacylated tRNA in bacterial ribosome is usually first transferred 
into the E-site before it leaves the ribosome, however, since an E-site is very weak or 
absent in the mammalian mitochondrial ribosome [Sharma et al., 2003] it is tempting to 
speculate whether the uncharged tRNA is released from the ribosome immediately 
upon translocation of the peptidyl-tRNA into the P-site. The ribosome moves then 3 nt 
further to expose the next codon in the A-site, which will be have delivered an aa-
tRNA-mtEFTu-GTP complex. The cycle will be repeated until a stop codon reaches the 
A-site.  
 
1.7.4 Translation termination in human mitochondria 
In 1998 mtRF1 was suggested to be the single omnipotent class I release factor (RF) in 
human mitochondria [Zhang and Spremulli, 1998], however, this factor failed to show 
any release activity in vitro [Soleimanpour-Lichaei et al., 2007]. In 2007 a second RF 
was identified, mtRF1a, which was shown to be able to recognise the stop codons UAA 
and UAG within the ribosomal A-site in a sequence-dependent manner in vitro 
[Soleimanpour-Lichaei et al., 2007]. This release factor catalyses the hydrolysis of the 
peptide chain from the peptidyl-tRNA within the P-site through its highly conserved 
GGQ domain, which is localised into the peptidyl-transferase centre (Figure 1.7 (3)). 
The function of a class I release factor within the ribosome will be described in more 
detail later (see 1.8). Since the sequence of the human mitochondrial genome was 
known [Anderson et al., 1981], it was for a long time suggested that there are four stop 
codons: UAA, UAG, AGA and AGG. Interestingly AGA and AGG would represent the 
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stop codons of only two mitochondrial transcripts, namely MT-CO1 and MT-ND6. 
However, there were no reports that had identified the protein factor that could 
recognise these triplets as stop codons. Further studies within this laboratory have 
shown that AGA and AGG represent “hungry codons”, causing a pause of the 
mitochondrial ribosome with an empty A-site. Additionally a stable secondary structure 
in the 3’-UTR (in case of MT-CO1 this is the antisense of tRNASer(UCN) and for MT-ND6 
this was a stem loop structure antisense of MT-ND5) downstream of both open reading 
frames are specific features that are crucial for a ribosome to perform frameshifting. 
Indeed by generating and expressing a mitochondrially targeted bacterial 
endonuclease, RelE, which cleaves specifically between nucleotides 2 and 3 of stop 
codons in the ribosomal A-site, it was proved that the human mitochondrial ribosome is 
able to perform a -1 frameshifting leading to an UAG stop codon of MT-CO1 and MT-
ND6 transcripts, which can be then again recognised by mtRF1a [Temperley et al., 
2010a]. Thus mtRF1a is able to terminate all 13 open reading frames within human 
mitochondria.   
In bacteria, a class II release factor (RF3) with GTPase activity is inducing a change in 
ribosomal conformation responsible for the dissociation of the class I RF from the 
ribosomal A-site after peptide release was performed [Gao et al., 2007]. To date no 
class II RFs have been identified in human mitochondria that are able to do this job. 
However, a similar mechanism probably exists so that the ribosomes can be further 
recycled.  
 
1.7.5 Mitochondrial Ribosome recycling 
In bacteria three translation factors are required for the recycling of the ribosome: RRF, 
EFG and IF3 [Hirokawa et al., 2006]. In 1998 the human mitochondrial ribosome 
recycling factor was bioinformatically identified [Zhang and Spremulli, 1998], however, 
its characterisation and importance for cell viability was described for the first time ten 
years later [Rorbach et al., 2008]. It has been shown that in the absence of mtRRF 
mitochondrial ribosomes accumulate probably as aggregates in the densest fractions of 
isokinetic sucrose gradients, leading to reduced level of free individual subunits. 
Furthermore it has been demonstrated that mtRRF is able to co-immunoprecipitate 
mitochondrial ribosomal proteins and additional translation factors. Interestingly one of 
those associated proteins turned out to be another member of the mitochondrial 
release factor family, ICT1, however neither mtRF1 nor mtRF1a was found in this 
immunoprecipitation. The fact that ICT1 was found in this IP together with other 
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proteins involved in mitochondrial protein synthesis made it an interesting candidate to 
study and will be discussed in more detail below.  
For the recycling of the ribosome an EFG is required. Most bacteria contain only one 
EFG, involved in both processes translation elongation and ribosome recycling. In 
human mitochondria two homologues of EFG were identified: mtEFG1 and mtEFG2 
[Hammarsund et al., 2001], which show sequence identities of approximately one third 
to each other [Spremulli et al., 2004]. Tsuboi et al. (2009) demonstrated that mtEFG1 is 
not able to recycle the ribosome together with mtRRF, however, mtEFG2, which shows 
no translocation activity in the other site, was able to split the ribosome when in 
conjunction with mtRRF. The same authors demonstrated the importance of GTP, 
which is required for the action of mtEFG2 in mitochondria. The GTP hydrolysis was 
suggested to be crucial for the release of mtEFG2 together with mtRRF from the 39S 
LSU after the recycling step since mtEFG2 and mtRRF stayed on the LSU in the 
presence of non-hydrolysable GTP analogue, but were able to split the ribosome in its 
subunits. Most of this work was done in vitro and therefore it is still unclear whether 
mtEFG2 is an essential protein in mammals as mtEFG1 is. Mutations within mtEFG1 
gene cause defects in mitochondrial translation, which leads to lethal mitochondrial 
disorders shortly after birth [Coenen et al., 2004]. However, no defect in mtEFG2 has 
been reported so far. Furthermore mutations in yeast mtEFG2 (MEF2) did not show 
any clear phenotype, whereas mutations of mtEFG1 (MEF1) caused defects in 
mitochondrial protein synthesis in vivo [Winzeler et al., 1999].  
The third factor, essential for complete dissociation of the mitochondrial ribosome, is as 
already described, mtIF3. In the absence of mtIF3 the 28S SSU and 39S LSU re-
associate to the 55S monosome after the release of mRNA and tRNA mediated by 
mtRRF and mtEFG2 [Tsuboi et al., 2009]. Experiments within this laboratory showed 
that the addition of mtIF3 alone to mitochondrial ribosomes immunoprecipitated by 
mtRRF could lead to the dissociation of the ribosomal subunits [unpublished data by 
Dr. J. Rorbach], which supports the hypothesis of an active role of mtIF3 in the 
recycling event, suggested by Christian and Spremulli (2009).  
 
1.8 
 
Translation release factors 
1.8.1 Bacterial Release Factors 
Bacteria contain two classes of release factors: class I release factors (RF1 and RF2) 
facilitate the hydrolysis of the peptide chain from the peptidyl-tRNA in a sequence-
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dependent manner [reviewed in Youngman et al., 2008], and class II RF (RF3) 
harbours GTPase activity and stimulates the release of the class I release factor by 
inducing a conformational change in the ribosome [Gao et al., 2007]. In contrast in the 
eukaryotic cytosol there is only one class I RF (eRF1), whose release activity is 
stimulated by the interaction with the class II RF (eRF3) [Petry et al., 2008, Cheng et 
al., 2009]. Bacteria utilise three stop codons: UAA is recognised by both RFs RF1 and 
RF2, whereas RF1 also interacts specifically with UAG and RF2 with UGA. There are 2 
peptide motifs that are crucial for distinguishing the stop codons. These are tri-peptide 
motifs: PXT in RF1- and SPF in RF2-types [Ito et al., 2000], and the tip of the α5-helix 
of RF that is localised in the decoding centre within the ribosome and therefore was 
proposed to be also essential for the codon recognition (Figure 1.8 D) [Petry et al., 
2005, Laurberg et al., 2008]. The ribosome itself with its 16S rRNA within the decoding 
site was also suggested to be involved in the discrimination of the stop codon 
[Laurberg et al., 2008]. For catalysing the hydrolysis of the peptide chain from the tRNA 
in the P-site the GGQ motif, which is conserved in all class I RFs, needs to be localised 
into the peptidyl-transferase centre in the ribosomal large subunit (Figure 1.8 D). 
Solutions structures of RFs are different from those bound to the ribosome (Figure 1.8 
A/B), which shows the conformational change of domain 3 induced by the rearranged 
elements of the rRNA within the ribosome, where an extension of α7 will flip the domain 
3 out of the core so that the GGQ motif can reach the PTC (Figure 1.8 B/D) [Petry et 
al., 2005, Laurberg et al., 2008]. It has been shown by several groups that mutations 
within this GGQ motif leads to dramatic loss of release activity [Frolova et al., 1999, 
Mora et al., 2003, Shaw and Green, 2007], where the two glycines seem to be the most 
critical residues for catalysing hydrolysis. The glutamine with less dramatic 
consequences for the hydrolysis activity was suggested to be crucial for the preferential 
selection of water for nucleophilic attack [Shaw and Green, 2007].  
The overall shape of a RF within the ribosome is reminiscent to that of a tRNA within 
the A-site (Figure 1.8 C). The CCA extension at the 3’-end of a tRNA, localised within 
the PTC, causes changes of the 23S rRNA, allowing the hydrolysis of the ester bond 
between the peptide chain and the P-site tRNA by a nucleophilic attack through the 
primary amine of the incoming aa-tRNA [Schmeing et al., 2005]. The GGQ motif of the 
RF, which is believed to mimic the CCA of the aa-tRNA in the A-site, allows similar 
conformational changes of the rRNA and the nucleophilic attack by water and thus the 
hydrolysis of the ester bond joining the peptide and the tRNA. Therefore it is a 
coordinated interplay between the class I RF and the ribosome that induces the 
peptidyl-tRNA hydrolysis and therefore a RF without the ribosome is not able to carry 
out its function. 
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Figure 1.8: Crystal structures of bacterial RF1. A) Crystal structure of isolated RF1 from T. 
maritima B) Structure of ribosome bound RF1 from T. thermophilus. Domain 3 with α7-helix 
(labelled in red) flipped out of the core (indicated by an arrow) to localise the GGQ domain 
within the PTC in the 50S LSU. C) Superimposition of RF1 (grey) and an A-site bound tRNA 
(dark red) shows the mimic of tRNA anticodon loop (green) and the CCA triplet (yellow) at the 
3’-end with the PXT tri-peptide motif and the GGQ motif of the RF, respectively. D) Bacterial 
70S ribosome with 30S SSU and 50S LSU shows tRNAs bound to the P- (purple) and E-site 
(pink) and RF1 within the A-site. The right panels demonstrate the localisation of the GGQ motif 
(purple) within the PTC, and of the PXT tri-peptide motif (blue) and the tip of the α5-helix 
(brown) within the decoding centre of the 30S SSU. (Images were adapted from Petry et al., 
2005)  
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1.8.2 The human mitochondrial release factor family 
As described above mtRF1a, recognising sequence specific UAA and UAG, is able to 
terminate all 13 open reading frames in human mitochondria [Soleimanpour-Lichaei et 
al., 2007, Temperley et al., 2010a]. This class I release factor is very similar to the 
bacterial RF1 with ~40% sequence identity and contains the conserved tri-peptide motif 
PXT. There are three further members of this family: mtRF1, ICT1 and C12orf65. 
Zhang and Spremulli (1998) identified mtRF1 as a mitochondrial release factor, which 
instead of PXT tri-peptide motif has the sequence PEVGLS and further some inserted 
nucleotides in the α5-helix domain. This RF completely failed to show any release 
activity in vitro [Soleimanpour-Lichaei et al., 2007]. However, the conserved GGQ motif 
and further sequence similarity between mtRF1 and mtRF1a leads to the speculation 
whether this RF has adapted those changes to work as an RF under different 
circumstances and not in a conventional termination process. ICT1 and C12orf65 are 
relatively small proteins in comparison to mtRF1a and mtRF1. Both harbour the GGQ 
motif, but do not show any similarity over the tri-peptide motif or the α5-helix domain 
(Figure 1.9), indeed those regions seem to be completely absent in ICT1 and 
C12orf65.  
Recently, mutations within the C12orf65 gene in patients with mitochondrial disorders 
have been reported by Antonicka et al. (2010). Those patients showed severe 
reduction in mitochondrial protein synthesis, leading to reduced level of OXPHOS 
complexes visualised by Blue Native PAGE and therefore to OXPHOS deficiency. 
However, the mt-RNA levels were relatively normal or even increased in comparison to 
the control. Those results strongly suggest that C12orf65 is in some way involved in 
mitochondrial protein synthesis, but this protein failed also to show any release activity 
in vitro using 70S E. coli ribosomes [Antonicka et al., 2010]. Since there are significant 
differences between the mitochondrial ribosome and the bacterial one (see 1.7.1), it 
can not be excluded that C12orf65, or mtRF1, can facilitate peptidyl-tRNA hydrolysis. 
The fourth member, ICT1 has been identified in association with mitochondrial 
ribosome immunoprecipitated by mtRRF [Rorbach et al., 2008]. This is very unusual for 
a class I RF, since in bacteria RRF and RF occupy the same site (A-site) within the 
ribosome, which also explains the absence of mtRF1a (or mtRF1 and C12orf65) in this 
IP. Alignment of all four mitochondrial RFs show some additional differences of ICT1 in 
comparison to the other three members (Figure 1.9), which could be due to a different 
function and might be in association with the fact that it was found in mtRRF-IP.   
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Since mtRF1a is able to recognise all 13 open reading frames in human mitochondria, 
why do they contain three further class I release factors? The facts that mutations in 
C12orf65 are causing decreased de novo synthesis and that ICT1 was found in 
association with the mitochondrial ribosome (and other translation factors, respectively) 
suggest that both proteins are at least involved in the mitochondrial protein synthesis. 
These functions remain to be investigated. 
mtRF1a  ------------------------------------MRSRVLWG-------AARWLWPRR 17 
mtRF1  MNRHLCVWLFRHPSLNGYLQCHIQLHSHQFRQIHLDTRLQVFRQNRNCILHLLSKNWSRR 60 
C12orf65 ------------------------------------------------------------ 
ICT1  ------------------------------------------------------------  
   
                                                                                  
mtRF1a  AVGPARRPLSSGSPP---LEELFTRGGPLRTFLERQAGSEAH---LKVRRPE---LLAVI 68 
mtRF1  YCHQDTKMLWKHKALQKYMENLSKEYQTLEQCLQHIPVNEENRRSLNRRHAELAPLAAIY 120 
C12orf65 ------------------------------------------------------------ 
ICT1  ------------------------------------------------------------  
 
                                                                                    
mtRF1a  KLLNEKERELRETEHLLHDENED----LRKLAENEITLCQKEITQLKHQIILLLVPSEET 124 
mtRF1  QEIQETEQAIEELESMCKSLNKQDEKQLQELALEERQTIDQKINMLYNELFQSLVPKEKY 180 
C12orf65 ------------------------------------------------------------ 
ICT1  -------------------------------------------------MAATRCLRWGL 11   
                                                                      
              
 
mtRF1a  DENDLILEVTAG--VGGQEAMLFTSEIFDMYQQYAAFKRWHFETLEYFPSELGGLRHASA 182 
mtRF1  DKNDVILEVTAGRTTGGDICQQFTREIFDMYQNYSCYKHWQFELLNYTPADYGGLHHAAA 240 
C12orf65 -------MSTVG---------LFH---FPTPLTRICPAPWGLRLWEKLTLLSPGIAVTPV 41 
ICT1  SRAGVWLLPPPAR-----------CPRRALHKQKDGTEFKSIYSLDKLYPESQGSDTAWR 60 
                      . .                             :   :       *   :   
                        
mtRF1a  SIGGSEAYRHMKFEGGVHRVQRVPKT---EKQGRVHTSTMTVAILPQPTEINLVINPKDL 239 
mtRF1  RISGDGVYKHLKYEGGIHRVQRIPEVGLSSRMQRIHTGTMSVIVLPQPDEVDVKLDPKDL 300 
C12orf65 QMAGKKDYPAL-----------------------------------------LSLDENEL 60 
ICT1  VPNGAKQADSD-------------------------------------------IPLDRL 77 
                *                                                  :  . * 
 
 
mtRF1a  RIDTKRASGAGGQHVNTTDS--AVRIVHLPTGVVSECQQERSQLKNK----ELAMTKLRA 293 
mtRF1  RIDTFRAKGAGGQHVNKTDS--AVRLVHIPTGLVVECQQERSQIKNK----EIAFRVLRA 354 
C12orf65 EEQFVKGHGPGGQATNKTSN--CVVLKHIPSGIVVKCHQTRSVDQNR----KLARKILQE 114 
ICT1  TISYCRSSGPGGQNVNKVNSKAEVRFHLATAEWIAEPVRQKIAITHKNKINRLGE
               .  :. *.*** .*....   * :   .:  : :  : :    ::    .:.   *   
LILTS 137 
 
 
mtRF1a  KLYSMHLEEEINKRQNARKIQIGSKGRSEKIRTYNFPQNRVTDHRINKTLHDLETFMQGD 353 
mtRF1  RLYQQIIEKDKRQQQSARKLQVGTRAQSERIRTYNFTQDRVSDHRIAYEVRDIKEFLCGG 414 
C12orf65 KVDVFYNGENSPVHKEKREAAKKKQERKKRAKET----------------------LEKK 152 
ICT1  ESSRYQFRNLADCLQKIRDMITEASQTPKEPTKEDVKLHRIRIEN-----------MNRE 186 
             .       :     :. *.         :.                          :    
 
 
mtRF1a  YLLDELVQSLKEYADYESLVEIISQKV---- 380 
mtRF1  KGLDQLIQRLLQSADEEAIAELLDEHLKSAK 445 
C12orf65 KLLKELWESSKKVH----------------- 166 
ICT1  RLRQKRIHSAVKTSRRVDMD----------- 206 
                .:  .   :  
 
Figure 1.9: Sequence Alignment (CLUSTALW) of human mtRF1a, mtRF1, C12orf65 and 
ICT1. Identities are indicated by a star (*), high levels of similarity by a colon (:) and lower 
levels by a full stop (.). The GGQ domain is indicated in red, the PXT-motif in blue and the tip 
of the α5-helix in brown. Predicted mitochondrial targeting peptides are indicated italics. 
Residues forming an additional helix in ICT1, absent in conventional class I release factors 
(see chapter 6, figure 6.1) and the other members of the mitochondrial release factor family 
are indicated italics, underlined, bold.  
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1.9 
 
Aims of this study 
This PhD project contains two main parts: 
Part I is focused on the characterisation of ICT1, and represents the major project of 
my PhD work. The following questions needed to be answered to investigate the 
function of ICT1 in human mitochondria:  
 i)  Is ICT1 a mitochondrial protein? 
 ii)  Is this protein essential for life? 
 iii)  Does the loss of ICT1 in human cell culture have any effect on   
  mitochondrial protein synthesis or steady state level of mitochondrial  
  proteins? 
 iv)  Does ICT1 interact with the mitochondrial ribosome and is it important  
  for mitochondrial ribosome biogenesis? 
 v)  Is the retained GGQ motif functional, meaning does ICT1 have release  
  activity? 
 vi)  Does ICT1 have another function in the mitochondrial translation   
  machinery, different from a conventional class I release factor? 
 
The characterisation of ICT1 will be represented in three result-chapters. Additionally 
one chapter will contribute to an initial characterisation of possible orthologues of ICT1 
in other organism.  
 
Part II, a project initiated by Dr. J. Rorbach, is an initial investigation of a possible 
mitochondrial ribosome assembly factor, called mtRbfA. The assembly of the 
mammalian mitochondrial ribosome has not been characterised. Since the bacterial 
ribosome can be assembled in vitro [reviewed in Nierhaus, 1991], it has been 
suggested that there are not so many factors involved in the ribosome assembly 
pathway in bacteria. However, those non-physiological conditions such as high 
temperatures and high salt concentration, used in those experiments, and further slow 
kinetics indicate that additional protein factors are probably required for the assembly 
pathway in vivo. There have been some proteins identified crucial for the assembly of 
either the 30S SSU or the 50S LSU in bacteria [reviewed in Culver, 2003, and Britton, 
2009]. However, in human mitochondria this field is still elusive and needs some more 
attention. So far, only ERAL1 and TFB1M have been characterised and described to 
be essential for the stability and maturation, respectively, of the 12S rRNA of the 28S 
SSU and therefore are critical for the assembly of the mitochondrial SSU [Dennerlein et 
al., 2010, Metodiev et al., 2009]. The m-AAA protease is required for the processing of 
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MRPL32 and it has been therefore proposed to be essential for the complete assembly 
of the mitochondrial ribosome [Nolden et al., 2005]. Just recently NOA1, a 
mitochondrial GTPase has been suggested to be important for 39S LSU assembly in 
mammals since a knockout of murine Noa1 led to decreased density of the 39S LSU 
revealed by isokinetic sucrose gradient and consequently to impaired mitochondrial 
protein synthesis [Kolanczyk et al., 2011]. Surprisingly its bacterial orthologue has been 
suggested to be involved in the assembly of the 30S SSU [Britton, 2009]. Thus NOA1 
seems to have adopted a function in mammalian mitochondria different from its 
bacterial counterpart.  
The bacterial RbfA is essential at low temperatures and has been extensively studied, 
which will be introduced at a later point in more detail. It was suggested to be involved 
in the maturation of the 16S rRNA of the 30S SSU and further in the later assembly 
process of the SSU in bacteria [Xia et al., 2003]. Since the ribosomal RNA and the 
ribosome itself differs remarkably between bacteria and mammalian mitochondria it will 
be interesting whether mtRbfA has maintained its function or whether it has adapted a 
different task in human mitochondria. Thus with the investigation of the following 
questions it will be perhaps possible to clarify the function of mtRbfA in humans: 
 i)  Is mtRbfA localised within human mitochondria? 
 ii)  Does this protein interact with the mitochondrial ribosome or ribosomal  
  subunits, respectively?  
 iii)  Does the depletion of mtRbfA from human cells show any effect on cell  
  growth, mitochondrial translation, assembly of the mitochondrial   
  ribosome or stability of mt-rRNA?   
 
The results of the investigations on the possible function of mtRbfA will be described 
and discussed in one chapter.  
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2 Chapter 2: Materials 
 
2.1 
 
Chemicals and Reagents 
For this research project all chemicals and reagents were used from Sigma-Aldrich 
Company unless otherwise stated. 
 
2.2 
 
Human Cell lines 
HeLa 
Human cervical cancer carcinoma cells from Henrietta La
 
cks. 
HEK293-Flp-InTMT-RExTM (Invitrogen) 
Human Embryonic Kidney cells. This cell line contains a Tet-repressor and an 
integrated Flp-recombination-target (FRT) site for generating a stable cell line with 
Tetracycline inducible expression of the gene of interest.  
 
143B 
Human osteosarcoma cells. 
 
143B-ρ0 (kind gift from Prof. R. Wiesner, Cologne) 
Those human osteosarcoma cells manipulated to lack mitochondrial DNA. 
 
2.3 
 
Bacteria strains 
 
Strain 
 
Genotype 
 
Use 
 
Company 
α-select 
chemically 
competent cells 
F- deoR endA1 relA1 gyrA96 hsdR17 
(rk
-mk
-) phoA supE44 thi-1 ∆(lacZYA-
argF)U169 Φ80δlacZ∆M15  
general cloning Bioline 
RosettaTM(DE3) 
competent cells 
F- ompT hsdSB (rB
-mB
-) gal dcm 
(DE3) pRARE (argU, argW, ileX, 
glyT, leuW, proL) 
for inducible 
overexpression of 
recombinant GST-
fusion protein 
Novagen 
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XL1-Blue 
supercompetent 
cells  
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 RelA1 lac [F’ proAB 
laclqZ∆M15 Tn10 (Tetr)] 
for transformation of 
QickChange 
Mutagenisis reaction  
Stratagene 
TOPO F- mcrA ∆(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 ∆lacX74 recA1 
araD139 ∆(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG 
for sequencing 
cloning for CLIP 
assay 
Invitrogen 
 
2.4 
 
Plasmids 
 
Plasmid 
 
Use 
 
Company/ source 
pcDNA5/FRT/TO Tetracycline inducible expression vector used for 
HEK293- Flp-InTM system.  
Hygromycin and ampicillin resistance. 
Invitrogen 
pOG44 For Co-transfection with pcDNA5/FRT/TO. 
Expresses the Flp- recombinase. 
Amicillin resistance. 
Invitrogen 
pGex-6P-1 IPTG inducible expression vector used for N-
terminus fusion of protein of interest with GST. 
Ampicillin resistance. 
Amersham Bioscience 
pTRC99A  
(-his-yaeJ) 
IPTG inducible expression vector used for 
complementation assays in E.coli by the 
laboratory of Prof. Varshney (Bangalore, India).  
pTRC99A-his-yaeJ was used as a template for 
YaeJ amplification. 
Ampicillin resistance. 
Kind gift from Prof. U. 
Varshney (Bangalore, 
India) 
pFL61 S. cerevisiae/ E. coli shuttle vector. Contains the 
URA3 gene as selection marker.  
Ampicillin resistance.  
Kind gift from Dr. N. 
Bonnefoy, CNRS Paris 
pTG1754 S. pombe/ E. coli shuttle vector. Contains the 
URA3 gene as selection marker.  
Ampicillin resistance. 
Kind gift from Dr. N. 
Bonnefoy, CNRS Paris 
pCR4-TOPO Sequencing vector for CLIP assay.  
Kanamycin and ampicillin resistance. 
Invitrogen 
pCMV-SPORT6-
ICT1 
Used as a template for ICT1-cDNA amplification. 
Ampicillin resistance.  
Geneservice  
(I.M.A.G.E. ID 
4418983) 
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3 Chapter 3: Methods 
 
3.1 
 
Cell culture 
All cell culture methods were carried out in a class II cabinet. The inverted microscope 
Axiovert25 (Zeiss) was used to monitor the cells daily. For any documentation the 
Axiovert200M (Zeiss) with camera was used.   
 
3.1.1 Cell culture maintenance  
HeLa, 143B/ 143B-ρ0 and HEK293-Flp-InTMT-RExTM cells were grown as monolayer in 
tissue culture flasks. HeLa cells were cultured in Earle’s Minimal Essential Medium 
(EMEM) containing 4500 mg/l glucose, 1 mM pyruvate, non-essential amino acids and 
L-glutamine (Sigma, product M0643), to which 2.2 g/l sodium bicarbonate and 10 % 
(v/v) foetal bovine serum (FBS) were added. 143B/ 143B-ρ0 and Hek293-Flp-In™ were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) with pyruvate and L-glutamine 
(Sigma, product D6429), supplemented with 1 x non-essential amino acids, 50 µg/ml 
uridine and 10 % (v/v) FBS. Untransfected HEK293-Flp-InTMT-RExTM cells were 
routinely cultured with 10 µg/ml blasticidin and 100 µg/ml zeocin. 
Usually all cells were seeded in 75 cm2 flasks and cultured at 37°C in 5 % CO2 
humidified atmosphere. The media was changed at least every 3rd day. If a confluence 
of approximately 80 % was reached the cells were harvested in 1 mM EDTA/PBS. After 
centrifugation at 230 xg for 4 minutes the cell pellet was resuspended in fresh medium 
and cells were seeded into new flask(s). The size of the flask was dependent on the 
planned experiment. 
To force cells to use oxidative phosphorylation they were cultured in glucose free 
media (Gibco, product 11966), containing 0.9 mg/ ml galactose, 1 mM pyruvate, 1 x 
non-essential amino acids, 50 µg/ml uridine and 10 % (v/v) FBS. 
 
3.1.2 Cell storage 
For longer storage, cells were harvested and the cell pellet was resuspended in 0.5 ml 
FBS containing 10 % (v/v) DMSO. For freezing those cells cryostorage vials were 
used. After 24 h storage at -80°C in a ‘temperature controlled’ cryo box the vials were 
transferred to liquid nitrogen.  
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To thaw cells, which should be done as fast as possible, the vial was briefly incubated 
in a 37°C water bath. Then pre-warmed medium was added very gently to the cells to a 
final volume of 5 ml. After centrifugation and resuspension the cells were transferred 
into a flask (same size of flask before freezing cells). 
 
3.1.3 Mycoplasma Detection 
Every 2 month or less, cells were tested for Mycoplasma infection by using MycoAlert® 
Mycoplasma Detection Kit (Lonza) following the manufacturer’s instruction. To 25 µl of 
cell culture supernatant/ media an equal volume of MycoAlert reagent was added and 
incubated for 5 min at room temperature. A first reading in the luminometer was taken 
(Reading A) before adding 25 µl of MycoAlert substrate and further incubation of 10 
min at room temperature. Finally the second reading was taken to calculate then the 
ratio of Reading B / Reading A. A ratio <1 means cells are not infected, ratio >1 should 
be considered as infected. In case of an infection cells were treated with Plasmocin 
(1:1000) for at least 2 weeks and the Mycoplasma test was repeated.  
 
3.1.4 Cell counting 
Cells were harvest as described above. The cell pellet was resuspended in a known 
volume of fresh media and 10 µl was added to a haemocytometer (Neubauer 
improved, with a 0.1 mm clearance). 4 main corner square sectors were counted. The 
average was multiplied by 104 to get the cell number per 1 ml.  
 
3.1.5 Stable Transfection of HEK293-Flp-InTMT-RExTM cells 
To generate a stable cell line with inducible overexpression of the gene of interest, 
HEK293-Flp-InTMT-RExTM were transfected with pcDNA5/FRT/TO (carrying the gene of 
interest, GOI) and pOG44 (Figure 3.1). The pOG44 vector expresses the Flp 
recombinase allowing the homologous recombination at the FRT sites of the 
pcDNA5/FRT/TO vector and the host cell line. This integration at this particular site of 
the genome of the host cell line will result in a zeocin sensitivity, but hygromycin 
resistance. The expression of the gene of interest is controlled by a Tet operator 2 
(TetO2). The Tet repressor (tetR) protein is expressed by the pcDNA6/TR vector 
(Blasticidin resistance) that was already independently integrated into the host cell line 
before. The adding of tetracycline (or doxacycline) to the cell culture media will result in 
the overexpression of the gene of interest by the hygromycin resistant cells. 
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Figure 3.1: Flp-In system. To generate stable inducible expression cell line pcDNA5/FRT/TO 
with the gene of interest (GOI) (left circle) and pOG44 (right circle) were co-transfected into 
HEK293-Flp-InTMT-RExTM cells. Flp recombinase, expressed by pOG44, mediates the homolog 
recombination via the FRT sites of the pcDNA5/FRT/TO-GOI vector and the genome of the host 
cell line. Successful integration (bottom) will result in hygromycin resistance and zeocin 
sensitivity. The expression of the GOI is controlled by CMV promotor with a Tet repressor and 
therefore inducible by tetracycline. 
 
To transfect HEK293-Flp-InTMT-RExTM cells (HEK293T) the protocol of “Stable 
Transfection of Adherent Cells” from QIAGEN was used (Superfect Transfection 
Reagent Handbook 12/2002). 
HEK293T cells were seeded in a 6-well plate the day before transfection was carried 
out. For transfection the confluence was approximately 50 %. For each transfection 
different DNA:Superfect ratios were used: 1:5; 1:7 and 1:10, although generally the 1:7 
was suitable. Tubes were prepared with 100 µl DMEM (no supplements), 2 µg of DNA 
(0.2 µg pcDNA5/FRT/TO-GOI + 1.8 µg pOG44) and the Superfect were added. After 
10 min incubation at room temperature, 600 µl of growth media (DMEM supplemented 
as described in 3.1.1) were added. The media covering the cells in the 6-well plate was 
discarded and the transfection mix was transferred carefully to the wells. After 2.5 h at 
37°C, 5% CO2, the media with the transfection reagent was discarded and after 2 
washing steps with PBS, fresh media was added. After 2 days selection was initiated 
by treatment with hygromycin B. As a control for antibiotic sensitivity, one well of 
untransfected cells was maintained under identical culture and antibiotic conditions. 
After approximately 2 weeks individual hygromycin resistance clones could be 
visualised, separated and propagated as single clonal cultures.  
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3.1.6 Protein-depletion: siRNA transfection of HeLa and HEK293T 
By transfecting cells with synthetic siRNA duplexes it is possible to transiently deplete 
the protein of interest. In nature small interference RNA duplexes are the product of the 
dicer complex in the RNA interference process. Those siRNAs are ~ 19-24 nt long with 
a 2-3 nt 3’-overhang, specific features that are recognised by the RNA-induced 
silencing complex (RISC) within the cell (Figure 3.2). After unwinding the siRNA, 
separating the strands of the duplexes the siRNA/RISC complex with incorporated anti-
sense strand will associate with the complementary target mRNA and finally cleave it. 
Thus no expression of this particular mRNA can occur. 
 
Figure 3.2: siRNA mediated gene silencing. Synthetic siRNA duplexes of 19-24 nt with 2-3 nt 
3’-overhang are recognised and bound by RISC. After unwinding duplexes RISC incorporates 
anti-sense strand. The activated siRNA/RISC complex associates with target mRNA, followed 
by cleavage and degradation of the mRNA. 
 
For growth curve analysis siRNA transfections were carried out in 6-well plates, and in 
25 cm2 or 75 cm2 flasks for protein and / or RNA analysis. Initial analyses were 
performed using the ‘forward’ transfection method and oligofectamine as the reagent, 
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improved efficiency was obtained later using lipofectamine in the ‘reverse’ transfection 
method. The advantage using lipofectamine as transfection reagent is that it is possible 
to use less siRNA (10 nM to 50 nM final concentration), to perform reverse transfection 
and the transfection efficiency in case of HEK293T cells is higher. 
 
3.1.6.1 
HeLa cells were seeded the day before transfection. Method and volumes are given 
here for 6-well plate seeded with 3x 104 cells per well. 
siRNA transfection using oligofectamineTM transfection reagent 
(12252011, Invitrogen) 
For each transfection 2 tubes were prepared; tube A with 125 µl Opti-
MEM®I+Glutatmax™I (Gibco 51985-026) and tube B with 15 µl. These were brought up 
to room temperature. To tube A 200 pmoles siRNA (= 10 µl of 20 µM stock) was added 
and to tube B 4 µl oligofectamine. Everything was gently mixed by pipette and after 10 
min the contents of tube B was transferred to tube A, followed by another incubation 
time of 25 min. During this incubation step the media from the wells were discarded, 
the cells were washed with PBS and 800 µl of complete growth media was added. 
Finally the transfection mix was transferred into the wells, followed by rocking the plate 
carefully. After 3 days the cells were harvested or re-transfected. 
For a 25 cm2 flask all volumes were doubled transfecting ~ 1.5x 105 cells.  
 
3.1.6.2 
For each transfection a tube with 250 µl Opti-MEM®I+Glutatmax™I was pre-warmed to 
room temperature.  siRNA (15 - 75 pmoles dependent on the efficiency of the siRNA) 
and 2 µl lipofectamine were added, followed by an incubation of 10 - 20 min at room 
temperature. The transfection mix was transferred to the well and 3x 104 cells in 1.25 
ml normal growth media were added.  
siRNA transfection using lipofectamineTM RNAiMAX (13778-150 
Invitrogen) 
For 25 cm2 flasks all reagent and media volumes were doubled to transfect 3x 105 
cells.  
For the MTT assay as described below 96-well plates were used to transfect ~ 5,000 
cells per well in a final volume of ~200 µl with appropriate amounts of siRNA and 
lipofectamine. 
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Table 3.1: Sequences of siRNA employed in this doctoral work 
No siRNA sequence 5’ → 3’ 
#1 si-ICT1-ORF A (220) sense CUA GAU CGC UUG ACA AUA U dTdT 
#2 si-ICT1-ORF B (419) sense GCC GCU AUC AGU UCC GGA A dTdT 
#3 si-ICT1-ORF C (179) sense GGG UCC CGA AUG GUG CAA A dTdT 
#4 si-Rbfa-ORF A (481) sense GGA GCU GUA UGA CCU UAA C dTdT 
#5 si-Rbfa-ORF B (691) sense GGG AAA UGC AGC UCU AGC U dTdT 
#6 si-Rbfa-ORF C (262) sense GAA CUG GCU CAA GAA AUU U dTdT 
#7 si-Rbfa-ORF D (862) sense GGC GCU CAA CAA GCA GAU U dTdT 
#8 si-Rbfa-ORF E (668) sense CCG AUA GUG UUU GUU CAA G dTdT 
#9 si-Rbfa-UTR F (1242) sense GGC AGU UGA UGG AGU UAA A dTdT 
#10 si-control  siRNA negative control duplex  OR-0030-NEG05 
siRNAs were stored as 20 µM or 100 µM stocks in RNase free water at -20°C. All 
siRNAs were custom synthesised by Eurogentec.  
 
3.1.7 MTT assay 
The MTT assay as a colorimetric assay can be used to measure relative cell viability in 
96-well plate format. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) is reduced to the purple formazan in living cells and as such can be used as 
an alternative to counting cells. 
This assay was mostly used to determine the relative cell growth after siRNA 
treatment. Cells were cultured under experimental conditions as described in 3.1.6.2 
until assay was performed. The MTT was always prepared fresh in PBS at a 
concentration of 5 mg/ ml and finally diluted to 0.5 mg/ ml in growth media. For the 
assay the growth media was aspirated from the plate and 200 µl of 0.5 mg/ ml MTT 
solution was added to each well. After 3 h incubation at 37°C the MTT solution was 
removed, 200 µl DMSO was added to dissolve the formazan crystals and incubated for 
5 min at 37°C. The absorbance was measured at 550 nm in a microplate-reader (Bio-
Tek). Each experimental sample was prepared a minimum of 4 times.  
 
3.1.8 Flow cytometry analysis 
All flow cytometry measurements were done on BD FACS CANTO II machine in the 
Centre for Life (Newcastle University, Flow Cytometry Core Facility) with kind 
assistance from Mr. Ian Dimmick. 
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3.1.8.1 
To measure changes in mitochondrial mass 10-n-nonyl-acridine orange (NAO, 
Invitrogen A1372) can be used as an indicator, because this fluorescent dye binds 
specifically to negatively charged cardiolipin of the mitochondrial inner membrane.  
Mitochondrial mass - NAO 
NAO was usually prepared in DMSO at a stock concentration of 5 mM that can be 
stored     at -20°C (light protected).  
Cells were cultured as required for the experiment, harvested and resuspended at 
approximately 1x 106 cells in 0.5 ml PBS. Samples were incubated for 10 min at 37°C 
5% CO2 in the presence of 10 µM NAO. Finally the cells were washed in 1 ml PBS and 
resuspended in 0.5 ml PBS and green fluorescence at 530 nm was detected. The 
results were analysed with BD FACSDIVATM software.  
 
3.1.8.2 
MitoSox Red (Molecular Probes, M36008) can be used as a specific indicator for 
mitochondrial ROS production. It can be exclusively oxidised to a fluorescent form by 
the superoxide, which is generated in the mitochondrial matrix.  
ROS species - MitoSox 
MitoSOXTM Red is delivered as 50 µg vial, to that 13 µl DMSO was added to get a 
stock solution of 5 mM. The stock could be stored at -20°C (light protected). 
Cells were harvested and resuspended in PBS. To approximately 1x 106 cells in 0.5 ml 
PBS 5 µM MitoSOX Red was added (0.5 µl of stock reagent), followed by incubation 
for 10 min at 37°C 5% CO2. Next, cells were washed in 1 ml PBS and finally 
resuspended in 0.5 ml PBS. The red fluorescence emission was measured at 585 nm 
and finally analysed using BD FACSDIVATM software.  
 
3.1.8.3 
JC 1 (Molecular Probes M34152) is a cationic dye, which accumulates in the 
mitochondria in a membrane potential dependent manner. This can be measured in a 
fluorescence emission shift from green to red. A loss in the mitochondrial membrane 
potential will result in a decrease of the red/green fluorescence ratio.  
Mitochondrial membrane potential - JC 1 
JC 1 was usually prepared as 2 mM stock in DMSO and stored in small aliquots at -
20°C (light protected). Cells were harvested and resuspended in 0.5 ml PBS. JC 1 was 
added to a final concentration of 2 µM. After 10 min incubation at 37°C 5% CO2 cells 
were washed in 1 ml PBS and finally the fluorescence emission was measured at 530 
nm (green) and 585 nm (red). As a positive control cells were treated with 2 µM to 10 
µM FCCP (mitochondrial uncoupler) for 10 min at 37°C prior to JC 1 staining, which 
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usually results in a substantial decrease of the red/green fluorescence ratio. All the 
measurements were finally analysed with BD FACSDIVATM software. 
  
3.1.8.4 
To measure the level of apoptosis the APO-DIRECTTM kit (556381 from BD 
Biosciences Pharmingen) was used. This method measured the level of DNA 
fragmentation, a later step in apoptosis, by terminal deoxynucleotidyltransferase dUTP 
nick end labelling (TdT or “TUNEL”). TdT add bromolated deoxyuridine triphosphates 
(Br-dUTP) to 3’-OH of ds or ss DNA. Incorporated Br-dUTPs are then recognised by 
FITC-labelled monoclonal anti-BrdU antibodies.    
Apoptosis 
The method was carried out following manufacturer’s instruction. 
 
Fixation 
Cells (25 cm2 flask at ~ 60% confluence) were harvested and the pellet was fixed in 1 
ml 1% (w/v) paraformaldehyde in PBS (pH 7.4) for 15 min on ice. Prior to centrifugation 
for 5 min at 300 xg 5 ml cold PBS was added to the cells. The supernatant was 
discarded and the pellet was washed in 5 ml PBS. The cells were then resuspended in 
0.5 ml 70% (v/v) ethanol and stored at -20°C for at least 30 min or several days.  
Staining 
Approximately 1x 106 fixed cells were centrifuged for 5 min at 300 xg followed by two 
washing steps with the wash buffer (provided from the kit). The pellet was then 
incubated in 50 µl staining solution for 1 h at 37°C. After the staining 1 ml rinse buffer 
was added prior to centrifugation for 5 min at 300 xg. Finally the pellet was 
resuspended in 0.5 ml PI/RNase staining buffer and incubated for 0.5 to 3 h prior to 
analysis by flow cytometry. 
For the measurements two dyes were used: the FITC-dUTP (measured at 530 nm), 
which indicates the apoptotic cells and PI (measured at 585 nm), which stains the total 
DNA. Finally the measurements were analysed using BD FACSDIVATM software. 
 
3.1.8.5 
There are four main states of cell-populations: two gap-phases, G1 (between M- and S-
phase) and G2 (between S-phase and mitosis), the S-phase and the M-phase. Using 
DNA staining methods, cells can be visualise in three categories: Cells with one copy 
of DNA (G1), cells with doubled amount of DNA after completed replication (G2/M), 
which will therefore cause a double of fluorescence intensity and cells in the S-phase, 
synthesising DNA will be in between the two gap phases.  
Cell cycle 
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To analyse the cell cycle status of cell-populations, the DNA of cells was stained with 
DAPI using the CyStain DNA 2 step kit from Partec (05-5005).  
Approximately 5x 105 cells were permeabilised with 200 µl extraction buffer as provided 
in the kit. After 20 min incubation at room temperature 1 ml DAPI solution was added, 
followed by incubation for 20 min at room temperature (light protected). The stained 
cells were then measured at 450 nm flow cytometry. For the analysis of the flow 
cytometry measurements the ModFit LT V3.2 software was used. 
 
3.2 
 
Bacterial Culture 
All bacteria were grown on LB agar plates or LB media in suspension with appropriate 
antibiotics at 37°C, usually overnight. For a longer storage bacteria were frozen in LB 
media containing 15 % (v/v) glycerol at -80°C.  
 
1 % (w/v) Bacto-tryptone 
LB (Luria-Bertani) 
0.5 % (w/v) Yeast extract 
1 % (w/v) NaCl 
(2 % (w/v) Agar for plates)   
pH 7.5 with NaOH 
 
3.2.1 Transformation 
3.2.1.1 
40 µl of α-select™ competent cells were thawed on ice. To those a maximum volume 
of 4 µl DNA were added. After 30 min incubation on ice the cells were placed at 42°C 
for 45 secs followed by 2 min on ice. Then 960 µl pre-warmed SOC medium was 
transferred to the bacteria, which were then incubated at 37°C for 1 h with shaking, 
cells were pelleted and resuspended in  a final volume of 100 µl to 300 µl fresh SOC 
and were plated out on LB agar with appropriate antibiotics. 
Transformation of α-select™ competent cells (Bioline) 
2 % (w/v) Bacto-tryptone      
SOC 
0.5 % (w/v) Yeast extract      
0.05 %  (w/v) NaCl 
2.5 mM  KCl       
10 mM   MgCl2 
20 mM   Glc 
 
Bacto-tryptone, yeast extract, NaCl and KCl were mixed in a final volume of 195 ml and 
the pH was set to 7.0 prior to autoclaving. Next, 1 ml of sterile 2M MgCl2 and 4 ml of 
1M Glc were added. Finally the SOC media was aliquoted à 1 ml and stored at -80°C.  
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3.2.1.2 
20 µl of Rosetta DE3 cells, carefully thawed on ice, were incubated with 100 ng 
plasmid DNA on ice, followed by a heat shock step of 30 secs at 42°C. After 2 min on 
ice 80 µl pre-warmed SOC medium was added to the bacteria, followed by an 
incubation of 1 h at 37°C. The 100 µl bacteria suspension was then plated out on LB 
agar containing appropriate antibiotics. 
Transformation of Rosetta DE3 (Novagen) 
 
3.2.2 Colony screening 
A swab of bacterial colony was transferred to an eppendorf tube and was lysed in 25 µl 
buffer containing 50 mM NaOH, 0.5 % (w/v) SDS, 5 mM EDTA, 10 % (v/v) glycerol and 
0.025 % (w/v) bromocresol green. The lysis mixture was vortexed and heated for 30 
min at 68°C, followed by centrifugation at 13,000 rpm for 8 min. 18 µl of the 
supernatant were loaded on a 0.75 % (w/v) agarose gel (lacking ethidium bromide). 
After electrophoresis of the gel at 65 V for approximately 40 min the gel was stained in 
0.2 µg/ ml ethidium bromide for 15 min and washed twice in water. Finally the gel was 
analysed with the UV transilluminator. 
 
3.2.3 Isolation of plasmid DNA 
A 5 ml small culture of bacteria was grown overnight in LB plus appropriate antibiotics. 
The plasmid DNA was isolated by using the Wizard Plus SV Minipreps kit (Promega 
A1460, centrifugation protocol) or (Fermentas K0503). Finally the DNA was eluted in 
50 µl sterile dH2O.  
 
3.3 
 
DNA manipulation 
3.3.1 Isolation of DNA from human cells 
Cells were harvested as already described. The pellet was resuspended in 200-400 µl 
10 mM Tris/ 1 mM EDTA, lysed with 1% (w/v) SDS and treated with 2 mg/ ml 
proteinase K (Roche) over-night at 37°C at 1,000 rpm (Thermomixer, Eppendorf). Next 
day DNA was isolated by phenol/chloroform extraction followed by ethanol 
precipitation. 
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3.3.2 Phenol chloroform extraction and ethanol precipitation of 
nucleic acids 
An equal volume of buffer saturated phenol (Sigma 108-95-2; pH 7.9 for DNA samples; 
pH 6.7 for RNA samples) was added to each sample, followed by vortexing and 
centrifugation for 2 min at 13,000 rpm. The aqueous phase was transferred to a new 
tube to which an equal volume of both phenol and chloroform:isoamylalcohol (24:1) 
was added and vortexed and centrifuged as before. This aqueous phase was 
transferred to a new tube containing the equal amount of chloroform:isoamylalcohol 
(24:1). To the final aqueous phase were added 1 µl linear acrylamide, 1/10 vol 3 M 
sodium acetate (pH 5.2) and 2.5 vol 100 % ethanol to precipitate the nucleic acids. 
After incubation at - 80°C for at least 1 h, the precipitated DNA/RNA was pelleted at 
20,000 xg for 15 min at 4°C. The DNA/RNA pellet was washed with 75% (v/v) ethanol 
and resuspended in 10 to 20 µl sterile dH2O. 
 
3.3.3 DNA electrophoresis 
For the DNA-gel electrophoresis 0.75 to 1.2 % (w/v) gels were used dependent on the 
size of the molecules to be separated and visualised. The agarose was dissolved in 1 x 
TAE buffer by heating in a microwave. After cooling 0.5 µg/ml ethidium bromide was 
added to the gels and the gel mix poured into the gel tray with comb. The DNA 
samples that were loaded on a gel contained 1 x DNA loading buffer. The 
electrophoresis was carried out in 1 x TAE at 65 to 100 V. The Invitrogen 1 kb ladder 
was used to estimate sizes. DNA was visualised using the UV transilluminator, and the 
result captured and stored with a digital camera and AlphaEasy software (Alpha 
Innotech). 
 
1 x TAE    
40 mM Tris-acetate   0.2 % (w/v) bromophenol blue 
6 x DNA loading buffer 
1 mM EDTA (pH 8.0)    0.1 M  EDTA (pH 8.0) 
     30 % (v/v) glycerol 
 
3.3.4 DNA extraction from agarose gels 
If DNA had to be extracted from agarose gels, low melting agarose was used. The 
DNA of interest was cut from the gel in as small a volume as possible. The gel was 
transferred to a 1.5 ml tube and dH2O was added up to 400 µl final volume. Next, the 
gel was melted for 10 min at 65°C at 1,000 rpm using Thermomixer from Eppendorf, 
followed by one “hot” phenol extraction (phenol pre-heated at 65°C) and one “cold” one 
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(at room temperature) prior to standard phenol/chlorform extraction as described in 
3.3.2. 
3.3.5 Measurement of DNA concentration 
To measure DNA (or RNA) concentration the absorption at 260 nm was taken by using 
the Spectrophotometer ND-1000 (NanoDrop). This generally used ~ 1.5 µl of undiluted 
sample. 
 
3.3.6 Polymerase Chain Reaction (PCR) 
The Polymerase chain reaction is a method for amplification of defined DNA regions. 
The PCR was performed in 0.5 ml thin walled tubes with a final volume of 20 µl or 50 
µl. Each reaction generally contained the following components: 
 
Standard PCR 
 to investigate cloning results  
PCR for cloning a gene of interest 
(Novagen) by using proofreading  
DNA polymerase 
 
1 µM    forward primer 
1 µM   reverse primer 
0.2 mM  dNTPs 
1.5 mM  MgCl2 
1 x   PCR reaction buffer 
20 - 100 ng  DNA template 
1 U   Taq 
 
1 µM   forward primer  
1 µM   reverse primer  
0.08 mM  dNTPs 
1.5 mM  MgSO4 
1 x   PCR reaction buffer 
20 - 100 ng  DNA template 
1 U   KOD HotStart 
 
The PCR was performed under the following conditions: 
denaturation: 94°C  2 min  
denaturation: 95°C  45 sec  
   30 cycles  annealing: xx°C1) 45 sec 
extension: xx°C3) xx sec 2) 
extension: xx°C3) 5 min  
 
1) The Annealing temperature (Ta) is specific for each oligonucleotide. It was calculated with the 
following formula: Ta = 69.5 + 0.41 * GC (%) - 500/ ntc - 5°C 
GC (%):GC content of oligonucleotide as a percentage 
ntc: number of nucleotides which are complement to the template 
2) The extension time is dependent on the length of PCR product, which should be amplified. 
3) 72°C using Taq- and 70°C using KOD DNA polymerase. 
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Table 3.2: Oligonucleotide sequences used in this investigation 
No oligonucleotide sequence (5’ → 3’) use 
#1 ICT1_FLAG 
(forward) 
CTT TCT TAA GCT T cloning ICT1 into pcDNA5/FRT/TO, 
restriction site HindIII (underlined), 
start codon (bold) 
CC 
ACC ATG GCG GCC ACC 
AGG TG 
#2 ICT1_FLAG 
(reverse) 
CTC TCC GAT ATC cloning ICT1 into pcDNA5/FRT/TO, 
restriction site EcoRV (underlined), 
primer contains FLAG sequence 
(italics)  
 CTA 
CTT ATC GTC GTC ATC 
CTT GTA ATC GTC CAT 
GTC GAC CCT C 
#3 ICT1_GST 
(forward) 
CTT TCT TGG ATC C cloning ICT1 into pGex-6P-1, 
restriction site BamHI (underlined), 
start codon (bold) 
AT 
GGC GGC CAC CAG GTG 
#4 ICT1∆29_GST 
(forward) 
CTT TCT TGG ATC C cloning ICT1∆29 (truncation of the 
n-terminus of 29 aa) into pGex-6P-
1, restriction site BamHI 
(underlined) 
CT 
GCA CAA GCA GAA AGA 
CG 
#5 ICT1_GST 
(reverse) 
CTC TCC CTC GAG cloning ICT1/ ICT1∆29 into pGex-
6P-1, restriction site XhoI 
(underlined) 
 TCA 
GTC CAT GTC GAC CCT 
C 
#6 pTRC99A_ICT1
∆29 (forward) 
CAC ACA CCA TGG cloning ICT1∆29 into pTRC99A, 
restriction site NcoI (underlined), E. 
coli ribosome binding site (italics) 
upstream of the TK1 start codon 
(bold) 
 AAG 
GAG GCG TAA TGC ACA 
AGC AGA AAG ACG GCA 
C 
#7 pTRC99A_ICT1
∆29 (reverse) 
CAC ACA GGA TCC cloning ICT1∆29 into pTRC99A, 
restriction site BamHI (underlined) 
 TCA 
GTC CAT GTC GAC CCT 
C 
#8 ICT1_yeast 
(forward) 
CTC TCC GCG GCC GC cloning ICT1 into yeast shuttle 
vector pFL61 or pTG1754, 
restriction site NotI (underlined), 
start codon (bold) 
A 
CGC GTC CGC TGA GCA 
TG 
#9 ICT1_yeast 
(reverse) 
CTC TCC GCG GCC GC cloning ICT1 into yeast shuttle 
vector pFL61 or pTG1754, 
restriction site NotI (underlined) 
G 
GTG TGA AAG TCC TCT 
CAG C 
#10 YaeJ_GST 
(forward) 
CTT TCT TGG ATC C cloning YaeJ into pGex-6P-1, 
restriction site BamHI (underlined), 
start codon (bold) 
AT 
GAT TGT GAT TTC CCG 
ACA TG  
#11 YaeJ_GST 
(reverse) 
ACA ACT CGA G cloning YaeJ into pGex-6P-1, 
restriction site XhoI (underlined) 
TT ATT 
CCC GAC CGC TGC G 
#12 YaeJ_FLAG 
(forward) 
ACA AGC GCG C cloning YaeJ into pcDNA5/FRT/TO 
with Su9 pre-sequence (italics), 
restriction site BssHII (underlined) 
CT ACT 
CTT CCA TTG TGA TTT 
CCC GAC ATG TTG C 
#13 YaeJ_FLAG 
(reverse) 
CTC TCC GGG CCC cloning YaeJ into pcDNA5/FRT/TO, 
restriction site ApaI (underlined), 
primer contains FLAG sequence 
(italics) 
 CTA 
CTT ATC GTC GTC ATC 
CTT GTA ATC TTC CCG 
ACC GCT GCG  
#14 mtRbfa∆30_ 
GST (forward) 
CTT TCT TGG ATC C cloning mtRbfa∆30 (truncation of 
the n-terminus of 30 aa) into pGex-
6P-1, restriction site BamHI 
(underlined) 
GA 
GCG GGG ACT TCA CTG 
CTC TGC TG 
#15 mtRbfa_GST 
(reverse) 
CTT TCT TCT CGA G cloning mtRbfa∆30 into pGex-6P-1, 
restriction site XhoI (underlined) 
GT 
GGG ATG GGC AGA GCC 
TCT CCA T 
#16 pTRC99A 
forward 
CAT CCG GCT CGT ATA 
ATG 
for sequencing of pTRC99A 
#17 pTRC99A 
reverse 
CAA AAC AGC CAA GCT 
TGC 
for sequencing of pTRC99A 
#18 CMV forward CGC AAA TGG GCG GTA 
GGC GTG 
for sequencing of pcDNA5/FRT/TO 
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#19 BGH reverse TAG AAG GCA CAG TCG 
AGG 
for sequencing of pcDNA5/FRT/TO 
#20 pFL61 forward TCG TAG TTT TCA AGT 
TCT TAG ATG C 
for sequencing of pFL61 
#21 pFL61 reverse GCG TAA AGG ATG GGG 
AAA GAG 
for sequencing of pFL61 
#22 pTG1754 
forward 
GAG AAT TCC ATT GTC 
TTG AC 
for sequencing of pTG1754 
#23 pTG1754 
reverse 
TGG CAT TGT TTG CAC 
ATT CC 
for sequencing of pTG1754 
#24 M13 forward GTA AAA CGA CGG CCA 
G 
colony screening in CLIP assay, 
sequencing primer in CLIP assay 
#25 M13 reverse CAG GAA ACA GCT ATG 
AC 
colony screening in CLIP assay, 
All oligonucleotides were custom synthesised by Eurogentec. 
 
3.3.7 PCR product purification 
For further experiments using a PCR product it was first purified using the PCR 
purification kit (QIAGEN 28106, centrifugation protocol). The DNA was eluted in 40 µl 
sterile dH2O. 
 
3.3.8 QuikChange Mutagenisis  
To mutate particular regions of gene of interest the QuikChange® II Site-Directed 
Mutagenesis Kit (Stratagene 200523) was used.  
The reaction was performed in 25 µl volume in 0.5 ml thin walled PCR tubes containing 
the following components: 
2.5 µl   reaction buffer (as provided in the kit) 
2.5 ng/ µl primer forward  
2.5 ng/ µl primer reverse  
0.5 µl   dNTP (as provided in the kit) 
50 ng   DNA template 
1.25 U  PfuUltra 
 
The amplification was performed under the following conditions: 
denaturation: 95°C  2 min  
denaturation: 95°C  1 min  
    20 cycles  annealing: xx°C1) 1 min 
extension: 68°C 8 min 
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After cooling down the reaction on ice, 5U DpnI was added to digest the parental 
methylated and hemi-methylated DNA template. After 90 min at 37°C 4 µl of the 
reaction were added to 40 µl supercompetent cells, followed by a transformation as 
described in 3.2.1. 
Table 3.3: Oligonucleotide sequences used for mutagenesis application  
No oligonucleotide sequence (5’ → 3’) use Ta 1) 
#1 ICT1_AGQ_ 
forward 
gta gtg gtc ctg cgg 
ggc aga atg 
generating mutation in ICT1  
263 G→C,  88 Gly→Ala 
50°C 
#2 ICT1_AGQ_ 
reverse 
cat tct gcc ccg cag 
gac cac tac 
generating mutation in ICT1  
263 G→C,  88 Gly→Ala 
50°C 
#3 ICT1_GSQ_ 
forward 
gtg gtc ctg ggt cgc 
aga atg tga ac 
generating mutation in ICT1  
265-266 GG→TC,  89 Gly→Ser 
50°C 
#4 ICT1_GSQ_ 
reverse 
gtt cac att ctg cga 
ccc agg acc ac 
generating mutation in ICT1  
265-266 GG→TC,  89 Gly→Ser 
50°C 
 
3.3.9 DNA Sequencing 
Most of the sequencing reactions were kindly carried out by Mr Geoff Taylor. 
Briefly 450 ng plasmid DNA were cycle sequenced in a total volume of 20 µl using 
BigDye(R)Terminator v.3.1 from AppliedBiosystems: 
 450 ng  DNA 
1.5 µl   5 x sequencing buffer v1.1, v3.1 
1 µl   primer (3.2 µM) 
3 µl   BigDyes(R)Terminator v.3.1 
 
The reaction was performed under the following conditions:  
denaturation: 95°C  5 min  
denaturation: 95°C  30 sec   
    30 cycles  
 
annealing: 50°C 10 sec 
extension: 60°C 4 min 
 
The samples were then precipitated in a 96-well plate and 10 µl HiDi were added, 
followed by incubation for 2 min at 95°C just prior to running on the sequencer 3130 xl 
Genetic Analyzer (AppliedBiosystems). Sequences were analysed with “Sequencing 
Analysis software - Version 5.1 © 2001-2003” (AppliedBioSystems). 
 
3.3.10 Restriction digest  
All diagnostic restriction enzyme digestions were performed in a volume of 10 µl to 20 
µl with 0.5 µg to 1.0 µg DNA. Preparatory digests were generally of ~ 4 µg plasmid 
DNA. 1 U restriction enzyme was used to digest 1 µg DNA. The enzymes were 
Chapter 3: Methods 
53 
supplied by Roche or New England Biolabs. The conditions chosen for each individual 
digestion were as recommended by the company.  
 
3.3.11 Vector dephosphorylation 
To avoid the re-ligation of a digested vector, samples were 5’ dephosphorylated. 
Therefore digested samples were incubated at 37°C for 1-2h in the presence of 1x 
dephosphorylation buffer and ~1U alkaline phosphatase per 1 µg DNA. 10x buffer and 
enzyme were delivered by Roche (713023). 
 
3.3.12 DNA ligation 
To ligate compatible DNA fragments such as digested plasmid and PCR fragments, the 
two DNA components were incubated together in a volume of 10µl in the presence of 1 
U T4 DNA ligase (Roche) and 1 x ligation buffer at 16°C overnight (supplemented with 
1mM ATP final). Three to six fold molar access of insert to vector were used for most 
ligations, with usually 50 ng vector DNA.  
 
3.4 
 
RNA manipulation 
For all work with RNA, the water used was DEPC pre-treated and autoclaved. 
 
3.4.1 Trizol extraction 
RNA from cells was isolated using Trizol from Invitrogen. Depending on the size of the 
cell pellet 0.5 ml or 1 ml Trizol was used to resuspend the pellet, followed by an 
incubation step for 5 min at room temperature. Then 0.1 ml chloroform (per 0.5 ml 
Trizol) was added to each sample, which was shaken by hand for 15 secs and further 
incubated for 3 min at room temperature. After centrifuging the samples at 12,000 xg 
for 15 min (4°C) the clear supernatant was transferred to a fresh tube and 250 µl 
isopropanol was added, mixed and incubated for 10 min at room temperature and 
finally centrifuged at 12,000 xg for 10 min (4°C). The pellet was washed in 75% (v/v) 
then 100% ethanol and then fully resuspended in 10 - 20 µl DEPC water, containing 1U 
RNAguard per µl. Before using or freezing the RNA, it was necessary to leave the RNA 
for at least 1 h on ice to ensure it had completely dissolved.  
 
Chapter 3: Methods 
54 
3.4.2 Northern Blot 
Samples were prepared in a 20 µl volume containing 1.5 to 3 µg RNA, 1x MOPS,      
5.5 % (v/v) formaldehyde and 35 % (v/v) formamide. These were denatured at 55°C for 
15 min. After cooling down the samples on ice ethidium bromide (0.1 µg/ µl final) and 
RNA loading buffer to a 1x final concentration were added before loading on the gel.  
The samples were separated on a 1.2 % (w/v) denaturing agarose gel (containing 1x 
MOPS and 0.9 % (v/v) formaldehyde) at 50 V for ~ 6 to 7 h. After the run the gel was 
rinsed 4 x in 5 volumes of DEPC water and transferred on a GeneScreen Plus 
membrane over-night in 10x SSPE buffer.  
The next day the membrane was rinsed in 2x SSPE and then the RNA was fixed to the 
membrane through baking at 80°C for 2 h under a vacuum. To avoid unspecific binding 
of the probe the membrane was pre-hybridised in 10 ml of 50 % (v/v) formamide, 5x 
SSPE, 1 % (w/v) SDS and 5x Denhardt’s solution for a minimum of 2 h at 42°C.  
The labelled probe was prepared with 50 to 100 ng DNA fragment that was denatured 
in 9 µl volume at ~ 95°C for 4 min. After cooling down the DNA on ice 3 µl random 
hexamer mix, 5U Klenow DNA polymerase I and 2 µl of 32P dCTP (~ 10-20 µCi; 
PerkinElmer NEG513H) were added, followed by incubation at 37°C for 1 h.  The probe 
was then purified through a Nick column as follows: the volume of the probe was 
increased up to 100 µl and then added to the column and allowed to fully enter the bed 
volume. A 400 µl volume of DEPC water was then added and allowed to enter the 
column. The first flow-through was discarded and a further 400 µl were added. The 
second flow-through was collected in a fresh tube containing the probe. The activity 
was estimated using a Cerenkov counter. Approximately 2x 106 cpm were added per 
10 ml hybridisation buffer incubating the membrane and incubated over-night at 42°C. 
The next day the membrane was washed twice 15 min each with 2x SSPE at room 
temperature, followed by at least one washing step for 15 min with 2x SSPE/ 2% (w/v) 
SDS at 65°C. The membrane was monitored to determine if further washes were 
necessary. Finally the membrane was put into Saran wrap and exposed to a Phosphor-
Imager cassette. Visualization and analysis of radiolabelled RNA species employed 
Phosphor-Imager and Image-Quant software (Molecular Dynamics, GE Healthcare). 
Prior to re-probing, the membrane was stripped by washing the membrane twice with 
boiling 0.1x SSC and once with 0.1x SSC/ 0.1% (w/v) SDS. Then the membrane was 
incubated with pre-hybridisation buffer and probed as described above. 
 
10x MOPS-buffer (pH 7.2)     
0.4 M  Morpholinopropanesulfonic acid (MOPS)  3 M  NaCl 
20x SSPE (pH 7.4) 
0.1 M  NaOAc      0.2 M  NaH2PO4 
10 mM  EDTA      20 mM  EDTA 
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10x RNA loading buffer     
50% (v/v)  glycerol     250 mM Tris/ HCl (pH 7.5) 
5x random hexamer mix 
1 mM   EDTA     50 mM   MgCl2 
0.25% (w/v) bromophenol blue   5 mM   DTT 
0.25% (w/v) xylene cyanol    0.5 mM  dATP 
       0.5 mM  dGTP 
       0.5 mM  dTTP 
 
50x Denhardts      
1% (w/v) Ficoll (Type 400)   3 M   NaCl 
20x SSC 
1% (w/v) polyvinylpyrrolidone   0.3 M   Na-citrate 
1% (w/v) BSA (Fraction V, Sigma) 
 
3.4.3 Reverse transcription 
Various RNA analyses were performed including Real Time PCR for which it was 
necessary to synthesise a cDNA from an RNA template. The reverse transcription was 
performed by using “SuperScript™ First-Strand Synthesis System for RT-PCR” 
(Invitrogen) using the random primer protocol. The first step was to mix RNA of interest 
(max. 0.5 µg) with 50 ng random hexamer, 1 μl 10 μM dNTP (final concentration 0.5 
µM) in a final volume of 10 μl. After an incubation at 65˚C for 5 min the mixture was 
transferred to ice for minimum 1 min to cool. The following components were then 
added: 2 μl 10 x first strand buffer, 4 µl 25 mM MgCl2 (final concentration 5 mM) 2 μl 
0.1 M DTT (final concentration 10 mM) and 1 μl RNaseOUT Recombinant 
Ribonuclease Inhibitor. This was incubated for 2 min at 25˚C before 50 U Superscript 
was applied. Finally the reaction was completed by 10 min at 25˚C (specific step for 
random hexamer primers), 50 min at 42˚C and 15 min at 70˚C.   
 
3.4.4 Real time PCR 
To estimate RNA levels in the starting material, Real Time PCR was performed by 
using “Fast start DNA Master SYBR Green I - kit” (Roche) and the Roche Lightcycler 
(capillary system). All reactions were made up in 20 μl volume with the following 
components in the cold block: 
0.5 μM  forward primer  
0.5 μM  reverse primer 
x mM  MgCl2 (primer dependent) 
1 μl   enzyme/ SYBR green mix (Roche) 
2 μl   template (cDNA or 10 ng/ µl DNA) 
x µl   dH2O 
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Conditions: 
 
 Temperature Hold time 
(secs) 
Slope  
(°C/ sec) 
1) Denaturation: 95°C  600 20 
2) Amplification (40 cycles)    
 Denaturation: 95°C  10 20 
 Annealing: xx°C1) 5 20 
 Extension: 72°C 10 20 
3) Melting curve 95°C 0 20 
  65°C 15 20 
  95°C 0 0.1 
4) Cooling 40°C 30 20 
 
Table 3.4: Oligonucleotides sequences used for Real Time PCR 
No Oligonucleotide Sequence (5’ → 3’) MgCl2 
[mM] 
Ta1)  
#1 12S forward ACA CTA CGA GCC ACA G 3 mM 53°C 
#2 12S reverse ACC TTG ACC TAA CGT C 3 mM 53°C 
#3 16S forward CCA ATT AAG AAA GCG TTC AAG 4 mM 57°C 
#4 16S reverse CAT GCC TGT GTT GGG TTG ACA 4 mM 57°C 
#5 MT-CO1 forward AAC CCA ATA CCA AAC GC 4 mM 52°C 
#6 MT-CO1 reverse CTT CAG GGT GAC CGA AA 4 mM 52°C 
#7 MT-CO2 forward CCT AGA ACC AGG CGA C 4 mM 54°C 
#8 MT-CO2 reverse GTC GTG TAG CGG TGA A 4 mM 54°C 
#9 MT-ND1 forward AAT CGC AAT GGC ATT CC 4 mM 64°C 
#10 MT-ND1 reverse CGA TGG TGA GAG CTA AGG 4 mM 64°C 
#11 β-actin forward TGC GTT ACA CCC TTT CT 5 mM 59°C 
#12 β-actin reverse CAA CCG ACT GCT GTC A 5 mM 59°C 
#13 B2M forward CAC TGA AAA AGA TGA GTA TGC C 5 mM 64°C 
#14 B2M reverse AAC ATT CCC TGA CAA TCC C 5 mM 64°C 
All the oligonucleotides for Real Time PCR were synthesised by Eurogentec or TAGN 
Ltd. 
 
3.5 
 
Protein manipulation 
3.5.1 Measurement of protein concentration - Bradford Assay 
The Bradford assay was performed to estimate the protein concentration. Samples 
were added to a final volume of 800 µl dH2O. 200 µl Bradford (BioRad) was added. 
After vortexing and 5 min incubation at room temperature 200 µl were transferred in 
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duplicate to a flat bottomed 96-well plate. Dilutions of bovine serum albumin (BSA) 
were used to generate a standard curve from which to finally calculate the protein 
concentration of the samples. The absorbance of all samples and BSA were read at 
595 nm in a microplate reader (ELx800, BioTek) and the standard curve was used to 
determine the concentration of samples. 
 
3.5.2 Preparation of cell lysate 
Cells were harvested as described in 3.1.1 and washed once with PBS. The volume of 
lysis buffer was dependent on the size of the cell pellet. Generally ~ 50 µl cold lysis 
buffer was added per 10 mg wet cell pellet, pipetted gently and the samples were 
incubated at 4°C on rotating wheel for 30 min prior to centrifugation for 10 min at 
12,000 xg at 4°C. The supernatant was transferred to a pre-chilled tube. Samples were 
either immediately used or frozen with liquid nitrogen and stored at -20°C (for few 
weeks) or -80°C (for longer storage).  
 
50 mM    Tris-HCl (pH 7.4) 
Lysis buffer (same as for IP and isokinetic sucrose gradient experiments) 
150 mM  NaCl 
1 mM  EDTA 
10 mM   MgCl2 
1 % (v/v) Triton X-100 
1x   PI-Mix 
1 mM   PMSF (added just before use) 
 
Lysis buffer excluding MgCl2 and PMSF was usually stored as 1 ml aliquots at -20°C.  
 
3.5.3 SDS-PAGE 
The SDS-PAGE is a method to separate denatured proteins on the basis of their size. 
The casting and running systems were used from Hoefer/Amersham. Depending on 
the size of the protein(s) of interest the resolving gels were prepared with 12 % to 15 % 
acrylamide. The resolving gel was poured first, followed by adding dH2O on the top to 
prevent inhibition of polymerization by air and to generate a clear straight interface. 
After the resolving gel was polymerised the stacking gel was poured on top. 
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Table 3.5: Components of a SDS-polyacrylamide gel  
 
12 %  
resolving gel 
15 %  
resolving gel 
3.75 %  
stacking gel 
29:1 30 % (w/v) acryl/ bis-
acrylamide 
2 ml 2.5 ml 0.625 ml 
3.75 M Tris/ HCl pH 8.5 0.5 ml 0.5 ml -- 
0.5 M Tris/HCl pH 6.8 -- -- 1.25 ml 
dH2O 2.395 ml 1.895 ml 3.02 ml 
10 % (w/v) SDS 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 
10 % (w/v) APS 50 µl 50 µl 50 µl 
final volume 5 ml 5 ml 5 ml 
Volumes are sufficient for 1x 0.5 mm thickness gel.  
 
The samples for the SDS-PAGE were treated with dissociation buffer (final 
concentration 1 x) and incubated for 3 min at 95°C or 30 min at 37°C. After cooling the 
samples down to room temperature, they were centrifuged at room temperature for 3 
min and loaded. The SDS-PAGE was performed in 1 x running buffer at 80 V through 
the stacking gel and at 120 V through the resolving gel. As a size marker 5 µl 
SpectraTM Multicolour Broad Range Protein Ladder (Fermentas, SM1841) was loaded 
on the gel.  
2 x dissociation buffer     
125 mM Tris-HCl (pH 6.8)    1.92 M  Glycine 
10 x Running (Towbin-) buffer pH 8.6 
4 % (w/v) SDS     250 mM    Tris 
20 % (v/v) glycerol     1 % (w/v) SDS 
0.02 % (w/v) bromophenol blue 
100 mM    DTT (always added just before use) 
 
3.5.4 Staining of Polyacrylamide gels 
3.5.4.1 
Proteins can be stained with Coomassie Brilliant Blue (CBB), because of the 
electrostatic binding of CBB to proton amino groups. The acrylamide gel was stained 
for ~ 15 min, at room temperature in staining solution and incubated in the destaining 
solution for 2 x 10 min or until banding was clear. 
Coomassie Brilliant Blue Staining 
Staining solution     
45 % (v/v) Methanol   45 % (v/v) Methanol 
Destaining solution 
10 % (v/v) Acetic acid   10 % (v/v) Acetic acid 
0.2 % (w/v) Coomassie blue R 
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3.5.4.2 
For staining that is more sensitive than the conventional staining with CBB it is possible 
to use Coomassie G-250 without containing methanol and acetic acid, enabling 
analysis by mass spectrometry. The protocol was carried out as provided from the 
company. Briefly the gel was washed 3x 5 min with dH2O, followed by a staining step 
for ~ 2h. Next, the gel was washed for 1 h in dH2O and to increase intensity 3.3 % (w/v) 
NaCl (final concentration) was added.  
SimplyBlueTM SafeStain (Invitrogen LC6060) 
 
3.5.4.3 
For proteins samples with low nanogram concentration the proteins can be visualised 
after separation on acrylamide gels by silver staining. Initially the gel is incubated in 50 
% (v/v) methanol for at least 1 h, followed by the staining step for 15 min. Three 
washing steps for 5 min each in dH2O were necessary before the gel was developed 
(for a few seconds, until the wished intensity was reached). The development of the gel 
was stopped by adding some fixer. Then, the solution was discarded and the gel was 
finally fixed. The quality of the SDS used in the gels is critical otherwise the silver 
staining will not be successful. The SDS delivered by Sigma-Aldrich gave always good 
results. All the solutions used for this procedure were made up fresh, just prior to using, 
in nanopure dH2O. The staining solution must be always a clear and clean liquid. A 
brown staining during the solution preparation should be not considered for further 
usage.   
Silver Staining 
Staining solution   Developer    
0.8 % (w/v)  AgNO3  0.055 % (v/v) Formaldehyde 45% (v/v)  Methanol 
Fixer 
1.4 % (v/v) NH4OH  0.05 % (w/v)  Citric acid  10 % (v/v) Acetic acid 
0.075 % (w/v)  NaOH 
 
3.5.5 Immunodetection of proteins 
3.5.5.1 
To detect proteins with specific antibodies it is necessary to transfer them after 
separation by SDS-PAGE on to a PVDF membrane. After electrophoresis the SDS gel 
was equilibrated in transfer buffer for approximately 10 min. The PVDF membrane 
(Millipore) was activated for ~20 secs in 100 % methanol and washed in transfer buffer 
before using it for the wet transfer The gel and membrane were assembled between 
Whatman paper and sponges in a cassette that was then transferred to the TE22 
apparatus from Hoefer. The transfer was performed for 2 h to 3 h at constant 100 Volt, 
4˚C, with agitation of the buffer.  
Western Blot 
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25 mM  Tris  
Transfer buffer (pH 8.6) 
192 mM Glycine 
0.02 % (w/v) SDS 
15 % (v/v) Methanol 
 
3.5.5.2 
The PVDF membrane was blocked for 1 h in 5% (w/v) milk/TBS-T at room temperature 
with rocking to minimise unspecific binding of the antibodies. The primary antibody was 
usually incubated overnight at 4°C, followed by 3 x washing in TBS-T for 10 min each 
at room temperature. The secondary antibody used was from Dako Cytomation and 
was coupled to HRP for use with the ECL+ kit from Amersham (GE Healthcare) for the 
detection step. After 1 h incubation of the secondary antibody at room temperature the 
washing steps were repeated and the detection was carried out by using the ECL+ kit 
following manufacturer’s instructions. For visualisation X-ray film or Phosphor-Imager 
(Storm 860 scanner) was used, the latter allowed accurate relative quantification of 
signals using Image-Quant software. 
Detection 
 
Table 3.6: Details of antibodies used in these investigations 
antibody dilution company 
 primary antibody  
anti NDUFB8/ 20 kDa SU complex I 
(mouse monoclonal) 
1:1000 Mitosciences (MS105) 
anti NDUFA9/ 39 kDa SU complex I 
(mouse monoclonal) 
1:1000 Mitosciences (MS111) 
anti SDH/ 70 kDa SU complex II 
(mouse monoclonal) 
1:10000 Mitosciences (MS204) 
anti COX1 (mouse monoclonal) 1:1000 Molecular Probes (A6403) 
anti COX2 (mouse monoclonal) 1:1000 Molecular Probes (A6404) 
anti Complex V-β (mouse 
monoclonal) 
1:2000 Mitoscience (MS503) 
anti porin (mouse monoclonal) 1:10000 Molecular probes (A31855) 
anti MRPL3 (goat polyclonal) 1:2000 Abcam (ab39268) 
anti MRPL12 (mouse monoclonal) 1:1000 Abcam (ab58334) 
anti DAP3 (mouse monoclonal) 1:1000 Abcam (ab11928) 
anti-MRPS6 (goat polyclonal) 1:500 Santa Cruz (sc-67918) 
anti-MRPS25 (rabbit polyclonal) 1:500 ProteinTech Group (15277-1-AP) 
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anti MRPS18B (rabbit polyclonal) 1:4000 ProteinTech Group (16139-1-AP) 
anti ICT1 (rabbit polyclonal) 1:800 ProteinTech Group (10403-1-AP) 
anti ERAL1 (rabbit polyclonal) 1:1000 ProteinTech Group (11478-1-AP) 
anti FLAG (mouse monoclonal) 1:2000 Sigma (F1804) 
anti β-actin (mouse monoclonal) 1:10000 Sigma (A1978) 
anti mtRF1 (rabbit polyclonal) 1:3000 
Custom synthesised by 
Eurogentec (affinity purified) 
anti mtRF1a (rabbit polyclonal) 1:1000 
Custom synthesised by 
Eurogentec (affinity purified) 
anti mtRRF (rabbit polyclonal) 1:3000  
Custom synthesised by 
Eurogentec (affinity purified) 
anti mtRbfA (rabbit polyclonal)  1:1000 
Custom synthesised by 
Eurogentec (affinity purified) 
 secondary antibody  
anti rabbit immunoglobulins/ HRP 
(swine polyclonal) 
1:3000 Dako Cytomation (P0399) 
anti mouse immunoglobulins/ HRP 
(rabbit polyclonal) 
1:2000 Dako Cytomation (P0260) 
anti goat immunoglobulins/ HRP 
(rabbit polyclonal) 
1:2000 Dako Cytomation (P0449) 
All antibodies were made up in 5 % (w/v) milk/ TBS-T.  
10 x TBS (pH 7.6)  
0.2 M   Tris   1 x  TBS 
TBS-T 
1.37 M NaCl   0.1 % (v/v) Tween-20 
 
3.5.6 Blue Native Polyacrylamide Gel Electrophoresis  
The Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) is a method to 
visualise whole native protein complexes like the OXPHOS complexes. It was 
performed as described by Nijtmans et al. (2002).  
As it is an analysis of native complexes everything has to be chilled and any contact 
with SDS or ethanol has to be avoided.  
 
3.5.6.1 
Cells from 2x 75 cm2 flasks with a confluence of ~ 60-70% were harvested in 1 mM 
EDTA/ PBS and washed twice with 1 ml cold PBS. The pellet was resuspended in 50 µl 
cold PBS and cells were permeabilised by adding an equal volume of 8 mg/ ml 
Sample preparation 
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digitonin (final concentration 4 mg/ ml; Sigma D141). After vortexing and 10 min 
incubation on ice the digitonin was diluted by adding 1 ml cold PBS, followed by 
centrifugation at 10,000 xg for 5 min at 4°C and one washing step. Next, the pellet was 
resuspended in 50 µl 1.5 M AminoCaproic acid, 75 mM Bis-Tris, pH 7.0 and 
mitochondria were solubilised by adding 10 µl of 10 % (w/v) n-Dodecyl β-D-maltoside 
(Sigma, D5172), vortexing and incubating on ice for 5 min prior to centrifugation for 30 
min at 10,000 xg at 4°C. The supernatant was transferred to a fresh chilled tube and 
protein concentration was measured by Bradford. 50 - 75 µg protein containing 1x BN 
sample buffer were loaded as quickly as possible on the BN gel. As a size marker 
Apoferretin (Sigma, A3660) was used, which migrates at 440 kDa as a monomer and 
at 880 kDa as a dimer. 
 
750 mM  AminoCaproic Acid 
2x Sample buffer (pH 7.0) 
50 mM   Tricine 
0.5 mM  EDTA 
0.02 % (w/v)  Serva Blue G-250 
 
3.5.6.2 
To prepare a 5% to 15% gradient gel a gradient mixer was used. The volumes (Table 
3.7) are adjusted for one 1.5 mm thick gel, small format (Hoefer casting system). 
BN PAG preparation 
 
Table 3.7: Composition of native gradient PAG 
 
5 %  
resolving gel 
15 %  
resolving gel 
4 %  
stacking gel 
29:1 40 % (w/v) acryl/ bis-
acrylamide 
0.63 ml 1.88 ml 0.50 ml 
Gel Buffer I  1.67 ml 1.67 ml 1.67 ml 
Glycerol -- 0.79 ml -- 
dH2O 2.71 ml 0.67 ml 2.83 ml 
TEMED 3.0 µl 1.5 µl 5.5 µl 
10 % (w/v) APS 30 µl 15 µl 55 µl 
 
When preparing a gradient gel it is very important to avoid any air bubbles, especially 
in the connection between the chambers of the gradient mixer. To prepare the 5% to 
15% gradient gel the chambers of the gradient mixer were filled with 3.5 ml of each 
resolving gel mix. After pouring the gradient gel a thin layer of dH2O was added on the 
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top of the gel as already mentioned above. When the resolving gel was solid, the water 
was discarded and the stacking gel was poured.  
 
1.5 M   AminoCaproic Acid 
Gel-buffer I (pH 7.4) 
150 mM Bis-Tris 
 
3.5.6.3 
The samples were electrophoresed at 50 V through the stacking gel and at 80 V 
through the resolving gel at 4°C. The Cathode buffer A was replaced by cathode buffer 
B as soon as the blue front was approximately 2/3 through the resolving gel. After the 
electrophoresis was finished the gel was either used for western blot or for enzyme in-
gel activity assay. 
Electrophoresis 
 
Cathode buffer A (pH 7.0)   Cathode buffer B (pH 7.0)  
15 mM   Bis-Tris   15 mM  Bis-Tris   50 mM Bis-Tris 
Anode buffer (pH 7.0) 
50 mM   Tricine   50 mM  Tricine 
0.02 % (w/v)  Serva Blue G-250 
 
3.5.6.4 
The gel was incubated in 1% (w/v) SDS/ 1% (v/v) β-mercaptoethanol for 30 min and in 
1x transfer buffer for 15 min prior to transfer for 1 h at 100 V at 4°C. 
Western Blot of BN-PAG 
 
3.5.6.5 
The BN-PAG was incubated at room temperature over-night with the following 
substrates: 
Enzyme in-gel activity assay 
Complex I: 2 mM   Tris/HCl pH 7.4 
  0.1 mg/ ml  NADH 
  2.5 mg/ ml  NitroTetrazolium Blue (NTB) 
 
Complex IV: 0.5 mg/ ml  3,3’-Diaminobenzidine Tetrahydrochloride (DAB)  
  50 mM  phosphate buffer pH 7.4 
  20 µg/ ml  Catalase 
  1 mg/ ml  reduced cytochrome c 
  75 mg/ ml  sucrose  
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3.5.7 35S metabolic labelling of mitochondrially encoded proteins 
This method was used to investigate changes in translation of mitochondrially encoded 
proteins after siRNA treatment or overexpression of a protein of interest. The 
procedure was adapted from Chomyn, 1996. The method was carried out in 6-well 
plates or 25 cm2 flasks. 
For 35S methionine/cysteine metabolic labelling it is necessary to first remove 
methionine by replacing the growth media with methionine/cysteine free DMEM (Sigma 
D0422) supplemented with L-glutamine, 50 µg/ ml uridine and 1 x non essential amino 
acids. The cells were incubated twice for 10 min in this methionine/cysteine free media 
before adding fresh methionine/cysteine free media additionally supplemented with 10 
% (v/v) dialysed FBS and 100 µg/ ml emetine dihydrochloride, which was added to 
inhibit the cytosolic translation. After 10 min incubation 20 µl/ ml 35S - methionine/ 
cysteine mix (~ 200 µCi/ ml; EasyTagTM express35S protein labelling mix - 
NEG772002MC from PerkinElmer) were added to the media. The labelling step was 
performed for 10 min to 30 min. To quench the reaction the labelling media was 
aspirated off and the cells were washed twice with chilled growth media containing 7.5 
µg/ ml unlabelled methionine. The cells were then harvested in cold 1 mM EDTA/PBS 
and washed 3x in chilled PBS. Finally the cell pellet was resuspended in 30 - 50 µl PBS 
containing 1x PI-Mix and 1 mM PMSF.  
The samples (up to 50 µg) were treated with 2 x dissociation buffer (20 % (v/v) glycerol, 
4 % (w/v) SDS, 250 mM Tris-HCl pH 6.8, 100 mM DTT) and 12 U Benzonase® 
nuclease (Novagen). After incubation for 1 h at room temperature the denatured 
protein samples were separated on a 15 % SDS-PAGE. The gel was fixed overnight in 
3 % (v/v) glycerol, 10 % (v/v) acetic acid, 30 % (v/v) methanol and finally dried under 
vacuum at 60°C for 4 h. The Phosphor-Imager system was utilised to visualise 
radiolabelled proteins and Image-Quant software (Molecular Dynamics, GE 
Healthcare) was used for analysis. 
 
3.5.8 Isolation of mitochondria from human cell lines 
Mitochondria were usually isolated from cells grown in a 300 cm2 flask at 80 % 
confluence. The cells were harvested as described in 3.1.1. The cell pellet was 
resuspended in 2 ml ice cold homogenisation buffer containing 0.1 % (w/v) BSA and 1 
mM PMSF. All subsequent steps were carried out in the cold room. The suspension 
was transferred into a 2 ml Glas-Col Homogeniser where it was subjected 15 passes 
by hand. The homogenate was then centrifuged at 400 xg for 10 min at 4°C to remove 
unbroken cells. The supernatant was transferred into pre-chilled tubes and the pellet 
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was resuspended in a further 2 ml buffer. The homogenisation and centrifugation step 
were repeated. The second homogenate was centrifuged at 400 xg for 10 min. Then all 
combined supernatants were re centrifuged at 400 xg for 5 min before the harder 
centrifugation step at 11,000 xg for 10 min was performed. This final mitochondrial 
pellet was washed in homogenisation buffer lacking BSA and also lacking PMSF if 
proteinase K treatment was to be performed. Depending on the size of the 
mitochondria pellet it was resuspended in a volume of 70 to 150 µl wash buffer. 
 
0.6 M      Mannitol 
Homogenisation buffer 
10 mM    Tris (pH 7.4) 
1 mM      EGTA 
 
To remove cytosolic contamination 4-5 mg mitochondria were treated with 2U RNase-
free DNaseI (Epicentre Biotechnologies) in 1 ml homogenisation buffer (containing 10 
mM MgCl2 and 1 mM CaCl2) for 15 min at room temperature prior to adding 5 µg 
proteinase K per 1 mg mitochondria on ice. After 30 min 1 mM PMSF (final 
concentration) was added to inhibit further reaction of proteinase K, followed by two 
washing steps with homogenisation buffer containing 1 mM PMSF. Next, mitochondria 
were permeabilised in 0.2 % (w/v) digitonin in homogenisation buffer for 15 min on ice, 
followed by 2 washing steps with homogenisation buffer and a further proteinase K 
treatment.  
Mitochondrial purification 
 
3.5.9 Immunoprecipitation  
To investigate protein-protein interactions or protein-nucleic acid interactions an 
immunoprecipitation step was performed. Proteins of interest were inducibly expressed 
in HEK293T cells as C-terminal tagged with the FLAG-octapeptide. This permitted 
immunoprecipitation of the proteins via the FLAG tag using the Immunoprecipitation kit 
from Sigma (product code FLAGIPT-1). The FLAG octapeptide is very hydrophilic 
hence it is most probably the case that the tag is on the surface of the protein, available 
for the affinity purification.  
The first step is the lysis of whole cells or mitochondria from a cell line expressing a 
FLAG tagged protein by adding 500 µl lysis buffer (supplemented with 10 mM MgCl2, 
PI-Mix, 1 mM PMSF and 60 U RNAguard) to a cell or mitochondrial pellet. This 
suspension was transferred to a rotating wheel, medium speed at 4°C for 30 min 
followed by a centrifugation step for 10 min at 12,000 xg at 4°C. The supernatant was 
transferred to a pre-chilled tube. For the binding step 40 µl M2 affinity resin suspension 
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(containing 50 % beads) per reaction, was added to a hydrophobic tube. The beads 
(finally 20 µl) were washed 3 x with 1 ml 1 x washing buffer (supplemented with 10 mM 
MgCl2, PI-Mix, 1 mM PMSF and 10 U RNAguard) before a defined protein amount of 
lysate was applied. The binding step was performed on a rotating wheel medium speed 
at 4°C for 3 h. After the binding step the beads were centrifuged for 30 secs at 5,000 xg 
at 4°C. The supernatant was discarded and the beads were washed at least 3 x with 1 
ml 1 x washing buffer (supplemented as described above) to remove non specific 
binding and contamination. To elute the target protein with its interacting partners 5 µg 
3 x FLAG peptide in 100 µl 1 x washing buffer was added to the beads, followed by an 
incubation step of 45 min, rocking gently at 4°C. After the beads were centrifuged 
briefly at 5,000 xg for 30 secs the elution fraction was transferred to a new pre-chilled 
tube. To analyse the efficiency of the elution the beads were washed again 3 times with 
1 x washing buffer and finally 20 µl to 40 µl 2 x dissociation buffer (section 3.5.3) was 
added. The supernatant was separated on a SDS-PAGE followed by Western Blot 
analysis.  
 
Lysis buffer      
(Sigma product Code L 3412)    (Sigma product Code W 0390) 
10 x Washing buffer  
50 mM  Tris-HCl (pH 7.4)   0.5 M Tris-HCl (pH 7.4) 
150 mM   NaCl    1.5 M    NaCl 
1 mM       EDTA 
1 % (v/v)  Triton X-100 
 
3 x FLAG peptide     
(Sigma product Code F 4799)    (Sigma product Code A 2220) 
ANTI-FLAG M2-Agarose Affinity Gel  
 
3.5.10 Crosslinking Immunoprecipitation - CLIP 
CLIP is a powerful tool to determine RNA species the potential RNA binding protein 
(RBP) is attached to. UV-irradiation on intact cells allows covalent binding of RNA and 
protein that are in close localization to each other. After covalently binding of the RNA 
to the protein, this particular RNA sequence is protected by the protein and thus after 
RNase treatment there is only this particular fragment left. With 5’-32P γATP end-
labelling it is possible to visualise the RNA within the protein-RNA complex on a 
membrane by exposing western blot membrane to X-ray film. The protein-RNA 
complex of interest migrates approximately 20 kDa above the molecular weight of the 
protein. This region of membrane is excised trying to keep the region to a minimum. 
Next, proteinase K is applied to the piece of membrane to remove the protein from the 
RNA. The independent ligation of specific RNA linkers to either the 5’- or 3’-end allows 
the reverse transcription and finally the amplification and cloning of the particular 
protected RNA species. The procedure was adapted as described in Ule et al. (2005).  
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Figure 3.3: Crosslinking immunoprecipitation. Cells were UV irradiated prior to lysis (1). Cell 
lysate was treated with RNase (2), where the crosslinked RNA sequence is protected by the 
interacting RNA binding protein (RBP). The 3’-end of the RNA has to be dephosphorylated (3) 
before RNA linker ligation can occur (4). With the addition of γ32P by the polynucleotide kinase 
(5) it is possible to visualise the protein-RNA complex via western blot analysis (6). Defined 
bands are cut out of the membrane and proteinase K digested to remove the protein from the 
RNA (7). Then another RNA linker can be ligated on the 5’-end (8) and cDNA can be 
synthesised via reverse transcription (9). This cDNA can then be amplified by PCR and cloned 
for sequencing analysis. (Image was adapted from Ule et al., 2005). 
 
The CLIP assay was adapted on the FLAG-IP kit as described in 3.5.9. Cells 
expressing FLAG tagged protein of interest were cultured in 150 mm petri dishes until a 
confluence of ~ 60-70% was reached. Then cells were washed with PBS, covered with 
little amounts of PBS and UV cross linked on ice. For UV irradiation the Stratalinker 
2400 with energy mode 4000 was used, which will deliver 400 mJ/ cm2. After the cross 
linking cells were harvested in chilled PBS/ 1 mM EDTA. The pellet was lysed in 1 ml 
lysis buffer containing 1x PI-mix and 200 U of RNAguard (Amersham) for 30 min at 
rotating wheel at 4°C. Next sample was treated with 50 U RNase-free DNase I 
(Epicentre Biotechnologies) at 37°C 1,000 rpm for 5 min (using Eppendorf 
thermomixer) to remove all the DNA. Then the sample was divided into two tubes to 
apply different amount of RNase T1 (Ambion): 2 U and 100 U respectively. After 10 min 
at 37°C at 1,000 rpm 30 U SUPERase-In (Ambion) were added to each tube to inhibit 
further RNase T1 activity. Samples were then centrifuged for 20 min at 21,000 xg at 
4°C and the supernatant was transferred to 20 µl M2-FLAG beads, which were 
equilibrated with five washing steps in 1x washing buffer provided from the FLAG-IP kit. 
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The samples were left rotating for 90 min at 4°C, followed by three washing steps with 
1x washing buffer and two with PNK buffer. Next the RNA was dephosphorylated using 
3 U alkaline phosphatase (Roche, 713023) in 80 µl volume containing 1x 
dephosphorylation buffer. The reaction was incubated in the thermomixer at 37˚C for 
10 min, 1,000 rpm every 3 min for 15 sec, followed by two washing steps with 
PNK+EDTA buffer and two with PNK buffer. Then the 3’-RNA linker ligation reaction 
was incubated over-night at 16°C at 1,000 rpm every 5 min for 15 secs containing 2 µM 
3’-RNA linker, 20 U T4 RNA ligase (NEB M0204S) and 1x T4 RNA ligation buffer (NEB, 
contains ATP) in a final volume of 80 µl. The next day the beads were washed three 
times with PNK buffer prior to T4 polynucleotide kinase (PNK) treatment on the beads. 
The PNK catalyses the transfer of the 32P from the γ position of ATP to the 5’-OH of the 
RNA: the reaction was incubated at 37˚C for 10 min (1,000 rpm every 4 min for 15 sec) 
containing 1 µl 32P-γATP (~ 10 µCi; PerkinElmer NEG002A), 40 U T4 PNK enzyme 
(NEB) and 1 x T4 PNK buffer in a total volume of 80 µl. Then 1 µM and 100 µM rATP 
were added, followed by incubation at 37°C for 5 min each time (1,000 rpm, every 2 
min for 15 sec). Next, the beads were washed with 200 µl PNK buffer, followed by two 
washing steps with 1 ml PNK buffer and one final washing step with 1 ml 1x washing 
buffer. The protein-RNA complex was eluted in 50 µl 1 x washing buffer containing 0.5 
µg/ µl 3x FLAG peptide for 45 min at 1,000 rpm at room temperature. The eluted 
samples containing 1x sample buffer (NuPAGE LDS) and heated for 10 min at 70°C 
were run on a 10% Novex pre-casted gel, following manufacturer’s protocol (Invitrogen, 
NuPAGE®Novex® Bis-Tris mini gels). The gel was electrophoresed in MES buffer at 
200 V, followed by the transfer on BA-85 nitrocellulose membrane at 30 V for 1 h using 
the Novex wet transfer apparatus (XCell II Blot Module EI9051). The membrane was 
washed in PBS after transfer and wrapped in Saran wrap, followed by exposure to X-
ray film over-night at -80°C. Matching the autoradiogram with the membrane allows the 
position of the protein-RNA complex of interest on the membrane to be identified and 
excised. Between the lower and higher RNase T1 digested samples there should be a 
shift in size of the immunoprecipitated protein which shows the protein within and 
without RNA-complex. The membrane was then digested in 200 µl 4 mg/ ml proteinase 
K solution for 20 min at 37°C at 1,000 rpm. Next 200 µl of ProtK buffer were added with 
1 mM PMSF (final concentration) to inhibit further proteinase K activity, incubated for 
another 5 min at 37°C at 1,000 rpm. The RNA was extracted by the addition of 400 µl 
phenol (pH 6.7) and 130 µl chloroform/IAA (24:1), incubated for 20 min at 37˚C at 
1,000 rpm. After centrifugation at top speed for 3 min the aqueous phase was 
transferred into a new 1.5 ml tube and the RNA was precipitated over-night at -20°C by 
the addition of 0.3 M NaOAc pH 5.2 (final concentration), 1 µl GlycoBlue (Invitrogen) 
Chapter 3: Methods 
69 
and 2.5 vol. isopropanol/ethanol (1:1). Next day the RNA was pelleted at 21,000 xg for 
15 min at 4°C and washed twice with 75 % (v/v) ethanol. The RNA was resuspended in 
8 µl DEPC treated dH2O and used for the 5’-linker ligation reaction. 7 µl RNA were 
incubated for 3 h at 37°C in the presence of 2 µM 5’-RNA linker, 4 U T4 RNA ligase 
and 1x T4 RNA ligation buffer in a total volume of 10 µl. The RNA was then again 
extracted and precipitated as previously described. This resulting RNA pellet was 
resuspended in 10 µl DEPC dH2O, which was then used for reverse transcription. The 
10 µl RNA solution was incubated with 10 pmoles P3 primer for 5 min at 65°C, followed 
by cooling down the tube on ice for 5 min prior to adding the master mix containing 1 µl 
10 mM dNTPs, 4 µl 5x 1st strand buffer, 2 µl 0.1 M DTT and 1 µl RNAguard. After an 
incubation for 5 min at 42°C the Superscript II enzyme was applied to the reaction, 
followed by the incubation for 1 h at 42°C and 15 min at 70°C. The reaction was then 
used for amplification via PCR with the following composition in a total volume of 30 µl: 
1x  buffer IV (ABgene)    
0.4 mM    dNTP mix     
2 mM       MgSO4  
0.4 µM      P5 primer  
0.4 µM      P3 primer 
3 U       Taq (ABgene)    
3 µl   reverse transcription reaction as the template 
 
programme:         
denaturation: 95°C  5 min  
denaturation: 95°C  20 sec  
   35 cycles  annealing: 67°C 30 sec 
extension: 72°C 30 sec  
extension: 72°C 5 min  
 
The PCR product (containing 5% (v/v) glycerol instead of DNA loading buffer) was 
visualised on a 4% (w/v) low melting agarose gel against a 50 bp ladder (NEB). A 
product of ~ 80 bp was cut out and the DNA was extracted as described in 3.3.4. 
Finally the DNA was either directly used for cloning or it was re-amplified in a total 
volume of 50 µl with the following conditions: 
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programme:         
denaturation: 95°C  5 min  
denaturation: 95°C  20 sec  
   20 cycles  annealing: 63°C 30 sec 
extension: 72°C 30 sec  
extension: 72°C 5 min  
 
For the cloning of the DNA the TOPO TA cloning kit for sequencing (Invitrogen) was 
used following the manufacture’s instructions. Briefly 2 µl PCR product were incubated 
for 5-10 min in the presence of 0.2M NaCl, 10 mM MgCl2 and 5 ng pCR4-TOPO vector 
in a total volume of 3 µl. The reaction was then transferred on ice and 1 µl was added 
to 25 µl TOP10 one shot chemically competent E. coli cells, followed by an incubation 
for 10 on ice and a heat shock step for 30 secs at 42°C. After cooling the reaction on 
ice for 2 min 125 µl SOC media was added and bacteria were incubated for 1 h at 37°C 
at 300 rpm prior to transfer on LB plates containing 100 µg/ ml ampicillin. Clones were 
screened by colony PCR using M13 primer: bacteria clones were lysed in 50 µl 10% 
(v/v) Triton X-100 via freeze-thawing cycle. 1.25 µl were used as a template for the 
PCR with the following conditions: 
1x  buffer (Fermentas, containing 2 mM MgCl2) 
0.5 µM     dNTPs 
1 µM      M13 forward 
1 µM      M13 reverse 
0.6 U      Dream Taq (Fermentas) 
 
programme: 
denaturation: 95°C  3 min  
denaturation: 95°C  45 sec  
   30 cycles  annealing: 48°C 1 min 
extension: 72°C 30 sec  
extension: 72°C 7 min  
 
The PCR products were visualised on a 2% (w/v) agarose gel against 50 bp ladder. 
Positive clones with an insert gave a PCR product of approximately 250 to 300 bp, of 
which 2.5 µl were treated with 1 µl ExoSap for 15 min at 37°C and 15 min at 80°C prior 
to cycle sequencing as described in 3.3.9 using M13 forward primer and 2 µl PCR 
product. 
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PNK buffer   PNK + EDTA buffer  
50 mM      Tris/HCl pH 7.4 50 mM      Tris/HCl pH 7.4 100 mM Tris/HCl pH 7.4 
ProtK buffer 
10 mM      MgCl2  20 mM      EDTA  50 mM   NaCl 
0.5% (v/v) NP-40  0.5% (v/v) NP-40  10 mM   EDTA 
 
L5: 5’–OH AGG GAG GAC GAU GCG G 3’-OH 
RNA linkers (Thermo): 
L3: 5’–P GUG UCA GUC ACU UCC AGC GG 3’-puromycin 
 
P5: 5’-AGG GAG GAC GAT GCG G-3’ 
DNA primers (Eurogentec): 
P3: 5’-CCG CTG GAA GTG ACT GAC AC-3’ 
 
3.5.11 Isokinetic sucrose gradient 
The sucrose gradient was used for analysing ribosome conformation. First, 10% (w/v) 
and 30% (w/v) sucrose were prepared in buffer containing 50 mM Tris/HCl (pH 7.2), 40 
mM NH4Cl, 10 mM MgOAc, 0.1 M KCl, 1 mM PMSF and 50 µg/ ml chloramphenicol. 
0.5 ml of 10% (w/v) sucrose was transferred to a polycarbonate centrifuge tube 
(Beckman 343778). With a 1 ml syringe and a needle 0.5 ml of 30% (w/v) sucrose was 
carefully added under the 10% (w/v) sucrose. Using the Gradient Master from Biocomp 
a linear gradient was prepared (Gradient Master ver 3.06L; TL55, 10-30% S1/1 
0:55/85.0/22). The gradients were always left to stabilise for 1h at 4°C before use.  
The samples for the gradient were either cell lysate or eluates from immunoprecipitated 
mitoribosomes. The cells were lysed as described in 3.5.2. The volume of lysis buffer 
added to the cells depended on the size of the pellet. Finally 700 µg of cell lysate or the 
IP-eluate (in 50 - 80 µl) was transferred to the top of the gradient.  
After centrifuging the gradient at 39,000 rpm (~ 100,000 xg; Beckman OptimaTMTLX 
Ultracentrifuge, Rotor TLS 55, Accel 1, Decel 4) for 135 min at 4°C, fractions of 100 µl 
from top to bottom were collected. 10 µl of each fraction were separated by SDS-PAGE 
(followed by Western Blot or Silver Staining after IP-gradient) or RNA was extracted 
from each fraction using Trizol-LS (Invitrogen).  
 
3.5.12 GST protein purification 
For purification of recombinant GST tagged protein a large culture of 0.5 L was 
inoculated with a 10 ml small culture. The bacteria culture was grown at 37°C at 200 
rpm until an OD600 ~ 0.4 to 0.6 was achieved. The culture was cooled down to 16°C 
and induced with 1 mM IPTG. The bacteria were incubated over-night at 16°C to allow 
controlled overexpression of recombinant protein. The following day the cells were 
harvested at 5,000 rpm for 15 min at 4°C. The pellet was frozen and thawed to achieve 
a more efficient break up of the bacteria during lysis. To lyse the cells, the pellet was 
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resuspended in PBS containing 1 mM PMSF, 1x PI-Mix and 50 U Benzonase and the 
suspension was sonicated 10 x 10 secs under chilled conditions, amplitude 18 
microns (Soniprep 150). To remove insoluble particles the suspension was 
centrifuged at 30,000 xg for 30 min at 4°C. The supernatant was filtered through a 0.45 
µm filter and finally transferred to a BioRad column containing 0.6 ml gluthathione-
Sepharose beads (GE Healthcare), pre-washed with dH2O and then PBS. The column 
was incubated over-night at 4°C on a rocker. The next day the beads were washed 5x 
with PBS containing 1 mM PMSF and PI-Mix and 5x with PBS without any Protease-
Inhibitor. To elute the target protein 48 U PreScission protease was added in 0.75 ml 
PBS containing 1 mM DTT and 1 mM EDTA. The eluate was collected next day in a 
chilled 1.5 ml tube.  
 
3.5.13 Antibody purification 
To raise polyclonal antibodies against the purified recombinant protein of interest, 
protein was sent to Eurogentec, Belgium. Two rabbits were injected 4 times over 3 
month with 100 µg protein each time. To purify the final bleed recombinant protein 
need to be covalently bound to NHS-activated Sepharose 4 Fast Flow.  
0.6 ml of NHS-activated Sepharose beads were washed with 1 mM HCl. 1-2 mg 
recombinant protein (in PBS) was added to those beads over-night at 4°C. The next 
day the beads were blocked with 0.1 M Tris/HCl (pH 7.4), before adding the serum. 7 
ml of the final bleed was filtered through a 0.45 µm and then a 0.2 µm filter. After 
increasing the volume up to 10 ml with PBS the serum was added to the column and 
left over-night rocking at 4°C. The next day the beads were washed twice with PBS, 
once with Tris-buffer pH 8.0 [50 mM Tris/HCl pH 8.0; 0.1% (v/v) Triton X-100; 0.5 M 
NaCl], followed by Tris-buffer pH 9.0 [50 mM Tris/HCl pH 9.0; 0.1% (v/v) Triton X-100; 
0.5 M NaCl] and finally sodium-phosphate-buffer pH 6.3 [50 mM sodium-phosphate pH 
6.3; 0.1% (v/v) Triton X-100; 0.5 M NaCl]. The antibodies were eluted with 5 ml glycine-
buffer pH 2.5 [50 mM glycine pH 2.5; 0.1% (v/v) Triton X-100; 0.15 M NaCl] and 
immediately neutralised with 1 ml 1M Tris/HCl pH 9.0. The elution was then 
concentrated and buffer exchanged (to PBS) by using Amicon® Ultra-15 centrifugal 
filter devices (Millipore). Antibodies were stored at -20°C containing 10 % (v/v) Glycerol 
and 0.02 % (w/v) sodium azide.  
 
3.5.14 In vitro translation termination assay 
To determine whether a potential class I release factor has any peptidyl-tRNA 
hydrolysis activity the recombinant protein was purified from bacteria and tested in the 
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in vitro translation termination assay. In this experiment isolated 70S E. coli ribosomes 
were used. These were incubated with an AUG RNA triplet and an aminoacylated-
tRNAMet carrying  3H- radiolabelled formyl-methionine to allow positioning of this 
substrate into the peptidyl-tRNA site (P-site). This acted as a mimic for a peptidyl-tRNA 
substrate for the release factor (RF). The aminoacyl-tRNA site (A-site) was then filled 
with the RNA triplet to be tested for recognition by the release factor.  
 
 
Figure 3.4: In vitro translation termination assay (schematic). 70S E. coli ribosomes are 
used to measure relative release activity by the applied release factor (RF). The peptidyl-tRNA 
(P) site carries a start codon and an aminoacylated tRNAMet with 3H- radiolabelled formyl-
methionine (*M). The aminoacyl-tRNA (A) site is filled with a stop codon in the decoding centre. 
The recombinant class I RF was independently added with each RNA codon to be tested to the 
70S preparation. This allowed the RF to be tested for recognition against a battery of RNA 
triplets. 
 
If a class I release factor recognise the specific stop codon sequence in the decoding 
centre, it will catalyse the hydrolysis of the ester bond between the formyl-methionine 
and the tRNA, releasing the radiolabelled amino acid and the free radioactivity is 
measured. The in vitro translation termination assays were carried out by Dr. Z. M. A. 
Chrzanowska-Lightowlers as described in Soleimanpour-Lichaei et al. (2007). 
 
3.6 
 
Statistical evaluation  
Means were usually presented with standard deviations. To examine observed 
differences on their significance t-test was performed using the following webpage: 
   
Differences with p > 0.05 were considered as to be not statistically significant, with p = 
0.01 to 0.05 as significant (*), p = 0.001 to 0.01 as very significant (**) and p < 0.001 as 
extremely significant (***).  
http://www.graphpad.com/quickcalcs/ttest1.cfm. 
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4 Chapter 4:                                                                         
ICT1 is an essential mitochondrial protein 
 
4.1 
 
Introduction 
As described earlier, ICT1 is one of four members of the mitochondrial release factor 
family. So far mtRF1a is the only mitochondrial release factor with ribosome-dependent 
peptidyl-tRNA hydrolysis activity with sequence specific recognition of UAA or UAG as 
stop codons [Soleimanpour-Lichaei et al., 2007]. Recent recognition of the ability for 
human mitochondrial ribosome to use a -1 frameshift shows that mtRF1a is able to 
terminate all 13 open reading frames by recognition of UAA/UAG codons [Temperley et 
al., 2010a]. C12orf65 was shown to have no release activity in the in vitro translation 
termination assay. It seems, however, to be crucial for mitochondrial protein synthesis 
as mutations of C12orf65 in two patients caused reduced level of mitochondrial 
translation, as monitored by 35S-met de novo synthesis and aberrant OXPHOS 
complex formation shown by Blue Native PAGE [Antonicka et al., 2010]. The function 
of C12orf65 within the mitochondria is still unknown. The fourth member of the family, 
mtRF1 was shown to be mitochondrial, but this candidate also did not have any release 
activity in vitro [Soleimanpour-Lichaei et al., 2007]. So far it has not been reported as a 
protein that is involved in the mitochondrial gene expression machinery. Further 
characterisation of mtRF1 and C12orf65 is part of the PhD project of A. Pajak in this 
laboratory.  
ICT1 was first described in 1995, called DS-1. Van Belzen et al. reported that ICT1 
transcripts were down regulated during differentiation of HT29-D4 and Caco-2 colon 
carcinoma cells. Furthermore they showed also western blots where ICT1 could be 
detected at two sizes, one band at predicted size of 25 kDa and the second, more 
prominent one of ~ 20 kDa. The authors explained the two species may result from 
possible post-translational processing. With hindsight this may reflect that it has a 
cleavable site removing the targeting peptide. 
In my host laboratory ICT1 was found in the immunoprecipitation of mtRRF-FLAG, 
where mitoribosomal proteins together with other translation factors and nucleoid 
components could be detected [Rorbach et al., 2008]. The fact that ICT1 was 
associated with this complex pulled down via mtRRF-FLAG suggests that ICT1 is 
probably a mitochondrial protein, and possibly involved in the mitochondrial gene 
expression machinery. Combined with the fact that it is described as belonging to the 
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mitochondrial release factor family and because mitochondrial translation termination 
processes are one of the main focuses within this laboratory, means that this protein is 
of great interest to me. There are a few initial facts that need to be considered when 
investigating the possible function of ICT1: First, mtRF1a is the main release factor 
terminating all 13 open reading frames. Therefore there is no need for another release 
factor to act in the same way. Second, mtRF1a was not found in the 
immunoprecipitation of mtRRF-FLAG, which is not a surprise, because mtRF1a and 
mtRRF accommodate the same site (A-site) within the mitochondrial ribosome. Thus if 
mtRRF is associated with the mitochondrial ribosome there is no space for mtRF1a. 
The fact that ICT1 was co-immunoprecipitated with mtRRF-FLAG suggests maybe a 
different location and therefore function of ICT1 in comparison to mtRF1a. Third, ICT1 
is a quite small protein, lacking the crucial domains for codon recognition (tip of the α5 
helix and the PXT/SPF motif) within the decoding centre. Thus it seems unlikely that 
ICT1 can act as a conventional class I release factor like mtRF1a does.  
It is therefore from great interest to identify the function of this protein. Initial 
investigations described in this chapter were directed at identifying i) the cellular 
location of ICT1 and ii) whether it is an essential protein. 
 
4.2 
 
Localisation of ICT1 
The first aim of this investigation was to determine whether ICT1 is a mitochondrial 
protein. From bioinformatic studies it belongs to the prokaryotic/ mitochondrial release 
factor family. Different programmes like PSORT II or TargetP 1.1 can be used to 
predict the localisation of the protein of interest. PSORTII predicted ICT1 to be a 
mitochondrial protein with a probability of 73.9% with a cleavage site for the 
mitochondrial pre-sequence at residue 29 (RRA | LH) (subprogramme “Gavel”). 
TargetP 1.1 gave also the prediction that ICT1 is localised to mitochondria. This 
programme has 5 reliability classes (RC), where RC 1 shows the strongest prediction. 
ICT1 was predicted to have a mitochondrial targeting peptide with RC 1 and again it 
specified a cleavage site at residue 29.  
To confirm the localisation of ICT1 within the mitochondria cell lysates and 
mitochondria were isolated from HeLa- and HEK293T cell lines and were analysed via 
western blot. To ensure that mitochondria were free from cytosolic contamination, 
these were also treated with DNase I and proteinase K, where mitochondrial proteins 
should be remained preserved by the intact mitochondrial membrane. The resulting 
data is shown in figure 4.1. Antibodies against ICT1 (ProteinTech Group 10403-1-AP) 
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that had been tested previously for specificity, showed a single band of ~ 20 kDa in cell 
lysate (lane 1 and 5), isolated mitochondria (lane 2 and 6) and was also protected 
against proteinase K treatment (lane 3 and 7), indicating ICT1 localisation within the 
mitochondria. As a control for proteinase K activity and also sensitivity of ICT1 to 
digestion, 1% Triton X-100 was added to mitochondria, which were treated with same 
amount of enzyme. After mitochondrial lysis proteinase K was able to digest ICT1 
protein (lane 4 and 8), demonstrating that ICT1 is sensitive to proteinase K and thus 
the data in lanes 3 and 7 really reflected that ICT1 was on the inside of mitochondria.  
 
 
 
Figure 4.1: Cellular localisation of ICT1. Western Blot analysis was performed on cell lysate 
(50 µg, lanes 1 and 5) and isolated mitochondria (10 µg, lanes 2-4 and 6-8) from HeLa and 
HEK293T cell lines. Mitochondria were treated with proteinase K (4 µg per 100 µg mitochondria) 
and without (lanes 3 and 7) or with (lanes 4 and 8) 1% Triton X-100, to confirm the proteinase K 
activity and sensitivity of the 3 proteins tested. Specific antibodies against ICT1 were used to 
determine the presence of ICT1 in each sample. MtRF1a was used as a mitochondrial matrix 
marker. The western blot membrane was further probed with antibodies against a cytosolic 
ribosomal protein (S6-RP) as a control for the non-mitochondrial compartment of the cell. 
Purified full length and N-terminal truncated recombinant ICT1 (50 ng) were electrophoresed in 
parallel to compare migration against the endogenous and potentially cleaved ICT1.     
 
Using antibodies against mtRF1a as a mitochondrial marker the same patterns as for 
ICT1 could be seen, whereas ribosomal protein S6 as a cytosolic marker could be only 
detected in cell lysate and was completely removed after proteinase K treatment. At 
this point it should be also mentioned that there was a 2-4 fold increase in the amount 
of ICT1 comparing cell lysate and isolated mitochondria, whereas the level of mtRF1a 
increased <2 folds. The cell lysates were prepared using 1% Triton X-100 followed by a 
centrifugation step at 12,000 xg as described in 3.5.2. Thus insolubilized membrane 
proteins will be removed by centrifugation whereas soluble proteins especially matrix 
Chapter 4: ICT1 is an essential mitochondrial protein 
77 
proteins will be recovered in the supernatant. The relatively low level of ICT1 in the cell 
lysate maybe already indicates a tighter association with the membrane whereas 
mtRF1a is clearly a soluble matrix protein. This point will be more discussed in the next 
chapter. 
Furthermore recombinant protein, which was used for in vitro experiments in a later 
chapter, was also loaded on the western to compare migration against endogenous 
ICT1 in human cell samples. The full-length (FL) ICT1 migrated consistently at a higher 
molecular weight, which suggests a possible mitochondrial cleavable target sequence 
as predicted from PSORTII or TargetP 1.1. A truncation of 29 amino acids of the N-
terminus resulted in a more similar size to the samples from human cell lines. 
 
4.3 
 
The importance of ICT1 in human cells 
4.3.1 Depletion of ICT1 causes a growth defect 
To investigate the possible function of ICT1, siRNAs were applied to deplete the 
endogenous protein from HeLa cells to determine the effect of the loss of ICT1 on cell 
growth and morphology and further on mitochondria function especially on 
mitochondrial protein synthesis.  
The approach taken was to deplete endogenous protein levels using siRNA 
technology. Initially the oligofectamine procedure, as described in 3.1.6.1, was used to 
transfect HeLa cells. First three different custom synthesised, pre-annealed siRNA 
duplexes (Table 3.1) were used at a 0.2 µM final concentration to test the depletion 
efficiency of ICT1 protein. One of those (si-ICT1 C) did not show any down regulation 
of the protein, but also no effect on cell growth or morphology and therefore just the 
remaining two were used for further investigation.  
As shown by western blot analysis of 20 µg and 50 µg cell lysate in figure 4.2, the 
endogenous ICT1 protein could be down regulated to a non-detectable level with both 
siRNAs within 3 days in comparison to a non-targeting siRNA (si-NT) used as control 
for specificity of targeted duplexes. β-actin was used as a loading control.  
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Figure 4.2: Effect of ICT1 depletion on HeLa cell growth and morphology. A) Western blot 
of 20 µg and 50 µg cell lysates confirmed depletion of ICT1 after 3 days transfection using 2 
different siRNAs (si-ICT1 A, si-ICT1 B) in comparison to non-targeting control (si-NT). β-actin 
was used as a loading control. B) Cell counts after 3 days and 6 days siRNA transfection were 
performed to monitor the effect on cell growth after ICT1 depletion. Cell numbers of si-ICT1 
treated samples were compared to si-NT on statistical significance using t-test. The graph 
represents the result from three independent experiments (n = 3; 3 days: si-ICT1 A: p = 
0.0008***; si-ICT1 B: p = 0.024*; 6 days: si-ICT1 A: p = 0.0001***; si-ICT1 B: p = 0.0001***). 
Initial starting cell number is shown as dotted line. C) Images show the morphology of the cells 
after 3 days transfection.  
 
Interestingly the depletion of ICT1 causes clearly a defect in cell growth (Figure 4.2 B 
and C). HeLa cells were treated with both siRNAs and the NT control and then counted 
after 3 and 6 days (Figure 4.2 B). In comparison to the control, ICT1 depleted cells 
showed a significant decrease in cell number after 3 days, which was even more 
dramatic after 6 days.  
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The morphology of ICT1 depleted cells was different comparing the two siRNA to each 
other after 3 days siRNA transfection (Figure 4.2 C). Thus it is possible that one of the 
siRNA is either more effective than the other or one of them is causing an off-target 
effect, meaning an unspecific binding of another mRNA transcript. To investigate the 
latter 143B-ρ0 were transfected with the siRNAs. Since 143B-ρ0 cells lack mitochondrial 
DNA, they cannot express mitochondrial encoded proteins like COX2 (Figure 4.3, A) 
and thus they do not need a mitochondrial gene expression machinery. Proteins which 
are usually involved in that machinery become redundant. Depletion of those factors 
should therefore not show any effect on the growth or morphology of 143B-ρ0 cells. 
Furthermore the expression level of some of those proteins is highly reduced or not 
detectable in this cell line like it is the case for the mitochondrial ribosomal proteins 
DAP3 (28S SSU) and MRPL3 (39S LSU), but also for ICT1 itself (Figure 4.3 A, far right 
lane).  
 
Figure 4.3 Testing the specificity of ICT1 directed siRNA duplexes. A) Western blot of 30 
µg cell lysates from HeLa, 143B and 143B-ρ0 cells probed with specific antibodies to show the 
relative expression level of ICT1, COX2, NDUFB8, SDH, DAP3, MRPL3 and RP-S6 (loading 
control) in the different cell lines. B) Equal numbers of HeLa- and 143B-ρ0 cells (~5,000) were 
transfected with si-ICT1 (A or B) and si-NT, respectively in a 96-well plate format. After 3 days 
the cell growth was monitored by MTT test. The graph represents the measurements of 4 to 8 
wells of each siRNA. The mean of the si-NT treated samples is marked as a dotted line.  
 
Thus using specific siRNAs against ICT1 should not have any effect, also because of 
the absence of the protein. To clarify whether this was indeed the case, the MTT-test 
was carried out as a relative measurement of cell numbers and it was established and 
optimized for the use in my host laboratory by Dr. J. Rorbach (as described in 3.1.7). 
This method is based on 96-well plate format and measured the absorbance of 
formazan which appears by reduction of MTT within the cell.   
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The MTT data clearly showed that using si-ICT1 A the growth of 143B-ρ0 cells was 
highly reduced down to ~40% (Figure 4.3 B) whereas si-ICT1 B showed similar results 
on cell growth as the si-NT, indicating that si-RNA A has an off-target effect but not si-
ICT1 B. The experiment also confirmed the growth defect of HeLa cells after ICT1 
depletion. Because of the off-target effect of si-ICT1 A, most of the following 
experiments were carried out with si-ICT1 B, or both siRNAs were used. 
 
4.3.2 ICT1 is important for mitochondrial gene expression 
As has been shown above, ICT1 is not expressed or is present at non-detectable levels 
in 143B-ρ0 cells. This suggests that ICT1 may be involved in the mitochondrial gene 
expression machinery of which many components are absent in mtDNA lacking ρ0 
cells. To investigate this possibility further 35S de novo mitochondrial protein synthesis 
was carried out as described in 3.5.7. By inhibiting translation in the cytosol using 
emetine, it is possible to visualise the incorporation of 35S-met into only the proteins 
encoded by the mitochondrial genome. Cells were labelled for 10 min at 37°C 5% CO2. 
Samples (50 µg) were then separated through a 15% SDS-PAGE, followed by drying 
the gel under vacuum at 60°C for 4 h. Phosphor-Imager system was used to visualise 
the radiolabelled proteins and Image-Quant software for the analysis. In comparison to 
the si-NT control the depletion of ICT1 after 3 days causes an extremely significant 
decrease to < 40% in mitochondrial protein synthesis (n = 3, p = 0.0001) using both 
siRNAs (Figure 4.4 A). To be certain about an even loading of samples, the gel was 
finally re-hydrated and stained with Coomassie Brilliant Blue (CBB, Figure 4.4 A lower 
panel).  
To see the effect of ICT1 depletion on steady state levels of mitochondrial protein, 20 
µg of HeLa cell lysates were analysed by western blot after 3 days transfection from 
three independent experiments (Figure 4.4 B). For measurements Image-Quant 
software was used. ICT1 protein was depleted to a non-detectable level as before. β-
actin was used as a relative loading control. There was already a significant reduction 
of the steady state level of the mitochondrial encoded protein COX2 after 3 days 
depletion (n = 3, si-ICT1 A:  71% p = 0.0197; si-ICT1 B: 69% p = 0.0222), but also of 
the nuclear encoded protein NDUFB8, which is frequently used as an indicator for the 
assembly and stability of Complex I (n = 3, si-ICT1 A: 79% p = 0.0013; si-ICT1 B: 72%, 
p = 0.0001). 
Chapter 4: ICT1 is an essential mitochondrial protein 
81 
 
 
Figure 4.4: Effect of ICT1 depletion on de novo mitochondrial protein synthesis and 
protein steady state level after 3 days. HeLa cells were treated with si-NT and si-ICT1 (A or 
B), respectively for 3 days, followed by either 35S-met de novo synthesis or western blot analysis 
A) 35S-met labelled mitochondrial encoded proteins were separated by SDS-PAGE (15%). The 
gel was fixed, dried and the radiolabelled proteins were visualised using the Phosphor-Imager 
system. Proteins were identified by comparison to Chomyn (1996) and individual radiolabelled 
mitochondrial proteins were quantified using Image-Quant software with consideration of the 
background in each case. The image is representative for at least three independent 
experiments. Lower panel depicts a section of the gel after staining with Coomassie Brilliant 
Blue (CBB) to confirm equal loading. B) Western blot of 20 µg cell lysates was probed with 
antibodies against ICT1, to ensure depletion, proteins of the OXPHOS complexes (Complex IV: 
COX2; Complex I: NDUFB8) and a component of the mitochondrial ribosome (MRPL3). β-actin 
was used to confirm consistent loading. The image is representative for 3 independent 
experiments. The graph below shows the means with standard deviations of the measured 
signals using Image-Quant software, in comparison to the si-NT control, marked as dotted line. 
* significant (p = 0.01 to 0.05), ** very significant (p = 0.001 to 0.01), *** extremely significant (p 
< 0.001). 
 
Often a decrease in synthesis of mitochondrial encoded proteins of Complex I, as it 
could be seen in the de novo mitochondrial protein synthesis, leads to instability of 
some nuclear encoded ones. Both COX2 and NDUFB8 reflect a significant decrease in 
the protein steady state level of the OXPHOS complexes after ICT1 depletion. 
Interestingly a component of the mitochondrial ribosome MRPL3 was also slightly, but 
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significant decreased in those samples, in comparison to the control (n = 3, si-ICT1 A: 
83% p = 0.0344; si-ICT1 B: 79% p = 0.0036). Thus it may be that not only the 
OXPHOS complexes, but also the mitochondrial ribosome is affected by the ICT1 
depletion. This possibility will be investigated and discussed in the next chapter. 
 
4.4 
 
Discussion 
ICT1 was so far an uncharacterized protein the abundance of which altered during 
differentiation in colon carcinoma cells [Van Belzen et al., 1995]. From bioinformatics 
studies ICT1 is classified as belonging to the prokaryotic/ mitochondrial release factor 
family as it carries the characteristic GGQ-motif, which is essential for peptidyl-tRNA 
hydrolysis. ICT1 is a relatively small protein in comparison to other class I release 
factors, comprising 206 amino acids it is approximately the half of mtRF1a (380 amino 
acids). The differences in size is mostly the result of the loss of the codon recognition 
sites (tip of α5-helix tip, PXT-motif) in ICT1 and probably suggests that there is another 
function for ICT1 instead of it being a typical class I release factor like mtRF1a.  
In this study it has been shown that ICT1 is indeed a mitochondrial protein as predicted 
from several programmes like PSORTII and TargetP 1.1 with a mitochondrial cleavable 
target site of approximately 30 residues. There are also initial indications that unlike 
mtRF1a, which is a soluble matrix protein, ICT1 is a more insoluble protein resulting in 
less recovery of the protein in the supernatant after lysing cells in 1% Triton X-100 
containing buffer followed by a hard centrifugation step.  
To determine the function of ICT1, siRNAs were applied to down-regulate the 
endogenous protein from human cells. The depletion of ICT1 caused a decrease in 
growth rate so that cell number was lower after 3 days in comparison to a control. This 
was even more severe after 6 days. What can be the reason for this dramatic growth 
defect? Interestingly ICT1 is not expressed in ρ0 cells, cells that have no mitochondrial 
DNA and thus a mitochondrial expression machinery is redundant in those cells. This 
could be already the first indication that ICT1 is involved in the mitochondrial gene 
expression machinery and a loss of ICT1 could result in problems in the synthesis of 
mitochondrial encoded proteins. Indeed this was shown via de novo 35S metabolic 
labelling, the depletion of ICT1 in HeLa cells that caused a dramatic reduction in 
protein synthesis of mitochondrial encoded proteins. This really suggests that ICT1 is 
essential for mitochondrial gene expression. At this point it should be mentioned that 
there was no effect on 35S metabolic labelling after depletion of mtRF1a [Soleimanpour-
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Lichaei et al., 2007], which again supports the idea that the function of ICT1 is different 
from mtRF1a.  
Also the protein steady state level of components of Complex I (NDUFB8) and 
Complex IV (COX2) decreases after 3 days depletion of ICT1 and again an effect that 
was not seen with the mtRF1a depletion. Those results are also in agreement with 
those reported by Antonicka et al. (2010), where clearly the knockdown of ICT1 in 
fibroblasts caused a substantial loss and aberrance of the native OXPHOS complexes 
showed by Blue Native PAGE.  
What is the reason of the dramatic effect on mitochondrial protein synthesis after the 
loss of ICT1? What is the function of ICT1 in the mitochondrial gene expression 
machinery? Surprisingly also the mitochondrial ribosomal protein MRPL3, a component 
of the 39S large subunit seemed to be reduced after ICT1 depletion. Does ICT1 cause 
an effect on the stability of the mitochondrial ribosome and thus on the mitochondrial 
protein synthesis? This possibility will be investigated and discussed in the next 
chapter. 
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5 Chapter 5:                                                                         
ICT1 is a component of the mitochondrial ribosome 
 
5.1 
 
Introduction 
As was discussed earlier ICT1 is important for human mitochondrial gene expression 
and a loss of ICT1 shows not only a substantial decrease in mitochondrial protein 
synthesis, but also a reduction in the steady state level of mitochondrial ribosomal 
protein MRPL3. The fact that ICT1 was detected after immunoprecipitation of the 
mitochondrial ribosome via mtRRF-FLAG is unusual for a class I release factor 
[Rorbach et al., 2008], because the interaction of a release factor with the ribosome is 
a transient process and thus hard to detect. Furthermore none of the other members of 
this family were detected in this mtRRF-FLAG immunoprecipitation, not even mtRF1a. 
This is not a surprise, because using mtRRF-FLAG to co-immunoprecipitate the 
mitochondrial ribosome means the A-site is occupied and thus there is no space for 
mtRF1a to interact with the mitochondrial ribosome. Therefore how could ICT1 as a 
class I release factor be found in this immunoprecipitation? And why does the depletion 
of ICT1 cause just a dramatic reduction on mitochondrial protein synthesis and 
furthermore a decreased steady state level of MRPL3?  
In this chapter the function of ICT1 in the mitochondrial protein synthesis was further 
investigated. The aim of this part is to show whether i) ICT1 is really associated with 
the mitochondrial ribosome as is reasonable to suppose from the mtRRF-FLAG-
immunoprecipitation data and ii) whether the depletion of ICT1 leads to a ribosomal 
defect as maybe inferred from the reduced steady state level of MRPL3.  
 
5.2 
 
Identification of interaction partners of ICT1 via FLAG-
immunoprecipitation 
To determine whether there is a direct interaction between the mitochondrial ribosome 
and ICT1, ICT1 was used for immunoprecipitation to isolate and investigate potential 
interaction partners. For this approach ICT1, which was fused with a C-terminal FLAG 
tag, needed to be inducible expressed in HEK293T cells. First, ICT1 cDNA was 
amplified using the pCMV-SPORT6-ICT1 vector (I.M.A.G.E. ID 4418983, Geneservice) 
as a template and the primer #1 and #2 (Table 3.2) of which the reverse primer 
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contains the sequence for the FLAG tag, allowing fusion of the tag to the C-terminus of 
ICT1. The amplicon and the target vector pcDNA5/FRT/TO were then digested with the 
restriction enzymes HindIII and EcoRV, followed by dephosphorylation of the vector 
and finally the ligation of vector and insert. After successful cloning and sequencing, 
HEK293-Flp-InTMT-RExTM cells were transfected with pcDNA5/FRT/TO-ICT1-FLAG and 
pOG44 as described in 3.1.5. After proving that the construct was expressed after 
tetracycline induction and also imported into the mitochondria, the cells were used for 
an immunoprecipitation via the FLAG tag as detailed in 3.5.9. As a control for 
unspecific binding in this experiment a mitochondrial targeted luciferase, fused with the 
Su9 pre-sequence from N. crassa [Viebrock et al., 1982] and also with a C-terminal 
FLAG tag (mtLuc-FLAG), was used under the same conditions. This cell line was kindly 
provided by Dr. M. Wydro (host laboratory).  
The results were analysed by silver staining and western blot, shown in figure 5.1.  
 
Figure 5.1: ICT1 is associated with mitochondrial ribosomal proteins. HEK293T cells 
expressing ICT1-FLAG were induced with 1 µg/ ml tetracycline. After 3 days cells were 
harvested, mitochondria isolated and purified prior to lysis. Mitochondrial lysates (3 mg) were 
used for immonprecipitation via FLAG tag. As a control mtLuc-FLAG was treated in the same 
way. Mitochondrial lysate (5 µg) of ICT1-FLAG and elution fractions (10%) of each sample were 
separated by SDS-PAGE (15%). (A) The SDS gel was analysed by silver staining, where (*) 
indicates the FLAG tagged protein. B) Western blot of the same samples was probed with 
antibodies against mitochondrial ribosomal proteins (39S LSU: MRPL3 and MRPL12; 28S SSU: 
MRPS6 and DAP3) and mtRRF. SDH, a component of Complex II, was used as a general 
negative control for unspecific binding. Antibodies against the FLAG epitope were used to 
confirm expression of the FLAG tagged protein and successful immunoprecipitation via the 
FLAG tag. 
 
The 5 µg mitochondrial lysate of ICT1-FLAG sample (Figure 5.1 A, left lane) 
demonstrate the pattern of “input” sample in this experiment on the silver stained gel. 
Separating proteins from each IP elution fraction on the same gel shows clearly a lot of 
additional bands in the eluate of ICT1-FLAG in comparison to the negative control 
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mtLuc-FLAG (Figure 5.1 A, right hand lanes). To determine whether mitochondrial 
ribosomal proteins co-immunoprecipitate with ICT1-FLAG a western blot with the 
elution fractions and 5 µg of input sample was probed with antibodies against MRPL3 
and MRPL12, both proteins of the mitochondrial ribosomal large subunit (39S LSU) 
and against MRPS6 and DAP3, components of the small subunit (28S SSU). All 
proteins could be detected in the elution fraction of ICT1-FLAG, but not in that of 
mtLuc-FLAG (Figure 5.1 B). Another test for unspecific binding was to check for an 
abundant protein namely the 70 kDa subunit of SDH, which was not present in either 
eluate, but could be detected in the input sample, proving that the antibody was 
working in this experiment. Additionally also the mitochondrial ribosome recycling factor 
(mtRRF) could be found at low level in the elution fraction of ICT1-FLAG. This is not a 
surprise as ICT1 was also one of the associated proteins in the mtRRF-FLAG IP 
[Rorbach et al., 2008], where the majority of mitochondrial ribosomal proteins could be 
also detected. These facts suggest strongly an association of ICT1 with the 
mitochondrial ribosome. 
Furthermore to be certain that ICT1 interacts with the whole mitochondrial ribosome as 
speculated the elution fraction was separated by SDS-PAGE, stained with 
SimplyBlueTM SafeStain (Invitrogen) as described in 3.5.4.2 and the gel lane was cut 
into three pieces. Together with a negative control elution, samples were sent for LC 
MS/MS (Liquid chromatography - tandem mass spectrometry) analysis to H. Wessels 
courtesy of Prof. J. Smeitink at UNMC, Nijmegen. For this approach it was essential 
that isolated mitochondria for the IP were stringently purified prior to lysis as described 
in 3.5.8 to avoid as much as possible unspecific bindings of cytosolic proteins 
especially ribosomal ones. The results from ICT1-FLAG elution were compared to the 
negative control to exclude contaminations, particularly the common keratin peaks. 
From the final data of the LC MS/MS approximately 200 proteins could be found in the 
ICT1-FLAG IP (See appendix 1) where the mitochondrial ribosomal proteins were the 
most abundant. 26 proteins of the 28S SSU and 41 of the 39S LSU could be detected 
(Table 5.1), which further supports the idea that ICT1 is strongly associated with the 
mitochondrial ribosome. 
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Table 5.1: Mitoribosomal proteins identified as co-purifying components of the ICT1 
immunoprecipitation 
 
Small Subunit (28S) - SSU 
  
Large Subunit (39S) - LSU 
 
MRPS2, MRPS5, MRPS6, 
MRPS7, MRPS9, MRPS10, 
MRPS11, MRPS14, MRPS16, 
MRPS17, MRPS18A, 
MRPS18B, MRPS21, MRPS22, 
MRPS23, MRPS24, MRPS25, 
MRPS26, MRPS27, MRPS28, 
MRPS29/DAP3, MRPS30, 
MRPS31, MRPS34, MRPS35, 
METT11D1 
  
MRPL1, MRPL2, MRPL3, MRPL4, MRPL9, 
MRPL10, MRPL11, MRPL12, MRPL13, 
MRPL14, MRPL15, MRPL16, MRPL17, 
MRPL18, MRPL19, MRPL20, MRPL21, 
MRPL22, MRPL23, MRPL24, MRPL27, 
MRPL28, MRPL31, MRPL32, MRPL37, 
MRPL38, MRPL39, MRPL40, MRPL41, 
MRPL43-a, MRPL43-b, MRPL44, MRPL45, 
MRPL46, MRPL47, MRPL48, MRPL49, 
MRPL50, MRPL51, MRPL54, MRPL55 
 
26 MRPS of 31 
  
41 MRPL of 50 
 
5.3 
 
ICT1 is associated with the 39S LSU and the 55S monosome 
5.3.1 Endogenous ICT1 is associated with the 39S LSU  
The advantage of expressing a FLAG tagged protein in the Flp-In system is that it 
provides the possibility of using it in a specific immunoprecipitation via the FLAG tag. 
The disadvantage is the fact that high levels of overexpression and/ or tagged proteins 
could cause artefactual results. Thus it has to be proved whether the endogenous ICT1 
is also associated with the mitochondrial ribosome. Therefore 700 µg cell lysate were 
separated on an isokinetic sucrose gradient as described in 3.5.11. Fractions, which 
were taken from top (1) to bottom (10), were analysed by western blot. ICT1 could be 
clearly seen to co-sediment with components of the 39S LSU, namely MRPL3 and 
MRPL12 in fraction 6 (Figure 5.2). MtRRF, located in fraction 1, can be used as a 
soluble marker under those conditions. DAP3 as a component of the 28S SSU was 
more detectable in fraction 4, 5 and a little bit in 6. 
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Figure 5.2: ICT1 co-migrates with components of the 39S LSU. HeLa cell lysate (700 µg) 
was separated on a 10 % to 30 % isokinetic sucrose gradient for 135 min at 100,000xg. 
Fractions (1-10) were taken from top to bottom and then analysed by western blot. The 
membrane was probed with antibodies against components of the 39S LSU (MRPL3 and 
MRPL12) and the 28S SSU (DAP3) to determine the relative sedimentation of the subunits 
within those gradients. Distributions of ICT1 and mtRRF are also shown.  
 
From this result it seems that the monosome is not detectable in these gradients. From 
more RNA based work in this laboratory on such gradients it is known that the cytosolic 
ribosomal RNA from the 60S (28S rRNA) is located approximately in fractions 8 and 9, 
visualised by ethidium bromide stained agarose gels. From the sedimentation 
coefficient it would be expected that the 55S mitochondrial monosome is also migrating 
in approximately the same position. However, there is clearly a lack of DAP3 in the 
later fractions, which suggest there is no monosome and ICT1 seems to be only 
associated with the 39S large subunit and not with the 28S, however, IP results show 
both components or the monosome respectively.  
 
5.3.2 ICT1-FLAG immunoprecipitation shows association of ICT1-
FLAG with the 39S LSU and the 55S monosome 
To distinguish whether ICT1 is associated with the 39S LSU or/ and with the 55S 
monosome, 80% of IP eluate was separated on the same range isokinetic sucrose 
gradient, followed by analysis via western blot (upper panels) and silver staining (lower 
panel) as shown in figure 5.3. On the silver stained gel the majority of co-
immunoprecipitated proteins was mainly localised in the later fractions 6 to 8. 
Furthermore a strong band that corresponds to the overexpressed ICT1-FLAG was 
seen in the earlier fractions 1 and 2.  
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Figure 5.3: ICT1-FLAG co-sediments with 39S and 55S of the mitochondrial ribosome 
after immunoprecipitation. Mitochondrial lysate (3 mg) from HEK293-ICT1-FLAG was used 
for the IP, from which 80% of the elution were separated by isokinetic sucrose gradient. The 
fractions (1-10) were analysed by silver staining (lower panel) and western blot (upper panels). 
Antibodies against MRPL3 and DAP3 were applied to the membrane to determine the level of 
co-immunoprecipitated 39S LSU, 28S SSU and 55S monosome, respectively. The relative 
positions of the ribosomal complexes within this gradient are indicated above the image. ICT1-
FLAG was detected by using antibodies against the FLAG octapeptide.  
 
To determine further where the ribosomal proteins migrated in the gradient, a western 
blot with the same fractions was probed with antibodies against MRPL3 and DAP3. 
MRPL3 was mostly found in fractions 6 to 8. Interestingly DAP3 shifted to the later 
fractions 7 and 8, where it co-sediment this time with MRPL3, the component of the 
LSU, which suggests that the 55S monosome migrates in those fractions. ICT1-FLAG 
was, besides the free form in fractions 1 and 2, also detectable in fractions 6 to 8 like 
MRPL3. From this experiment it can be concluded that ICT1-FLAG is associated with 
the 39S LSU and with the 55S monosome, but not with the 28S SSU alone. 
 
5.3.3 ICT1 is strongly associated with protein components of LSU 
Besides ribosomal proteins, an intact ribosome contains also the ribosomal RNA 
(rRNA). The structure of the rRNA within the ribosome depends not only on the protein 
factors but also on Mg2+. 
After depletion of Mg2+ from the experiment, by using a chelating agent such as EDTA, 
it is possible to disturb the RNA structure and therefore the interactions of proteins that 
are more dependent on the RNA or an intact ribosome. To determine whether ICT1 is 
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more associated with the ribosome via the RNA or whether there are more protein-
protein interactions, a similar IP as above was carried out, but instead of containing 10 
mM MgCl2 there was 50 mM EDTA added to the experiment. Separating this IP eluate 
on a gradient showed clear differences (Figure 5.4). On the silver stained gel (lower 
panel) the majority of proteins shifted to fraction 5 and 6, whereas they were mostly 
located in fraction 6 to 8 before. This is a clear indication of a substantial loss in the 
size of the complex, but still there were a lot of proteins co-immunoprecipitated in the 
ICT1-FLAG immunoprecipitation even in the presence of 50 mM EDTA.  
 
 
Figure 5.4: Interaction of ICT1 with components of the 39S LSU is not RNA dependent. 
Mitochondrial lysate (3 mg) of ICT1-FLAG overexpressor was treated with 50 mM EDTA to 
deplete Mg2+. After IP, 80% of the eluate was separated by isokinetic sucrose gradient. 
Fractions were analysed by silver staining (lower panel) and western blot (upper panels). 
MRPL3 and DAP3 were used as before to visualise the level of co-immunoprecipitated 
ribosomal complexes by ICT1-FLAG, which was detected by using FLAG antibodies.  
 
This suggests that there are several protein-protein interactions, which is one of the 
specific features of the mammalian mitochondrial ribosome [Sharma et al., 2003]. The 
western blot demonstrates that there was clearly a loss of DAP3, meaning that with 
loss of the RNA, there is no longer a monosome. In contrast there was still a strong 
interaction with MRPL3. It would be interesting to know which other proteins remain 
associated with the ICT1-FLAG IP under these conditions, however further antibodies 
to MRPL peptides are not available with which to probe this blot. In conclusion ICT1 
can be seen as an integral component of the mitochondrial ribosomal large subunit, 
because the interaction with the mitochondrial ribosome is not transient, it shows 
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clearly strong protein-protein interactions and the endogenous form could not be 
detected free, but always in association with the LSU. 
 
5.3.4 The association of ICT1-FLAG with the 55S monosome is not 
caused by overexpression or by the FLAG tag 
To exclude that the overexpression of ICT1-FLAG causes an accumulation of the 55S 
monosome, as seen in the IP eluate gradient, several control experiments needed to 
be done. First, 700 µg cell lysate of the ICT1-FLAG overexpressor were analysed by 
sucrose gradient after 3 days induction. The resulting data is shown on western blot in 
figure 5.5. As before, a lot of the overexpressed form was localised in the earlier 
fractions 1 to 4, however, in this experiment ICT1-FLAG was further only seen in 
fraction 6, but nothing in the later fractions. DAP3 also did not co-migrate this time with 
MRPL3 in the later fractions. This is a clear indication that at least the overexpression 
of ICT1-FLAG is not the reason for the appearance of the monosome on those 
gradients of IP-ed eluate.  
 
 
 
Figure 5.5: ICT1-FLAG co-migrates with 39S LSU and its overexpression causes no 
accumulation of 55S. HEK293-ICT1-FLAG cells were induced with 1 µg/ ml tetracycline. After 
3 days cells were harvested and lysed. Cell lysate (700 µg) was separated on a 10 to 30% 
sucrose gradient and fractions were analysed by western blot. To determine the relative level of 
individual ribosomal subunits and the 55S monosome, respectively after ICT1-FLAG 
overexpression, antibodies against markers for the 39S LSU (MRPL3) and the 28S SSU 
(DAP3) were applied to the western blot membrane. The distribution of ICT1-FLAG is also 
shown by using FLAG antibodies.  
 
Another control was to run similar experiments with FLAG-tagged components of the 
28S SSU and the 39S LSU. Therefore overexpressed MRPS27-FLAG and MRPL20-
FLAG (expressing cell lines were kindly provided by Dr. J. Rorbach and Dr. P. Smith, 
respectively both from host laboratory) were used to co-immunoprecipitate the 
mitochondrial ribosome and of course the individual intermediates, which were then 
separated on an isokinetic sucrose gradient as before.  
Western blot in figure 5.6 A showed that MRPS27-FLAG co-immunoprecipitated a 
substantial amount of the 28S SSU and intermediates of it, but it did not pull down a lot 
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of the monosome. However, it clearly shows that also in this experiment it was possible 
to visualise the monosome in fraction 8, as ICT1, MRPL3, DAP3 and of course 
MRPS27-FLAG all co-migrated in this fraction.  
 
Figure 5.6: Association of ICT1 with 55S monosome is not FLAG tag dependent. 
Mitochondrial lysates from cells expressing MRPS27-FLAG (A) or MRPL20-FLAG (B) were 
used for IP, from which the elution fractions (80%) were separated on an isokinetic sucrose 
gradient. The distribution of co-immunoprecipitated ribosomal subunits and 55S monosome was 
determined by western blot using antibodies against DAP3, representing the 28S SSU, and 
MRPL3, a member of the 39S LSU. The migration of endogenous ICT1 within these 
experiments was visualised by probing the western blot membrane with specific antibodies 
against ICT1.  
 
In contrast, MRPL20-FLAG shows association with the 39S LSU (Figure 5.6 B), where 
the main population was again located in fraction 6 with relatively strong signals of 
ICT1 and MRPL3. As in the gradient with ICT1-FLAG eluate, DAP3 was shifted to 
fraction 8, where it co-localised with ICT1, MRPL3 and MRPL20-FLAG. 
 
In conclusion it can be said that ICT1 is an integral component of the 39S LSU and 
therefore of the 55S monosome. ICT1-FLAG is able to pull down the monosome, which 
migrates on a sucrose gradient mainly in fraction 8. The association of ICT1 with the 
monosome, which could not be seen before, is not a result of overexpression the 
protein, as the same association could be seen with the endogenous ICT1 in 
mitochondrial ribosome co-immunoprecipitated with MRPS27-FLAG and MRPL20-
FLAG.  
 
5.4 
 
ICT1 depletion causes conformation changes in the 39S LSU 
and a loss of the 55S monosome 
If ICT1 is really a component of the 39S LSU it would be important to analyse what 
would happen to the mitochondrial ribosome after a loss of ICT1. Therefore HeLa cells 
were treated with si-ICT1 B or si-NT, respectively for 3 days and the cell lysates were 
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separated on isokinetic sucrose gradient. The fractions were analysed by western blot 
as shown in figure 5.7.  
 
Figure 5.7: ICT1 depletion affects assembly of 39S LSU. ICT1 depleted cell lysate (600 µg) 
was subjected to an isokinetic sucrose gradient. The fractions (1-10) were analysed by western 
blot using antibodies against ICT1 to ensure depletion in the siRNA targeting sample (lower 
panels) and further to visualise the distribution of ICT1 in the control (upper panels). The effect 
of ICT1 depletion on the ribosomal profile was determined by probing the membrane with 
MRPL3- (39S LSU) and DAP3 (28S SSU) antibodies.  
 
Using anti-ICT1 antibodies showed clearly successful depletion of ICT1 in samples 
from cells treated with si-ICT1 B, but not those treated with si-NT. Interestingly, MRPL3 
showed a difference in the migration on the gradients between the two samples. In the 
si-NT sample it was located as usually, mainly in fraction 6 and a little in 7, whereas in 
the depleted sample MRPL3 shifted to fraction 5 and 6, which indicates a loss in the 
sedimentation of the 39S LSU. DAP3 did not show obvious differences and was 
located in fraction 4 and 5 as before. Those data suggests that the depletion of ICT1 
causes a conformation change of the 39S LSU but not the 28S SSU which remains 
unchanged. 
 
To be absolutely certain about the result that ICT1 depletion causes a defect in 
formation of the 39S LSU and also to analyse what would happen to the monosome, 
another approach needed to be used. As shown before MRPS27-FLAG can be used to 
co-immunoprecipitate the 55S monosome, therefore it was utilised as a tool to 
investigate consequences of ICT1 depletion at the level of monosome formation. The 
hypothesis would be that the loss of ICT1 will cause a conformation change in the 39S 
LSU, which would lead to a reduced ability of the 39S LSU to interact with the 28S to 
form a 55S monosome. Therefore the depletion of ICT1 should result a decrease 
amount of co-immunoprecipitated 55S monosome via MRPS27-FLAG in comparison to 
the si-NT control (Figure 5.8 A).  
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HEK293T cells expressing MRPS27-FLAG were transfected with si-ICT1 B and si-NT, 
respectively for 3 days using lipofectamine as described in 3.1.6.2. After one day 
transfection cells were induced with 1 µg/ ml tetracycline to give the cells 2 days time to 
overexpress MRPS27-FLAG. The elution fractions of both immunoprecipitations were 
analysed by western blot (Figure 5.8 B) and signals were measured using Image-
Quant software.  
 
 
Figure 5.8: ICT1 depletion causes a loss of the 55S monosome. A) The cartoon 
demonstrates the loss of the ability of the 39S LSU to interact with the 28S SSU after ICT1 
depletion. Using MRPS27-FLAG to co-immunoprecipitate the 55S monosome would result in 
decreased amounts of 39S LSU components (MRPL3 and MRPL12) in the elution fraction of 
ICT1 depleted samples, whereas the relative level of components of the 28S SSU (DAP3) 
should be unaffected. B) HEK293T cells expressing MRPS27-FLAG were treated with si-NT or 
si-ICT1 B for 3 days. Equal amounts of cell lysates (~ 2 mg) were used for immunoprecipitation 
via MRPS27-FLAG. The elution fractions were analysed by western blot and the relative 
amount of monosome was determined by measuring the level of MRPL3 and MRPL12 from 3 
independent experiments. The mean of measured signals of the si-NT control is marked as a 
dotted line. (n = 3; MRPL3 p = 0.001; MRPL12 p = 0.0002; ICT1 p = 0.0001; ** very significant: 
p = 0.001 to 0.01; *** extremely significant: p < 0.001)  
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The results as presented in the graph in figure 5.8 B reflect three independent 
experiments, where after ICT1 depletion (to ~ 10%; p = 0.0001) the level of MRPL3 (p 
= 0.001) and MRPL12 (p = 0.0002) decreased to ~ 30%, but DAP3 remained at similar 
level as in si-NT treated samples (marked as dotted line).  
Concluding from those results, there is not only a conformation change in the 39S LSU 
there is also a loss in the level of the 55S monosome after ICT1 depletion, which more 
strongly supports the hypothesis that ICT1 is an integral component of the 
mitochondrial ribosome. 
 
5.5 
 
Discussion 
ICT1 as one of the four members of the mitochondrial release factor family was 
identified after immunoprecipitation of the mitochondrial ribosome via mtRRF-FLAG 
[Rorbach et al., 2008]. None of the other members (mtRF1a, mtRF1 and C12orf65) 
were detectable in this IP, which is not unexpected, because the interaction of the 
release factor with the ribosome is usually a transient process and thus difficult to 
detect. Furthermore using mtRRF for immunoprecipitating the mitochondrial ribosome 
means that the A-site is occupied by mtRRF and thus there is no room to 
accommodate a class I release factor. Therefore why could ICT1 be found in the IP of 
mtRRF-FLAG?  
In the present study it could be shown that the mitochondrial ribosome has been co-
immunoprecipitated with ICT1-FLAG (Figure 5.1), which is the first time that a release 
factor has been shown in strong association with ribosomal proteins using 
immunoprecipitation procedure. Under the same conditions but using mtRF1a-FLAG, it 
is not possible to detect immunoprecipitation of the mitochondrial ribosome (data not 
shown). In addition to mitochondrial ribosomal proteins there were also trace amounts 
of mtRRF detectable in the elution, which was expected as mtRRF-FLAG originally 
immunoprecipitated ICT1. The fact that mtRRF and ICT1 can interact with the same 
mitochondrial ribosome, suggests that ICT1 does not occupy the A-site as either 
mtRRF or the class I release factor mtRF1a. This again supports the idea that ICT1 
functions in another way to mtRF1a.  
Furthermore it could be shown that endogenous ICT1 migrates with the 39S LSU on an 
isokinetic sucrose gradient (Figure 5.2), but under those conditions no 55S monosome 
could be detected. The western blot (Figure 5.1 B) and LC MS/MS analysis (Table 5.1) 
from ICT1-FLAG immunoprecipitation, however, suggested that ICT1 is associated 
either with the 55S monosome or with the 28S SSU and 39S LSU, respectively. Again 
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the fact that mtRRF, as a marker for the 55S particle, was detected within the ICT1-
FLAG elution supports the hypothesis that ICT1 interacts with the 55S monosome. 
Separating the ICT1-FLAG IP eluate on an isokinetic sucrose gradient showed that 
ICT1-FLAG co-sediments with the 39S LSU and also with the 55S monosome, but not 
with the 28S SSU (Figure 5.3).  
 Why is the 55S monosome only detectable after immunoprecipitating the 
mitochondrial ribosome? The overexpression of ICT1 has been excluded as the reason 
because cell lysate of the overexpressor showed only the 39S LSU and the 28S SSU, 
on a sucrose gradient analysed by western blot (Figure 5.5). Furthermore with 
immunoprecipitation of MRPS27-FLAG and MRPL20-FLAG a purification of the 55S 
monosome is possible where the endogenous ICT1 was also detected within the 55S 
particle (Figure 5.6). The difficulty to see the monosome has also been reported in 
other studies [Nolden et al., 2005, Williams et al., 2005].  
 What is the difference in the gradients and what is causing the appearance of 
the 55S monosome only after IP? A difference of buffer conditions during lysis and the 
actual gradient can be excluded as they are the same. One point could be that the 
immunoprecipitation effectively concentrates the amount of mitochondrial ribosome in 
the sample, whereas in contrast the concentration of the monosome in cell lysate can 
be to low and therefore more below the levels of sensitivity of western detection. This 
would leave the question whether a low amount of 55S monosome is the physiological 
situation within the mitochondria or whether it is caused by the experimental 
procedure? However, the main difference between the gradient of cell lysate and IP-ed 
eluate is most likely the difference in incubation time of the IP-ed samples. For the 
binding step in the IP the samples, which are mitochondrial lysates, are left for 3 hours 
to allow binding of the FLAG antibody to the FLAG tag. In contrast for a standard 
gradient cell lysates are prepared and applied immediately to the gradient. What can 
happen during those 3 hour incubation? It is possible that mRNA is degraded and 
potentially mtIF3 is too diluted under those conditions to inhibit the formation of the 
55S. Results from real time PCR within this study, and also those of another PhD 
student, A. Pajak, both showed that the mt-mRNA is indeed absent in those IP-ed 
monosomes, whereas mt-ribosomal RNAs were still present. The possibility that mtIF3 
is not present in sufficient concentration is also in agreement with the fact that the 
elution fraction of immunoprecipitated mtRRF-FLAG shows substantial amounts of the 
associated mitochondrial ribosome. There are suggestions that mtIF3 plays an active 
role and is thus absolutely critical for the ribosome recycling process [Christian and 
Spremulli, 2009]. In addition to mtIF3, mtEFG2 (mtRRF2) [Tsuboi et al., 2009] is also 
needed for successful disassembly of the 55S into the 28S SSU and the 39S LSU. In 
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summa it seems probable that the mt-mRNA is degraded during lysis and over the 3 
hour incubation time, which then allows, in combination with the diluted amounts of 
mtIF3 and/ or mtEFG2 the ribosomal subunits to reform the 55S monosome. Another 
support of this theory is that the endogenous mtRRF is normally located in the earlier 
fractions on isokinetic sucrose gradient (Figure 5.2), but after incubating lysates for 3 
hours a shift of mtRRF to the later fractions was observed, suggesting binding of this 
factor to the ribosome [Rorbach et al., 2008].  
Thus, it is possible to detect the 55S monosome under certain experimental conditions 
and ICT1 was shown to be associated with it. However, it is still unclear what the 
physiological situation is, meaning are the majority of 28S SSU and 39S LSU free and 
only a limiting amount of them part of a translating 55S monosome or is the 55S 
particle the more prominent stage within the mitochondria and only the experimental 
procedure is causing the disassembling of the subunits? One characteristic feature of 
the mitochondrial ribosome is a tight association with the inner mitochondrial 
membrane (IMM) [Liu and Spremulli, 2000]. It has been proposed that mitochondrially 
encoded proteins are translated at this site of the IMM where they will be assembled 
into the OXPHOS complexes allowing a co-translational insertion into the membrane 
[Koc et al., 2010]. This might suggest that only membrane bound ribosomes are 
translationally active as also proposed by Nolden et al. (2005). Using a detergent such 
as Triton X-100 to lyse the cells will lead to a disruption of the interaction of most of the 
mitochondrial ribosomes with the inner membrane. Therefore, maybe as a 
consequence of losing the interaction with the inner membrane, the 55S monosome 
initially comes apart into the 28S SSU and 39S LSU and only by increasing the 
incubation time, where mRNA gets degraded and mtIF3 and/ or mtEFG2 are limited, 
the subunits reassemble again into the 55S monosome. Currently this is just a 
hypothesis, the testing of which will be challenging.  
 
The interaction of ICT1 with the 39S LSU was shown to be RNA independent, as the 
presence of high EDTA concentration still allowed the co-immunoprecipitation of a 
large complex with ICT1-FLAG located in fractions 5 and 6 in sucrose gradient (Figure 
5.4). One of the proteins that remained associated was MRPL3. It was shown 
previously that after treatment with EDTA the 55S monosome is no longer retained 
intact [Rorbach et al., 2008]. Proteins such as mtRRF lose their ability to show 
association with the mitochondrial ribosome as their interaction are dependent on rRNA 
structure and/ or an intact 55S monosome. Consistent with those results, after EDTA 
treatment ICT1-FLAG shows no longer an association with the 55S monosome as 
evidenced by the loss of DAP3 from the later gradient fractions. The components of the 
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complex that remains after EDTA treatment, suggests that there is a tight interaction of 
ICT1 with mitochondrial ribosomal proteins. Thus this result and the fact that the 
endogenous protein was always co-migrating with MRPL3 in fraction 6 and never free 
(Figure 5.2) suggest that ICT1 is actually an integral component of the 39S LSU.  
One of the specific characteristics of mammalian mitochondrial ribosome is that it is 
very protein rich (~69%) and relatively RNA poor (~31%) in comparison to the bacterial 
one as described in 1.7.1 [reviewed in O’Brien 2002; Sharma et al., 2003] where the 
proportions are reversed. It was suggested that the truncations of the ribosomal RNAs 
within the mammalian mitochondria are compensated through an increase in size of 
existent homologous proteins or additional proteins [O’Brien 2002]. Therefore 
approximately half of the proteins are homologous to bacterial ones and the other half 
are specific for the mammalian mitochondrial ribosome. These additional proteins 
appear sometimes to pre-exist and/ or to be bi-functional. Examples for those bi-
functional proteins are DAP3 (MRPS29) and PDCD9 (MRPS30), both suggested to be 
involved in apoptosis [Koc et al., 2001a]. Another example is MRPL12 that directly 
interacts with POLRMT in addition to being a mitochondrial ribosomal protein of the 
39S LSU [Wang et al., 2007], suggesting a further function as a transcription-
translation coupling factor. Another example is MRPL39, which shows similarity to the 
N-terminal domain of the mitochondrial threonyl-tRNA synthetase [Spirina et al., 2000]. 
It was proposed that mitochondrial threonyl-tRNA synthetase was recruited into the 
mitochondrial ribosome and then lost its C-terminal domain. It is tempting to speculate 
that ICT1 is another example of a pre-existing protein that has been recruited into the 
mitochondrial ribosome. Whether the codon recognition motifs were lost before or after 
the recruitment of ICT1 into the mitochondrial ribosome is unclear, but the results 
presented in this chapter show clear evidence that ICT1 has become a mitochondrial 
ribosomal protein. This data was published [Richter et al., 2010] prior to writing of this 
thesis and this finding was subsequently also the subject of a ‘commentary’ [Haque 
and Spremulli, 2010] and review by others as Koc et al. (2010) where ICT1 was 
designated MRPL58 for consistence with the accepted nomenclature.  
Why was ICT1 not previously reported to be a mitochondrial ribosomal protein in 
mammals [O’Brien, 2002]? 
There can be many reasons why so far ICT1 was missing in the screenings from 
O’Brien or Spremulli and colleagues [O’Brien, 2002; Koc et al., 2001a/b]. It is possible 
that harsh isolation procedures lead to the loss of some 55S members [Matthews et al., 
1982]. Another possibility is that a protein like ICT1 was present, but was originally 
considered to be a contaminant. In the past few years bioinformatical predictions 
concerning mitochondrial localisation have become more sophisticated and an 
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advantageous tool, whereas 10 to 20 years ago those kinds of predictions were more 
difficult to achieve. Thus it is also possible that there are still some proteins missing. In 
fact the available structure of the bovine mitochondrial ribosome [Sharma et al., 2003] 
shows a quite porous structure caused by the loss of rRNA, however, there are also 
gaps, where it is tempting to speculate whether there are some missing proteins that 
would fill these spaces.   
 
The association of ICT1 with the mt-LSU seems to be quite late during the assembly 
process of the 39S. This conclusion is derived from the result in figure 5.3, where ICT1 
is not interacting with a lot of large subunit intermediates as is the case with MRPL20 
(Figure 5.6 B). ICT1 is likely to interact with the 39S LSU at a quite late stage, when the 
assembly is almost complete, because as shown in the silver stained gel in figure 5.3 
the ribosomal complex co-immunoprecipitated with ICT1 is quite dense, starting in 
fraction 6. This would be also in agreement that the depletion of ICT1 that is causing a 
ribosomal defect shows “only” a shift of the mitochondrial ribosomal LSU component 
MRPL3 from fractions 6/7 to 5/6 (Figure 5.7), meaning there is a loss of density/ size of 
the 39S LSU, but there is still a quite big complex in the absence of ICT1. However, 
these are only suggestions according to the presented data in this chapter. 
The resulting defect in the 39S LSU after depletion of ICT1 is further causing a loss of 
intact 55S monosome (Figure 5.8). Using MRPS27-FLAG as a tool to co-
immunoprecipitate the 55S monosome it was possible to measure changes in the level 
of associated ribosomal components after the loss of ICT1. In comparison to the 
control, the depletion of ICT1 caused a decrease in the level of associated MRPL3 and 
MRPL12 proteins by MRPS27-FLAG to approximately 30%, whereas DAP3 remained 
unchanged. Those data strongly suggest that ICT1 as a ribosomal protein is essential 
for the assembly of the 39S LSU and a defect in the 39S LSU caused by a loss of ICT1 
leads to a reduced level of translationally active monosome. This result is also in 
agreement with the 35S-met de novo synthesis, where mitochondrial protein synthesis 
decreased to <40% after ICT1 depletion (Figure 4.4). Thus the reason for the dramatic 
reduction in mitochondrial translation after downregulation of ICT1 is actually the loss 
of the 55S monosome.  
Concluding so far ICT1 was shown to be an integral component of the 39S LSU and 
the 55S monosome. A loss of ICT1 leads to a ribosomal defect in the 39S LSU, 
causing less translationally active monosome and thus a decrease in mitochondrial 
protein synthesis.  
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6 Chapter 6:                                                                         
ICT1 is a ribosome-dependent, but codon-
independent peptidyl-tRNA hydrolase 
 
6.1 Introduction 
 
Data presented so far has shown that ICT1 is an important mitochondrial protein, 
essential for mitochondrial protein synthesis and a component of the mitochondrial 
ribosomal large subunit. This is unexpected as from the bioinformatic point of view 
ICT1 is defined as a member of the prokaryotic/ mitochondrial release factor family. 
This classification is mainly based on ICT1 harbouring the highly conserved GGQ motif 
(Figure 6.1), which is essential for promoting the catalysis of the peptidyl-tRNA 
hydrolysis within the ribosome.  
 
 
Figure 6.1: Structure alignment of RF1 (Thermus thermophilus) and ICT1 (Mus 
musculus). Available structures from a bacterial class I release factor RF1 (grey, Thermus 
thermophilus, PDB: 3D5A, Laurberg et al., 2008) and ICT1 (green, Mus musculus, PDB: 1J26 
unpublished) were superimposed using PyMOL. RF1 is shown with 4 domains. The GGQ motif 
within a flexible loop in domain 3 is labelled in red. The crucial motifs for stop codon recognition, 
namely the tip of the α5 helix and the PXT tripeptide motif, are shown in brown and blue, 
respectively within domain 2. The arrow shown within the ICT1 structure indicates an additional 
helix absent in bacterial RF1.  
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It is not only the GGQ motif that is critical for the function of a class I release factor, 
also the codon recognition motifs (tip of α5 helix and PXT/SPF) are absolutely crucial 
features for a conventional class I release factor to recognise sequence specific the 
stop codon in the decoding centre of the ribosomal A-site. ICT1 is a relatively small 
protein with 206 aa and lacks both of these motifs (Figure 6.1). Thus it is unlikely that it 
acts like a typical class I release factor in the manner of mtRF1a. The fact that it has 
become incorporated as part of the mitochondrial ribosome, a circumstance not 
previously reported for a release factor, strongly supports the hypothesis that ICT1 
functions in a different way to a classical release factor. Two facts however indicate 
that ICT1 maintained its ability to catalyse peptidyl-tRNA hydrolysis activity. These are 
the presence of the GGQ motif in a flexible loop and also the structural similarity of 
ICT1 to the domain 3 of a class I release factor (Figure 6.1), which in conventional RFs 
flips out from the core to localise the GGQ motif in the peptidyl-transferase centre 
(PTC) [Petry et al., 2005]. 
In this chapter ICT1 is further investigated on its possible function as a peptidyl-tRNA 
hydrolase. Therefore analysis will follow two main approaches that will be: 
 i)  recombinant protein will be tested for release activity using the in vitro  
  translation termination assay and  
 ii)  the effect on the function of ICT1 harbouring a mutation within the  
  conserved GGQ motif that is known to abolish activity will be   
  investigated in vitro and in vivo.  
 
6.2 Purification of recombinant ICT1 
 
To investigate the possibility that ICT1 has retained the same activity as a class I 
release factor, a recombinant form of ICT1 needed to be recombinant generated, 
purified and tested in the in vitro translation termination assay. For this approach ICT1 
was cloned into pGex-6P-1 using primers #3 and #5 (Table 3.2) for cDNA amplification 
and BamHI and XhoI for restriction digest. This allowed a 5’-ligation of ICT1 to 
Glutathione-S-transferase (GST) tag, the expression of which is under an IPTG 
inducible promotor on the pGex-6P-1 vector. RosettaTM(DE3) bacteria were finally 
transformed with pGex-6P-1 carrying the GST-ICT1 fusion construct. The purification of 
recombinant full length ICT1 (ICT1 FL) was performed as detailed in 3.5.12. ICT1 FL 
was very insoluble, resulting in a low recovery of the protein in soluble fraction after 
sonication. Thus the amount of purified ICT1 FL was relatively low. Furthermore 
western blot as shown in chapter 4 (Figure 4.1) suggests a mitochondrial cleavable 
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target site approximately 30 aa from the N-terminus. Therefore a truncated version of 
ICT1 using oligonucleotides #4 and #5 (Table 3.2) needed to be cloned in-frame at the 
C-terminus of the GST-tag in pGex-6P-1, which was then used for E. coli 
RosettaTM(DE3) transformation. The resulting amplicon excluded 87 nt from the 5’-end 
of the open reading frame, which leads to a truncation of 29 residues from the N-
terminus (ICT1∆29). The induced overexpression of ICT1∆29-GST with a calculated 
molecular weight of 46 kDa showed more protein in the soluble fraction (Figure 6.2, 
“Input” lane 1), which could be successfully purified in higher yields than the full length 
version of ICT1 using the same condition of the protocol as described in 3.5.12 (Figure 
6.2, compare lane 5 and 6).  
 
 
 
Figure 6.2: Purification of recombinant ICT1∆29 and ICT1 full length (FL). Bacteria (OD600 ~ 
0.4 to 0.6) were cultured at 16°C over night in the presence of 1 mM IPTG allowing 
overexpression of GST-ICT1∆29 or -FL. Bacteria were sonicated and centrifuged. The soluble 
fraction (lane 1, Input, 5 µl of 10 ml) was subjected to equilibrated glutathione Sepharose 4B 
beads. The flow-through (lane 2, 5 µl of 10 ml) after the binding step showed that a reasonable 
amount of the fusion protein had bound to the beads (lane 3, 2.5 µl of 0.6 ml) resulting in a 
decreased amount of ICT1-GST in the flow-through. ICT1 was then cleaved off the GST-tag 
using PreScissionTM Protease. The GST-tag (~ 26 kDa) stayed on the beads (lane 4), whereas 
ICT1 could be recovered as the elution fraction (ICT1∆29: lane 5, 10 µl of 0.75 ml, ~ 5 µg; ICT1 
FL: lane 6, 10 µl of 0.75 ml, ~ 2 µg).  
 
In general it was noticed that the overexpression of ICT1-GST (FL and ∆29) caused 
some problems in the growth rate of the bacteria, whereas similar approaches to 
mtRF1a∆32-GST (expressing bacteria strain was kindly provided by Dr. H. R. 
Soleimanpour-Lichaei) did not seem to have any change in growth pattern. The 
possible reason for this will be discussed later on.  
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6.3 ICT1 shows codon-independent, but ribosome-dependent 
release activity in vitro  
 
To prove whether ICT1 has any release activity, 50 pmol of purified recombinant 
ICT1∆29 was subjected to the in vitro translation termination assay using different 
codons in comparison to the positive control, the main mitochondrial release factor 
mtRF1a. For this approach mtRF1a with a truncation of 32 residues from the N-
terminus (mtRF1a∆32) was used as reported in Soleimanpour-Lichaei et al. (2007).  
For the further analysis, the terms were simplified from ICT1∆29 to ICT1 and 
mtRF1a∆32 to mtRF1a.  
For in vitro assay, carried out by Dr. Z. M. A. Chrzanowska-Lightowlers, 70S E. coli 
ribosomes were used with a tRNAMet carrying 3H- radiolabelled formyl-methionine 
(f[3H]met) in the peptidyl-tRNA (P) site and a vacant aminoacyl-tRNA (A) site. By the 
addition of RNA triplets, a specific codon can be added to the decoding centre. A class 
I release factor such as mtRF1a that has sequence specificity will recognise the stop 
codon and catalyse the hydrolysis of the ester bond between the f[3H]met and the 
tRNAMet. As shown in the graph below (Figure 6.3) mtRF1a showed release activity in 
the presence of UAA and UAG codons in the decoding centre, whereas other codons 
such as UGA (that is recognised as a stop codon in E. coli, but encodes for Trp in 
human mitochondria) UGG (encoding Trp in E. coli and human mitochondria), AGA or 
AGG (both encodes Arg in E. coli; no tRNA or protein recognises these codons in 
human mitochondria, but they are critical features for -1 frameshift within the human 
mitochondrial ribosome) could not cause the hydrolysis of the f[3H]met from the tRNAMet 
in the presence of mtRF1a. Not surprisingly in the absence of the codon mtRF1a, as a 
codon-dependent release factor, did not show activity in the in vitro assay. In contrast 
ICT1 showed release activity independent of the sequence of the A-site, and also 
without a codon ICT1 was able to cause hydrolysis of the f[3H]met from the tRNAMet. In 
the absence of a 70S ribosome however, neither mtRF1a nor ICT1 can release the 
f[3H]met from the f[3H]met-tRNAMet, suggesting that ICT1 has a codon-independent, but 
ribosome-dependent release activity in vitro.  
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Figure 6.3: Release activity of ICT1 and mtRF1a in the in vitro translation termination 
assay. 50 pmol of recombinant ICT1 or mtRF1a were used in this in vitro assay, in the 
presence or absence of E. coli 70S ribosomes (5 pmol). Those ribosomes were programmed 
with P-site f[3H]met-tRNAMet and A-site codons as indicated. The reactions without 70S particle 
contained UAA as a stop codon. Non-limiting amounts of RNA triplet (400 pmol) were used in 
this assay. The relative release activity was measured as hydrolysis of the radiolabelled 
f[3H]met from its tRNAMet and is shown in counts per minute [cpm]. Means and standard 
deviations were calculated from at least three experiments (n > 3).  
 
Another difference between the activity of ICT1 and mtRF1a in the in vitro translation 
termination assay is the necessity of the addition of ethanol to the reaction. Usually the 
class I release factor like mtRF1a needs the presence of 10 % ethanol as reported in 
Tate and Caskey (1990) or Soleimanpour-Lichaei et al. (2007). Ethanol probably helps 
to loosen the structure of the ribosome and more easily allows the entrance of the RF 
and therefore its conformation change within the ribosome. In the absence of ethanol 
mtRF1a does not show any significant release activity in the presence of UAG stop 
codon (Figure 6.4). In contrast ICT1 does not seem to require ethanol in this in vitro 
assay. This protein showed release activity in the presence, but also in the absence of 
10% ethanol (Figure 6.4). It is possible that ICT1 is small enough to enter the ribosome 
without loosening its structure and conformational changes of ICT1 are not necessary 
to go in an active formation. Another possibility is that ICT1 acts from another position 
within the ribosome and not directly in the A-site as a conventional class I release 
factor. These observations will be discussed at a later point in this chapter.  
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Figure 6.4: Release activity in the presence and absence of ethanol on UAG stop codon. 
The in vitro translation termination assay was performed with 50 pmol recombinant protein 
(ICT1 or mtRF1a), 5 pmol 70S ribosomes and 400 pmol UAG codon in the presence (red bars) 
or absence (yellow bars) of 10% ethanol (EtOH). The graph shows the results of 3 repeats (n = 
3, p < 0.001***).  
 
6.4 A mutation in the GGQ motif causes an activity loss of ICT1 in 
vitro  
 
From the translation termination assay it seems that ICT1 has a peptidyl-tRNA 
hydrolase activity, which is codon-independent, but ribosome-dependent. Reason for 
this activity is probably the highly conserved GGQ motif in a flexible loop, which in the 
case of standard class I RFs is usually flipped out with respect to domain 3 and thus 
located in the peptidyl-transferase centre (PTC) within the ribosome. Reports from 
several groups [Frolova et al., 1999; Mora et al., 2003; Shaw and Green 2007] describe 
that a mutation in the GGQ motif, especially of the first or second glycine causes a loss 
of hydrolysis activity and it is therefore absolutely essential for the activity of a class I 
RF. To determine whether the GGQ motif of ICT1 has retained functionality, it was 
mutated by using QuikChange® II Site-Directed Mutagenisis Kit from Stratagene as 
described in 3.3.8. The primers listed in table 3.3 were used to generate a mutation at 
position 88 G → A (AGQ mutant) or at position 89 G → S (GSQ mutant), respectively. 
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As a template the pGex-6P-1-ICT1∆29-GST was used to generate GST fusion 
products of the mutants. Purified recombinant ICT1∆29 carrying the individual 
mutations were then tested in the in vitro translation termination assay with the GGQ 
wildtype as a positive control. As presented below (Figure 6.5) ICT1 mutants showed 
no hydrolysis activity in this assay, suggesting that the GGQ motif is necessary for the 
release activity of ICT1 at least in vitro.  
 
Figure 6.5: Mutation in the GGQ motif causes loss of hydrolysis activity of ICT1 in vitro. 
Purified recombinant ICT1 with mutation within the GGQ motif (AGQ- and GSQ mutant) was 
tested in the in vitro translation termination assay in the presence of 400 pmol UAG codon and 
5 pmol 70S ribosomes. ICT1-GGQ wildtype was used as a positive control. (n = 3, GGQ: 100%, 
AGQ: 0.8%, GSQ: 1.1%, p = 0.0001***) 
 
6.5 Mutation in the GGQ motif does not effect the interaction of 
ICT1 with the mitochondrial ribosome 
 
So far it has been shown that ICT1 can act as a codon-independent peptidyl-tRNA 
hydrolase within a 70S E. coli ribosome and that a mutation in the conserved GGQ 
motif results in the loss of release activity in vitro. What happens in vivo? The ribosome 
used in the in vitro assay is a 70S particle and bacterial ribosomes are different in 
several aspects when compared to the 55S mammalian mitochondrial ribosome as 
described in 1.7.1 [reviewed in Koc et al., 2010]. Therefore it is not the natural 
environment for ICT1, where it could be already shown that it has become recruited 
into the mitochondrial ribosome in human. The question is, has ICT1 retained its 
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activity also within the 55S particle or has this activity become redundant once ICT1 
has become an integral component of the mitochondrial ribosome? To address those 
issues ICT1 mutants needed to be investigated in vivo. Therefore pcDNA5/FRT/TO-
ICT1-FLAG was used as a template for site directed mutagenesis as it was done for 
pGex-6P-1-ICT1∆29-GST using the same primers and conditions to then generate 
stable transfected HEK293T cells expressing ICT1AGQ-FLAG and ICT1GSQ-FLAG. After 
confirming by sequencing that the constructs carried the mutation, HEK293T cells were 
transfected with those plasmids as described in 3.1.5. Individual clones were then 
tested for overexpression of the FLAG-tagged proteins before further experiments were 
carried out. The first question that needed to be answered was whether the mutation in 
the GGQ motif causes problems in the integration of ICT1 into the mitochondrial 
ribosome. Therefore immunoprecipitation via the FLAG tag as described before was 
carried out for ICT1 mutants in comparison to ICT1 wildtype. The resulting data were 
analysed by silver staining and western blot as shown in figure 6.6.  
 
 
 
Figure 6.6: ICT1 GGQ mutants can integrate into the mitochondrial ribosome. HEK293T 
cells were transfected with pcDNA5/FRT/TO-ICT1-FLAG carrying the AGQ or GSQ mutation. 
Cells were induced with 1 µg/ ml tetracycline for 3 days and mitochondrial lysates (3 mg) were 
subjected to immunprecipitation via FLAG tag. The elution fractions (10% each) were separated 
by SDS-PAGE (15%) and further analysed by silver staining (A) or western blot (B). The 
western blot membrane was probed with antibodies against DAP3 (28S SSU) and MRPL3 (39S 
LSU) to determine the level of co-immunoprecipitated ribosomal complexes by ICT1 mutants 
(AGQ and GSQ) compared to the wildtype (GGQ). FLAG antibodies were used to ensure the 
presence of the FLAG tagged proteins in the elution fraction at relative similar level.  
 
Chapter 6: ICT1 is a ribosome-dependent, but codon-independent peptidyl-tRNA hydrolase 
108 
Silver staining of the elution fractions did not show any significant differences in the 
pattern of the mutants compare to the wildtype (Figure 6.6 A). Western blot analysis 
showed strong signals for DAP3 and MRPL3 for all three strains (Figure 6.6 B). Those 
results suggest that ICT1 mutants are able to interact with the mitochondrial ribosome 
comparable to the wildtype.  
 
To be certain that it is not just an artefact of the conditions used in the 
immunoprecipitation protocol, especially concerning about the 3 h incubation time, cell 
lysate expressing the GGQ mutation were subjected to isokinetic sucrose gradient. The 
results were analysed by western blot, presented in figure 6.7.  
 
 
Figure 6.7: ICT1 GGQ mutants co-sediment with 39S LSU on isokinetic sucrose 
gradients. HEK293T cells expressing wildtype or mutant derivatives of ICT1-FLAG were 
induced with 1 µg/ ml tetracycline. After 3 days cells were harvested and lysates (700 µg) were 
subjected to isokinetic sucrose gradient. The fractions (1-10) were analysed by western blot 
using antibodies against MRPL3, marker for the 39S LSU, and DAP3, component of the 28S 
SSU. The distributions of the FLAG tagged proteins within these gradients were determined by 
probing the western blot membranes with FLAG antibodies. The mtLuc-FLAG, treated in the 
same way, was used as control for artefacts caused by overexpression.  
 
It was shown earlier in figure 5.5 that ICT1-FLAG co-migrated with MRPL3 in fraction 6, 
indicating the position of 39S LSU. Due to the overexpression, in these gradients a lot 
of the ICT1-FLAG protein was also seen in the earlier fractions 1 to 4. Testing the AGQ 
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and GSQ FLAG tagged mutant in such gradients, a similar profile was observed, 
meaning the ICT1 mutants were also associated with the 39S LSU. As a negative 
control cell lysate of overexpressed mtLuc-FLAG was also subjected to a sucrose 
gradient. There mtLuc-FLAG was localised in fraction 1 to 4, but no signal in lane 6 
was detected, which supports that the co-sedimentation of ICT1 mutants with the 39S 
LSU is not caused by the overexpression of any protein or the FLAG tag, respectively. 
 
6.6 ICT1GSQ mutant failed to suppress the ICT1 depletion 
phenotype in vivo 
 
To analyse the effect of the mutation in ICT1-FLAG on the level of cell viability, it had to 
be investigated at first whether the overexpression of ICT1-FLAG wildtype itself has 
any effect on cell growth in comparison to a control. No inhibition in growth in standard 
glucose containing growth media was noticed for the ICT1 overexpressor. Therefore 
HEK293T cells expressing ICT1-FLAG were induced for 6 days, cultured in glucose-
free media, supplemented with 0.9 mg/ ml galactose. Using galactose media for this 
kind of analysis forces the cells to generate ATP via oxidative phosphorylation and thus 
growth defects as a result of mitochondrial dysfunction are more obvious than in 
glucose media. For the experiment cells were pre-cultured in galactose media for 2-3 
days prior to induction with 1 µg/ ml tetracycline. After 3 and 6 days overexpression cell 
growth was monitored by cell counting. As shown in the graph below (Figure 6.8) the 
overexpression of ICT1-FLAG is causing a decrease in cell number after 3 days, which 
is even more obvious and statistically significant after 6 days in comparison to 
untransfected HEK293T wildtype cells (WT) in galactose media. 
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Figure 6.8: Overexpression of ICT1-FLAG causes growth defect of HEK293T cells in 
galactose containing media. HEK293T cells untransfected (wildtype, WT) or inducible 
expressing ICT1-FLAG (ICT1 o/e) were cultured in glucose free media, supplemented with 
galactose, and induced with 1 µg/ ml tetracycline. Cells were counted prior to induction (Day 0) 
and after 3 and 6 days overexpression. The graph represents the means and standard 
derivations of 3 experiments (n = 3; * significant, p = 0.0161). 
 
Because there was clearly a growth defect caused by overexpression ICT1 wildtype it 
was necessary to manipulate the experiment in order to express only endogenous 
levels of mutant ICT1. Therefore different concentrations (5 nM, 10 nM and 15 nM) of 
siRNA B against ICT1 were used to deplete the endogenous ICT1 from the cells and 
also to titrate the level of ICT1 overexpressors to a protein level equivalent to the usual 
endogenous form. First, cells were cultured in galactose media for at least 2 days, and 
then induced for 1 day prior to siRNA transfection. After siRNA application cells were 
cultured in the presence of 1 µg/ ml tetracycline for 3 days. Cell lysates were analysed 
by western blot and the protein levels were measured using Image-Quant software. 
The results are presented in figure 6.9, where western blot showed a slightly different 
migration of ICT1-FLAG in comparison to the endogenous protein. This phenomenon 
was noticed in previous experiments and was also seen with other FLAG tagged 
proteins. The reason for this is probably the positive charge of the FLAG tag, rather 
than the additional size of the octapeptide.  
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Figure 6.9: Titration of overexpressed ICT1-FLAG protein using different concentration of 
si-ICT1 B. HEK293T untransfected wildtype (1 and 2) or ICT1-FLAG expressing (3 to 5) cells 
were cultured in the presence of different amounts of si-ICT1 B (5 nM: 2 and 5; 10 nM: 4; 15 
nM: 3) for 3 days and induced for 4 days with 1 µg/ ml tetracycline. Cell lysates (45 µg) of 
overexpressor were compared on the relative protein level via western blot to non treated 
wildtype cells (1). The ICT1 protein level was measured using Image-Quant software (right 
panel). β-actin was used as a loading control.  
 
From the control experiment as shown above it was decided that a concentration of 10 
nM gave reasonable depletion of endogenous ICT1 and a good down regulation of the 
ICT1 overexpressor to the relative endogenous level (Figure 6.9, lane 4). Thus for the 
following experiment HEK293T cells, cultured in galactose media, were induced with 1 
µg/ ml tetracycline for 1 day prior to transfection with 10 nM si-ICT1 B using 
lipofectamine to analyse the effect of the GGQ mutations.  If the GGQ motif is really 
essential for the function of ICT1 in vivo, it was expected that the overexpression of the 
GGQ mutants would not rescue the phenotype caused by depletion of endogenous 
ICT1. The graph in figure 6.10 presents the result of cell counts taken after 3 days and 
6 days transfection. There is a growth defect of ICT1 depleted cells in comparison to 
the control wildtype HEK293T (WT) treated with NT siRNA, as was observed before in 
HeLa cells (Figure 6.10, compare 1 and 2: 6 days, n = 3, p = 0.0008). The 
overexpression of ICT1GGQ-FLAG (ICT1 o/e, 3) showed a very significant suppression 
of the ICT1 depleted cell phenotype (compare 3 and 2: 6 days, n = 3, p = 0.004). The 
relative amount of ICT1 protein was analysed by western blot after 3 days (Figure 6.10, 
right panel), where a lower level was detected in the ICT1GGQ-FLAG overexpressor 
(lane 3, ~ 48.9%) in comparison to the endogenous level (lane 1). This might be also 
the reason, why the growth phenotype could be just rescued approximately to 46%. 
Surprisingly a similar result was also observed using the ICT1AGQ-FLAG mutant (AGQ 
o/e, 4), where ICT1AGQ-FLAG mutant was shown a rescue of about 43%, suggesting 
that ICT1AGQ-FLAG can also suppress the phenotype of ICT1 depleted cells (compare 
4 and 2: 6 days, n = 3, p = 0.0089), whereas in the case of the ICT1GSQ-FLAG mutant 
no rescue could be noticed (compare 5 and 2: 6 days, n = 3, p = 0.3245; 5 and 3: 6 
days, n = 3, p = 0.0057).  
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Figure 6.10: ICT1GSQ mutant is not able to rescue the phenotype caused by endogenous 
ICT1 depletion. HEK293T cells (wildtype (WT; 1 and 2) or expressing ICT1 derivatives (3 to 5)) 
were cultured in galactose media, transfected with 10 nM si-NT (1) or si-ICT1 B (2 to 5), 
respectively. The overexpressors (3 to 5) were induced with 1 µg/ ml tetracycline 1 day prior to 
transfection and further cultured in the presence of inducer. Cell growth was monitored by cell 
counting after 3 days and 6 days transfection. For each transfection 3x 104 cells were used, 
marked as dotted line is starting cell number. The relative protein level was analysed via 
western blot after 3 days (25 µg cell lysates, right panel). ICT1 protein levels were measured 
using Image-Quant software (1: 100,0%, 2: 9,2%, 3: 48,9%, 4: 42,1%, 5: 41,1%). β-actin was 
used as loading control.  
 
Interestingly the two mutants gave different results in vivo, whereas in vitro both lost 
the hydrolysis activity. Possible reasons will be discussed later on, but for further 
investigations only the GSQ mutant was used.  
In a direct repeat of the experiment described above cells were counted after 4 days 
prior to cell lysate preparation. Those cell counts showed a 102% rescue of ICT1 
depletion by the ICT1GGQ-FLAG overexpressor (Figure 6.11, compare 3 to 2: n = 3, p = 
0.0036; 1 to 2: n = 3, p = 0.0005), whereas the ICT1GSQ-FLAG mutant failed again to 
suppress the phenotype (~ 6% “rescue”) (Figure 6.11, compare 4 to 2: n = 3, p = 
0.8101; 4 to 1: n = 3, p = 0.0004). Thus the ability to suppress the phenotype caused 
by ICT1 depletion is very significant comparing the ICT1GGQ wildtype and the ICT1GSQ 
mutant (Figure 6.11, compare 3 to 4: n = 3, p = 0.0036). 
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In this case the relative protein level was closer to the endogenous form (ICT1GGQ-
FLAG: ~ 120%; ICT1GSQ-FLAG: ~ 60%), probably caused by different batches of 
tetracycline used in those experiments. This reflects also that this approach is not the 
optimal way forward. Certainly it would be better to use siRNA that targets the UTR or 
to generate an overexpressor with silent mutations within the siRNA region, thus 
rendering the introduced ICT1 sequence to be unaffected by the siRNA that targets the 
endogenous mRNA. However, the experiment could clearly show that GSQ mutant 
was not able to suppress the phenotype caused by ICT1 depletion.  
Additionally the steady state level of mitochondrial ribosomal proteins were analysed by 
western blot and again there was a decrease in MRPL3 as it was seen before in ICT1 
depleted cells (Figure 4.4), whereas MRPS18B, a component of the 28S SSU seems 
 
Figure 6.11: Further investigations of ICT1GSQ-FLAG mutant A) HEK293T cells (WT: 1 and 
2; ICT1GGQ wildtype: 3; ICT1GSQ mutant: 4) were cultured in galactose media and treated with 
10 nM si-NT (1) or si-ICT1 B (2 to 4). Cell counts were taken after 4 days siRNA transfection 
and 5 days induction of ICT1 overexpressors (3 and 4). Cell lysates were analysed by western 
blot and ICT1 protein level was measured using Image-Quant software. β-actin and SDH were 
used as loading control. Western blot membrane was also probed for MRPL3 and MRPS18B 
to determine the relative level of ribosomal defect caused by ICT1 depletion. B) 35S-met de 
novo synthesis of ICT1GSQ-FLAG mutant in comparison to mtLuc-FLAG. Cells were labelled for 
15 min and 30 min with 35S-met. 50 µg of each sample were separated on a 15% PAG. After 
exposure on Phosphor-Image screen to visualise radiolabelled proteins, the gel was stained 
with CBB to prove even loading (lower panel). 
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to be unaffected. As it was discussed before the ICT1 depletion causes an assembly 
defect of the 39S LSU and therefore results in a decreased stability of MRPL3, a good 
marker therefore for the intact LSU. The defect in 39S LSU conformation caused by 
ICT1 depletion in WT seems to be rescued by the ICT1GGQ-FLAG wildtype 
overexpressor, leading to a higher protein level of MRPL3 (Figure 6.11 A, lower panels, 
compare 3 and 2). Using the ICT1GSQ-FLAG mutant gave a similar result (compare 4 
and 2), suggesting that the mutant is able to suppress the defect on the level of 
mitochondrial ribosome assembling, which is in agreement with the fact that ICT1 
mutants could be integrated into the mitochondrial ribosome as is the ICT1 wildtype. 
To investigate whether the loss of peptidyl-tRNA hydrolysis activity is causing problems 
in mitochondrial protein synthesis, ICT1GSQ-FLAG was also analysed by 35S-met 
metabolic labelling in comparison to mtLuc-FLAG. Therefore cells were induced for 3 
days and labelled for 15 min or 30 min, respectively as described in 3.5.7. The resulting 
data are shown in figure 6.11 B. There was no visible effect on de novo synthesis, 
supporting the idea that defect in mitochondrial protein synthesis is only caused by the 
loss of 55S particle and not by the loss of peptidyl-tRNA hydrolysis activity in ICT1 
depleted cells.  
However the ICT1GSQ mutant showed clearly a loss of cell viability and thus it is highly 
likely that the GGQ motif of ICT1 is functional.  
 
6.7 Discussion  
 
The results presented in this chapter show evidence that ICT1 has maintained its 
peptidyl-tRNA hydrolysis activity. Using recombinant purified ICT1 protein in the in vitro 
translation termination assay showed that ICT1 is able to catalyse the hydrolysis of the 
ester bond between the tRNA (tRNAMet) and the “peptide-chain” (f[3H]met) at least in 
vitro. This activity was shown to be codon-independent, but ribosome-dependent 
(Figure 6.3). Those results are in agreement with sequence/ structure of the ICT1 
protein, where it was shown in Figure 6.1 that the tip of the α5 helix and the PXT (or 
SPF) motif, which are crucial for codon recognition, are missing in ICT1. The presence 
of a GGQ motif in a flexible loop however classifies ICT1 as a member of the class I 
release factor family. It was proposed that the GGQ motif mimics the CCA motif of the 
tRNA within the A-site [reviewed in Youngman et al., 2008]. Both are causing an 
induced fit mechanism promoting a conformational change within the ribosome, 
allowing new peptide bond formation (tRNA) or peptidyl-tRNA hydrolysis (release 
factor), respectively. The presence of the release factor with the GGQ motif within the 
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ribosome allows therefore the nucleophilic attack in the peptidyl-transferase centre and 
thus the hydrolysis of the ester bond between the P-site tRNA and the peptide chain 
[Schmeing et al., 2005]. It is therefore not the class I release factor, which hydrolyses 
the peptidyl-tRNA, it is actually the ribosome. Therefore the GGQ alone is not able to 
hydrolyse the ester bond, only within the ribosome at the PTC can it catalyse the 
hydrolysis. Therefore the results of the ribosome-dependent hydrolysis activity by ICT1 
stay in agreement with a functional GGQ motif.  
 
Furthermore it was shown that a mutation in the highly conserved GGQ motif (GGQ → 
AGQ or GGQ → G SQ) causes a loss of the hydrolysis activity of ICT1 at least in vitro 
(Figure 6.5). However, the conditions used in the in vitro assay are quite different from 
the normal physiological environment of ICT1. As it was shown in the previous chapter 
ICT1 has been recruited into the 55S mitochondrial ribosome which as already 
described (section 1.7.1) is different in many aspects to the 70S bacterial ribosome that 
is used in the in vitro assay. To be sure that the GGQ motif is indeed functional also in 
vivo, ICT1 with mutation within this motif were tested in cell culture. At first it was 
shown that a GGQ mutation does not affect the integration of ICT1 in the mitochondrial 
ribosome (Figures 6.6 and 6.7). With siRNA technology the endogenous ICT1 was 
depleted and expressed ICT1-FLAG wildtype or the mutants were tested for their ability 
to suppress the phenotype caused by ICT1 depletion. Surprisingly the two GGQ 
mutants gave different results: the GSQ failed to suppress the phenotype caused by 
ICT1 depletion whereas the expression of the AGQ mutant showed a level of rescue 
similar to the ICT1 wildtype (Figure 6.10). The reason for the difference could be the 
55S mitochondrial ribosome itself that is as already said different from its bacterial 
counterpart. Shorter ribosomal RNAs and additional proteins make it more porous than 
the 70S particle. As shown by Schmeing et al. (2005) the induced-fit mechanism within 
the ribosome caused by a tRNA or a class I release factor facilitates a conformation 
change of the ribosomal RNA and allows nucleophilic attack. Maybe ICT1 within the 
55S ribosome works in a slightly different fashion. To investigate this possibility further 
it would be an enormous benefit if the position of ICT1 within the mitochondrial 
ribosome would be known.  
However, it was clearly shown that the GSQ mutant was not able to rescue the 
phenotype caused by the ICT1 depletion (Figures 6.10 and 6.11), even if it was able to 
be integrated into the mitochondrial ribosome. This suggests that the GGQ motif is 
indeed essential for the function of ICT1 within the ribosome. It could be also shown by 
Shaw and Green (2007) that mutation of the second glycine has more effect on 
function than mutation of the first one. They demonstrated that the AGQ variant caused 
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loss in catalytic activity of 800-fold, whereas the GAQ mutation leaded to a decrease of 
3300-fold.  
 
Another point that is in agreement that the GGQ motif is functional, catalysing 
hydrolysis activity, is the actual growth rate of the ICT1 wildtype overexpressor. The 
overexpression of ICT1GGQ-FLAG in galactose containing media caused a significant 
decrease in growth in comparison to the control. The reason for this could be that free 
ICT1 can go spontaneously into the A-site and release the nascent peptide chain in a 
codon-independent manner, as it was shown in vitro. Therefore a balanced 
concentration of ICT1 is crucial for cell viability. An inhibition in growth was also noticed 
when ICT1 was overexpressed in bacteria. Again it is reasonable to assume that a 
spontaneous hydrolysis of the peptidyl-tRNA catalysed by ICT1 can be the reason. 
Those facts also suggest that the conserved GGQ motif in ICT1 is indeed functional.  
Concluding so far it was shown that ICT1 has ribosome-dependent but codon-
independent peptidyl-tRNA hydrolase (PTH) activity in vitro. The highly conserved 
GGQ motif is crucial for the function of ICT1 in vitro and in vivo.  
 
What can be the function of a ribosome bound codon-independent PTH? Besides the 
class I release factors there exists another class of PTH that do not have a GGQ motif 
and act on soluble peptidyl-tRNAs, dropped off the ribosome when elongation is 
disrupted [reviewed in Das and Varshney, 2006]. Those soluble peptidyl-tRNA 
hydrolases have two classes: the PTH1 in eubacteria and the PTH2 in archaea. They 
are esterases that cleave the ester bond between the C-terminus of the nascent 
peptide chain and the 2’OH end of the tRNA. So far there is no clear evidence of a 
mitochondrial PTH, but there are suggestions of candidates [De Pereda et al., 2004.]. 
Those PTHs are essential to recycle peptidyl-tRNAs, which are released from a stalled 
ribosome. Sometimes ribosomes do not reach a stop codon, for example when mRNA 
has been degraded and the termination codon is absent. Those stalled complexes 
need to be recycled. Singh et al. (2008) proposed that those pre-termination complexes 
are recycled by the ribosome recycling factor (RRF) and the elongation factor G 
(EFG(2)) (Figure 6.12 B). The specific interaction between the two factors within the 
ribosome leads to a transient separation of the ribosomal subunits and to the exposure 
of the initiation factor 3 (IF3) binding site on the small ribosomal subunit. The binding of 
IF3 to the SSU leads to complete disassembly of the ribosome into the subunits and to 
the release of peptidyl-tRNAs, which are then recycled by the PTH (figure 6.12 B). An 
accumulation of peptidyl-tRNAs after inactivation of PTH was shown to be lethal in E. 
coli [Menninger, 1978]. It has been further demonstrated that those peptidyl-tRNA 
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hydrolases can neither act on the ribosome nor on initiator tRNAfMet [Das and 
Varshney, 2006]. The perfect substrates for those peptidyl-tRNA hydrolases are 
peptidyl-tRNAs containing four to five residues. What recycles peptidyl-tRNAs with 
longer nascent peptide chains? What happens if the ribosomal A-site runs out of RNA 
triplets during elongation with a peptidyl-tRNA that has a quite long peptide chain 
attached, which starts already folding outside the ribosome? Those “long” chain 
peptidyl-tRNAs can not be dropped off the ribosome so easily as the “short” ones. One 
mechanism that could be used under those circumstances in bacteria is the tmRNA 
system that mimics both tRNA and mRNA to allow coordinated translation termination 
and degradation of the tagged nascent peptide and leads therefore to recycling of 
those stalled ribosomes and peptidyl-tRNAs [reviewed in Moore and Sauer, 2007]. In 
mitochondria however, there is no evidence that such a tmRNA exists. This means 
those stalled complexes with long chain peptidyl-tRNAs must be rescued in a different 
way. After recycling stalled ribosomes that requires RRF (mtRRF), EFG (mtEFG2) and 
IF3 (mtIF3), the peptidyl-tRNA will be stuck in the ribosomal large subunit, because it 
can not leave the ribosome with the tRNA through the tRNA exit or the polypeptide exit 
tunnel/ -site (Figure 6.12 C). Thus a ribosome-dependent PTH (ICT1, Figure 6.12 C) 
has to catalyse the hydrolysis of the peptidyl-tRNA to recycle the ribosomal large 
subunit and the peptidyl-tRNA to be available for the next translation round. ICT1 as a 
member of the mitochondrial ribosomal large subunit carries all the features that would 
be required to act as such a ribosome-dependent PTH and is therefore proposed to be 
involved in the rescue of stalled ribosomes/ recycling of the 39S LSU. This PTH activity 
can not be present all the time, because this would result in an overall translation 
inhibition caused by uncoordinated hydrolysis of peptidyl-tRNAs. Therefore a specific 
signal must occur, probably a conformational change within the 39S LSU after the 
disassembling of the 55S monosome into its subunits that allow ICT1 to act as a PTH 
only under those specific circumstances.  
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Figure 6.12: Proposed model of the function of ICT1 as ribosome-dependent peptidyl-
tRNA hydrolase (PTH) involved in the recycling-process of stalled ribosomes in human 
mitochondria. A) When the ribosome reaches a stop codon, mtRF1a (RF1a; green) recognises 
this stop codon and will catalyse the hydrolysis of the peptide chain from the tRNA. The nascent 
peptide chain can leave the ribosome through the polypeptide exit tunnel/ -site. The post-
termination complex is then further recycled by mtRRF (RRF; red) and mtEFG2 (EFG2; brown). 
The binding of mtIF3 (IF3; orange) to the small ribosomal subunit completes the disassembly of 
the 55S and inhibit the reassembling of the subunits. B) and C) Abortive elongation can occur 
and lead to stalled ribosomes. The reason for this can be e.g. degradation of mRNA and thus 
no RNA triplet in the decoding centre or no sufficient supply of amino-acylated tRNAs to the A-
site. RRF and EFG2 interact with pre-termination complex. The interaction will result in a 
transient state, where IF3 binding site on the ribosomal small subunit is exposed. The binding of 
IF3 results to the complete disassembly of the ribosome into its subunits. Short-chain peptidyl-
tRNAs will be released by this mechanism and can be further processed by soluble peptidyl-
tRNA hydrolase (PTH) (B). In contrast long-chain peptidyl-tRNAs cannot leave the ribosome 
with the tRNA through the tRNA exit or through the polypeptide exit tunnel/ -site. This leads to 
aborted large ribosomal subunit with stuck peptidyl-tRNAs that need to be released by a 
ribosome-dependent codon-independent PTH: ICT1 (C). (Proposed model is based on Singh et 
al., 2008) 
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How could this hypothesis be tested? Experiments using human cells expressing GSQ-
mutant failed to detect an accumulation of peptidyl-tRNAs. Prof. U. Varshney 
(Bangalore, India) who works on peptidyl-tRNAs in E. coli explained that it is difficult to 
detect those peptidyl-tRNAs under such conditions. In the bacterial system the 
overexpression of AGA-minigenes or ung-stopless (uracil DNA glycosylase gene) 
constructs can be used as advantageous tool to induce artificial a high production of 
peptidyl-tRNAs, which can be then detected [Singh et al., 2008]. An overexpression of 
such constructs in human mitochondria is not possible to date. Therefore collaboration 
with the laboratory of Prof. U. Varshney was initiated to test ICT1 in the bacterial 
system. There ICT1 wildtype and mutants can be tested on possible suppression of 
phenotype in E. coli strains with temperature sensitive mutations in PTH (PTHts), also 
in combination with a deletion in ssrA gene (tmRNA). Further the effect of ICT1 
expression in a strain overexpressing AGA-minigene can be investigated in bacteria, 
which would be not possible in human mitochondria.  
As it was reported by Prof. U. Varshney’s group in Singh et al. (2008) the 
overexpression of AGA-minigene is toxic to E. coli. The overexpression of RRF can 
rescue the host from this toxicity by releasing the peptidyl-tRNA from the stalled 
ribosome (Figure 6.12). So far it was shown that ICT1 can not rescue the toxicity 
caused by overexpression of AGA-minigene, but it supports a weak rescue of the host 
if RRF is downregulated. To prove whether this weak rescue is specific for PTH activity 
of ICT1, ICT1 mutants need to be tested in similar experiments.  
The fact that ICT1 does not show a rescue of the AGA-minigene overexpression at 
“normal” RRF level maybe supports the idea that it acts more on the long chain 
peptidyl-tRNA stacked in the ribosome or ribosomal subunit. The expression of the 
AGA-minigene leads to a peptidyl-tRNA with a short-peptide chain of 3 residues, which 
would probably drop off the ribosome after recycling by RRF and then be processed by 
soluble PTH. The downregulation of RRF in an overexpressing AGA-minigene strain 
would lead to an accumulation of more stalled ribosomes with the short-chain peptidyl-
tRNA in the P-site. Maybe in the absence of RRF ICT1 can also act on those 
substrates and therefore at least rescue the sequestering of tRNAArg4, leading to the 
weak suppression of the phenotype.  
Further it would be interesting to identify whether ICT1 would show a higher rescue if a 
longer stopless mRNA would be expressed as with the ung-stopless construct, which 
would result in a long-chain peptidyl-tRNA, immobilised within the ribosomal P-site after 
recycling the ribosome by RRF. It was already shown that the overexpression of RRF 
can also rescue this strain by releasing the ung-mRNA from the stalled ribosome, but 
this suppression is rather weak. Maybe this minimal rescue is caused by the peptidyl-
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tRNA stuck within the large ribosomal subunit, which cannot be processed by the 
soluble PTH. It would be therefore interesting whether ICT1 expression under those 
circumstances would increase the suppression level, because of further “recycling” the 
ribosomal large subunit with the long-chain peptidyl-tRNA (Figure 6.12 C). 
 
Another point that would be important to address is which protein can act as a soluble 
mitochondrial PTH in human. PTH2 was shown to process peptidyl-tRNAs in vitro, but 
its localisation within the mitochondrial intermembrane space makes it quite unlikely to 
act as a soluble PTH on matrix substrates [De Pereda et al., 2004; Jan et al., 2004]. 
Therefore which protein is responsible for this job in human mitochondria? 
 
In conclusion it can be said that ICT1 as one of four members of the human 
mitochondrial release factor family has been recruited into the mitochondrial ribosome 
and further maintained its peptidyl-tRNA hydrolase (PTH) activity. This PTH activity is 
proposed to be essential for processing peptidyl-tRNAs within stalled ribosomes or 
within the ribosomal large subunit after recycling the pre-termination complex by 
mtRRF.  
 
The highly conserved GGQ motif that is present in all four members of the 
mitochondrial release factor family was shown to be functional and essential for the 
PTH activity of ICT1. It is tempting to speculate whether the remaining two members, 
mtRF1 and C12orf65, have maintained a similar activity. Both were shown to be non-
functional in the translation termination assay using E. coli ribosomes [Soleimanpour-
Lichaei et al., 2007; Antonicka et al., 2010]. Interestingly the 35S-met de novo 
syntheses from two different patient cell lines carrying a mutation within the C12orf65 
gene were dramatically reduced (~ 30%) [Antonicka et al., 2010], reminiscent of the 
decreased level in mitochondrial protein synthesis after ICT1 depletion. The 
mitochondrial RNA levels were similar or even higher when compared to control. Thus 
it seems that also C12orf65 plays a critical role in mitochondrial translation. Surprisingly 
those authors showed also a partial rescue of COX activity and its assembly in those 
patient cell lines upon overexpression of ICT1, and suggest that C12orf65 and ICT1 
may have similar or overlapping functions. Of the other two release factors, neither 
mtRF1a nor mtRF1 were able to suppress the phenotype, only ICT1. However, there 
are some major differences between ICT1 and C12orf65. ICT1 has been recruited into 
the human mitochondrial ribosome, whereas C12orf65 appears more like mtRF1a or 
mtRF1 as it was never detected within co-immunoprecipitated mitochondrial ribosomes 
[Rorbach et al., 2008; this study]. C12orf65 did not show any activity in the translation 
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termination assay in vitro, in contrast to ICT1 that demonstrated PTH activity in a 
ribosome-dependent and codon-independent manner. However, there are also 
similarities between the two proteins: both are quite small proteins in comparison to a 
conventional class I release factor like mtRF1a, both have lost the crucial domains for 
codon recognition, and both contain the highly conserved GGQ domain. The presence 
of the GGQ motif within C12orf65 leads one to speculate that this protein has also 
maintained its ability to promote hydrolysis activity and maybe because of experimental 
restriction, namely using the 70S bacterial ribosome instead of the 55S mammalian 
mitochondrial ribosome in this assay, it is not possible to show evidence for it. 
However, the GGQ motif within C12orf65 suggests also in this case a ribosome-
dependent PTH activity as soluble peptidyl-tRNA hydrolases do not require a GGQ 
motif for their function. Therefore it would be a surprise if C12orf65 with the GGQ motif 
would act on soluble peptidyl-tRNAs. Furthermore if C12orf65 does not have any PTH 
activity it would leave the question what feature of ICT1 is responsible for the partial 
rescue? 
To investigate the possibility further whether the GGQ motif of C12orf65 is functional, 
causing hydrolysis activity, it would be interesting to see whether the overexpression of 
C12orf65 with mutation within the GGQ motif would rescue the phenotype of those 
patient cell lines as the wildtype form did. Additionally the expression of ICT1-GSQ 
mutant in comparison to ICT1 wildtype could be also tested in those patient lines with 
mutations in C12orf65. This might answer the question whether it is the PTH activity of 
ICT1 that can partially rescue the phenotype of the C12orf65 patient cell line. However, 
Antonicka et al. (2010) showed clearly that C12orf65 is essential for mitochondrial 
protein synthesis. To answer the question of its specific function within mitochondria it 
still needs some further investigations and these are ongoing in my host laboratory.  
There is still no report whether mtRF1 is essential for the mitochondrial gene 
expression machinery and whether its GGQ motif is functional. The further 
characterisation of mtRF1 and also C12orf65 is part of the PhD project of A. Pajak 
within this laboratory.  
 
Possible future experiments concerning function of ICT1 in human mitochondria: 
Besides the work in the bacterial system carried out by the group of Prof. U. Varshney, 
there are maybe still some experiments that could be considered in the human cell 
system. One approach that has not been tried to investigate the role of the PTH activity 
of ICT1 in human cells was to use chemical crosslinking (e.g. DFDNB, BMH, DSG and 
MBS as reported by Gruschke et al., 2010) to determine direct ICT1 interaction 
partners. Those results could then be used to clarify the position of ICT1 within the 
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mitochondrial ribosome that would be an enormous benefit. The presence of the GGQ 
motif leads to speculation that ICT1 is probably localised quite close to the PTC. 
However this fact needs also to be considered when using chemical crosslinkers as it 
is possible that proteins within the core of the mitochondrial ribosome are not 
accessible for crosslinking and only proteins closer to the surface can be investigated 
for direct interactions with this method.  
If crosslinking of ICT1 would be possible then it would be further interesting whether 
also nascent peptide chains that could be labelled with 35S-met are detectable after IP 
via ICT1-FLAG. There the ICT1GSQ mutant should show more nascent peptide chains 
as they accumulate in the 39S LSU. 
If crosslinking of ICT1 itself is not possible then proteins at the polypeptide tunnel exit 
(as it was reported from yeast in Gruschke et al., 2010) or OXA1L could be used for 
crosslinking IP after 35S-met labelling of the nascent peptide chain within the ribosome. 
Again this should show a higher accumulation of co-immunoprecipitated cross-linked 
nascent peptide chains in the ICT1GSQ mutant than in the ICT1GGQ wildtype. Those kind 
of experiments need at first an established system of co-expressing two construct 
independently in one cell line or good antibodies that allow immunoprecipitation of 
OXA1L or one of the mitochondrial ribosomal proteins located at the polypeptide tunnel 
exit.  
Another possibility would be to do 35S-met labelling in an ICT1GGQ depleted background 
but expressed ICT1GSQ mutant followed by separation on isokinetic sucrose gradient. 
There more of nascent polypeptide chain should be accumulated in fraction 6, 
representing immobilised nascent chain within the 39S LSU. Again, the amount of 
those nascent peptides could be quite limited and maybe not detectable as an artificial 
accumulation of non-stop mRNA within human mitochondria is so far not possible. It 
may be that a depletion of mtRF1a would lead to a higher accumulation of nascent 
peptide chain. Furthermore it is possible that because of a co-insertion of the nascent 
peptide chain into the membrane, one might expect to see a higher accumulation of 
those blocked complexes in the insolubilised membrane fraction in the pellet during 
preparations.   
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7 Chapter 7: Identification of possible ICT1 
orthologues in yeast (Schizosaccharomyces pombe) 
and bacteria (Escherichia coli)  
 
7.1 
 
Introduction 
As discussed in the previous chapter the possible function of ICT1 is the rescue of 
stalled large ribosomal subunit with bound peptidyl-tRNA, which in the case of a long 
peptide chain cannot leave the ribosome with the tRNA attached through either the 
tRNA exit or through the polypeptide exit tunnel. The hydrolysis of the peptide chain 
from the tRNA that is catalysed by a ribosome-dependent, but codon-independent 
release factor is crucial for the recycling of those stalled complexes. ICT1 harbours all 
the critical features that are necessary to perform this function. The question is whether 
those “truncated” class I release factors are conserved or whether it is a unique class 
present only in mitochondria of higher eukaryotes.  
By bioinformatical searches Dr. N. Bonnefoy identified MUG82 from 
Schizosaccharomyces pombe as a possible mitochondrial yeast candidate. Prof. U. 
Varshney and also other groups [Jiang et al., 2009; Hayes and Keiler 2009] see in 
YaeJ the potential bacterial orthologue of ICT1.  
The aim of this investigation is a first initial characterisation of those proteins. First, 
protein sequence alignment by using CLUSTALW was performed to establish similarity 
of MUG82 and YaeJ to ICT1. As shown in figure 7.1 all share the highly conserved 
GGQ motif. However, it is not only the GGQ tripeptide that is present, MUG82 
especially shows also high similarity over the GGQ containing domain, whereas YaeJ 
is slightly less similar to ICT1 over this region. Overall MUG82 shares 49 identities 
(~27%) to ICT1 whilst YaeJ shares 31 identities (~22%) to ICT1 and 28 (20%) to 
MUG82.  
All three proteins are relatively small: ICT1 with 206 residues is the largest of them 
compared to MUG82 with 182 amino acids and YaeJ with 140 amino acids. None of 
them show the critical features for codon recognition (tip of α5-helix and PXT/SPF) of a 
conventional class I release factor.  
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The region from residue 107 to 132 in ICT1 (Figure 7.1 underlined, italics) does not 
align with the other members of the mitochondrial release factor family and forms a 
helix (α1) that is absent in class I release factors (Chapter 6, Figure 6.1). This may 
suggest that this helix is possibly responsible for ribosome interaction that occurs with 
ICT1 but not the other known RFs. No high similarity can be found in MUG82 or YaeJ. 
Just recently Handa et al. (2010a) proposed that the C-terminal region of ICT1, which 
is basic-residue-rich and unstructured or flexible, is maybe involved in ribosome 
binding, and once within the ribosome would become structured. The same authors 
speculated that the negatively charged residues over the groove between β2-(310-2)-
α1-(310-3)-β3 may be interaction points with RNA or proteins. However, Handa et al. 
(2010a) do not mentioned any differences between mammalian ICT1 and the possible 
bacterial orthologue. Since the bacterial ribosome is already well characterised it would 
be a surprise if YaeJ has been recruited into the 70S ribosome and had been missing 
in all the analysis for such a long time. Thus MUG82 and YaeJ may perhaps act as 
codon-independent release factors, but the possibility that they are part of the ribosome 
seems quite unlikely. These are just speculations, therefore experiments would need to 
be done to analyse the potential release activity of MUG82 and YaeJ. Additionally it 
would need to be investigated as to whether they can be integrated into the ribosome.  
 
As this is a collaborative project, some studies will be done in yeast in the laboratory 
from Dr. N. Bonnefoy, and others in bacteria in the laboratory from Prof. U. Varshney. 
ICT1     MAATRCLRWGLSRAGVWLLPPPARCPRRALHKQKDGTEFKSIYSLDKLYPESQGSDTAWR 60 
MUG82     -----------------MFANFRNCFKIKNSRLIYDNINKCLLTKEETNQLLKFIHLKWK 43 
YaeJ     -----------------------------------------MIVISRHVAIPDG------ 13 
                                             :   ..     .        
 
ICT1     VPNGAKQADSDIPLDRLTISYCRSSGPGGQNVNKVNSKAEVRFHLATAEWIAEPVRQKIA
MUG82     PAK-----------DQVQISFSRSSGPGGQNVNKLNTKVIVNLPFKQLESCIPMFLINHF 92 
 120 
YaeJ     ---------------ELEITAIRAQGAGGQHVNKTSTAIHLRFDIR-ASSLPEYYKERLL 57 
                   .: *:  *:.*.***:*** .:   :.: :   .        .   
 
ICT1     ITHKNKINR--LGE
MUG82     KTCEMLRNYRIQNGIKIYSQKTRSQHKNIEDALNKISDLLNKSAETLYV--PDTPPEKIA 150 
LILTSESSRYQFRNLADCLQKIRDMITEASQTPKE--PTKEDVKLH 176 
YaeJ     AASHHLISS--DGVIVIKAQEYRSQELNREAALARLVAMIKELTTEKKARRPTRPTRASK 115 
     : .   .    . : : ::. * *  *   .* ::  ::.: :       *         
 
ICT1     RIRIEN--MNRERLRQKRIHSAVKTSRRVDMD 206 
MUG82     RISILKKESNEKRLSEKKYKQKKKTQRRITMD 182 
YaeJ      ERRLAS---KAQKSSVKAMRGKVRSGRE---- 140 
    .  : .   : ::   *  :   :: *.   
 
Figure 7.1: Sequence alignment (CLUSTALW) of human ICT1, yeast MUG82 (S. pombe) 
and bacterial YaeJ (E. coli). Identities are indicated by a star (*) and/or grey highlighting, high 
level of similarity by a colon (:) and lower levels by a full stop (.). The GGQ motif is labelled in 
red. The region of ICT1, which does not show sequence similarities to the other human 
mitochondrial release factors, is shown italic, underlined.  
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The further characterisation of ICT1 in the bacterial system allows as already 
discussed in the previous chapter the investigation of its function on peptidyl-tRNAs, 
stuck in the ribosome/ ribosomal large subunit. The study presented in this chapter will 
mainly contribute an initial investigation of MUG82 and YaeJ in human cell lines and 
further the analysis of their potential translation termination activity in the in vitro assay 
(carried out by Dr. Z. M. A. Chrzanowska- Lightowlers).  
 
7.2 
 
Imported MUG82 in human mitochondria is able to interact 
with mitoribosomal proteins 
To investigate whether MUG82 is able to interact with the human mitochondrial 
ribosome MUG82 was cloned into pcDNA5/FRT/TO with a C-terminal FLAG tag in two 
forms, either with or without Su9-presequence from N. crassa [Viebrock et al., 1982] for 
mitochondrial targeting. The constructs were kindly provided by Dr. N. Bonnefoy. After 
transfecting HEK293T cells with the different constructs, and successful selection for 
hygromycin resistance, the cells were induced and tested for expression of FLAG 
tagged protein. The cells carrying the construct without the Su9-presequence showed 
expression of MUG82-FLAG at very low level, but no import into human mitochondria. 
In contrast Su9-targeted MUG82-FLAG (mtMUG82-FLAG) was highly expressed after 
induction with tetracycline and also showed import of the protein into the mitochondria, 
as demonstrated by the protection against proteinase K treatment of the mitochondrial 
preparation. As shown in figure 7.2 mtMUG82-FLAG, with a calculated molecular 
weight of ~ 21.5 kDa, could be detected in cell lysate, in isolated mitochondria and was 
also maintained after the addition of proteinase K. The lysis of mitochondria in the 
presence of proteinase K led to the digestion of mtMUG82-FLAG by the enzyme 
demonstrating both the activity of proteinase K within the whole experiment and also 
the sensitivity of the tested proteins to proteinase K. The molecular weight of MUG82-
FLAG without the cleavage of Su9-presequence from the N-terminus would be 
approximately 29 kDa. The migration of mtMUG82-FLAG in the SDS-PAGE suggests 
that the Su9-presequence (~ 7.5 kDa) was successfully cleaved off. MRPS18B, a 
component of the small ribosomal subunit was used as a mitochondrial marker and 
showed a similar pattern as mtMUG82-FLAG. 
 
  
 Chapter 7: Identification of possible ICT1 orthologues in yeast and bacteria 
126 
 
Figure 7.2: Cellular localisation of Su9-MUG82-FLAG within HEK293T cells. HEK293T cells 
expressing mtMUG82-FLAG were induced for 3 days. Cell lysate (50µg, lane 1) and isolated 
mitochondria (10 µg) untreated (lane 2) or treated with proteinase K, in the absence (lane 3) or 
presence of 1% Triton X-100 (lane 4) were analysed by western blot. To determine the 
presence of mtMUG82-FLAG in each fraction antibodies against the FLAG epitope were applied 
to the western blot membrane. MRPS18B, a member of the mitochondrial ribosomal small 
subunit was used as a positive control.  
 
This cell line was then used for immunoprecipitation via the FLAG tag to determine 
whether mtMUG82-FLAG is able to interact with the human mitochondrial ribosome. To 
this end HEK293T-mtMUG82-FLAG cells were induced for 3 days and mitochondria 
were isolated. Prior to lysis, mitochondria were treated with DNase I and proteinase K 
to minimise unspecific binding from cytosolic proteins. The elution fraction of 
mtMUG82-FLAG was then analysed by silver staining and western blot in comparison 
to ICT1-FLAG. As shown in figure 7.3 A the elution fraction of mtMUG82-FLAG showed 
several bands, but the pattern was different to the ICT1-FLAG eluate and the intensity 
of co-immunoprecipitated proteins was also weaker. To see whether there were 
mitochondrial ribosomal proteins present in this elution fraction eluate was examined 
by western blot (Figure 7.3 B). There, components of the 39S LSU (MRPL3 and 
MPRL12) and of the 28S SSU (DAP3 and MRPS18B) were detected in the elution of 
mtMUG82-FLAG. The relative level of co-immunoprecipitated mitochondrial ribosomal 
proteins was lower in mtMUG82-FLAG in comparison to ICT1-FLAG, whereas the 
levels of FLAG tagged protein were relatively similar. Endogenous ICT1 could be not 
detected in the elution of mtMUG82-FLAG. 
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Figure 7.3: Yeast mtMUG82-FLAG is able to interact with human mitochondrial ribosomal 
proteins. HEK293T-mtMUG82-FLAG cell line was induced for 3 days with 1 µg/ ml tetracycline. 
Mitochondrial lysate was used for immunopreciptiation via the FLAG tag. The elution fraction 
(10%) of mtMUG82-FLAG was analysed by silver staining (A) and western blot (B) in 
comparison to ICT1-FLAG. A) * indicates FLAG tagged protein. B) Antibodies against MRPL3, 
MRPL12, ICT1, DAP3 and MRPS18B were used to determine the relative level of co-
immunoprecipitated ribosomal complexes by mtMUG82-FLAG. To ensure the presence of the 
FLAG tagged protein in each elution fraction FLAG antibodies were applied.   
 
Concluding from this result the possible yeast orthologue is able to interact with human 
mitochondrial ribosomal proteins. However, the affinity of mtMUG82-FLAG to the 
human mitochondrial ribosome seems to be weaker than from ICT1-FLAG.  
 
7.3 
 
Yeast MUG82-FLAG is not able to suppress ribosomal 
defects, caused by ICT1 depletion 
To determine whether mtMUG82-FLAG is able to rescue the phenotype caused by 
ICT1 depletion, analysis of isokinetic sucrose gradient was performed. As described 
before in 5.4 (Figure 5.7) ICT1 depletion caused a conformation change of the 39S 
LSU, resulting in a shift of MRPL3 as a member of the LSU, from fractions 6/7 to 5/6. 
To test whether mtMUG82-FLAG can suppress this defect, HEK293T-WT- and 
HEK293T-mtMUG82-FLAG cells were treated with either si-NT or si-ICT1 B for 3 days. 
The cells were induced also for 3 days with 1 µg/ ml tetracycline. Then, cells were 
harvested, lysed and 700 µg of each sample was separated on a 10 to 30% sucrose 
gradient as described in 3.5.11. The isolated fractions were then analysed by western 
blot as shown in figure 7.4. The HEK293T-WT (WT) treated with si-NT showed ICT1 
mostly in fraction 6, co-migrating with MRPL3, which was mainly present in fractions 6 
and 7. DAP3 as member of the SSU was present in fractions 4 and 5. After ICT1 
depletion in WT MRPL3 was also detectable in fraction 5. The si-NT treated mtMUG82-
 Chapter 7: Identification of possible ICT1 orthologues in yeast and bacteria 
128 
FLAG samples showed a similar result as WT, where ICT1 was present mostly in 
fraction 6 as MRPL3. Interestingly the expressed mtMUG82-FLAG was only detectable 
in the earlier fractions 1 to 3, but not in fraction 6, suggesting that under those 
conditions mtMUG82-FLAG was not associated with the 39S LSU like ICT1. After the 
depletion of ICT1 in mtMUG82-FLAG expressing cells there was also MRPL3 
detectable in fraction 5, whereas in si-NT samples MRPL3 migration started in fraction 
6.  
 
Figure 7.4: MtMUG82-FLAG cannot suppress the mitochondrial ribosomal defect caused 
by ICT1 depletion. HEK293T-WT- and HEK293T-mtMUG82-FLAG cells were treated with si-
NT or si-ICT1 B, respectively, for 3 days. FLAG tagged protein was expressed for 3 days at the 
same time. Cells were then harvested and lysed. Lysates (700 µg) were subjected to sucrose 
gradients. The fractions (1-10) were analysed by western blot using antibodies against ICT1 to 
ensure ICT1 depletion in the siRNA targeting samples. The ribosomal profile in each sample 
was investigated by applying MRPL3 and DAP3 antibodies to all membranes. The distribution of 
mtMUG82-FLAG was also analysed by using antibodies against the FLAG octapeptide.  
 
These results indicate that mtMUG82-FLAG is not able to suppress the mitochondrial 
ribosomal defect, which is caused by ICT1 depletion. The absence of mtMUG82-FLAG 
in the later fractions, where the 39S LSU sediments, suggests that under the 
experimental conditions mtMUG82-FLAG is not associated with the mitochondrial 
ribosome, despite the fact that the immunoprecipitation clearly showed some 
interaction with it. This phenomenon was seen previously with mtRRF-FLAG [Rorbach 
et al., 2008] where the reason for this is believed to be the extended incubation time 
during IP. One explanation could be that what was visible by IP, was the interaction 
over this time period of mtMUG82-FLAG via the A-site of the ribosome. In order to 
prove this hypothesis, further experiments need to be carried out, e.g. isokinetic 
sucrose gradient of IP-ed eluate to analyse whether the co-immunoprecipitated 
complex is the 55S monosome and / or the 39S LSU. It should be further investigated 
whether mtRRF was present in the IP-ed ribosomal complexes. The absence of mtRRF 
in the IP eluate would suggest an interaction of mtMUG82-FLAG via the ribosomal A-
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site. Furthermore the in vitro translation termination assay will answer the question as 
to whether MUG82 has any peptidyl-tRNA hydrolase activity. 
 
7.4 
 
Mitochondrial imported YaeJ is able to co-purify human 
mitochondrial ribosomal proteins.  
For the investigation of YaeJ in human cell lines it needed first to be cloned into 
pcDNA5/FRT/TO with a mitochondrial targetting sequence such as the Su9-
preseqence from N. crassa [Viebrock et al., 1982]. To generate this construct primer 
#12 and #13 listed in table 3.2 and plasmid pTRC99A-his-YaeJ (kindly provided from 
Prof. U. Varshney) as the template were used for amplification of YaeJ. The forward 
primer contains the 3’-end of the Su9-preseqence and further a BssHII restriction site. 
This then allowed an in frame 5’-ligation of YaeJ to Su9-presequence, using as the 
target vector pcDNA5/FRT/TO-Su9-PARN (kindly provided by A. Bobrowicz), where 
the PARN insert was cut out with BssHII and ApaI. The reverse primer contains the 
sequence for the FLAG epitope and the ApaI restriction site. After successful cloning 
and confirmatory sequencing of the plasmid, HEK293T cells were transfected with 
pcDNA5/FRT/TO-Su9-YaeJ-FLAG and pOG44 to generate a stable inducible 
expressing cell line. HEK293T clone expressing Su9-YaeJ-FLAG, which was tested 
and confirmed to show inducible expression, was then used for further experiments: 
immunoprecipitation and isokinetic sucrose gradient. For immunoprecipitation cells 
were induced for 3 days with 1 µg/ ml tetracycline. Mitochondria were then isolated and 
treated with DNaseI and proteinase K, prior to lysis. As shown in figure 7.5 A mtYaeJ-
FLAG is present in this mitochondrial lysate, which also confirmed successful import of 
mtYaeJ-FLAG via the Su9-presequence. YaeJ is a relatively small protein with a 
predicted size of 15.6 kDa. The addition of 69 amino acids from the Su9-presequence 
would result in a molecular weight of 23 kDa close to the size of ICT1-FLAG, but there 
is a substantial difference in size between ICT1-FLAG and mtYaeJ-FLAG (Figure 7.5 
A). In agreement with the cleavage of the presequence are also the results shown in 
figures 7.5 C and 7.7, where the molecular weight of mtYae-FLAG, expressed in 
human cell line and recombinant YaeJ purified from E. coli are relatively similar. The 
slightly slower migration of mtYaeJ-FLAG can be caused by the FLAG tag, which is 
highly positively charged. A small difference in migration between endogenous and 
FLAG tagged protein could be also seen in case of ICT1 (Figure 6.9) and of mtRbfA in 
the next chapter. 
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The mitochondrial lysate was then incubated with M2 FLAG beads to allow 
immunprecipitation of mtYaeJ-FLAG via the FLAG tag. The elution fractions were then 
analysed by silver staining and western blot.  
 
 
Figure 7.5: Mitochondrial imported YaeJ-FLAG shows interaction with human 
mitochondrial ribosomal proteins after immunoprecipition via FLAG tag. HEK293T cells 
expressing mtYaeJ-FLAG or ICT1-FLAG were induced with 1 µg/ ml tetracycline. After 3 days 
cells were harvested and mitochondria isolated, purified and finally lysed. A) Mitochondrial 
lysate (5 µg) of each sample was analysed by western blot using FLAG antibodies to ensure 
expression and mitochondrial import of FLAG tagged proteins. B) Each elution fraction (10%) 
was analysed by western blot on the presence of co-immunoprecipitated ribosomal proteins 
such as MRPL3, MRPL12, ICT1 (components of the 39S LSU), DAP3 and MRPS18B (members 
of the 28S SSU) and also of the FLAG tagged protein itself. C) As for western blot analysis 10% 
of each elution were analysed by silver staining. * indicates the FLAG tagged protein. 
 
As shown in figure 7.5 C as with mtMUG82-FLAG the pattern and the intensity of co-
purified proteins in mtYaeJ-FLAG elution is different from that of ICT1-FLAG. Western 
blot confirmed that mtYaeJ-FLAG is also able to immunprecipitate human 
mitochondrial ribosomal proteins of the LSU (MRPL3 and MRPL12) and of the SSU 
(DAP3 and MRPS18B), but with lower affinity than ICT1-FLAG. No ICT1 protein was 
detectable in the elution of mtYaeJ-FLAG. The lower affinity of mtYaeJ-FLAG cannot 
be caused by lower expression of the tagged protein, as western blot of input and 
elution confirms relatively similar amounts of FLAG tagged ICT1 and YaeJ. 
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7.5 
 
Mitochondrial targeted YaeJ-FLAG does not co-migrate with 
39S LSU on isokinetic sucrose gradient 
To analyse whether the interaction of mtYaeJ-FLAG with human mitochondrial 
ribosomal proteins is caused by the incubation time during the immunoprecipitation, 
isokinetic sucrose gradients of cell lysate were performed. Thus HEK293T cells 
expressing mtYaeJ-FLAG were induced for 3 days with 1 µg/ ml tetracycline. The cells 
were then harvested and lysed as described in 3.5.2. Cell lysate (700 µg) was 
separated on a 10 to 30% sucrose gradient as previously described. The fractions (1-
10) were analysed by western blot, shown in figure 7.6. There, mtYaeJ-FLAG, as seen 
with mtMUG82-FLAG, did not co-migrate with MRPL3, and thus it did not show 
association with the 39S LSU under those conditions. Therefore it is unlikely that 
mtYaeJ-FLAG would be able to rescue the ribosomal defect caused by ICT1 depletion. 
  
 
Figure 7.6: Mitochondria targeted YaeJ-FLAG does not co-migrate with the 39S LSU. 
Lysate (700 µg) of mtYaeJ-FLAG expressing cells was separated on an isokinetic sucrose 
gradient. The mitochondrial ribosomal profile within this gradient was analysed by western blot 
using specific antibodies against MRPL3, representing the 39S LSU, and DAP3, component of 
the 28S SSU. The distribution of mtYaeJ-FLAG was determined by applying FLAG antibodies to 
the western blot membrane.   
 
As with MUG82 it seems highly likely that the association with the human mitochondrial 
ribosome after immunoprecipitation is caused by the 3 hour incubation step and it likely 
represents the interaction of both proteins via the A-site, where proteins that stimulate 
peptidyl-tRNA hydrolysis activity interact.  
 
7.6 
 
YaeJ shows codon-independent release activity in vitro 
To test whether YaeJ has really peptidyl-tRNA hydrolysis activity, the recombinant 
protein had to be purified and then tested in the in vitro translation termination assay by 
Dr. Z. M. A. Chrzanowska-Lightowlers. Therefore YaeJ was amplified using primer #10 
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and #11 (Table 3.2) and pTRC99A-his-YaeJ as the template. The amplicon and target 
vector pGex-6P-1 were digested with BamHI and XhoI, allowing then 5’-ligation of YaeJ 
to the GST-tag on the pGex-6P-1 vector. Finally, E. coli RosettaTM(DE3) was 
transformed with this plasmid, allowing overexpression of YaeJ-GST under IPTG 
inducible promotor. The bacteria were cultured over night at 16°C in the presence of 1 
mM IPTG. The next day cells were harvested and used for recombinant protein 
purification as detailed under 3.5.12. As shown in figure 7.7 a significant amount of the 
overexpressed fusion protein (~ 41.6 kDa) was recovered in the soluble fraction that 
was used for successful purification. The protein with a molecular weight of 
approximately 15.6 kDa was finally eluted by the cleavage of the GST-tag (26 kDa) by 
PreScission protease.  
 
Figure 7.7: Recombinant protein purification of YaeJ. Bacteria were cultured over-night at 
16°C in the presence of 1 mM IPTG allowing overexpression of YaeJ-GST (~ 41.6 kDa) fusion 
protein. Cells were harvested, sonicated and soluble proteins (input, 2) were separated from 
insoluble ones (1) by centrifugation. The soluble fraction was subjected to glutathione 
sepharose beads. After binding step the flow through (3) was discarded and the beads (4) 
washed with PBS. By the addition of PreScission protease the GST-tag was cleaved off and 
YaeJ (~ 15.6 kDa) could be eluted (5), whereas GST-tag (~ 26 kDa) stayed on the beads (6).  
 
For the in vitro translation termination assay 50 pmol of recombinant protein were then 
further used. As shown in the graph in figure 7.8 YaeJ was able to cause hydrolysis of 
the radiolabelled f[3H]met from the tRNAMet in the presence, but also in the absence of 
a stop codon (UAA). This suggests that YaeJ has like ICT1 a codon-independent, and 
probably ribosome-dependent release activity. To be sure about the latter an assay in 
the absence of a 70S ribsome needs to be done. 
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Figure 7.8: YaeJ shows release activity in the in vitro translation termination assay. 
Purified recombinant YaeJ protein (50 pmol) was tested in the in vitro assay. E. coli 70S 
ribosomes were programmed with f[3H]met-tRNAMet in the P-site and either in the presence or 
absence of a stop codon (400 pmol UAA) in the decoding centre. ICT1 was used as a positive 
control for ribosome-dependent codon-independent release activity. Means and standard 
deviations were calculated from three experiments. 
 
However, it is highly likely that the function of YaeJ is also ribosome-dependent, 
because of the presence of the GGQ motif, which is a typical feature of a ribosome-
dependent peptidyl-tRNA hydrolase. As already explained before, it is believed that the 
GGQ motif mimics the CCA motif of the aminoacyl-tRNA at the PTC centre within the 
ribosome [reviewed in Youngman et al., 2008] and it is not really the class I release 
factor that hydrolyses the ester bond between the peptide chain and the tRNA, it is the 
ribosome itself that allows after conformational change with the release factor a 
hydrophilic attack and therefore hydrolysis [Schmeing et al., 2005]. Thus hydrolysis 
activity catalysed by class I release factor with a GGQ motif needs the context of a 
ribosome. This result led to the speculation that there is possibly release activity 
catalysed MUG82. It is highly likely that MUG82 also shows similar activity in vitro. 
However recombinant protein needs to be purified to finally do the experiment to prove 
this hypothesis.  
 
7.7 
 
Discussion 
Sequence alignment as shown in figure 7.1 demonstrates clearly similarity between 
human ICT1, yeast MUG82 and bacterial YaeJ. The named proteins harbour the GGQ 
motif that is essential for catalysing the hydrolysis of the ester bond between the P-site 
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tRNA and its attached peptide chain within the ribosome. Additionally MUG82 and ICT1 
share 49 (~27%) identities and YaeJ and ICT1 31 (~22%). None of them shows the 
crucial motifs for codon recognition (tip of α5 helix and PXT/SPF tripeptide) like a 
conventional class I release factor. All three proteins are quite small with approximately 
15 kDa to 20 kDa, whereas mtRF1a is around twice as large at ~ 40 kDa.  
ICT1 was already shown in the previous chapters to be a mitochondrial ribosomal 
protein with ribosome-dependent, but codon-independent peptidyl-tRNA hydrolase 
(PTH) activity, proposed to be involved in the recycling of stalled ribosomes or abortive 
ribosomal large subunit with immobilised peptidyl-tRNAs.  
The aim of the experiments shown in this chapter was an initial characterisation of the 
possible orthologues (MUG82 and YaeJ) of human ICT1 to see, whether ~  
 i)  those orthologues can also be integrated into the human mitochondrial  
  ribosome 
 ii)  they show ribosome-dependent and codon-independent PTH activity in  
  the in vitro translation termination assay  
 iii)  they are able to suppress the defect caused by ICT1 depletion. 
 
To analyse possible function of MUG82 and YaeJ, they were both targeted to human 
mitochondria using Su9-presequence from N. crassa [Viebrock et al., 1982] and further 
fused with a C-terminal FLAG tag to allow specific immunoprecipitation via the FLAG 
epitope. Both, MUG82 and YaeJ were able to co-purify human mitochondrial ribosomal 
proteins (Figure 7.3 and 7.5), but with an overall lower affinity than ICT1. Interestingly 
instead of co-migrating with the 39S LSU both were located more in the earlier 
fractions (1 to 3) on isokinetic sucrose gradients (Figure 7.4 and 7.6). This suggests 
that under those conditions neither MUG82 nor YaeJ was associated with the 
mitochondrial ribosomal large subunit like ICT1, demonstrating that the interaction seen 
after IP was caused probably by the incubation time of 3 hours where MUG82 or YaeJ 
may be able to access the A-site as was seen before with mtRRF [Rorbach et al., 
2008]. Thus it seems unlikely that MUG82 or YaeJ can be integrated into the human 
mitochondrial ribosome as is ICT1. This is also in agreement with the fact that MUG82 
was not able to suppress the ribosomal defect caused by ICT1 depletion.  
It would be further interesting whether the association of both proteins with the 
mitochondrial ribosome is really through the A-site. Therefore it needs to be further 
analysed whether mtRRF is present in those immunoprecipitated ribosomal complexes. 
The absence of mtRRF would suggest that MUG82 or YaeJ, respectively can interact 
with the ribosome via the A-site.  
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It is further from great interest whether those two proteins interact with the yeast 
mitochondrial or the bacterial ribosome, respectively. An integration of YaeJ into the 
70S bacterial ribosome would be a surprise, as the E. coli ribosome is very well 
characterised. However, very recently Handa et al. (2010b) have shown that YaeJ is 
most of the time associated with the 70S ribosomes and polysomes, but also with the 
30S SSU in bacteria. In contrast to ICT1 YaeJ is not essential for cell growth and 
further a deletion of YaeJ in bacteria has no effect on the ribosome profile revealed by 
density sucrose gradients, suggesting that it is not important for ribosome assembly as 
is ICT1. It seems therefore that the recruitment of ICT1 into the mitochondrial ribosome 
is unique in mammals and that ICT1 is one example of the additional ribosomal 
proteins that do not have homologues in the 70S bacterial ribosome [reviewed in Koc 
et al., 2010]. Interestingly YaeJ was also found in association with the bacterial 30S 
SSU, which is different from ICT1, a member of the mitochondrial ribosomal large 
subunit. Handa et al. (2010b) suggested that the C-terminus of YaeJ, which was shown 
to be important for ribosome binding, is maybe fixed in the 30S SSU and as soon as a 
ribosome gets stalled the domain 3-like portion of YaeJ with the GGQ domain will be 
located towards the PTC. However, the way how ICT1 and YaeJ interact with the 
mitochondrial ribosome or bacterial ribosome, respectively, must be different as ICT1 
has been recruited into the 39S LSU and YaeJ does not represent a ribosomal protein 
and further shows besides interaction with 70S ribosome also an association with the 
30S SSU in bacteria.  
 
Thus far there is some evidence that also YaeJ can act as a codon-independent 
peptidyl-tRNA hydrolase, probably in a ribosome-dependent manner, as YaeJ showed 
clearly hydrolysis activity in the presence and absence of a stop codon in the in vitro 
translation termination assay using 70S E. coli ribosomes (Figure 7.8). Handa et al. 
(2010b) demonstrated that the GGQ motif is also essential for the PTH activity of YaeJ, 
however, it is unclear whether the first glycine is really important as the authors did not 
show results of YaeJ with mutation just in this one residue. This would be particularly 
interesting since the PTH activity of ICT1 seems to be the same for ICT1GGQ wildtype 
and ICT1AGQ mutant in vivo. 
To determine the function of YaeJ in E. coli in vivo Prof. U. Varshney and his group will 
investigate this protein further in different bacterial background strains. Thus far they 
have shown that the expression of YaeJ was not able to rescue the pthts strain at 
nonpermissive temperatures. This could be in agreement with a ribosome-dependent 
PTH activity and therefore the non-ability to replace a soluble ribosome-independent 
PTH. The pthts strain can be rescued by the downregualtion of RRF as less peptidyl-
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tRNAs are released during recycling by RRF and therefore the accumulation of 
peptidyl-tRNA, which is lethal [Menninger, 1978], is reduced. Under those conditions 
YaeJ may act as a ribosome-dependent PTH and leads to the hydrolysis of those 
peptidyl-tRNA within the ribosome, thus rescuing the sequestering of tRNAs. A 
depletion of YaeJ in a pthts-dnRRF background resulted in a growth defect again. It 
would be interesting whether an expression of ICT1 under those circumstances would 
replace YaeJ and suppress the growth defect.  
Furthermore as ICT1, YaeJ was not able to rescue the host from the toxicity caused by 
AGA-minigene overexpression, which again supports the idea that ICT1 and YaeJ act 
more on long-chain peptidyl-tRNAs within the ribosome and not on dropped off short-
chain peptidyl-tRNAs as discussed in the previous chapter. However, it would still be of 
great interest to see whether YaeJ expression would rescue the strain if RRF is 
downregulated as the peptidyl-tRNA would be then stuck in the ribosome and not 
accessible for soluble PTH.  
However, it would be still from great interest to identify whether both ICT1 and YaeJ 
show more of an effect in the ung-mRNA overexpressor. Moreover this strain can be 
rescued by RRF the suppression is weaker than in the AGA-minigene overexpressor. It 
was shown that RRF overexpression releases the ung-mRNA [Singh et al., 2008], 
meaning the ribosome gets recycled. The rather weak rescue of the strain by RRF 
expression may be due to the possibly blocked peptidyl-tRNA within the ribosomal 
large subunit (Figure 6.12 C). This could be tested by separating those samples on 
isokinetic sucrose gradients, where the peptidyl-tRNA should be detectable in the 
fraction where the LSU migrates. If this would be the case then it would be interesting 
whether ICT1 or YaeJ would suppress the phenotype further by catalysing the 
hydrolysis of the peptidyl-tRNA and therefore the release of the peptide chain and 
tRNA from the ribosomal subunit.  
 
To date not much is known from the yeast orthologue MUG82. However, also if 
MUG82 was not able to rescue the ribosomal defect caused by ICT1 depletion in 
human mitochondria, it would be still interesting to confirm whether ICT1 could replace 
MUG82 in yeast.  
 
Concluding so far ICT1 orthologues are present in yeast (S. pombe: MUG82) and 
bacteria (E. coli: YaeJ). It seems that these orthologues are like ICT1 ribosome-
dependent, but codon-independent peptidyl-tRNA hydrolases according to the 
sequences and the activity of YaeJ in the in vitro translation termination assay. Neither 
YaeJ nor MUG82 can be integrated into the human mitochondrial ribosome, however, 
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both probably get access to the ribosomal A-site during incubation and can thus 
interact with human mitochondrial ribosomal proteins. As this is only an initial 
characterisation of MUG82 and YaeJ further experiments need to be done, especially 
testing MUG82 in the in vitro translation termination assay, and also further 
investigations in the yeast and bacterial system, respectively.  
However, the results presented in this study and by Handa et al. (2010b) suggest that 
this class of “truncated” class I release factors including ICT1, YaeJ and potentially 
MUG82 represents ribosome-dependent peptidyl-tRNA hydrolases that are involved in 
the rescue of stalled ribosomes.  
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8 Chapter 8:                                                                 
Investigation of human ribosome binding factor A 
 
As a consequence of the ICT1 project, where it transpired that ICT1 is a component of 
the mitochondrial ribosome, there was a great interest in the human mitochondrial 
ribosome and its assembly. Therefore the investigation of the human ribosome binding 
factor A (C18orf22; mtRbfA), as a potential ribosome assembly factor, that had been 
initiated by Dr. J. Rorbach, was continued.  
 
8.1 Introduction 
 
The bacterial orthologue RbfA was initially identified as a high-copy suppressor for a 
mutation (C23U) in the 5’-end helix of the 16S ribosomal RNA of the 30S small subunit 
[Dammel and Noller, 1995]. Furthermore it was shown that a pool of RbfA is associated 
with the 30S SSU, but not with either the 50S LSU or with the 70S ribosome or 
polysome [Dammel and Noller, 1995; Xia et al., 2003]. Its role in the maturation of the 
30S SSU is due to its processing of the 16S rRNA [Xia et al., 2003]. A deletion of RbfA 
in E. coli leads to an accumulation of 17S rRNA, a precursor to the 16S rRNA [Inoue et 
al., 2003; Xia et al., 2003] and thus to an increased level of free 30S SSU and 50S 
LSU. This consequently leads to decreased amounts of translating polysomes, 
probably caused by the inability of the 30S SSU with precursor 16S rRNA to interact 
with the 50S LSU and so be incorporated into the 70S ribosome. RbfA is also a cold 
shock protein [Jones and Inouye, 1996; Xia et al., 2003] whose abundance increases 
upon low temperature to adapt the translation machinery to those conditions. After a 
cold shock the translation rate in bacteria decreases. The upregulation of cold shock 
proteins such as RbfA is probably to facilitate rapid maturation of the 30S SSU and 
therefore to overcome the translational block. This cold shock protein, which is bound 
to 20% 30S SSU at 37°C, but to 40% of 30S after cold shock, is therefore crucial in E. 
coli to adapt to low temperature [Xia et al., 2003].  
Available structures of bacterial RbfA [Huang et al., 2003; Datta et al., 2007] 
demonstrate that RbfA has a type-II KH-domain fold, which is a characteristic of an 
RNA-binding domain in archaeal or bacterial proteins. It is suggested that KH folds 
mediate RNA-dependent protein-protein interactions. The solution structure of E. coli 
RbfA is a monomeric protein with 3 helices and 3 β-strands (α1-β1-β2-α2-α3-β3), where 
the βααβ subunit shows a helix-kink-helix (hkh) motif with a conserved AXG sequence. 
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Datta et al. (2007) showed that this hkh motif of Thermus thermophilus faces the 
junction between the top of helix44 (h44) and the base of helix45 (h45) of the 16S 
rRNA within the 30S SSU. It was further suggested that the interaction of RbfA with the 
neck region of the 30S SSU leads to an induced fit-like mechanism with a shift of h44 
and h45. Furthermore they demonstrated that RbfA interacts with the C-terminal 
extension of ribosomal proteins S9 and S13 within the P-site, and the h18 and the 
ribosomal protein S12, which overlaps with the binding site of IF1. Because of the 
flexibility of the C-terminal region of RbfA it was proposed that this region relocates 
towards h18 and thus it can interact with the loop region of h1 at the 5’-end of the 16S 
rRNA. It was suggested that bound RbfA inhibits the interaction of 50S LSU with 30S 
SSU precursor if h1 is unformed and the 5’-end unprocessed.  
Bacterial RbfA is a relatively small protein with 95 amino acids (T. thermophilus) or 133 
amino acids (E. coli). The sequence identity between different RbfA homologues is 
very low (~20%), but the structural similarity is remarkable [Datta et al., 2007].  
The putative human mitochondrial orthologue (C18orf22) of bacterial RbfA was found 
in the immunoprecipitation of mtRRF-FLAG [Rorbach et al., 2008]. C18orf22 (mtRbfA) 
at 343 amino acids is approximately 3 times as big as the bacterial counterpart. 
Sequence alignment of bacterial RbfA (E. coli and T. thermophilus) and human mtRbfA 
shows only a few identities (Figure 8.1 A). Low sequence similarity was also seen 
between other bacterial RbfA homologous as it is also shown in figure 8.1 (compare E. 
coli and T. thermophilus). Interestingly available structures from human mtRbfA from 
residue Arg86 to Asp201 demonstrate high similarity between E. coli RbfA and human 
mtRbfA over this region (Figure 8.1 B). This solution structure shows the typical type-II 
KH-domain fold.  
Bacterial RbfA is involved in the processing of the 16S rRNA and thus in the maturation 
of the 30S SSU. Xia et al. (2003) suggested that the 16S precursor, which accumulates 
in RbfA depleted cells in bacteria, is potentially the pre-16S rRNA, which is processed 
at the RNase III site (115 nt upstream of the 5’-end of the mature form). It seems 
reasonable to hypothesise that mtRbfA is involved in a similar process in human 
mitochondria. The 12S rRNA (MT-RNR1) within the 28S SSU in human mitochondria, 
however, does not appear to have the kind of precursor form as is the case for the 16S 
rRNA in bacteria. In human mitochondria 12S rRNA is flanked by tRNAPhe (5’-end) and 
tRNAVal (3’-end) in an intronless polycistronic transcript [Anderson et al., 1981; Ojala et 
al., 1981], whose cleavage requires tRNase Z and RNase P processing at the 3’- and 
5’-end, respectively of the tRNAs.  
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A 
RbfA E. coli           -------------------------------------------------- 
RbfA T. thermophilus   -------------------------------------------------- 
mtRbfA H. sapiens      MWAAAGGLWRSRAGLRALFRSRDAALFPGCERGLHCSAVSCKNWLKKFAS 50 
                     
 
RbfA E. coli           -----------------------------------MAKEFGRPQRVAQEM 15 
RbfA T. thermophilus   -------------------------------------MAYGKAH-LEAQL 12 
mtRbfA H. sapiens      KTKKKVWYESPSLGSHSTYKPSKLEFLMRSTSKKTRKEDHARLRALNGLL 100  
                                                              ..: : :   : 
 
RbfA E. coli           QKEIALILQR-EIKDPRLGMMTTVSGVEMSRDLAYAKVYVTFLNDKDEDA 64 
RbfA T. thermophilus   KRALAEEIQ--ALEDPRL-FLLTVEAVRLSKDGSVLSVYVEAFREEE--- 56 
mtRbfA H. sapiens      YKALTDLLCTPEVSQELYDLNVELSKVSLTPDFSACRAYWKTTLSAEQN- 149 
                        : ::  :    :.:    :   :. * :: * :   .*     . :    
 
RbfA E. coli           VKAGIKALQEASGFIRSLLGKAMRLRIVPELTFFYDNSLVEGMRMSNLVT 114 
RbfA T. thermophilus   --GALRALSRAERRLVAALARRVRMRRLPRLEFL---------------- 88  
mtRbfA H. sapiens      -AHMEAVLQRSAAHMRHLLMSQQTLRNVPPIVFVQDKGNAALAELDQLLA 198 
                             .*..:   :   *     :* :* : *.                 
 
RbfA E. coli           SVVKHDEERRVNPDDSKED------------------------------- 133 
RbfA T. thermophilus   -------PWRASPA------------------------------------ 95  
mtRbfA H. sapiens      VADFGPRDERDNFVQNDFRDPDAPQPCGTTEPTTSSSLCGIDHEALNKQI 248 
                                * .                                       
 
RbfA E. coli           -------------------------------------------------- 
RbfA T. thermophilus   --------------------------------------------------  
mtRbfA H. sapiens      MEYKRRKDKGLGGLVWQGQVAELTTQMKKGRKRAKPRLEQDSSLKSYLSG 298 
 
 
RbfA E. coli           ---------------------------------------------  
RbfA T. thermophilus   ---------------------------------------------  
mtRbfA H. sapiens      EEVEDDLDLVGAPEYECYAPDTEELEAERGGGRTEDGHSCGASRE 343 
 
B 
 
Figure 8.1: Sequence and structure alignment of bacterial RbfA and human mtRbfA. A) 
Sequence alignment (CLUSTALW) of RbfA from E. coli and T. thermophilus and mtRbfA from 
H. sapiens. Identities are indicated by a star (*), high level of similarity by a colon (:) and lower 
levels by a full stop (.). The basic residues Arg7, Arg10, Arg45, Arg80, Lys85, Arg88, Arg90 
(bold) in E. coli RbfA are maybe involved in RNA-binding [Huang et al., 2003]. The Ala75 
(green) of the AXG sequence forms an inter-helical kink (see B below). A well-conserved 
“sequence signature” (IRXXLXXXXXLRXVPXLXFXXD), located in the C-terminal region of E. 
coli RbfA is labelled in red. Human mtRbfA shares not all, but most of those named 
characteristic features of E. coli RbfA. B) Structures of E. coli RbfA (grey, PDB: 1KKG; Huang et 
al., 2003) and human mtRbfA (red, PDB: 2E7G, unpublished) were superimposed using 
PyMOL. Both show the type-II KH-domain fold with three helices and three β-strands. Human 
mtRbfA shows an additional small helix, whose sequence is underlined in (A). The inter-helical 
kink formed by Ala75 in E. coli RbfA and by Ser159 in human mtRbfA is showed as green 
sticks. 
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Thus even if mtRbfA is still involved in the maturation of the ribosomal small subunit in 
human mitochondria, it must have adopted a distinct function. A substantial increase in 
the size of the protein supports the idea that mtRbfA may function in different way to its 
bacterial counterpart. Recently Dennerlein et al. (2010) reported that ERAL1 the 
orthologue of the bacterial Era GTPase, is a 12S rRNA chaperone in human 
mitochondria, binding to the 3’-end of the 12S rRNA. The loss of ERAL1 in human cells 
leads to a substantial reduction in the steady state level of 12S rRNA. In bacteria it has 
been shown that Era is also involved in the maturation of the 16S rRNA, where it 
facilitates the processing of the 3’-end. Datta et al. (2007) demonstrated that Era and 
RbfA interact with common elements of the 30S SSU, especially the helix 28 (h28). It 
was suggested that Era’s interaction with h28 stabilises h1 indirectly, which is 
supposed to be a direct function of RbfA in bacteria. This is in agreement with the 
report by Inoue et al. (2003), where it was demonstrated that Era is able to partially 
suppress the cold sensitive phenotype and the defect in ribosome assembly caused by 
lack of RbfA in strains with deletions. Human ERAL1 has maintained its function in 28S 
SSU maturation operating as does its counterpart Era in bacteria. The question then is, 
whether the same is true for mtRbfA? Is mtRbfA involved in the maturation or assembly 
of the 28S SSU in human mitochondria? To answer those questions two main 
approaches were applied: 
i)  Immunoprecipitation and isokinetic sucrose gradient were utilised to investigate 
 whether mtRbfA interacts with the 28S SSU  
ii)  siRNA technology was used to determine the cellular and molecular effect of 
 mtRbfA depletion.  
  
8.2 Localisation of the human ribosome binding factor A 
(mtRbfA)  
  
The first aim of this project was to identify whether mtRbfA is really a mitochondrial 
protein. TargetP 1.1 predicts mitochondrial targeting of mtRbfA with RC1 and cleavage 
site of the targeting peptide after residue 41. The cleavage site prediction using 
PSORTII is quite different from TargetP 1.1. PSORTII predicts RbfA to be a 
mitochondrial protein with 43.5% with a possible cleavage site for mitochondrial 
presequence at residue 21 (subprogramme “Gavel”).  
To determine whether human ribosome binding factor A (mtRbfA) is a mitochondrial 
protein, cellular fractionation and mitochondrial preparations were made and analysed 
by western blotting to show whether the localisation of mtRbfA was within the 
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mitochondria fraction. For this approach specific antibodies against mtRbfA are 
essential. Therefore recombinant bacterially overexpressed protein generated by Dr. J. 
Rorbach was purified and sent to Eurogentec, Belgium to inject 2 rabbits 4 times over 3 
months with 100 µg protein each time. The antiserum was tested on cell lysate and 
isolated mitochondria. As shown in figure 8.2 (left panel) the non-purified antiserum 
gave many non-specific interactions. Thus it needed to be purified to be useful for 
further investigations in this study. 
 
Figure 8.2: Analysis of specificity of antiserum (rabbit anti human mtRbfA polyclonal 
antibody). Western blot of 50 µg lysate from HEK293T cells (CL) and 10 µg isolated 
mitochondria (M) were probed with non-purified antiserum (dilution 1:500) and with affinity 
purified antibodies against human mtRbfA (dilution 1:1000).  
 
For antibody purification approximately 1-2 mg of affinity purified recombinant protein 
was needed. Because the bacterially expressed full length recombinant mtRbfA-GST 
was mostly insoluble, a construct had to be made that would result in a higher recovery 
in the soluble fraction. A truncation of the N-terminus, which is usually quite 
hydrophobic in case of mitochondrial proteins, was made to help to resolve this 
problem. Therefore sequence encoding the mtRbfA was amplified with a truncation of 
90 nucleotides at the 5’-end using the primer-pair #14/#15 (Table 3.2) and as the 
template pGex-6P-1-mtRbfA (containing full length mtRbfA; provided by Dr. J. 
Rorbach). The amplicon and the vector pGex-6P-1 were digested using BamHI and 
XhoI, the vector was dephosphorylated and finally vector and insert were ligated. After 
successful cloning the construct was used for E. coli RosettaTM(DE3) transformation. 
The strain was then utilised to purify a 30 amino acids N-terminus truncated 
recombinant mtRbfA via the GST-tag, which was then used for the antibody purification 
as described in 3.5.13. As shown in figure 8.2 (right panel) the purified antibodies 
recognised a single band in cell lysate and isolated mitochondria with the expected 
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molecular weight of approximately 40 kDa (Uniprot database - Q8N0V3 - calculation: 
38.359 kDa of isoform 1). This result also suggests that the protein is localised to and 
potentially within mitochondria.  
As shown later on in this study the antibodies are confirmed as specifically recognising 
mtRbfA, as the signal disappears after depletion of mtRbfA and furthermore increases 
when mtRbfA was overexpressed in cell culture.  
 
To analyse whether mtRbfA is localised within mitochondria a western blot shown in 
figure 8.3 was performed with cell lysate (lane 1), isolated mitochondria (lane 2) and 
isolated mitochondria treated with proteinase K to remove cytosolic contaminations 
(lane 3). Lysed mitochondria were treated with the same amount of enzyme to be sure 
about the activity of proteinase K and the sensitivity of the tested proteins against the 
enzyme (lane 4). As a mitochondrial marker MRPS18B, a component of the 
mitochondrial ribosomal small subunit was used and clearly MRPS18B was detectable 
in cell lysate, isolated mitochondria and was also protected from the proteinase K 
treatment by the intact mitochondrial membrane. Mitochondria lysis allowed the 
digestion of MRPS18B by proteinase K, demonstrating its sensitivity to the enzyme. 
RP-S6 as a cytosolic marker was detectable in cell lysate, but completely disappeared 
in the fraction of proteinase K treated mitochondria. mtRbfA followed the same pattern 
as MRPS18B and thus concluding from this experiment mtRbfA is localised within the 
mitochondria.  
 
 
Figure 8.3: Cellular localisation of mtRbfA. Western blot shows 50 µg lysate of HEK293T 
cells (lane 1), 10 µg isolated mitochondria (lane 2) and 10 µg isolated mitochondria treated with 
proteinase K in the absence (lane 3) and presence (lane 4) of 1% Triton X-100. Using specific 
antibodies against mtRbfA a single band of ~ 40 kDa was detectable in cell lysate and in intact 
mitochondria. After mitochondrial lysis mtRbfA was no longer detected. MRPS18B was used as 
a mitochondrial marker and RP-S6 as a cytosolic marker. 
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8.3 mtRbfA is associated with the mitochondrial ribosomal small 
subunit 
 
As suggested from the studies of RbfA in bacteria, the human orthologue is potentially 
involved in the maturation of the mitochondrial ribosomal small subunit. As a first step 
to investigate this possibility it had to be shown that mtRbfA is associated/ interacting in 
some way with the mitochondrial ribosomal small subunit. Therefore 700 µg of lysate 
from HEK293T cells were separated on a 10 - 30% isokinetic sucrose gradient, the 
fractions of which were analysed by western blot (Figure 8.4). Fraction 1 represents the 
top of the gradient containing particles with lighter sedimentation, whereas fraction 10, 
the bottom of the gradient shows complexes with heavier sedimentation.  
 
 
Figure 8.4: Endogenous mtRbfA co-migrates with 28S SSU on isokinetic sucrose 
gradient. HEK293T cell lysate (700 µg) was separated on a 10-30% sucrose gradient. 
Fractions, which were taken from top to bottom (labelled as 1-10 under the figure) were 
analysed by western blot. Using specific antibodies against components of the 28S SSU (DAP3 
and MRPS18B) and the 39S LSU (MRPL3 and MRPL12) allowed the determination of the 
sedimentation of the ribosomal subunits within these gradients. The relative position of the 
mitochondrial ribosomal subunits and the monosome are indicated at the top of the image. The 
distribution of mtRbfA within this gradient was determined by using specific antibodies against 
the protein.   
 
Under these conditions the 28S SSU was localised in fraction 4 and 5, represented by 
the migration of DAP3 and MRPS18B, components of the 28S SSU. MRPL3 and 
MRPL12, components of the 39S LSU were mostly detectable in fractions 6 and 7. 
MtRbfA was localised in fractions 1 (~18% of total mtRbfA protein), 2 (~9%) and also 3 
(~5%), but the majority co-sediment with the 28S SSU in fractions 4 (~36%) and 5 
(~26%), a first indication that mtRbfA is maybe associated with the 28S SSU.  
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8.4 MtRbfA-FLAG is able to co-immunoprecipitate
  
 mitochondrial 
ribosomal proteins 
To confirm whether the observation of mtRbfA interacting with the 28S was real and 
also to investigate whether it is also associated with the 55S monosome, which is not 
visible with this kind of gradient, another experiment was performed. A cell line 
expressing mtRbfA-FLAG HEK293T, generated by Dr. J. Rorbach, was used to 
perform immunoprecipitation of mtRbfA via the FLAG tag as described in 3.5.9. As a 
negative control for any non-specific interaction in the immunoprecipitation, a 
mitochondrial targeted Luciferase (mtLuc-FLAG) was treated in the same way as 
mtRbfA-FLAG. To avoid unspecific interactions with cytosolic proteins mitochondria 
were isolated and purified as described in 3.5.8 prior to lysis. The elution fractions of 
mtRbfA-FLAG and mtLuc-FLAG were analysed by silver staining and western blot as 
presented in figure 8.5.  
 
 
Figure 8.5: MtRbfA-FLAG is associated with mitochondrial ribosomal proteins. A) Equal 
amounts of each elution fraction (10%) were separated on 12% SDS-PAG followed by silver 
staining. * indicates the FLAG tagged protein. B) Western blot of the elution fractions were 
probed with markers of the 28S SSU (DAP3, MRPS18B, MRPS25 and MRPS6), the 39S LSU 
(MRPL3 and MRPL12) and with 12S rRNA chaperone ERAL1. Mitochondrial targeted Luc-
FLAG was used as a control, confirming specificity of the IP. FLAG tagged proteins were 
detected in each elution fraction with specific antibodies against the FLAG epitope.   
 
On the silver staining mtRbfA-FLAG showed several additional signals in comparison 
to the mtLuc-FLAG. The pattern is suggestive of ribosomal proteins, thus western blot 
of the eluates were probed with antibodies against components of the 28S SSU (DAP3, 
MRPS18B, MRPS25, MRPS6) and the 39S LSU (MRPL3, MRPL12), respectively. All 
tested components were detectable in the elution of mtRbfA-FLAG, but not in the 
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control of mtLuc-FLAG. ERAL1, a 12S rRNA chaperone was also associated within this 
immunoprecipitated complex. This result suggested that mtRbfA-FLAG is not just 
associated with the 28S SSU. There are also some interactions with the components of 
the 39S LSU or the 55S monosome. 
For more detailed analysis of the elution fraction, samples were sent by Dr. J. Rorbach 
for LC MS/MS (Liquid chromatography - tandem mass spectrometry) analysis to H. 
Wessels and Prof. J. Smeitink at UNMC, Nijmegen.  
The majority of co-immunoprecipitated proteins by mtRbfA-FLAG were mitochondrial 
ribosomal proteins as listed in table 8.1 (See also appendix 2).  
 
Table 8.1: Mitochondrial ribosomal proteins identified as co-purified components of the 
mtRbfA-FLAG immunoprecipitation 
 
Small Subunit (28S) - SSU 
  
Large Subunit (39S) - LSU 
 
MRPS2, MRPS5, MRPS6, 
MRPS7, MRPS9, MRPS10, 
MRPS11, MRPS16, MRPS15, 
MRPS17, MRPS18A, MRPS18B, 
MRPS21, MRPS22, MRPS23, 
MRPS25, MRPS26, MRPS27, 
MRPS28, MRPS29/DAP3, 
MRPS30, MRPS31, MRPS34, 
MRPS35, METT11D1 
  
MRPL1, MRPL2, MRPL3, MRPL4, 
MRPL9, MRPL11, MRPL12, MRPL13, 
MRPL14, MRPL15, MRPL16, MRPL17, 
MRPL18, MRPL19, MRPL20, MRPL21, 
MRPL22, MRPL23, MRPL24, MRPL28, 
MRPL31, MRPL37, MRPL38, MRPL39, 
MRPL40, MRPL41, MRPL43a, MRPL43b, 
MRPL44, MRPL45, MRPL46, MRPL47, 
MRPL48, MRPL49, MRPL50, MRPL51, 
MRPL54, MRPL55, MRPL58/ICT1 
 
25 MRPS of 31 
  
39 MRPL of 51 
 
Overall there was a balanced ratio of members of the 28S SSU and the 39S LSU, 
suggesting an interaction of mtRbfA with either the monosome or the separated 
subunits, respectively. However, the ribosomal proteins with the highest EMPAI value1
 
, 
were components of the 28S SSU: MRPS26, MRPS21, MRPS7, MRPS22 and 
MRPS17 (from high to low). 
Furthermore mtIF2 was also detected within this IP, suggesting an association of 
mtRbfA with the translation initiation complex, which harbours the 28S SSU and mtIF2. 
                                                 
1 EMPAI (experimental modified protein abundance index) value represents an estimation of molar 
abundance of proteins in the analysed sample, calculated by H. Wessels. The protein abundance index 
(PAI) is a semi-quantitative representation of the relative amount of protein in the sample, relating the 
number of identified tryptic peptides to the number of theoretically observable ones.   
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The 12S rRNA chaperone, ERAL1 [Dennerlein et al., 2010] was also seen in this IP, 
supporting the idea that mtRbfA has a preference for the ribosomal small subunit. 
Another protein that was detected with a relatively high EMPAI value was SLIRP, an 
RNA-binding protein whose stability itself was shown to be RNA dependent [Baughman 
et al., 2009]. Surprisingly mtRRF was absent in the mtRbfA-FLAG-IP, whereas mtRbfA 
was co-immunoprecipitated with mtRRF-FLAG [Rorbach et al., 2008]. mtRRF is a good 
indicator for a 55S monosome and thus this result suggest that mtRbfA is maybe not 
associated with the 55S mitochondrial monosome. 
 
To distinguish whether mtRbfA is associated with the 55S monosome or with the 39S 
LSU besides the 28S SSU, immunoprecipitated eluate was separated on an isokinetic 
sucrose gradient. Fractions were analysed by silver staining (Figure 8.6 A, lower panel) 
and western blot (Figure 8.6 A, upper panel). As shown in figure 8.6 mtRbfA-FLAG 
migrated mainly in fractions 1, 2 and 4, 5, but it was also detectable in every other 
fraction at lower level. Components of the 28S SSU, including DAP3, MRPS18B and 
MRPS25, co-sediment with mtRbfA-FLAG represented mostly in fractions 4, 5 and also 
6. There was no signal in fraction 8, the approximate position of the 55S monosome, 
suggesting that mtRbfA-FLAG is not associated with the 55S. Components of the 39S 
LSU (MRPL3, MRPL12 and trace amounts of ICT1) were detectable mainly in fraction 
6, which represents the 39S LSU alone and not the monosome. Interestingly, MRPL12 
was also located at higher level in fractions 1 and 2. This protein was also detected 
with increased amounts from fraction 7 to 8, but this would make MRPL12 as the only 
indicator that mtRbfA is potentially associated with the 55S. ERAL1 was detected in 
fractions 4 and 5 with the 28S SSU, but also in relative similar intensity in fractions 1 
and 2. Analysing those fractions by silver staining (Figure 8.6 A, lower panel) showed 
again the majority of bands, especially with lower molecular weight, in fractions 4 to 6, 
but not in 8. Interestingly there were also several strong bands with higher molecular 
weight in the earlier fractions 1 to 5. Most of the mitochondrial ribosomal proteins have 
a molecular weight less than 45 kDa [Koc et al., 2001b/c], suggesting that those bands 
represent other interaction partners than components of the mitochondrial ribosome. 
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Figure 8.6: Gradients of complexes co-immunoprecipitated with mtRbfA-FLAG and 
MRPS27-FLAG. HEK293T cell lines expressing mtRbfA-FLAG (A) or MRPS27-FLAG (B) were 
induced for 3 days with 1 µg/ ml tetracycline. After a standard IP using 3 mg mitochondrial 
lysates, eluates (80%) were separated by isokinetic sucrose gradients. Fractions (1-10) were 
analysed by silver staining (lower panels) and western blot (upper panels). Immunoprecipitated 
ribosomal complexes were detected using antibodies against members of the 28S SSU (DAP3, 
MRPS18B and MRPS25) and the 39S LSU (MRPL3, MRPL12 and ICT1). The distribution of 
ERAL1 is also shown. To examine the presence of the FLAG tagged protein in each fraction 
antibodies against the FLAG octapeptide were applied to each western blot membrane.  
 
As a control for this experiment MRPS27-FLAG was treated in the same way and IP 
eluate was also separated on an isokinetic sucrose gradient. MRPS27-FLAG was able 
to pull down the 28S SSU and the 55S monosome using anti-FLAG antibodies as was 
already shown in chapter 5. On this gradient DAP3 migrated mostly in fraction 4, 5 and 
6, but was also detectable in fraction 8, showing the 55S monosome. MRPS18B and 
MRPS25 co-migrated with MRPS27-FLAG in fractions 2 and 3, representing 28S SSU 
intermediates. They were also detectable in fractions 4 and 5, representing the 28S 
SSU, and also in fraction 8, thus within the 55S monosome. MRPL3, MRPL12 and 
ICT1 migrated mainly in fraction 8 as part of the 55S monosome. Interestingly the 
endogenous mtRbfA co-sediment only with the 28S SSU in fractions 4 to 6, but not with 
the 55S particle in fraction 8. Similarly the 12S rRNA chaperone ERAL1 was mostly 
detectable in fractions 4 to 6 and just trace amounts in fractions 1 and 2.  
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Concluding from this experiment mtRbfA is associated with the 28S SSU, but not with 
the 55S. So far it can not be excluded whether mtRbfA is really interacting with the 39S 
LSU or whether the result of co-migrating of mtRbfA-FLAG with components of the 39S 
after immunoprecipitation is more unspecific binding caused by the overexpression of 
mtRbfA-FLAG.  To exclude the latter lower amount of mtRbfA-FLAG need to be used 
for the same kind of experiment. 
 
To ensure that the mtRbfA-FLAG was present at an approximately similar level to the 
endogenous form within the mitochondria, the latter expression levels had to be 
determined. This experiment might also clarify whether the majority of the expressed 
FLAG tagged protein is imported into the mitochondria.  
To this end untransfected HEK293T cells (HEK293-wildtype; HEK293-WT) were used 
as the control for relative expression level of endogenous mtRbfA, in parallel HEK293T 
cells expressing mtRbfA-FLAG were analysed uninduced and induced with 1 ng/ ml 
doxycycline (DOX). The reason for using HEK293-WT cells and uninduced HEK293-
mtRbfA-FLAG cells is because of possible leaky expression of trace amounts of the 
FLAG tagged protein without adding the inducer.  
By western blot as shown in figure 8.7 cell lysate, isolated mitochondria and isolated 
mitochondria treated with proteinase K in the absence and presence of 1% Triton X-
100 were analysed for each sample.  
 
 
Figure 8.7: Titration of mtRbfA protein level. Western blots show samples of cell lysates (50 
µg) and isolated mitochondria (10 µg) from untransfected HEK293-wildtype (HEK293-WT) cells, 
uninduced or induced HEK293-mtRbfA-FLAG. To ensure that mitochondria were free from 
cytosolic contamination mitochondria were treated with proteinase K. Lysed mitochondria were 
analysed in the same way to confirm the activity of the enzyme and the sensitivity of the tested 
proteins against it. The relative protein level of mtRbfA (+FLAG tag) in each sample was 
determined by using specific antibodies against mtRbfA. MRPS18B was used as a loading 
control.  
 
As a loading control MRPS18B was used. The samples of HEK293-WT showed as 
before that the localisation of mtRbfA within the mitochondria as it was protected from 
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proteinase K treatment by the intact mitochondrial membrane. The uninduced HEK293-
mtRbfA-FLAG samples showed a doublet when mtRbfA antibodies were used. This 
doublet is also resistant against proteinase K. It was noticed before that the FLAG tag 
can change migration of proteins (ICT1-FLAG migrated also slightly above the 
endogenous form, figure 6.9). Thus it was assumed that there was an expression of the 
mtRbfA-FLAG at a relatively similar level to the endogenous form even without adding 
inducer. Reason for the “leaking” can be trace amounts of tetracycline in the FBS, 
which is added to the culture media. Using 1 ng/ ml DOX for 3 days resulted in an 
increase of mtRbfA-FLAG up to 5 fold. Thus for further investigations the uninduced 
form was used, as it showed approximately similar expression level as the endogenous 
form. 
 
Using the uninduced mtRbfA-FLAG for IP, followed by separation of the eluate on a 
sucrose gradient (Figure 8.8) showed clear differences to the result achieved with the 
induced sample earlier.  
 
Figure 8.8: mtRbfA-FLAG is predominantly associated with the 28S SSU. Mitochondrial 
lysate (3 mg) from mtRbfA-FLAG expressing cells at level similar to endogenous mtRbfA were 
used for IP via FLAG tag. IP eluate (80%) was subjected to 10 - 30% isokinetic sucrose 
gradient. Isolated fractions (1-10) were analysed by western blot, using antibodies against the 
FLAG octapeptide to examine the distribution of mtRbfA-FLAG within this gradient. The level of 
co-immunoprecipitated ribosomal complexes was determined by using antibodies against 
components of the 28S SSU (DAP3, MRPS18B and MRPS25), the 39S LSU (MRPL3 and 
MRPL12) and further ERAL1.  
 
Here the mtRbfA-FLAG was mainly detectable in fractions 1, 2 and 4, 5, whereas the 
highly overexpressed form was detectable in every fraction. The components of the 
28S SSU DAP3, MRPS18B and MRPS25 co-migrated all in fractions 4 and 5, whereas 
componets of the 39S LSU (MRPL3 and MRPL12) were not detectable or only at very 
Chapter 8: Investigation of human ribosome binding factor A 
151 
low level in 5 and 6. ERAL1, which was present in 1, 2 and 4, 5 in the previous over-
expressed experiment, also disappeared.  
In conclusion it appear that mtRbfA does not interact with the 55S monosome, further it 
seems as though an association with the 39S LSU is quite unlikely. The reason for this 
apparent association in the previous experiment is most likely to be due to the relatively 
high overexpression, which might lead to artefacts.  
 
8.5 EDTA treatment results in the loss of the association of 
mtRbfA-FLAG with mitochondrial ribosomal proteins 
 
There is a possibility that the association of mtRbfA with the 28S SSU is caused by the 
interaction of mtRbfA with the ribosomal RNA, as it is the case for the bacterial RbfA. 
Therefore to destabilise the RNA structure within the ribosome EDTA was used within 
the immunoprecipitation samples to deplete Mg2+, which is necessary for correct RNA 
folding. For this experiment the uninduced mtRbfA-FLAG was used for the IP rather 
using the high overexpressed form to avoid the artefacts previously observed and 
described above. As a control HEK293-WT cells were used. Mitochondria were 
isolated from both cell lines and purified prior to immunoprecipitation. Both were 
analysed in the absence and presence of 50 mM EDTA, as shown in figure 8.9.  
 
 
Figure 8.9: Depletion of Mg2+ causes a loss of mtRbfA’s association with the 28S SSU. 
Mitochondrial lysates from HEK293-mtRbfA-FLAG (uninduced, lane 1 and 3) and HEK293-WT 
(lane 2 and 4) were treated with (lane 3 and 4) or without (1 and 2) 50 mM EDTA prior to 
immunoprecipitation. Elution fraction (10%) of each sample was analysed by silver staining (A) 
or western blot (B). A) * indicates the mtRbfA-FLAG. B) Antibodies against mitochondrial 
ribosomal proteins were applied to the western blot membrane to determine the relative level of 
co-immunoprecipitated ribosomal complexes in each sample. To ensure similar level of mtRbfA-
FLAG in EDTA untreated and treated sample (lane 1 and 3) antibodies against the FLAG 
epitope were used. The level of ERAL1 was also investigated.  
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On silver staining the elution fraction of mtRbfA-FLAG showed again several bands, of 
which most of which were lost after the EDTA treatment. The negative control (WT) 
showed only a few bands, which represents some unspecific bindings and IgG chains. 
On the western blot the mitochondrial ribosomal proteins were detected in the elution 
fraction of mtRbfA-FLAG. There, also MRPL3 and MRPL12 could be detected, which 
were almost absent in the gradient of co-immunoprecipitated eluates. Therefore those 
signals represent no interaction complex of mtRbfA with 39S LSU.   
All signals were absent in the control except trace amounts of MRPL12. After the EDTA 
treatment none of the mitochondrial ribosomal proteins were detectable in the elution of 
mtRbfA-FLAG. Only MRPL12 was present, and at low levels, which is comparable to 
the relative unspecific binding in the control sample (WT). This result suggest that the 
interaction of mtRbfA with the 28S SSU is Mg2+ dependent, possibly indicating that 
mtRbfA’s association with the 28S SSU is caused by RNA-protein rather than protein-
protein interaction. 
 
8.6 Crosslinking immunoprecipitation (CLIP) failed to 
consistently identify interacting RNA species of mtRbfA  
 
CLIP as described in 3.5.10 is a method to identify short RNA species that may be 
interacting closely with the protein of interest. Bacterial RbfA with a type-II KH-domain 
is responsible for the processing of 16S rRNA and thus it is possible that mtRbfA-FLAG 
that also contains a type-II KH-domain fold, and whose structure is very similar to 
bacterial RbfA, may also act as a RNA binding protein.  
For the CLIP, HEK293T-mtRbfA-FLAG cells were UV irradiated to crosslink the RNA to 
the protein. Cells were not induced, only the “leaky” form of mtRbfA-FLAG generating 
approximately endogenous levels of protein. Shown in figure 8.10 is the autoradiogram 
post RNase T1 cleavage and end-labelling. The under-digested sample (2U T1) 
showed a number of bands, which made it difficult to decide with high confidence which 
protein-RNA complex to excise. Assuming that mtRbfA-FLAG is approximately 40 kDa, 
the RNA-complex should be 20 kDa above and thus around 60 kDa, where a thin band 
was removed of the membrane.  
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Figure 8.10: Analysis of UV crosslinked protein-RNA complexes by western blot. 
HEK293T cells expressing mtRbfA-FLAG were UV irradiated and used for IP. After RNase T1 
treatment protein-RNA complexes of different sizes were detectable by 5’-γ32P endlabelling. The 
potential mtRbfA-RNA complex with assumed migration of approximately 60 kDa was excised 
the membrane, indicated by *.  
 
Following the protocol the final products were cloned into pCR4-TOPO vector. 
Individual colonies were then tested by colony PCR and products of approximately 250 
to 300 bp were considered for sequencing. As shown in figure 8.11 most of the 
colonies produced amplicons of the expected size and were analysed by sequencing. 
Colonies that showed more than one product (e.g. #1 in figure 8.11) were excluded 
from further analysis. 
 
Figure 8.11: Colony PCR analysis after CLIP. Bacterial colonies derived from CLIP assay 
were analysed by colony PCR as described in 3.5.10. 5 µl of each reaction containing 10% 
glycerol were separated on a 2% agarose gel against 50 bp ladder. The image represents an 
example of colony PCR, with products of expected size > 250 and < 300 bp. 
 
Most of the derived sequences could be not identified by BLAST searches or it 
appeared that the linkers were amplified. The only sequences that could be clearly 
identified were (numbers of clones with that sequence are indicated): 
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1x 12S mt-rRNA (MT-RNR1)  
MTRNR1 1539  CATTTATATAGAGGAGACAAGTCGTAACATGGTAAGTGTACTGGAAAGTGCACTTGGAC  1597 
             |||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| 
CLIP   59    CATTTATATAGAGGAGACAAGTCGTAACATCGTAAGTGTACTGGAAAGTGCACTTGGAC  1 
 
2x 5S rRNA 
5S     2  TCTACGGCCATACCACCCTGAACGCGCCCGATCTCGTCTGATCTCGGAAGCTAAGCAGGGTCGGGCCTGG 
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CLIP  91  TCTACGGCCATACCACCCTGAACGCGCCCGATCTCGTCTGATCTCGGAAGCTAAGCAGGGTCGGGCCTGT 
 
  TTAGTACTTGGATGGGAGACC 92 
  ||||||||||||||||||||| 
  TTAGTACTTGGATGGGAGACC 132 
 
5S     2  TCTACGGCCATACCACCCTGAACGCGCCCGATCTCGTCTGATCTCGGAAGCTAAGCAGGGTCGGGCCTGG  71 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CLIP   70  TCTACGGCCATACCACCCTGAACGCGCCCGATCTCGTCTGATCTCGGAAGCTAAGCAGGGTCGGGCCTGG  1 
 
2x 28S rRNA (cytosolic) 
CLIP   1     CGAAGGATCAAAAAGCAACGTCGCTATGAACGCTTGGCTGCCAC  44 
             |||||||||||||||| ||||||||||||||||||||| ||||| 
28S    4418  CGAAGGATCAAAAAGCGACGTCGCTATGAACGCTTGGCCGCCAC  4375 
 
CLIP   1     ATGTTCAACTGCTGT  15 
             ||||||||||||||| 
28S    2419  ATGTTCAACTGCTGT  2405 
 
1 x EST product of unknown status 
CLIP  1      CTGAGCAGCTCCTAGCAGTTTGGCTGTCAAAAGGCCACTGAATAAACAAATTGATAGGAATGGCGGAC  68 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
EST   39135  CTGAGCAGCTCCTAGCAGTTTGGCTGTCAAAAGGCCACTGAATAAACAAATTGATAGGAATGGCGGAC  39068 
 
1x SSRP1 mRNA (cytosolic) 
CLIP   1     GTACTGGCTAGTTCTTCTTCTTCAGAGT  28 
             |||||||||||||||||||||||||||| 
SSRP1  2354  GTACTGGCTAGTTCTTCTTCTTCAGAGT  2327 
 
 
The experiment was repeated twice and no improvement in terms of “real” CLIP 
sequences could be achieved. Also cutting slices from the nylon membrane at higher 
or lower molecular weight did not improve the yield of identifiable sequences.  
It is still an open question whether mtRbfA acts as an RNA binding protein and whether 
it is important for ribosomal RNA processing (as in bacteria) or organisation. Therefore 
further investigations are crucial to determine the function of mtRbfA within human 
mitochondria. 
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8.7 Depletion of mtRbfA in human cell culture 
 
8.7.1 Expression level of mtRbfA is highly reduced in mtDNA 
lacking ρ0 cells 
The data shown so far suggest that mtRbfA, because of its association with the 28S 
SSU, may be involved in the mitochondrial gene expression machinery. To address 
this possibility it was investigated whether mtRbfA is present in 143B-ρ0 cells, cells that 
lack mtDNA and therefore do not need a mitochondrial gene expression machinery. A 
number of factors including certain mitochondrial ribosomal proteins are absent in such 
cells, e.g. DAP3 and MRPL3 as shown on the western blot in figure 8.12. Interestingly 
mtRbfA was almost not detectable in 143B-ρ0 cells, further suggesting that mtRbfA may 
be involved in the mitochondrial gene expression and is thus redundant in 143B-ρ0 
cells.  
To investigate this issue further and to analyse whether mtRbfA is important for 
mitochondrial function and thus for cell viability siRNA were applied to HEK293T cells 
to investigate the consequences of mtRbfA depletion in human cells. 
 
Figure 8.12: Expression level of mtRbfA protein is highly reduced in 143B-ρ0 cells. 
Lysates (30 µg) from HeLa, 143B parental and -ρ0 cells were analysed by western blot. Specific 
antibodies against mitochondrial proteins including mtRbfA, components of the OXPHOS 
complexes such as COX2, NDUFB8 and SDH, and members of the mitochondrial ribosome 
DAP3, MRPL3 and MRPS18B were used to determine the relative expression level in each cell 
line. Cytosolic marker RP-S6 was used as loading control. 
 
8.7.2 The effect of mtRbfA depletion on cell growth 
Dr. J. Rorbach has previously tested 6 different siRNAs sequences targeted to mtRbfA 
transcripts (Table 3.1) in the MTT assay to distinguish which siRNA shows an effect on 
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growth of 143B-ρ0 cells. Those siRNAs that were considered to have off-target effect 
were not used for further analysis.  
For this study si-RbfA A and B were chosen for further analysis. Neither showed a 
growth defect on 143B-ρ0, whereas in HeLa cells both duplexes resulted in a decrease 
in growth rate after 3 days when estimated by the relative cell number compared to the 
si-NT control (si-RbfA A: 56%; si-RbfA B: 60%). 
Next, it was tested by western blot how efficient the protein depletion was using both 
siRNAs independently. Therefore HEK293T cells were transfected with 50 nM siRNA 
using lipofectamine as transfection reagent. After 3 days cell lysates were prepared 
and analysed by western blot in comparison to si-NT control. As shown in figure 8.13 
(top left panel) mtRbfA protein was down regulated to 10.7 % (+ 5.4 %) using si-RbfA A 
and to 17.8% (+ 10.2 %) in case of si-RbfA B compared to si-NT.  
 
 
Figure 8.13: Effect of mtRbfA depletion on cell growth and morphology. HEK293T cells 
were treated with si-NT and si-Rbfa (A and B), respectively for 3 and 6 days. Western blot (top 
left panel) with 25 µg cell lysates was probed with antibodies against mtRbfA to confirm down 
regulation of mtRbfA protein after 3 days in comparison to si-NT. β-actin was used as loading 
control. The effect of mtRbfA depletion on cell growth was monitored by cell counting after 3 
and 6 days siRNA treatment. For this experiment 3x 104 cells were used as starting point, 
marked as dotted line. *** extremely significant (n = 3, 3 days: si-RbfA A: p = 0.0004; si-RbfA B: 
p = 0.0006; 6 days: si-RbfA A: p = 0.0001; si-RbfA B: p = 0.0001). The phenotype of mtRbfA 
depleted cells and control was documented by using inverted microscope Axiovert200M (Zeiss) 
with camera (right panels).  
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In addition to the MTT assay, cell counts were also performed to confirm the effect on 
cell growth. In both cases the depletion of mtRbfA caused an extremely significant 
growth defect after 3 and 6 days in comparison to si-NT (Figure 8.13, graph bottom 
left). Cells transfected with si-RbfA B grew faster than those treated with si-RbfA A, 
which is probably due to the level of protein depletion as shown with the western blot 
analyses. Therefore si-RbfA A was considered to be more effective than si-RbfA B and 
was thus chosen for use in the remaining investigations, although both were used in 
some occasions. Both treatments showed a similar phenotype after 3 days of depletion 
as shown in figure 8.13, right panels. 
 
8.7.3 No severe changes in level of mitochondrial ribosome could 
be observed after the loss of mtRbfA 
Because of the fact that mtRbfA is associated with the 28S SSU the effect of mtRbfA 
depletion on the level of ribosome assembly was further investigated. Therefore cells 
transfected with si-RbfA A for 3 or 6 days were analysed by sucrose gradient 
(described in 3.5.11). The fractions were analysed by western blot in comparison to si-
NT (Figure 8.14).  
 
 
Figure 8.14: The effect of mtRbfA depletion on mitochondrial ribosomal subunits. Lysates 
(700 µg) of mtRbfA depleted and control cells were separated by isokinetic sucrose gradient 
after 3 and 6 days post siRNA transfection. Fractions (1-10) were analysed by western blot, 
probed with antibodies against mtRbfA to confirm successful depletion in si-RbfA treated 
samples. To determine changes in mitochondrial ribosomal profile, specific antibodies against 
MRPS18B, representing the 28S SSU and MRPL3, a member of the 39S LSU were applied to 
the western blots, individually.  
 
The control showed that mtRbfA was free in fraction 1, but also associated with the 
28S SSU in fractions 4 and 5. Interestingly the relative ratio of free mtRbfA to the 
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bound form to the 28S SSU changed between 3 and 6 days si-NT treatment. This 
could be due to the relatively high confluence of the cells after 6 days and possibly 
starvation. Thus it would be interesting to monitor the relative level of associated 
mtRbfA under different growth or stress situations. The 28S SSU, represented by 
MRPS18B, migrated mainly in fractions 4 and 5. MRPL3, a member of the 39S LSU 
was mostly located in fractions 6 and 7. After the depletion of mtRbfA MRPS18B 
migrated still in fractions 4 and 5, but was also present in relatively higher levels in 
comparison to si-NT in fraction 6. MRPL3 was similar between the mtRbfA depleted 
samples and the non-targeting control. From this experiment it cannot be shown that 
the depletion of mtRbfA has an effect on the 28S SSU that would cause a loss of the 
conformation of the 28S SSU. 
 
To confirm the result that there was no dramatic effect of mtRbfA depletion, and also to 
investigate the relative level of monosome formation, immunoprecipitation of the 28S 
SSU and the 55S monosome was performed using the MRPS27-FLAG cell line. If the 
depletion of mtRbfA would have an effect on the 28S SSU that could cause a loss of 
the ability of the 28S SSU to interact with the 39S LSU to create an intact 55S 
monosome, then the prediction would be that there would be a loss of MRPL3 and 
MRPL12 in the elution fraction of MRPS27-FLAG. 
The experiment was performed after 3 days depletion (si-RbfA A) and after 2 days 
induction. This was to allow overexpression of the FLAG-tagged protein and assembly 
into the mitochondrial ribosome. The cells were then harvested, lysed and equal 
amounts of cell lysate were used for the immunoprecipitations. The elution fractions 
were analysed by western blot. As shown in figure 8.15 MRPS27-FLAG in the si-NT 
treated sample is associated with DAP3 and MRPS18B, each present in both the 28S 
SSU and 55S monosome, and LSU components (MRPL3 and MRPL12), which 
represented the relative level of the monosome. The level of mtRbfA in the depleted 
samples was reduced to 20%. DAP3 was significant reduced to 71%, but MRPS18B 
with ~98% was similar to the control. MRPL3 and MRPL12 showed also a decrease to 
74% and 77%, respectively, however, the result was not statistically significant. 
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Figure 8.15: The level of 55S monosome after mtRbfA depletion. HEK293T cells expressing 
MRPS27-FLAG were utilised to co-immunoprecipitate the 28S SSU and the 55S monosome. 
Cells were transfected either with si-NT or si-RbfA for 3 days and induced with 1 µg/ ml 
tetracycline for 2 days. For IP equal amounts of cell lysates (2.5 mg) were applied to M2 FLAG 
beads. The elution fractions (10% each) were analysed by western blot and relative protein 
levels were measured by using Image-Quant software. Immunoprecipitated proteins in si-RbfA 
treated samples were compared to si-NT control, whose mean is marked as a dotted line. For 
statistical evaluation signals from three independent experiments of both si-RbfA and si-NT 
treated samples were measured and used for t-test. (n = 3; *significant p = 0.05 to 0.01; *** 
extremely significant p < 0.001) 
 
Concluding from this experiment the relative level of monosome after 3 days mtRbfA 
depletion was unchanged or only subtly changed, under the conditions of the 
performed experiment.  
 
8.7.4 Depletion of mtRbfA does not cause an instability of 
mitochondrial ribosomal RNAs  
Since bacterial RbfA processes the 16S rRNA, I wanted to assess whether human 
mtRbfA played a similar role in ribosomal subunit or 12S rRNA (MT-RNR1) assembly 
or stability. Therefore the steady state levels of mitochondrial RNAs were analysed by 
Northern blot after 3 and 6 days mtRbfA depletion. Probes were used to detect levels 
of the mt-rRNAs [12S (MT-RNR1), 16S (MT-RNR2)], the mt-mRNAs and cytosolic 18S 
rRNA as a loading control. Figure 8.16 represents the result from three RNA isolations 
from independent 3 days siRNA transfections for the targeting and the non-targeting 
samples.  
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Figure 8.16: Northern blot analysis of mitochondrial RNA steady state level after 3 days 
mtRbfA depletion. Cells were transfected with si-RbfA-A or -B, or si-NT. After 3 days RNA (3 
µg) was analysed by Northern blot. Specific probes against mitochondrial RNAs were used to 
visualise the transcript of interest. The cytosolic 18S rRNA was used as a loading control. The 
blot with graph shows the result from 3 independent experiments of each siRNA relative to the 
mean of signals observed in the si-NT treated samples (dotted line). (n = 3;** very significant p 
= 0.01 to 0.001; *** extremely significant p < 0.001) 
 
The signals, measured by using Image-Quant software, were calculated relative to the 
si-NT. Both siRNAs against mtRbfA showed a subtle increase of the 12S rRNA steady 
state level up to 125% and 112%, so there was no indication that there was a loss of 
the stability of the 12S rRNA. Furthermore the 16S rRNA steady state level was also 
increased up to 129% using si-RbfA A (and 105% for si-RbfA B). The mt-mRNAs 
showed also no loss in the stability, all of them showed an increase, ranging from 
110% to 165%. There could be no obvious pattern detected between the different 
transcripts.  
 
After seen in figure 8.17, 6 days treatment, the 12S rRNA showed a modest increase in 
steady state levels (129% si-RbfA A; 111% si-RbfA B) indicating there was no loss of 
12S rRNA stability. This was similar to that seen after 3 days mtRbfA depletion.  
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Figure 8.17: Northern blot analysis of mitochondrial RNA steady state level after 6 days 
mtRbfA depletion. 6 days after siRNA transfection, RNA was extracted and analysed by 
Northern blot (3 µg). The cytosolic 18S rRNA was used as a loading control. The blot shows the 
result from 2 independent experiments of each siRNA transfection in comparison to si-NT, 
whose mean is marked as dotted line. (n = 3; * significant p = 0.05 to 0.01; ** very significant p = 
0.001 to 0.01; *** extremely significant p < 0.001) 
 
The steady state level of 16S rRNA was not significantly changed when si-RbfA B was 
used, but was increased up to 147% in case of si-RbfA A. The mt-mRNAs also showed 
an increase, especially for si-RbfA A, where all the transcripts were up-regulated from 
150% upwards, except MT-CYB, which was only increased to 118%. Using si-RbfA B 
showed an increase in the transcripts MT-ND2 and MT-ND3 to ~150%. MT-RNA7 
(ND4/ND4L) and MT-CYB were increased to 120% and MT-ND5, MT-CO1, MT-CO2 
and MT-CO3 were just slightly up or very similar to control. 
Concluding from these results it can be said that both siRNAs against mtRbfA caused a 
general but modest increase in the level of the mt-RNAs. Interestingly the 12S rRNA 
seems to be stable without mtRbfA, which is in contrast to the situation with ERAL1 
depletion [Dennerlein et al., 2010].  
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8.7.5 The effect of mtRbfA depletion on mitochondrial protein de 
novo synthesis 
To determine whether the depletion of mtRbfA has any effect on mitochondrial protein 
synthesis, 35S de novo synthesis was performed (described in 3.5.7) post 3 and 6 days 
si-RNA treatment. Each sample (30 µg left panels, 3 days depletion; 50 µg right panels, 
6 days depletion) was separated by 15% SDS-PAGE and the results analysed using 
Image-Quant software (Figure 8.18). Therefore individual bands were measured with 
the software with considering the background in each case. 
 
 
 
Figure 8.18: 35S-met de novo synthesis after mtRbfA depletion. HEK293T cells were 
transfected with si-NT or si-RbfA A for 3 or 6 days. Mitochondrial encoded proteins were 
labelled with 35S-met for 15 min prior to cell harvesting. Samples (30 µg left panels; 50 µg right 
panels) were loaded on a 15% SDS-PAG. Mitochondrial encoded proteins were identified by 
comparison to Chomyn (1996). Coomassie brilliant blue (CBB) staining (lower panels) 
confirmed the even loading. Images are representative of two independent experiments each (n 
= 2).  
 
After 3 days mtRbfA depletion the mitochondrial protein synthesis was slightly 
upregulated of approximately 1.5 fold in comparison to si-NT. This differed from the 
situation after 6 days transfection where a subtle decrease in de novo synthesis of 
approximately 15 - 20% was noticed.  
Concluding from this experiment, no defect in mitochondrial protein synthesis was seen 
after 3 days depletion of mtRbfA with a subtle decrease after 6. 
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Further experiments need to be done to investigate the possible function of mtRbfA 
within the mitochondrial gene expression machinery and furthermore to find the reason 
why the depletion of mtRbfA is causing a growth defect in human HEK293T cells.  
 
8.7.6 Analysis of steady state levels of mitochondrial proteins and 
OXPHOS complexes after mtRbfA knockdown 
In addition to the de novo synthesis, the steady state level of mitochondrial proteins 
was analysed after 3 and 6 days mtRbfA depletion. To this end treated cells were 
harvested, lysed and same amounts of proteins were separated by SDS-PAGE 
followed by western blot. As shown on figure 8.19 mtRbfA was successfully down-
regulated.  
 
Figure 8.19: Western blot analysis of steady state levels of proteins after 3 and 6 days 
mtRbfA depletion. Cell lysates (25 µg) of si-NT and si-RbfA (A and B) treated samples were 
analysed after 3 and 6 days transfection. The western blot was probed with antibodies against a 
number of mitochondrial proteins including mtRbfA, components of OXPHOS (COX2 and 
NDUFB8) and members of the mitochondrial ribosome (DAP3, MRPS18B and MRPL3). β-actin 
was used as a loading control. Signals were analysed using Image-Quant software. The results 
are representative for at least two independent experiments of each sample (n > 2).  
 
After 3 and 6 days depletion there was no significant change in the steady state level of 
mitochondrial ribosomal proteins (DAP3, MRPS18B and MRPL3) when compared to si-
NT. COX2 as a mitochondrial encoded protein from Complex IV was up-regulated at 3 
days (141% si-RbfA A; 123% si-RbfA B) and at 6 days increased to 122% with si-RbfA 
A, whilst with si-RbfA B there was a decrease to 65%. NDUFB8 as a nuclear encoded 
protein of Complex I was relatively similar in both cases compared to si-NT after 3 
days. Again after 6 days NDUFB8 behaved in a similar way to COX2: it was slightly up-
regulated to 121% using si-RbfA A, but decreased to 71% in case of si-RbfA B. 
However, no dramatic change in the mitochondrial protein steady state level was 
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observed using si-RbfA, even after 6 days depletion that could explain the growth 
defect.  
The differences between the two mtRbfA siRNAs may be the result of the different 
efficiencies, or one of them may also affect levels of another unpredicted mRNA, which 
also encodes a mitochondrial protein. The latter cannot be excluded, because the MTT 
assay using 143B-ρ0 cells can only exclude siRNAs that have an off-target effect 
outside the mitochondrial gene expression machinery.   
 
A consistent observation seen with both siRNAs was that in general there was an initial 
increase in the steady state level of COX2, which dropped after 6 days, but was still 
higher in siRbfA A treated sample than in control. To determine whether the COX2 
protein generated under these conditions is still incorporated and functional in the 
OXPHOS complexes, Blue Native acrylamide gel electrophoresis with western blot or 
in-gel enzyme activity assay (detailed in 3.5.6) was performed after 6 days transfection. 
The relative level of the complexes was determined by western blot using the following 
antibodies: 1) Complex I - NDUFA9, 2) Complex II - SDH 70 kDa subunit, 3) Complex 
IV - COX2, 4) Complex V - β-subunit. Complex I, IV and V, which all harbour 
mitochondrial encoded proteins were increased in comparison to si-NT, whereas 
Complex II (completely nuclear encoded) was similar to control (Figure 8.20). Problems 
with efficiency of transfer led to relatively high standard deviations of the measured 
level of protein complexes. The overall tendency (n = 3 independent experiments), 
however, was an increase in the mitochondrial encoded protein containing complexes. 
In-gel enzyme activities were repeatable, consistent and in agreement with the western 
blot, where Complexes I and IV showed a higher enzyme activity after mtRbfA 
depletion in comparison to si-NT.  
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Figure 8.20: Analysis of OXPHOS complexes by Blue Native PAGE after mtRbfA 
depletion. Samples for BN-PAGE were 30-50 µg (western blot) and 75 µg (in gel enzyme 
activity). A) Western blot showed the relative level of the complexes using antibodies to 
NDUFA9 (Complex I), SDH 70 kDa (Complex II), COX2 (Complex IV) and β-subunit of Complex 
V. The signals were measured using Image-Quant software. Images are representative of all 
results n = 3 B) To determine the relative activity of Complex I and IV (left panels) gels were 
incubated over-night in specific substrate solutions (detailed in 3.5.6.5). The BN-PAG (right 
panel) showed migration of complex and the relative loading.  
 
Concluding so far, the depletion of mtRbfA causes an increase in COX2 and NDUFB8 
using si-RbfA A. Additionally the OXPHOS complexes, which contain mitochondrial 
encoded proteins, were also upregulated in comparison to the control. Complex II was 
present at similar levels to control, but since the signal for SDH 70 kDa was very strong 
and thus maybe saturated, differences cannot be distinguished when measuring with 
Image-Quant software. Since western blots are only semi-quantitative and there was a 
high standard deviation within the experiment the data have to be interpreted with 
caution. However, the results of the in-gel enzyme activity assay are again in 
agreement with the higher protein and thus complex level.  
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8.7.7 The mitochondrial DNA content is unchanged after mtRbfA 
depletion  
Such an increase in the protein level as seen above can have several reasons: 1) 
translation is upregulated, 2) the turnover of the complexes/ protein is changed 3) 
mitochondrial mass is increased or 4) mtDNA copy number is higher with a 
commensurate increase in gene expression.  
To investigate the latter mitochondrial DNA levels were measured by SYBR green Real 
Time PCR. Therefore DNA was extracted from cells as described in 3.3.1 after 6 days 
transfection (3 independent transfection experiments). Each DNA sample (10 ng) was 
applied to three independent PCR experiments. As a mitochondrial marker, primer pair 
#9/ #10 (Table 3.4) were used for one PCR reaction to amplify the MT-ND1 region and 
B2M primer pair #13/ #14 to measure the relative level of nuclear DNA in a second 
PCR. The relative mtDNA level was calculated as followed: first, the ∆CT of each 
sample was calculated [∆CT = CT (B2M) - CT (MT-ND1)], then the differences between 
the ∆CT of si-NT and si-RbfA were taken [∆∆CT = ∆CT(si-RbfA) - ∆CT(si-NT)]. The mean 
∆∆CT was -0.57 cycle (+ 0.54). Due to the exponential amplification during real time 
PCR, one cycle represents a difference of 50% mtDNA content. Assuming that nuclear 
DNA stays consistent then the mtRbfA depletion resulted in an average mtDNA 
decrease of 28.7% (+27.1%), which can be considered as experimental error with a 
sensitive method such as Real Time PCR. Concluding from this experiment there is no 
obvious change in mtDNA after 6 days mtRbfA depletion.  
 
8.7.8 Flow cytometry analysis: measurements of mitochondrial 
mass, reactive oxygen species and mitochondrial membrane 
potential after mtRbfA depletion 
No change in the mtDNA level could be measured after RbfA depletion. Additionally it 
was tested whether an increase of mitochondrial mass was the reason for the 
increased mitochondrial protein steady state level. Therefore after 6 days siRNA 
transfection, cells were treated with NAO (10-n-nonyl-acridine orange), which binds 
specifically to cardiolipin in the inner mitochondrial membrane (described in 3.1.8.1). 
FACS analysis of mtRbfA depleted samples showed only a subtle increase of 
mitochondrial mass to 113% in comparison to the control as shown in figure 8.21.  
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Figure 8.21: FACS analysis of mitochondrial mass (NAO), reactive oxygen species 
(MitoSox) and mitochondrial membrane potential (JC1) after mtRbfA depletion. HEK293T 
cells were treated with si-NT (red bars) or si-RbfA (yellow bars), respectively for 6 days. Cells 
were harvested, resuspended in PBS and treated with the dyes NAO (10 µM), MitoSox Red (5 
µM) or JC1 (2 µM), respectively for 15 min at 37°C 5% CO2 (light protected). This was followed 
by PBS washing step and measurements at the individual wavelengths using BD FACS CANTO 
II machine. The results were analysed using BD FACSDIVATM software with great support from 
Mr. Ian Dimmick (Centre for Life, Newcastle upon Tyne). The graph represents the results of at 
least 4 experiments each (NAO: n = 7, p = 0.0028**; MitoSox: n = 4, p = 0.4433; JC1: n = 4, p = 
0.2180).  
 
In addition to mitochondrial mass, mitochondrial reactive oxygen species (ROS) were 
measured using MitoSox Red. These parameters were analysed as unbalanced activity 
of the OXPHOS complexes, or increased stress within the cell could potentially result in 
an increase amount of ROS. There was no significant difference detected in 
superoxide production between si-NT and si-RbfA after 6 days treatment (Figure 8.21), 
suggesting that mtRbfA depletion does not cause an upregulation of ROS, which could 
have been reason for the growth phenotype. As a positive control for mitochondrial 
ROS production Guf1, a mitochondrial protein investigated by S. Dennerlein in this 
laboratory, was depleted and samples were treated in the same way, resulting in 
dramatic increase in ROS (data not shown).  
The mitochondrial membrane potential, measured by JC1 as detailed in 3.1.8.3, did not 
show any significant alteration after the loss of mtRbfA (Figure 8.21). As a positive 
control for JC1 measurements, cells were uncoupled with FCCP, which resulted in a 
decrease of mitochondrial membrane potential (data not shown). 
In summary neither mitochondrial ROS production nor mitochondrial membrane 
potential were altered indicating that the growth defect after mtRbfA depletion was not 
due to changes in either of these parameters. The mitochondrial mass was increased, 
but this subtle effect also cannot explain the phenotype caused by si-RbfA transfection.  
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8.7.9 The effect of mtRbfA depletion on the cell cycle  
To investigate whether the cell cycle was disrupted following mtRbfA depletion, the 
state of replication of cell-populations the DNA of the cells was stained with DAPI as 
detailed in 3.1.8.5 and further analysed by flow cytometry.  
There are four phases of the cell cycle. Cell populations tend to be distributed across 
these phases: the G1 phase (G = gap), S phase (DNA synthesis), G2 phase and M 
phase (mitosis). Cells in the G1 phase have one copy of DNA, whereas in the G2/M 
phase there are 2 copies. Thus the relative fluorescence of the G2/M is double that of 
G1. During the S phase cells are replicating the DNA and therefore the DNA content 
and value for the fluorescence intensity increases between the G1 and G2/M phases.  
As shown in the graph of figure 8.22 after the depletion of mtRbfA there was an 
increased proportion of cells in the G1 phase (si-NT: 52.5%; si-RbfA: 60.2%) and 
decrease in S phase (si-NT: 42.3%; si-RbfA: 32.7%) in comparison to the si-NT. These 
results were statistically extremely significant and the reason for the arrest in the G1 
phase could be a mitochondrial defect caused by the depletion of mtRbfA. It could also 
partially explain the growth defect seen resulting from mtRbfA depletion. It is unlikely 
that a decrease from 42.3% (si-NT) to 32.7% (si-RbfA) in the S phase would be the 
only reason for the growth defect seen following mtRbfA depletion. Furthermore there 
was a subtle increase in the G2/M phase comparing si-NT (~5.1%) to si-RbfA (~7.1%). 
Interestingly the amount of debris in si-RbfA treated cells was approximately 20% 
higher than in si-NT. Debris represent fluorescence below diploid, often arising from 
cell fragmentation during preparation. This explanation is unlikely to account for the 
difference since si-RbfA- and si-NT cells were treated in the same way. The reason 
may be the actual depletion of mtRbfA itself. 
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Figure 8.22: Analysis of state of cell-population after mtRbfA depletion. HEK293T cells 
were treated with si-NT and si-RbfA, respectively for 6 days. The phenotype was monitored by 
using the inverted microscope Axiovert200M (Zeiss) with camera (top panels). Cells were 
stained with DAPI using CyStain DNA 2 step kit (Partec), followed by flow cytometric 
measurements at 450 nm. The results were analysed with kind assistance from Mr. Ian Dimmick 
using ModFit LT V3.2 software. The images (middle panels) are representative for at least 3 
experiments (n > 3) and the results are summarised in the graph below. (t-test * significant p = 
0.05 to 0.01; *** extremely significant p < 0.001; G = gap; S = synthesis).  
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8.7.10 MtRbfA depletion does not cause high level of apoptosis 
To test whether the debris in mtRbfA depleted samples described above could 
represent cells that are senescent or apoptotic, DNA fragmentation was measured after 
6 days siRNA transfection using APO-DIRECTTM kit (BD Biosciences Pharmingen) 
(described in 3.1.8.4). Surprisingly there was no dramatic increase (approximately 6% 
higher than NT control) in the amount of apoptotic cells (Figure 8.23) as had been seen 
with ERAL1 [Dennerlein et al., 2010]. This result was statistically significant, but in 
comparison to the effect seen of ERAL1 depletion, where ERAL1 depletion caused ~ 
35% of cells to go into apoptosis after only 3 days siRNA treatment, it can be probably 
excluded as the main reason for the growth defect.  
 
 
Figure 8.23: Depletion of mtRbfA does not result in high levels of apoptosis. HEK293T 
cells were treated for 6 days with si-NT or si-RbfA, respectively. Cells were then measured for 
DNA fragmentation using APO-DIRECT kit to estimate the proportion of apoptotic cells. Two 
dyes were used for measurements: FITC-dUTP (measured at 530 nm, y axis) indicating the 
apoptotic cells and PI (measured at 585 nm, x axis) staining the DNA of the whole population. 
The results of the flow cytometry (using ~ 5,000 cells) were analysed (assisted by Mr. Ian 
Dimmick) using BD FACSDivaTM software. The images are representative examples for 
primary FACS data for si-NT and si-RbfA treated samples. Healthy cells are labelled in red and 
apoptotic ones in blue. The depletion of mtRbfA resulted in 7.4% (+ 3.3%) apoptotic cells, 
compared to si-NT with 1.7% (+ 0.5%). (n = 3, p = 0.0167*) 
 
8.8 Discussion 
 
The data presented in this chapter represents a first characterisation of the human 
mtRbfA orthologue of bacterial RbfA, a cold shock protein involved in the processing of 
the 16S rRNA precursor (17S) and therefore maturation of the 30S SSU in bacteria. 
Bacterial RbfA was proposed to bind the loop region of h1 at the 5’-end of the 16S 
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rRNA. It therefore probably inhibits the interaction of 50S LSU with 30S SSU with 16S 
rRNA precursor whilst the h1 remains unformed and the 5’end unprocessed. As 
previously described the structure of human mtRbfA from residue Arg86 to Asp201 
shows high structural similarities to that of bacterial RbfA, with a typical type-II KH-
domain fold that is proposed to facilitate RNA-binding. A clear difference between 
bacterial RbfA and human mtRbfA is the size of the proteins. Human mtRbfA is around 
three times larger than its bacterial counterpart, potentially indicating adapted changes 
in the function. A further difference is that the human 12S rRNA is transcribed as part 
of a polycistronic transcript, directly flanked by tRNAPhe at the 5’-end and by tRNAVal at 
the 3’-end. Since the mitochondrial genome contains no introns in combination with the 
proposed tRNA punctuation model of RNA processing [Ojala et al., 1981] the resulting 
cleavage by RNase P and tRNase Z would result in the excision of the fully processed 
12S rRNA. Therefore a rRNA precursor such as 17S rRNA in bacteria does not exist in 
human mitochondria. Therefore what is the function of mtRbfA in human? My project 
aimed to answer whether: human mtRbfA is a mitochondrial protein? Is it important for 
mitochondrial function and therefore for cell viability? Has it maintained a function in the 
maturation of the 28S SSU? 
The data presented here shows that mtRbfA is indeed a mitochondrial protein (Figure 
8.3) and its depletion causes a growth defect in human HEK293T cells (Figure 8.13). It 
was further demonstrated by isokinetic sucrose gradients that endogenous mtRbfA co-
migrates with components of the 28S SSU in fractions 4 and 5 (Figure 8.4), suggesting 
an association of mtRbfA with the mitochondrial SSU. These findings are similar to the 
situation found in the bacterial system. However, the ratio of free and associated 
mtRbfA is quite different compared to this one of its bacterial counterpart. In bacteria 
~20% of RbfA protein are associated with the 30S SSU under normal growth 
conditions, which increases up to ~40% after cold shock [Xia et al., 2003]. In human 
mitochondria the relative level of associated mtRbfA, migrating in fractions 4 and 5, 
seems to be higher with ~60%. This may also reflect that the overall ratio of free 28S 
SSU to 55S monosome is higher in human mitochondria than of the bacterial ratio of 
30S SSU to 70S particle/ polysome. It would be interesting to identify whether this ratio 
would change under certain stress conditions such as cell culturing in galactose 
(glucose-free) containing medium. Under those circumstances would there be less 
mtRbfA associated with the 28S SSU and therefore a higher possibility to form the 55S 
monosome? For the future it would be sensible to investigate the level of associated 
mtRbfA with the 28S SSU under different growth conditions. 
Surprisingly when mtRbfA-FLAG was used for immunoprecipitation there were not only 
components of the 28S SSU found in its elution fraction, but also a number of 39S LSU 
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proteins (Figure 8.5, table 8.1). However, an association of mtRbfA with the 39S LSU 
was not suggested from the results revealed by isokinetic sucrose gradients of cell 
lysates (Figure 8.4). An association of mtRbfA with the 55S monosome has now been 
excluded since separating co-immunoprecipitated complexes by mtRbfA-FLAG did not 
show co-migration of components of the 28S SSU and 39S LSU in fraction 8. This was 
also confirmed by the control experiment, where the eluate of MRPS27-FLAG-IP was 
applied to isokinetic sucrose gradient. There endogenous mtRbfA also did not co-
migrate with the 55S monosome in fraction 8.  
Interestingly the 28S SSU complex co-purified by mtRbfA-FLAG migrated mainly in 
fractions 4 and 5 (Figure 8.6 A and 8.8), suggesting an association of mtRbfA with the 
28S SSU relatively late in the maturation process of the 28S SSU. In contrast 
MRPS27-FLAG-IP showed also some 28S SSU intermediates revealed by the co-
sedimentation of MRPS27-FLAG with MRPS25 and MRPS18B in fractions 2 and 3 
(Figure 8.6 B). However, there was no mtRbfA found in those earlier fractions, which is 
in agreement with the suggestion that mtRbfA is associated with the 28S SSU at a late 
assembly point. This would be similar to the situation found in bacteria, where a loss of 
RbfA leads to an accumulation of 50S LSU and 30S (precursor) SSU, but not to a 
complete loss in assembly of the ribosomal small subunit. Another interesting result of 
the separated immunoprecipitated eluate was the localisation of MRPL12 in the earlier 
fractions (Figure 8.6 A), suggesting a more direct interaction of mtRbfA with MRPL12. 
MRPL12 was shown to interact directly with the POLRMT [Wang et al., 2003] and is 
therefore proposed to be a kind of transcription-translation coupler. It is possible that 
mtRbfA represents a similar factor. As it is potentially involved in the late maturation of 
the 28S SSU, it is tempting to speculate an involvement of mtRbfA in the initiation 
complex, where the synthesised transcript by POLRMT is loaded onto the small 
ribosomal subunit. Interestingly, mtIF2, which is part of the initiation complex and 
delivers the fmet-tRNA to the P-site in the 28S SSU [reviewed in Spremulli et al., 2004], 
was found within the IP of mtRbfA. Furthermore POLRMT was also detectable by LC 
MS/MS. Another protein that was found in the mtRbfA-FLAG-IP by LC MS/MS was 
SLIRP, an RNA binding protein usually found in conjunction with LRPPRC. However, 
the latter was not detectable in mtRbfA-FLAG-IP. Sasarman et al. (2010) showed that 
both, SLIRP and LRPPRC interact in a ribonucleoprotein (RNP) complex that is 
important for stabilising mt-mRNA transcripts. The form of SLIRP found in the IP of 
mtRbfA-FLAG potentially reflects the protein stabilising mRNA, which is transported 
towards the 28S SSU for the translation initiation. It would be interesting to clarify 
whether mtRbfA could be also co-immunoprecipitated by SLIRP. This protein is being 
investigated further in this laboratory by Dr. P. Smith and A. Rozanska. The co-
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sedimentation of ERAL1, which binds preferentially to the 28S SSU [Dennerlein et al., 
2010] in fractions 4 and 5, but also in the earlier fractions 1 and 2 after mtRbfA-FLAG-
IP (Figure 8.6 A) suggests potentially a direct interaction of mtRbfA with ERAL1. 
However, it is also possible that ERAL1 has lost its association with the 28S SSU 
during this experimental procedure. A direct interaction between bacterial Era and RbfA 
has not been reported, but because of some overlapping binding sites within the 30S 
SSU it is difficult to exclude this possibility completely (Figure 8.24).  
 
 
Figure 8.24: Binding sites of RbfA and Era on the 30S SSU in bacteria. A) 30S SSU 
(yellow) is shown with h-head, b-body, p-platform, sp-spur and bound RbfA (red) and Era 
(magenta). B) Both RbfA and Era are interacting with the helix 28 (h28; green). The C-terminus 
of RbfA is directed to the helix 1 (h1; blue) and facilitates its processing. Era can indirectly 
stabilise the h1 over its interaction with h28. (bk: beak) (Images taken from Datta et al., 2007) 
 
The possibility of an association of mtRbfA-FLAG with the 39S LSU was further 
examined since the results of IP and gradients were in disagreement. By decreasing 
the expression of mtRbfA-FLAG relatively to endogenous level led to the suggestion 
that the interaction of mtRbfA-FLAG with the 39S LSU was due to the high 
overexpression, probably causing artefacts (Figure 8.8).  
Interestingly this experiment also indicated that the association with ERAL1, which was 
seen previously within the mtRbfA-FLAG-IP may also have been caused by the high 
overexpression of mtRbfA-FLAG. This result indicates that mtRbfA and ERAL1 
probably interact at different stages with the 28S SSU. In contrast to mtRbfA, ERAL1 is 
as a 12S rRNA chaperone probably involved in an earlier assembly process.  
However, the association of mtRbfA with the 28S SSU was confirmed to be real and 
not an overexpression artefact. What can cause those unspecific interactions seen with 
the 39S LSU? One possibility is that mtRbfA is indeed a KH-domain RNA-binding 
protein and that an excess may result in nonphysiological unspecific binding of RNA 
species potentially within the 39S LSU. 
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Is mtRbfA really a RNA-binding protein and is the type-II KH-domain functional? The 
loss of the ability to interact with mitochondrial ribosomal proteins in the presence of 
EDTA strongly suggests that the association of mtRbfA with the 28S SSU is RNA 
dependent. However, the CLIP (Crosslinking Immunoprecipitation) assay failed to 
identify with high confidence associated RNA species. Possible explanations for this 
could be: i) the method is not compatible with this particular protein or wrong decisions 
were made during the whole procedure in terms of size of RNA-complex, ii) it is also 
possible that even with the presence of the type-II KH-domain mtRbfA is not a RNA 
binding protein, and iii) the particular RNA species may not be exposed and therefore 
not available to be crosslinked. A further general problem occurring during the CLIP 
experiment with mtRbfA-FLAG could be the 28S SSU itself. If mtRbfA really interacts 
with either mt-rRNA or mt-mRNA only within the ribosomal subunit then it is possible 
that the RNase T1 digestion is not efficient enough. Liao and Spremulli (1989) showed 
that even with high concentration of RNase T1, the bound mRNA in a complex with the 
28S SSU is protected over an approximately 45 nucleotides stretch. Therefore it is 
possible that the mt-rRNA, which is known to have a complex structure [Koc et al., 
2001b, Sharma et al., 2003] within the core of the 28S SSU, is crosslinked to all its 
interacting protein partners and further protected against RNase T1 treatment by the 
intact and probably almost completely assembled 28S SSU complex. The same could 
be correct for the mt-mRNA if it is already loaded onto the 28S SSU in the presence of 
mtRbfA. Therefore the UV-crosslinked protein-RNA complex containing mtRbfA is 
probably much larger than predicted. It would therefore have to be first denatured so 
that RNase T1 would get access to the RNA species protected by the 28S SSU. Thus it 
is possible that most of sequences, which could not be identified by BLAST searches, 
represent just artefacts caused by PCR amplification.  
From the sequences that were identified, 1 represented the 3’-end of the 12S rRNA, 
identical to the binding site of human ERAL1, and 2 of them were the 5S rRNA. The 5S 
rRNA in bacteria is part of the ribosomal large subunit, whereas in human mitochondria 
it has never been shown that the 5S rRNA is present in the human mitochondrial 
ribosome [Sharma et al., 2003]. However, it has been shown by several groups that 
cytosolic 5S rRNA is imported into mitochondria [Entelis et al., 2001; Smirnov et al., 
2010; Wang et al., 2010]. Further a defect in the relevant import machinery is reported 
to lead to decreased imported level of 5S rRNA in mitochondria, which in turn leads to 
a reduced level in mitochondrial translation [Smirnov et al., 2010]. This suggests an 
important role of the 5S rRNA within the mitochondrial gene expression machinery. 
However, the precise role of the 5S rRNA in human mitochondria is still unknown. It is 
an exciting possibility that the sequences of 5S rRNA found with the mtRbfA CLIP are 
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relevant and specific protein-RNA interactions within the mitochondria and further 
experiments needs to be addressed to this question in the future.  
Even if the CLIP failed under those conditions, probably caused by inefficient access of 
the RNase T1 as already discussed, it cannot be excluded that mtRbfA is a RNA-
binding protein. It would undoubtedly be better to use the endogenous mtRbfA instead 
of the FLAG tagged protein. It can never be ruled out that the FLAG tag can cause 
problems with some approaches, however both FLAG tagged and endogenous mtRbfA 
showed a similar association with the 28S SSU, and did not impede efficient CLIP in 
other mitochondrially targeted-FLAG tagged proteins. Thus the FLAG tag can 
realistically be eliminated as a possibility for unsuccessful CLIP assay. 
Generation of mutations within the KH-domain could potentially answer whether this 
proposed RNA-binding domain is really functional. If this would be the case then a 
mutation within this domain would be predicted to cause a dominant negative effect on 
cell growth. Another possibility to investigate the possible RNA-binding activity of 
mtRbfA would be to perform IP of UV-crosslinked samples under denaturing 
conditions, followed by real time PCR to determine the presence of mt-rRNAs or mt-
mRNA in comparison to a non-crosslinked sample or a control such as mtLuc-FLAG.  
Another way forward would be to investigate possible direct protein interaction partners 
by using chemical crosslinking. In bacteria RbfA interacts in the head of the SSU with 
ribosomal protein S9, S13 and further with S12, which is located in the body of the SSU 
(Figure 8.25) [Datta et al., 2007].  
 
 
Figure 8.25: Protein interaction partners of bacterial RbfA in the 30S SSU. The C-terminal 
extension of bacterial ribosomal proteins S13 (green) and S9 (cyan) are located towards the P-
site of the 30S SSU and interact with RbfA (red). The other binding site of RbfA within the SSU 
involves helix18 (h18, blue) and the ribosomal protein S12 (yellow), which overlaps with the 
interaction site of IF1. In human mitochondria a bacterial homologue for S13 is absent [Koc et 
al., 2010] and there is no mitochondrial IF1. An additional domain in mtIF2 substitutes for the 
function of IF1 in human mitochondria [Gaur et al., 2008]. (Image was taken from Datta et al., 
2007) 
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As previously described the mammalian mitochondrial ribosome differs in a many 
aspects to its bacterial counterpart. It is therefore highly likely that the way in which 
mtRbfA is associated with the mitochondrial ribosome, including the potentially 
interacting ribosomal proteins may not be the same as in the bacterial system. 
In the LC MS/MS analysis of mtRbfA-FLAG-IP MRPS9 (orthologue of bacterial S9) was 
detectable, but no MRPS12, which is the most highly conserved protein of the SSU 
with 48% identity to E. coli S12. Curiously MRPS12 was not found in the LC MS/MS 
analysis of any mitochondrial samples that were sent from this laboratory for mass 
spectrometry analysis (not in mtRRF, ICT1, ERAL1 or in MRPS27). Thus it is possible 
that MRPS12 is present and just not detectable as it is also a quite small protein with a 
calculated molecular weight of 12.5 kDa as mature protein [Koc et al., 2001b]. Further 
in the head of the mitochondrial 28S SSU a homologue for bacterial S13 is absent, one 
of the described differences between the mitochondrial and bacterial ribosome. 
Therefore it would be interesting to identify how mtRbfA has adapted to those changes. 
Once the protein interaction partners are identified, it could indicate whether any RNA 
structure would be close enough for mtRbfA to bind.  
Thus far it cannot be answered whether mtRbfA is involved in SSU maturation in way 
that involves rRNA processing or stabilisation within the SSU. However the results 
represented in this chapter show clear evidence that mtRbfA interacts mainly with the 
28S SSU. To determine the function of mtRbfA within the 28S SSU further experiments 
need to be done. One approach presented in this study was the investigation of the 
effect of mtRbfA depletion at the cellular and molecular level. It was shown that the loss 
of mtRbfA leads clearly to a growth defect (Figure 8.13), yet the reason for this defect 
is still not clear. On isokinetic sucrose gradient no obvious defect on the conformation 
of the ribosomal subunit could be observed (Figure 8.14). The protein steady state 
level of the mitochondrial ribosomal proteins was also not altered after 6 days mtRbfA 
depletion. These results are in agreement with the hypothesis that mtRbfA is 
associated with the 28S SSU at a very late maturation point. Since the 28S SSU to 
which mtRbfA is bound might be almost completely assembled, it cannot unequivocally 
be expected that mtRbfA depletion would lead to a complete loss of 28S SSU 
assembly.  
It was expected that analogous to the situation in bacteria, the loss of mtRbfA would 
lead to an accumulation of SSU and LSU and thus to a reduced level of 55S 
monosome. After 3 days however, there was no significant loss of the 55S particle 
(Figure 8.15). One explanation may be that it would need more time to see a significant 
decrease in 55S monosome after mtRbfA depletion. Therefore it would be probably 
sensible to repeat the MRPS27-FLAG-IP after 6 days transfection. Another protein that 
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immunoprecipitates the 55S monosome at higher levels than MRPS27 such as ICT1, 
should be used for IP after mtRbfA depletion. This may give clearer results and would 
deliver another control.  
Since bacterial RbfA is important for the processing of the 16S rRNA, it was expected 
that mtRbfA is in some way involved in the assembly of the mitochondrial SSU by 
binding/ stabilising the 12S rRNA. However, mtRbfA depletion did not cause any loss of 
mt-RNAs (Figure 8.16 and 8.17). If there was any change in the relative level of mt-
RNA then there was more an increase instead of a decrease. Even the level of the 12S 
rRNA was slightly increased, which is in complete contrast to the situation after ERAL1 
depletion, which leads to a dramatic reduction in the 12S rRNA level [Dennerlein et al., 
2010]. What is in common between mtRbfA and ERAL1 depletion is the increased 
steady state level of the mt-mRNA transcripts. This phenomenon was also reported by 
Metodiev et al. (2007). This group showed that the knockout of murine Tfb1m, which is 
required for dimethylation on A1006 and A1007 on 12S rRNA, leads to a reduced 
stability of 12S rRNA, whereas mt-mRNA transcripts are either almost unaffected or 
also increased. The remained stability of mt-mRNA transcripts in cells with a ribosome 
assembly defect is probably caused by the association of the RNA with the RNP 
complex. This reflects potentially a form of temporary store for transcripts before being 
loaded onto the 28S SSU. The similar increase in the transcripts after mtRbfA depletion 
was observed with ERAL1 knockdown and partially with the Tfb1m knockout mice 
leads to the speculation whether this reflects also a ribosome assembly defect. 
However, since mtRbfA is probably associated with the 28S SSU at a late maturation 
phase, it is also possible that the mt-mRNA transcripts are already bound to the 28S 
SSU. It is therefore likely that the transcripts are stabilised by the ribosomal subunit 
itself.  
There was no dramatic loss of 35S-met de novo synthesis even after 6 days depletion 
of mtRbfA, which was reminiscent to the results found after down-regulation of mtRF1a 
[Soleimanpour-Lichaei et al., 2007], mtRRF [Rorbach et al., 2008] and ERAL1 
[Dennerlein et al., 2010]. These are all proteins that are involved in the mitochondrial 
gene expression machinery and yet their loss did not show significant decrease in de 
novo mitochondrial protein synthesis. Thus it can be sometimes relatively difficult to 
interpret results from 35S-met labelling experiments. Clearly, if there is a loss in de novo 
synthesis as it was the case e.g. after ICT1 depletion, in patient samples with MRPS16 
or C12orf65 mutations [Miller et al., 2004, Antonicka et al., 2010] or in the Tfb1m 
knockout mice [Metodiev et al., 2009] then it can be concluded that there is indeed a 
defect in mitochondrial protein synthesis. However, if there is no change in synthesis 
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then it is hard to conclude (not exclude) a defect in the mitochondrial translation 
machinery.  
Surprisingly the steady state level of COX2 and partially also of NDUFB8 were 
upregulated. Additionally also the complexes of which they are components, namely 
Complex I and IV were increased and showed a higher in-gel activity (Figure 8.20). The 
reason for the increased level of mitochondrial proteins or complexes is still unknown, 
since mtDNA level was similar to control, the mitochondrial mass revealed by NAO 
measurements was not dramatically increased and also the mitochondrial translation 
seemed not to be changed in way that would explain the increased level of OXPHOS 
complexes. What was not investigated in this study and needs to be addressed in the 
future is the actual turnover of the proteins. It is possible that an overall change in the 
turnover of the components of the OXPHOS complexes occurred and is causing an 
increased amount of OXPHOS complexes. To address this possibility translation needs 
to be inhibited (e.g. by thiamphenicol treatment) and the decay of the existing protein 
monitored. A “positive” change in the turnover should lead to an increased stability/ 
half-life of the proteins. Another possibility to prove this hypothesis would be a 35S-met 
pulse-chase experiment.  
However, none of these discussed results can explain the growth defect after mtRbfA 
depletion. Interestingly an increased amount of cells was detected in the G1 phase 
after the loss of mtRbfA and further approximately 25% less in the S phase in 
comparison to the control (Figure 8.22). This could reflect a mitochondrial dysfunction 
where less energy production leads to a reduced DNA synthesis within the cell. Those 
results however, are relatively subtle and probably cannot be the main reason for the 
growth defect. The proportion of apoptotic cells after 6 days si-RbfA transfection was 
only slightly increased compared to the control. In comparison to the results that were 
observed after 3 days ERAL1 depletion [Dennerlein et al., 2010], it can be considered 
as a minimal effect and not as the main reason for the growth defect. Thus it is still not 
clear what is causing the growth defect in the mtRbfA depleted cells. However, it still 
needs to be considered whether si-RbfA A, which was used for most of the 
experiments, has an off target effect. As previously described the reason for chosen 
this particular siRNA was the high efficiency in down-regulating the endogenous 
mtRbfA protein. Additionally this siRNA did not show any effect on 143B-ρ0 cells, 
suggesting that it does not target another protein coding transcript with an important 
function outside mitochondria. Therefore it should be analysed in the future whether 
this phenotype caused by si-RbfA A is really specific, by testing if it can be rescued by 
the expression of mtRbfA with a silent mutation within the siRNA region.  
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What can be the function of mtRbfA in human mitochondria?  
In summary, it was shown that mtRbfA is associated preferentially with the 28S SSU, 
probably at a quite late assembly point. Furthermore the virtually non-detectable level 
of mtRbfA protein in mtDNA lacking ρ0 cells suggests a role in the mitochondrial gene 
expression machinery. Its presence therefore in mtDNA lacking cells becomes 
redundant as was also found with other proteins including mitochondrial ribosomal 
ones. It is possible that mtRbfA is directly or indirectly involved in the translation 
initiation, where it dissociates from the 28S SSU just when everything is correctly 
placed for the start of protein synthesis. In agreement with this idea was the presence 
of mtIF2 in the LC MS/MS analysis after mtRbfA-FLAG-IP but not in IP analyses from 
mtRRF, ICT1, ERAL1 or MRPS27. In human mitochondria mRNA are not modified, 
containing neither a 5’-cap structure nor a Shine-Dalgarno sequence that would 
facilitate the correct positioning of the mRNA within the ribosomal SSU. The human 
mitochondrial mRNAs are leaderless and their start codon is generally located within 
the first 3 nucleotides at the 5’-end [Montoya et al., 1981; Anderson et al., 1981]. There 
are still a lot of questions how the mammalian mitochondrial ribosome can 
preferentially select the first AUG at the 5’-end of those leaderless mRNAs. It is 
possible that some additional factors are required for this step. As described in chapter 
1, Christian and Spremulli (2010) proposed a model where the mRNA starting with the 
5’-end enters the 28S SSU through the mRNA entrance gate, which is unique to the 
mammalian mt-SSU. After the first 17 nucleotides have entered the 28S SSU, there 
appears to be an inspection on the codon at the 5’-end of the mRNA, causing a pause. 
The authors suggested that this step gives mtIF2 time to promote binding of the fmet-
tRNA in a codon-anticodon dependent manner to the AUG start codon, which then 
leads to the formation of a stable initiation complex. It is possible that mtRbfA plays a 
critical quality control role within this initiation complex before the 28S SSU is then 
released to interact with the 39S LSU to perform translation elongation.  
However, so far there is no clear evidence for such a role of mtRbfA in translation 
initiation control. Certainly it would be a great benefit to know the position of mtRbfA 
within the 28S SSU and furthermore whether it has maintained its RNA-binding 
function. Besides the suggested future experiments in the human cell system it might 
be also interesting to identify whether the human mtRbfA is able to replace RbfA in 
bacteria. This could potentially also answer the question whether it can still function as 
a RNA-binding protein. However, the substantial increase in size has to be considered. 
Therefore only the domain from residue Arg86 to Asp201 should be used for this kind 
of analysis.  
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9 Chapter 9:                                                             
Concluding remarks 
 
This PhD project was focused mainly on the characterisation of two proteins, ICT1 and 
mtRbfA, both of which were found in association with the human mitochondrial 
ribosome initially co-immunoprecipitated with mtRRF [Rorbach et al., 2008]. I will make 
concluding remarks for each of these sections individually below. 
 
9.1 
 
Part I: ICT1 - a functional peptidyl-tRNA hydrolase that has 
been recruited into the human mitochondrial ribosome 
ICT1 studies constituted the main part of this PhD project. Results from this study 
revealed the first indication that a rescue system for stalled ribosomes exists in human 
mitochondria, for which ICT1 is probably indispensable.  
My experiments have defined the following characteristics of ICT1, which is described 
as a member of the mitochondrial release factor family. ICT1 is: 
 i) localised within human mitochondria 
 ii) important for cell life 
 iii) essential for mitochondrial protein synthesis 
 iv) a previously unidentified member of the mitochondrial ribosomal large  
  subunit 
 v) a ribosome-dependent, but codon-independent peptidyl-tRNA hydrolase  
  (PTH), whose  GGQ motif is both functional and essential for cell   
  viability. 
 
The function of ICT1 with its PTH activity within the mitochondrial ribosome is still not 
clear. The data presented here and further the investigations of ICT1 orthologues (also 
by other groups) however, strongly suggest an involvement of ICT1 in the recycling of 
stalled mitochondrial ribosomes and/ or 39S LSU with bound peptidyl-tRNA. Further 
experiments need to be done to prove this hypothesis. The determination of the 
localisation of ICT1 within the mitochondrial ribosome would be particularly beneficial in 
elucidating its function. 
If I had the time I would have liked in particular to perform the following experiments: 
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 i) Chemical crosslinking immunoprecipitation to identify direct protein  
  interaction partners of ICT1. This would help to of where ICT1 is   
  integrated within the mitochondrial ribosome.   
 ii) Isokinetic sucrose gradients after 35S-met labelling for ICT1GGQ wildtype  
  and ICT1GSQ mutant samples (potentially after mtRF1a depletion). This  
  experiment may permit visualisation of the peptidyl-tRNA bound to the  
  ribosome. It may be that the level of peptidyl-tRNAs is too low for  
  detection using Phosphor-Imaging, however, utilising a scintillation  
  counter after precipitating the relevant fraction may resolve this problem. 
 
9.2 
 
Part II: Human ribosome binding factor A is associated with 
the 28S mitochondrial ribosomal small subunit 
As a potential mitochondrial ribosome assembly factor mtRbfA was investigated with 
respect to its function in human mitochondria. The work presented in this thesis has 
demonstrated that mtRbfA is: 
 i) a mitochondrial protein 
 ii) important for cell growth 
 iii) present in much lower steady state level in cells lacking mtDNA than in  
  control cells 
 iv) preferentially associated with the 28S SSU, probably at a point late in  
  subunit assembly. 
 
The characteristics of mtRbfA that I have defined do not, however, clarify the precise 
function of mtRbfA within human mitochondria. The presence of a type-II KH-domain is 
known in other cases to facilitate RNA-binding, and such a fold is clearly present within 
the mtRbfA structure. It is of great interest, therefore, to identify whether mtRbfA is also 
able to bind RNA. This could be not answered with the experiments shown within the 
time limit of this study. However, there is still the possibility that with the optimisation of 
the CLIP assay specific RNA species can be identified, to which mtRbfA may bind. 
Generations of mutations within this KH-domain would also address the question as to 
whether this domain is really important for mtRbfA function.  
Since bacterial RbfA is a cold shock protein, which is essential for bacteria growth at 
low temperature permitting adaptation of the translation machinery at those conditions, 
it would be interesting to investigate whether mtRbfA can also act as a kind of a stress 
response factor. To address this I would liked to have been able to analyse the 
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expression level and ratio of free and 28S SSU bound mtRbfA under different growth 
and stress conditions (using conditions such as low temperature, FBS starvation or cell 
culturing in glucose-free galactose containing media).  
Even if the function of mtRbfA within human mitochondria is still elusive it seems highly 
likely that it is involved in the mitochondrial gene expression machinery, possibly in the 
late maturation of the 28S SSU as a potential quality control factor for translation 
initiation. However, this is a hypothesis that needs to be tested in the future. I would 
have planned various experiments to further this investigation that would have 
included: 
 i) perform CLIP under denaturing conditions 
 ii) examine the effect of mutations in the KH domain on cellular and  
  molecular level 
 iii) determine the function of mtRbfA as a potential stress response factor  
 iv)  extend experiments to have longer mtRbfA  depletion, which may lead to 
  clearer results (e.g. level of immunoprecipitated 55S by MRPS27 after  
  mtRbfA depletion). 
In summary mitochondrial translation in humans clearly requires quality control 
mechanisms to ensure that mitochondrial encoded proteins, which are all components 
of the OXPHOS complexes, are correctly expressed and assembled in the individual 
complexes. To prevent the occurrence or accumulation of failed translation events 
control mechanism are absolutely crucial. Defects in the translation machinery can 
cause mitochondrial dysfunction, harm to the cell and further human diseases, which 
are currently untreatable. Many mutations in patients associated with OXPHOS defects 
have been identified in mtDNA encoded tRNAs and rRNAs. However, in the past few 
years there were many reports of mutations in nDNA encoded proteins, functioning in 
the mitochondrial translation machinery [reviewed in Smits et al., 2010]. These defects 
are usually associated with combined OXPHOS deficiencies. The understanding of the 
basic biology of the human translation machinery with all its components and control 
mechanisms is therefore essential to understand also the disease state and possibly to 
develop a way of treatment. The investigations presented here contribute with the 
characterisation of two proteins involved in this machinery some aspects concerning 
mitochondrial ribosome composition, assembly and possibly recycling when stalled.  
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Appendix 1: LC MS/MS analysis – ICT1-FLAG IP 
The LC MS/MS was carried out and analysed by H. Wessels (UNMC, Nijmegen).  
The identified proteins are listed in the table below from high (green) to low (red) 
EMPAI value. Contaminants such as keratin, but also cytosolic ribosomal proteins were 
not included. Proteins with uncertain prediction for mitochondrial localisation are written 
in grey. 
 PROTEIN IDENTIFICATION INFORMATION 
 
EMPAI VALUES 
Gene UNIPROT PROT ID PROT NAME control ICT1 
1 ICT1 Q14197 NP_001536.1 immature colon carcinoma transcript 1 0.221677349 26.21338768 
2 MRPS21 P82921 NP_061870.1 mitochondrial ribosomal protein S21 0.333521432 16.7827941 
3 SSBP1 Q04837 NP_003134.1 single-stranded DNA binding protein 1 0.668100537 13.67799268 
4 MRPL15 Q9P015 NP_054894.1 mitochondrial ribosomal protein L15 0.311133937 13.03003723 
5 MRPL11 Q9Y3B7 NP_057134.1 mitochondrial ribosomal protein L11 isoform a 0 11.45197085 
6 MRPL28 Q13084 NP_006419.2 mitochondrial ribosomal protein L28 0 9.926008611 
7 MRPL47 Q9HD33 NP_065142.2 mitochondrial ribosomal protein L47 isoform a 0 8.006280202 
8 MRPL17 Q9NRX2 NP_071344.1 mitochondrial ribosomal protein L17 0.274274986 7.858667904 
9 MRPS26 Q9BYN8 NP_110438.1 mitochondrial ribosomal protein S26 0.311133937 7.733261624 
10 MRPL55 Q7Z7F7 NP_852130.1 mitochondrial ribosomal protein L55 isoform a 0 7.376776401 
11 HSPD1 P10809 NP_955472.1 chaperonin 1.392147081 6.564633276 
12 MRPL51 Q4U2R6 NP_057581.2 mitochondrial ribosomal protein L51 0 5.812920691 
13 MRPL24 Q96A35 NP_663781.1 mitochondrial ribosomal protein L24 0 5.628703162 
14 MRPL43 Q8N983-4 NP_115488.2 mitochondrial ribosomal protein L43 isoform a 0.245197085 5.449466771 
15 LRPPRC P42704 NP_573566.2 leucine-rich PPR motif-containing protein 2.346494873 5.43788433 
16 MRPS9 P82933 NP_872578.1 mitochondrial ribosomal protein S9 0.158323286 5.434438263 
17 MRPS6 P82932 NP_115865.1 mitochondrial ribosomal protein S6 0.389495494 5.105402297 
18 C14orf156 Q9GZT3 NP_112487.1 SRA stem-loop-interacting RNA-binding protein 1.894266125 4.878016072 
19 MRPL1 Q9BYD6 NP_064621.2 mitochondrial ribosomal protein L1 0.258925412 4.843414134 
20 MRPL12 P52815 NP_002940.2 mitochondrial ribosomal protein L12 0.930697729 4.779692884 
21 MRPL43 Q8N983 NP_789762.1 mitochondrial ribosomal protein L43 isoform b 0.245197085 4.779692884 
22 MRPS22 P82650 NP_064576.1 mitochondrial ribosomal protein S22 0.350314038 4.76593265 
23 MRPL22 Q9NWU5 NP_054899.2 mitochondrial ribosomal protein L22 isoform a 0.100694171 4.623413252 
24 MRPS7 Q9Y2R9 NP_057055.1 mitochondrial ribosomal protein S7 0.185971012 4.504789808 
25 MRPL4 Q9BYD3 NP_057040.2 mitochondrial ribosomal protein L4 isoform a 7.01E-02 4.43618362 
26 MRPL21 A6NKU0 NP_852615.1 mitochondrial ribosomal protein L21 isoform d 0 4.379838403 
27 HSPA9 P38646 NP_004125.3 heat shock 70kDa protein 9B precursor 0.803422821 4.24218321 
28 MRPL19 P49406 NP_055578.2 mitochondrial ribosomal protein L19 6.42E-02 4.043159487 
29 MRPP2 Q99714 NP_004484.1 mitochondrial ribonuclease P protein 2, HSD17B10 0.711328304 4.011872336 
30 MRPS25 P82663 NP_071942.1 mitochondrial ribosomal protein S25 0.122018454 4.011872336 
31 MRPS17 Q9Y2R5 NP_057053.1 mitochondrial ribosomal protein S17 0.584893192 4.011872336 
32 MRPL2 Q5T653 NP_057034.2 mitochondrial ribosomal protein L2 0.193776642 3.923882632 
33 MRPS31 Q92665 NP_005821.1 mitochondrial ribosomal protein S31 0.188502227 3.73151259 
34 MRPL44 Q9H9J2 NP_075066.1 mitochondrial ribosomal protein L44 0.136463666 3.641588834 
35 MRPL16 Q9NX20 NP_060310.1 mitochondrial ribosomal protein L16 0 3.641588834 
36 MRPL39 Q9NYK5-2 NP_542984.2 mitochondrial ribosomal protein L39 isoform b 0 3.555505605 
37 MRPL41 Q8IXM3 NP_115866.1 mitochondrial ribosomal protein L41 1.275845926 3.393970561 
38 MRPL20 Q9BYC9 XP_001125910.1 mitochondrial ribosomal protein L20 0 3.393970561 
39 PTCD3 Q96EY7 NP_060422.4 Pentatricopeptide repeat domain 3 0.250898933 3.354004654 
40 MRPL49 Q13405 NP_004918.1 mitochondrial ribosomal protein L49 0.232846739 3.328761281 
41 MRPS34 P82930 NP_076425.1 mitochondrial ribosomal protein S34 0.100694171 3.216965034 
42 MRPL38 B2R894 NP_115867.1 mitochondrial ribosomal protein L38 0.154781985 3.216965034 
43 MRPL9 Q9BYD2 NP_113608.1 mitochondrial ribosomal protein L9 0.172102298 3.175318937 
44 GADD45GIP1 Q8TAE8 NP_443082.2 growth arrest and DNA-damage-inducible, gamma 
interacting protein 1 
0.193776642 3.124626383 
45 MRPL23 Q16540 NP_066957.2 mitochondrial ribosomal protein L23 0.291549665 3.084238653 
46 MRPS35 P82673 NP_068593.2 mitochondrial ribosomal protein S35 6.80E-02 2.981071706 
47 MRPL45 Q9BRJ2 NP_115727.3 mitochondrial ribosomal protein L45 6.42E-02 2.931828756 
48 MRPL13 Q9BYD1 NP_054797.2 mitochondrial ribosomal protein L13 9.26E-02 2.775053205 
49 RNMTL1 Q9HC36 NP_060616.1 RNA methyltransferase like 1 0 2.62095835 
50 MRPL48 Q96GC5 NP_057139.1 mitochondrial ribosomal protein L48 0.291549665 2.593813664 
51 MRPL10 Q7Z7H8 NP_660298.2 mitochondrial ribosomal protein L10 isoform a 8.57E-02 2.433320018 
52 MRPS16 Q9Y3D3 NP_057149.1 mitochondrial ribosomal protein S16 0 2.383855153 
53 MRPL37 Q9BZE1 NP_057575.2 mitochondrial ribosomal protein L37 0.193776642 2.305451348 
54 ATP5A1 P25705 NP_001001937.1 ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit prec. 
0.77827941 2.16227766 
55 MRPS14 O60783 NP_071383.1 mitochondrial ribosomal protein S14 0.211527659 2.16227766 
56 MRPL40 Q9NQ50 NP_003767.2 mitochondrial ribosomal protein L40 0.110336318 2.16227766 
57 MRPL18 Q9H0U6 NP_054880.2 mitochondrial ribosomal protein L18 0.110336318 2.16227766 
58 MRPL50 Q8N5N7 NP_061924.1 mitochondrial ribosomal protein L50 0 2.16227766 
59 NME4 O00746 NP_005000.1 nucleoside-diphosphate kinase 4 0 1.993577295 
60 MRPL14 Q6P1L8 NP_115487.2 mitochondrial ribosomal protein L14 0.274274986 1.976351442 
61 COX2 P00403 NP_536846.1 cytochrome c oxidase subunit II 0.311133937 1.955209235 
62 MRPS2 Q9Y399 NP_057118.1 mitochondrial ribosomal protein S2 0.333521432 1.942727176 
63 MRPL54 Q6P161 NP_758455.1 mitochondrial ribosomal protein L54 0.193776642 1.894266125 
64 MRPS30 Q9NP92 NP_057724.2 mitochondrial ribosomal protein S30 0 1.861025569 
65 MRPS18A Q9NVS2 NP_060605.1 mitochondrial ribosomal protein S18A 0.110336318 1.848035868 
66 MRPS27 Q92552 NP_055899.1 mitochondrial ribosomal protein S27 0.304321387 1.768902684 
67 MRPS28 Q9Y2Q9 NP_054737.1 mitochondrial ribosomal protein S28 0.221677349 1.721338768 
68 MRPL46 Q9H2W6 NP_071446.2 mitochondrial ribosomal protein L46 0.218187912 1.682695795 
69 DAP3 P51398 NP_387506.1 death-associated protein 3 0.264855217 1.559547923 
70 TUFM P49411 NP_003312.3 Tu translation elongation factor, mitochondrial 0.536174947 1.55140652 
71 MRPS5 P82675 NP_114108.1 mitochondrial ribosomal protein S5 0 1.536619456 
72 CHCHD1 Q96BP2 NP_976043.1 coiled-coil-helix-coiled-coil-helix domain containing 
1 
0 1.511886432 
73 MRPS10 P82664 NP_060611.2 mitochondrial ribosomal protein S10 8.57E-02 1.470911228 
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74 MRPL3 P09001 NP_009139.1 mitochondrial ribosomal protein L3 0 1.32195425 
75 COX4I1 P13073 NP_001852.1 cytochrome c oxidase subunit IV isoform 1 
precursor 
0 1.3101297 
76 MRPS23 Q9Y3D9 NP_057154.2 mitochondrial ribosomal protein S23 0.445439771 1.290867653 
77 GRPEL1 Q9HAV7 NP_079472.1 GrpE-like 1, mitochondrial 9.65E-02 1.290867653 
78 DHX30 Q7L2E3 NP_619520.1 DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 1 
0.14504757 1.15443469 
79 PRDX3 P30048 NP_006784.1 peroxiredoxin 3 isoform a precursor 0.467799268 1.15443469 
80 NDUFAF3 Q9BU61 NP_951032.1 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex assembly factor 
0.165914401 1.15443469 
81 DDX28 Q9NUL7 NP_060850.1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 28 0 1.127496491 
82 TFB1M Q9Y384 NP_057104.1 transcription factor B1, mitochondrial 0 1.075263132 
83 MRPS18B Q9Y676 NP_054765.1 mitochondrial ribosomal protein S18B 9.26E-02 1.030917621 
84 PGAM5 Q96HS1-2 NP_612642.1 Bcl-XL-binding protein v68 0.291549665 1.020949938 
85 MTERFD1 Q96E29 NP_057026.3 MTERF domain containing 1 0 1.005975301 
86 PHB2 Q99623 NP_009204.1 prohibitin 2 0.110336318 0.974488213 
87 VDAC1 P21796 NP_003365.1 voltage-dependent anion channel 1 (porin) 0 0.930697729 
88 ATP5L O75964 NP_006467.4 ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit G 
0 0.930697729 
89 MRPL32 Q9BYC8 NP_114109.1 mitochondrial ribosomal protein L32 0 0.895735652 
90 PYCR2 Q96C36 NP_037460.2 pyrroline-5-carboxylate reductase family, member 2 0 0.887391822 
91 MRPL27 Q9P0M9 NP_057588.1 mitochondrial ribosomal protein L27 isoform a 0.165914401 0.847849797 
92 UQCRC2 P22695 NP_003357.2 ubiquinol-cytochrome c reductase core protein II 0 0.802245515 
93 SLC25A5 P05141 NP_001143.1 solute carrier family 25, member 5 0.211527659 0.77827941 
94 ISCA1 Q9BUE6 NP_112202.2 HESB like domain containing 2 0 0.77827941 
95 ALDH2 P05091 NP_000681.2 mitochondrial aldehyde dehydrogenase 2 precursor 4.44E-02 0.759069582 
96 OAT P04181 NP_000265.1 ornithine aminotransferase precursor 0.264855217 0.757510625 
97 SLC25A6  NP_001627.1 solute carrier family 25, member A6 0.132541315 0.750827032 
98 TRUB2 O95900 NP_056494.1 TruB pseudouridine (psi) synthase homolog 2 0 0.750827032 
99 DHX30 Q7L2E3-2 NP_619519.1 DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 3 
0.102943312 0.714125253 
100 NDUFS3 O75489 NP_004542.1 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 
30kDa 
0 0.711328304 
101 POLRMT O00411 NP_005026.3 mitochondrial DNA-directed RNA polymerase 
precursor 
0 0.70125428 
102 HADHA P40939 NP_000173.2 mitochondrial trifunctional protein, alpha subunit 
precursor 
0.193776642 0.70125428 
103 YARS2 Q9Y2Z4 NP_001035526.1 tyrosyl-tRNA synthetase 2 (mitochondrial) 0 0.684283113 
104 PTCD1 O75127 NP_056360.2 pentatricopeptide repeat domain 1 0 0.668100537 
105 DLD B2R5X0 NP_000099.2 dihydrolipoamide dehydrogenase precursor 0.148153621 0.659586907 
106 MRRF Q96E11 NP_620132.1 mitochondrial ribosome recycling factor isoform 1 0 0.637893707 
107 ACOT9  NP_001028755.2 acyl-Coenzyme A thioesterase 2, mitochondrial 
isoform b 
8.41E-02 0.623776739 
108 MRPS11 P82912 NP_073750.2 mitochondrial ribosomal protein S11 isoform a 0.128837892 0.623776739 
109 MTERFD2 Q7Z6M4 NP_872307.2 MTERF domain containing 2 0 0.619206824 
110 C6orf203 Q9P0P8 NP_057571.1 hypothetical protein LOC51250 0 0.615598098 
111 MDH2 P40926 NP_005909.2 mitochondrial malate dehydrogenase precursor 0.193776642 0.603718744 
112 GTPBP10 A4D1E9 NP_149098.2 claudin 12 isoform 2 0 0.598467106 
113 ATP5O P48047 NP_001688.1 mitochondrial ATP synthase, O subunit precursor 0 0.584893192 
114 PRDX5 P30044 NP_036226.1 peroxiredoxin 5 precursor, isoform a 0 0.557068405 
115 CECR5 Q9BXW7-2 NP_060299.4 cat eye syndrome chromosome region, candidate 5 
isoform 1 
6.42E-02 0.545927736 
116 SARS2 Q9NP81 NP_060297.1 seryl-tRNA synthetase 2 7.46E-02 0.539926526 
117 SLC25A1 P53007 NP_005975.1 solute carrier family 25 (mitochondrial carrier; 
citrate transporter), member 1 
0 0.539926526 
118 NSUN4 Q96CB9 NP_950245.2 NOL1/NOP2/Sun domain family 4 protein 0 0.539926526 
119 TRAP1 Q12931 NP_057376.1 TNF receptor-associated protein 1 0.174268583 0.534781344 
120 UQCRFS1 A8K519 NP_005994.1 ubiquinol-cytochrome c reductase, Rieske iron-
sulfur polypeptide 1 
0 0.508590709 
121 MRPS24 Q96EL2 NP_114403.1 mitochondrial ribosomal protein S24 0.105295141 0.492495545 
122 MRPP1 Q7L0Y3 NP_060289.2 Mitochondrial ribonuclease P protein 1, RG9MTD1 0 0.4896249 
123 ATP5C1 P36542 NP_001001973.1 ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma subunit iso. L 
0.172102298 0.487352107 
124 NGRN Q9NPE2 NP_001028260.2 mesenchymal stem cell protein DSC92 isoform 2 0 0.483981789 
125 THNSL1 Q8IYQ7 NP_079114.2 threonine synthase-like 1 0 0.474601593 
126 SLC25A4 P12235 NP_001142.2 solute carrier family 25 (mito. carrier; adenine 
nucleotide translocator), mem. 4 
6.61E-02 0.467799268 
127 ATP5H O75947 NP_006347.1 ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d isoform a 
0 0.467799268 
128 PGAM5  XP_001126125.1 PREDICTED: similar to phosphoglycerate mutase 
family member 5 
8.73E-02 0.457593301 
129 METT11D1 Q9H7H0 NP_073571.1 methyltransferase 11 domain containing 1 isoform 
2 
0 0.456348478 
130 C7orf30 Q96EH3 NP_612455.1 hypothetical protein LOC115416 0 0.44974067 
131 DBT Q5VVL8 NP_001909.2 dihydrolipoamide branched chain transacylase 
precursor 
0 0.447819047 
132 STOML2 Q9UJZ1 NP_038470.1 stomatin (EPB72)-like 2 0.128837892 0.438449888 
133 WBSCR16 Q96I51 NP_110425.1 Williams-Beuren syndrome chromosome region 16 0 0.430722989 
134 MTG1 Q9BT17 NP_612393.2 GTP_binding protein 0 0.430722989 
135 SFXN1 Q9H9B4 NP_073591.2 sideroflexin 1 0 0.42510267 
136 C4orf14 Q8NC60 NP_115689.1 hypothetical protein LOC84273 0 0.422136151 
137 NDUFS1 P28331 NP_004997.4 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
75kDa precursor 
0 0.422136151 
138 NDUFA13 Q9P0J0 NP_057049.3 cell death-regulatory protein GRIM19 0 0.417474163 
139 LOC729317 A6NLE7 XP_001133585.1 PREDICTED: similar to voltage-dependent anion 
channel 2 
0 0.417474163 
140 ALDH1L2 Q3SY69 NP_001029345.1 aldehyde dehydrogenase 1 family, member L2 0 0.415121244 
141 LONP1 P36776 NP_004784.2 mitochondrial lon peptidase 1 2.51E-02 0.414287277 
142 FASTKD2 Q9NYY8 NP_055744.2 FAST kinase domains 2 0 0.409081686 
143 C17orf42 Q6PJ19 NP_078959.2 hypothetical protein LOC79736 0 0.406527242 
144 PUSL1 Q8N0Z8 NP_699170.1 pseudouridylate synthase-like 1 0 0.403003723 
145 ALDH18A1 P54886 NP_002851.2 pyrroline-5-carboxylate synthetase isoform 1 4.71E-02 0.380384265 
146 UQCRC1 P31930 NP_003356.2 ubiquinol-cytochrome c reductase core protein I 0 0.380384265 
147 SLC25A3 Q00325-2 NP_002626.1 solute carrier family 25 member 3 isoform b 
precursor 
6.61E-02 0.376857165 
148 HADHB P55084 NP_000174.1 mitochondrial trifunctional protein, beta subunit 
precursor 
9.45E-02 0.371686619 
149 SHMT2 P34897 NP_005403.2 serine hydroxymethyltransferase 2 (mitochondrial) 3.78E-02 0.345960324 
150 RPUSD3 Q6P087 NP_775930.1 RNA pseudouridylate synthase domain containing 
3 
0 0.333521432 
151 MMAB Q96EY8 NP_443077.1 cob(I)alamin adenosyltransferase precursor 0 0.318256739 
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152 MCCC2 Q9HCC0 NP_071415.1 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 3.98E-02 0.314147363 
153 PAPD1 Q9NVV4 NP_060579.2 Poly(A) RNA polymerase (PAP) associated domain 
containing 1 
0 0.305996548 
154 PMPCA Q10713 NP_055975.1 peptidase (mitochondrial processing) alpha 0 0.302429122 
155 SLC25A11 Q02978 NP_003553.2 solute carrier family 25 (mitochondrial carrier; 
oxoglutarate carrier), member 11 
0 0.301025217 
156 ATAD3A Q8N275 NP_060658.2 ATPase family, AAA domain containing 3A 6.80E-02 0.301025217 
157 ACAD9 Q9H845 NP_054768.2 acyl-Coenzyme A dehydrogenase family, member 
9 
3.61E-02 0.281422389 
158 C18orf22 Q8N0V3 NP_079081.1 Putative ribosome-binding factor A, mitochondrial 0 0.274274986 
159 NDUFV1 P49821 NP_009034.2 NADH dehydrogenase (ubiquinone) flavoprotein 1, 
51kDa 
0 0.264855217 
160 DNAJA3 Q96EY1 NP_005138.2 DnaJ (Hsp40) homolog, subfamily A, member 3 0 0.24782547 
161 TARS2 Q9BW92 NP_079426.2 threonyl-tRNA synthetase-like 1 0 0.2466504 
162 VDAC3 Q9Y277 NP_005653.3 voltage-dependent anion channel 3 0 0.240937761 
163 SLC25A13 Q9UJS0 NP_055066.1 solute carrier family 25, member 13 (citrin) 0 0.239747763 
164 MCAT Q8IVS2 NP_775738.3 mitochondrial malonyltransferase isoform a 
precursor 
0 0.238862924 
165 PMPCB O75439 NP_004270.2 mitochondrial processing peptidase beta subunit 
precursor 
0 0.237635028 
166 PNPT1 Q8TCS8 NP_149100.1 polyribonucleotide nucleotidyltransferase 1 2.68E-02 0.235816596 
167 LOC648605  XP_944686.1 PREDICTED: similar to Trimethyllysine 
dioxygenase, mitochondrial precursor 
0 0.232846739 
168 ACADVL P49748 NP_000009.1 acyl-Coenzyme A dehydrogenase, very long chain 
isoform 1 precursor 
5.85E-02 0.220168343 
169 CCDC109A Q8NE86 NP_612366.1 coiled-coil domain containing 109A 0 0.218187912 
170 PCCB P05166 NP_000523.2 propionyl Coenzyme A carboxylase, beta 
polypeptide 
0 0.204051772 
171 MTERF Q99551 NP_008911.1 mitochondrial transcription termination factor 
precursor 
0 0.197929811 
172 ERAL1 O75616 NP_005693.1 Era G-protein-like 1 0 0.193776642 
173 ETFA P13804 NP_000117.1 electron transfer flavoprotein, alpha polypeptide 0 0.193776642 
174 NDUFS2 O75306 NP_004541.1 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 
49kDa 
0 0.189793791 
175 ALDH1B1 Q8WX76 NP_000683.3 aldehyde dehydrogenase 1B1 precursor 0 0.189793791 
176 SDHA P31040 NP_004159.1 succinate dehydrogenase complex, subunit A, 
flavoprotein precursor 
3.39E-02 0.181581733 
177 RPUSD4 Q96K56 NP_116184.1 RNA pseudouridylate synthase domain containing 
4 
0 0.174268583 
178 VIM P08670 NP_003371.2 vimentin 0 0.172102298 
179 HARS2 P49590 NP_036340.1 histidyl-tRNA synthetase-like 0 0.168951816 
180 AGK Q53H12 NP_060708.1 multiple substrate lipid kinase 0 0.158323286 
181 KARS Q15046 NP_005539.1 lysyl-tRNA synthetase 3.72E-02 0.157422881 
182 SUPV3L1 Q8IYB8 NP_003162.2 suppressor of var1, 3-like 1 0 0.152732121 
183 AARS2 A2RRN5 NP_065796.1 alanyl-tRNA synthetase like 0 0.142068906 
184 ATAD3B Q5T9A4 NP_114127.3 AAA-ATPase  TOB3 3.30E-02 0.13851309 
185 NDUFA9 Q16795 NP_004993.1 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 9, 39kDa 
0 0.133823501 
186 RHOT1 Q8IXI2-3 NP_001028740.1 ras homolog gene family, member T1 isoform 1 0 0.132541315 
187 MUT P22033 NP_000246.1 methylmalonyl Coenzyme A mutase precursor 0 0.122018454 
188 PUS1 Q9Y606 NP_079491.2 pseudouridylate synthase 1 isoform 1 0 0.122018454 
189 AASS Q9UDR5 NP_005754.2 aminoadipate-semialdehyde synthase 0 0.099606032 
190 SLC25A12 O75746 NP_003696.2 solute carrier family 25 (mitochondrial carrier, 
Aralar), member 12 
0 9.26E-02 
191 PEO1 Q96RR1 NP_068602.2 twinkle 0 9.14E-02 
192 GLDC Q2M2F8 NP_000161.2 glycine dehydrogenase (decarboxylating) 0 8.99E-02 
193 VARS2 Q5ST30 NP_065175.3 valyl-tRNA synthetase 2-like 0 8.49E-02 
194 FASTKD1 Q8TEA9 NP_078898.2 FAST kinase domains 1 0 7.38E-02 
195 MOV10 Q9HCE1 NP_066014.1 Mov10, Moloney leukemia virus 10, homolog 0 6.08E-02 
196 KIAA0564 A3KMH1 NP_055873.1 hypothetical protein LOC23078 isoform a 0 3.93E-02 
197 TTN  NP_596869.3 titin isoform N2-A 0 2.40E-03 
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Appendix 2: LC MS/MS analysis – mtRbfA-FLAG IP 
The LC MS/MS was carried out and analysed by H. Wessels (UNMC, Nijmegen).  
The identified proteins are listed in the table below from high (green) to low (red) 
EMPAI value. Contaminants such as keratin, but also cytosolic ribosomal proteins were 
not included. Proteins with uncertain prediction for mitochondrial localisation are written 
in grey. 
  PROTEIN IDENTIFICATION INFORMATION 
 
EMPAI VALUES  
Gene UNIPROT PROT ID PROT NAME control mtRbfa 
1 MRPS26 Q9BYN8 NP_110438.1  mitochondrial ribosomal protein S26  1.253933905 21.53933905 
2 MRPS21 P82921 NP_061870.1  mitochondrial ribosomal protein S21  0 12.33521432 
3 C18orf22 Q8N0V3 NP_079081.1  Putative ribosome-binding factor A, mitochondrial  0 7.858667904 
4 MRPS7 Q9Y2R9 NP_057055.1  mitochondrial ribosomal protein S7  0.531740464 7.431909293 
5 HSPA9 P38646 NP_004125.3  heat shock 70kDa protein 9B precursor  0.961927374 6.551770453 
6 HSPD1 P10809 NP_955472.1  chaperonin  2.274549163 4.925530976 
7 C14orf156 Q9GZT3 NP_112487.1  SRA stem-loop-interacting RNA-binding protein  0.42510267 4.878016072 
8 MRPS22 P82650 NP_064576.1  mitochondrial ribosomal protein S22  0.916940777 4.216645252 
9 MRPS17 Q9Y2R5 NP_057053.1  mitochondrial ribosomal protein S17  0.584893192 4.011872336 
10 PTCD3 Q96EY7 NP_060422.4  Pentatricopeptide repeat domain 3  0.250898933 3.948168092 
11 MRPL11 Q9Y3B7 NP_057134.1  mitochondrial ribosomal protein L11 isoform a  0.245197085 3.641588834 
12 MRPS34 P82930 NP_076425.1  mitochondrial ribosomal protein S34  0.100694171 3.641588834 
13 GADD45GIP1 Q8TAE8 NP_443082.2  growth arrest and DNA-damage-inducible, gamma 
interacting protein 1  
0.193776642 3.506570338 
14 MRPL28 Q13084 NP_006419.2  mitochondrial ribosomal protein L28  0 3.506570338 
15 MRPS31 Q92665  NP_005821.1  mitochondrial ribosomal protein S31  0.333521432 3.466835922 
16 SLC25A5 P05141 NP_001143.1  solute carrier family 25, member 5  6.61E-02 3.354004654 
17 MRPL1 Q9BYD6 NP_064621.2  mitochondrial ribosomal protein L1  0.165914401 3.298662347 
18 MRPS35 P82673 NP_068593.2  mitochondrial ribosomal protein S35  0.692666615 3.251786303 
19 MRPL15 Q9P015 NP_054894.1  mitochondrial ribosomal protein L15  0.403003723 3.14616956 
20 MRPL48 Q96GC5 NP_057139.1  mitochondrial ribosomal protein L48  0.467799268 3.084238653 
21 SLC25A6   NP_001627.1  solute carrier family 25, member A6  0 2.931828756 
22 MRPL47 Q9HD33 NP_065142.2  mitochondrial ribosomal protein L47 isoform a  0.232846739 2.898603703 
23 MRPL22 Q9NWU5 NP_054899.2  mitochondrial ribosomal protein L22 isoform a  0.333521432 2.83118685 
24 MRPL21 A6NKU0 NP_852615.1  mitochondrial ribosomal protein L21 isoform d  9.26E-02 2.775053205 
25 MRPS9 P82933 NP_872578.1  mitochondrial ribosomal protein S9  0.158323286 2.753773682 
26 MRPL41 Q8IXM3 NP_115866.1  mitochondrial ribosomal protein L41  0.930697729 2.72759372 
27 ATP5A1 P25705 NP_001001937.1  ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit prec. 
0.995262315 2.686945065 
28 SLC25A1 P53007 NP_005975.1  solute carrier family 25 (mitochondrial carrier; 
citrate transporter), member 1  
0 2.651741273 
29 MRPL39 Q9NYK5-2 NP_542984.2  mitochondrial ribosomal protein L39 isoform b  0.251875026 2.63894599 
30 MRPL24 Q96A35 NP_663781.1  mitochondrial ribosomal protein L24  0 2.433320018 
31 PRDX3 P30048 NP_006784.1  peroxiredoxin 3 isoform a precursor  0.995262315 2.414548874 
32 MRPL4 Q9BYD3 NP_057040.2  mitochondrial ribosomal protein L4 isoform a  0.311133937 2.383855153 
33 MRPL43 Q8N983-4 NP_115488.2  mitochondrial ribosomal protein L43 isoform a  0.55051578 2.340484984 
34 MRPL49 Q13405 NP_004918.1  mitochondrial ribosomal protein L49  0.232846739 2.16227766 
35 MRPS25 P82663 NP_071942.1  mitochondrial ribosomal protein S25  0.995262315 2.16227766 
36 MRPS6 P82932 NP_115865.1  mitochondrial ribosomal protein S6  0.930697729 2.16227766 
37 SLC25A4 P12235 NP_001142.2  solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator) 
0 2.16227766 
38 MRPL9 Q9BYD2 NP_113608.1  mitochondrial ribosomal protein L9  0.268961003 2.039195382 
39 MRPL12 P52815 NP_002940.2  mitochondrial ribosomal protein L12  0.730195739 1.993577295 
40 MRPL43 Q8N983 NP_789762.1  mitochondrial ribosomal protein L43 isoform b  0.55051578 1.993577295 
41 MRPL44 Q9H9J2 NP_075066.1  mitochondrial ribosomal protein L44  0.211527659 1.966348839 
42 C1QBP Q07021 NP_001203.1  complement component 1, q subcomponent 
binding protein precursor  
0.193776642 1.894266125 
43 MRPL55 Q7Z7F7 NP_852130.1  mitochondrial ribosomal protein L55 isoform a  0 1.894266125 
44 HADHA P40939 NP_000173.2  mitochondrial trifunctional protein, alpha subunit 
precursor  
0.163949307 1.894266125 
45 MRPL45 Q9BRJ2  NP_115727.3  mitochondrial ribosomal protein L45  6.42E-02 1.880444153 
46 MRPS15 P82914 NP_112570.2  mitochondrial ribosomal protein S15  0.333521432 1.872984833 
47 MRPL40 Q9NQ50 NP_003767.2  mitochondrial ribosomal protein L40  0.110336318 1.848035868 
48 DAP3 P51398 NP_387506.1  death-associated protein 3  0.389495494 1.811768698 
49 MRPS5 P82675 NP_114108.1  mitochondrial ribosomal protein S5  0 1.797747463 
50 TUFM P49411  NP_003312.3  Tu translation elongation factor, mitochondrial  0.726983291 1.758531618 
51 MRPP2 Q99714 NP_004484.1  Mitochondrial ribonuclease P protein 2, HSD17B10  0.711328304 1.712272579 
52 HADHB P55084 NP_000174.1  mitochondrial trifunctional protein, beta subunit 
precursor  
0.435035831 1.700054616 
53 MRPL16 Q9NX20 NP_060310.1  mitochondrial ribosomal protein L16  0 1.682695795 
54 MRPL2 Q5T653 NP_057034.2  mitochondrial ribosomal protein L2  0 1.648969288 
55 ATAD3A Q8N275 NP_060658.2  ATPase family, AAA domain containing 3A  0.103715503 1.595886586 
56 MRPS16 Q9Y3D3 NP_057149.1  mitochondrial ribosomal protein S16  0.311133937 1.58086154 
57 MRPL18 Q9H0U6 NP_054880.2  mitochondrial ribosomal protein L18  0.110336318 1.565020906 
58 MRPL19 P49406 NP_055578.2  mitochondrial ribosomal protein L19  0 1.543345761 
59 MRPS27 Q92552 NP_055899.1  mitochondrial ribosomal protein S27  0.363375184 1.534230736 
60 MRPL46 Q9H2W6 NP_071446.2  mitochondrial ribosomal protein L46  0 1.511886432 
61 SLC25A11 Q02978 NP_003553.2  solute carrier family 25 (mitochondrial carrier; 
oxoglutarate carrier), member 11  
0 1.511886432 
62 SSBP1 Q04837 NP_003134.1  single-stranded DNA binding protein 1  0.668100537 1.448436747 
63 SLC25A3 Q00325-2 NP_002626.1  solute carrier family 25 member 3 isoform b 
precursor  
6.61E-02 1.448436747 
64 MRPL37 Q9BZE1 NP_057575.2  mitochondrial ribosomal protein L37  0.142068906 1.424462017 
65 MRPS18B Q9Y676 NP_054765.1  mitochondrial ribosomal protein S18B  0 1.424462017 
66 MRPL14 Q6P1L8 NP_115487.2  mitochondrial ribosomal protein L14  0.438449888 1.335721469 
67 MRPL17 Q9NRX2 NP_071344.1  mitochondrial ribosomal protein L17  0.274274986 1.335721469 
68 MRPL50 Q8N5N7 NP_061924.1  mitochondrial ribosomal protein L50  0.110336318 1.3101297 
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69 ICT1 Q14197 NP_001536.1  immature colon carcinoma transcript 1  0.221677349 1.227542952 
70 TFAM Q00059 NP_003192.1  transcription factor A, mitochondrial  0.304321387 1.218982341 
71 MRPS2 Q9Y399 NP_057118.1  mitochondrial ribosomal protein S2  0 1.206734069 
72 NDUFAF3 Q9BU61 NP_951032.1  NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex assembly factor 3 
0 1.15443469 
73 MRPL23 Q16540  NP_066957.2  mitochondrial ribosomal protein L23  0.467799268 1.15443469 
74 GRPEL1 Q9HAV7 NP_079472.1  GrpE-like 1, mitochondrial  0.318256739 1.089296131 
75 ATAD3B Q5T9A4 NP_114127.3  AAA-ATPase  TOB3  3.30E-02 1.041075901 
76 MRPL13 Q9BYD1 NP_054797.2  mitochondrial ribosomal protein L13  0.42510267 1.030917621 
77 MRPL54 Q6P161 NP_758455.1  mitochondrial ribosomal protein L54  0 1.030917621 
78 MRPS28 Q9Y2Q9 NP_054737.1  mitochondrial ribosomal protein S28  0.492495545 1.015337686 
79 SLC25A13 Q9UJS0 NP_055066.1  solute carrier family 25, member 13 (citrin)  0 0.96486779 
80 IDH2 P48735 NP_002159.2  isocitrate dehydrogenase 2 (NADP+), 
mitochondrial precursor  
0.042753889 0.953930405 
81 MRPS10 P82664 NP_060611.2  mitochondrial ribosomal protein S10  0.279802214 0.930697729 
82 NME4 O00746 NP_005000.1  nucleoside-diphosphate kinase 4  0 0.930697729 
83 MRPL20 Q9BYC9 XP_001125910.1  mitochondrial ribosomal protein L20  0 0.930697729 
84 MRPL38 B2R894 NP_115867.1  mitochondrial ribosomal protein L38  0.240937761 0.910952975 
85 MRPS23 Q9Y3D9 NP_057154.2  mitochondrial ribosomal protein S23  0.445439771 0.905460718 
86 NDUFS3 O75489 NP_004542.1  NADH dehydrogenase (ubiquinone) Fe-S protein 
3, 30kDa  
0.258925412 0.847849797 
87 AFG3L2 Q9Y4W6 NP_006787.1  AFG3 ATPase family gene 3-like 2  2.62E-02 0.813121744 
88 PGAM5 Q96HS1-2 NP_612642.1  Bcl-XL-binding protein v68  6.61E-02 0.77827941 
89 DCI P42126 NP_001910.2  dodecenoyl-Coenzyme A delta isomerase 
precursor  
0 0.77827941 
90 MRPL10 Q7Z7H8 NP_660298.2  mitochondrial ribosomal protein L10 isoform a  0 0.77827941 
91 MRPL51 Q4U2R6 NP_057581.2  mitochondrial ribosomal protein L51  0 0.77827941 
92 PHB2 Q99623 NP_009204.1  prohibitin 2  0.36887451 0.77827941 
93 ACOT9   NP_001028755.2  acyl-Coenzyme A thioesterase 2, mitochondrial 
isoform b  
0 0.760410844 
94 MRPS30 Q9NP92 NP_057724.2  mitochondrial ribosomal protein S30  5.13E-02 0.734324802 
95 MCCC2 Q9HCC0 NP_071415.1  methylcrotonoyl-Coenzyme A carboxylase 2 (beta)  3.98E-02 0.726983291 
96 ACAD9 Q9H845 NP_054768.2  acyl-Coenzyme A dehydrogenase family, member 
9  
3.61E-02 0.70125428 
97 DHX30 Q7L2E3 NP_619520.1  DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 1  
0.14504757 0.693394598 
98 COX4I1 P13073 NP_001852.1  cytochrome c oxidase subunit IV isoform 1 
precursor  
0 0.687612476 
99 MRPS18A Q9NVS2 NP_060605.1  mitochondrial ribosomal protein S18A  0.110336318 0.687612476 
100 ATP5H O75947 NP_006347.1  ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d isoform a  
0.136463666 0.668100537 
101 AIFM1 O95831 NP_004199.1  programmed cell death 8 isoform 1  0 0.668100537 
102 MRPL3 P09001 NP_009139.1  mitochondrial ribosomal protein L3  5.78E-02 0.657723886 
103 ATP5L O75964 NP_006467.4  ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit G  
0 0.637893707 
104 PMPCB O75439 NP_004270.2  mitochondrial processing peptidase beta subunit 
precursor  
0 0.598467106 
105 SLC25A10 Q9UBX3 NP_036272.2  solute carrier family 25 (mitochondrial carrier; 
dicarboxylate transporter)  
0 0.561523006 
106 DNAJA3 Q96EY1 NP_005138.2  DnaJ (Hsp40) homolog, subfamily A, member 3  0 0.557068405 
107 MRPP1 Q9NRG5 NP_060289.2  Mitochondrial ribonuclease P protein 1, RG9MTD1  4.53E-02 0.557068405 
108 TRUB2 O95900 NP_056494.1  TruB pseudouridine (psi) synthase homolog 2  0 0.545927736 
109 YME1L1 Q96TA2 NP_647473.1  YME1-like 1 isoform 1  0 0.539926526 
110 POLDIP2 Q9Y2S7 NP_056399.1  DNA polymerase delta interacting protein 2  0 0.519911083 
111 LOC729317 A6NLE7 XP_001133585.1  PREDICTED: similar to voltage-dependent anion 
channel 2  
0.149756995 0.519911083 
112 ALDH18A1 P54886 NP_002851.2  pyrroline-5-carboxylate synthetase isoform 1  4.71E-02 0.513561248 
113 TI21L Q9BVV7 NP_054896.1  TIM21-like protein, mitochondrial 0 0.508590709 
114 GBAS O75323 NP_001474.1  nipsnap homolog 2  0.14504757 0.501310729 
115 ATP5C1 P36542 NP_001001973.1  ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma subunit iso. L  
8.26E-02 0.487352107 
116 CCDC109A Q8NE86 NP_612366.1  coiled-coil domain containing 109A  0 0.483981789 
117 VDAC1 P21796 NP_003365.1  voltage-dependent anion channel 1 (porin) 0.218187912 0.483981789 
118 SLC25A12 O75746 NP_003696.2  solute carrier family 25 (mitochondrial carrier, 
Aralar), member 12  
0 0.467799268 
119 NDUFS8 O00217 NP_002487.1  NADH dehydrogenase (ubiquinone) Fe-S protein 
8, 23kDa  
9.65E-02 0.445439771 
120 MRPS11 P82912 NP_073750.2  mitochondrial ribosomal protein S11 isoform a  0 0.438449888 
121 NIPSNAP1   NP_003625.1  nipsnap homolog 1  7.46E-02 0.43301257 
122 SARS2 Q9NP81 NP_060297.1  seryl-tRNA synthetase 2  0 0.43301257 
123 ERAL1 O75616 NP_005693.1  Era G-protein-like 1  0 0.42510267 
124 C4orf14 Q8NC60 NP_115689.1  hypothetical protein LOC84273  2.75E-02 0.422136151 
125 HARS2 P49590 NP_036340.1  histidyl-tRNA synthetase-like  0 0.420830833 
126 ME2 P23368 NP_002387.1  malic enzyme 2, NAD(+)-dependent, mitochondrial  0 0.410112399 
127 GTPBP10 A4D1E9 NP_149098.2  claudin 12 isoform 2  0 0.406527242 
128 POLRMT O00411 NP_005026.3  mitochondrial DNA-directed RNA polymerase 
precursor  
1.62E-02 0.402339435 
129 TIMM50 Q3ZCQ8-2 NP_001001563.1  translocase of inner mitochondrial membrane 50 
homolog  
0.18350673 0.400688179 
130 PGAM5   XP_001126125.1  PREDICTED: similar to phosphoglycerate mutase 
family member 5  
0.042753889 0.397830607 
131 MCAT Q8IVS2 NP_775738.3  mitochondrial malonyltransferase isoform a 
precursor  
0 0.378906706 
132 PHB P35232 NP_002625.1  prohibitin  0 0.376857165 
133 PNPT1 Q8TCS8 NP_149100.1  polyribonucleotide nucleotidyltransferase 1  8.26E-02 0.373823796 
134 YARS2 Q9Y2Z4 NP_001035526.1  tyrosyl-tRNA synthetase 2 (mitochondrial)  0 0.355424938 
135 GLUD1 P00367 NP_005262.1  glutamate dehydrogenase 1  0.14280206 0.350314038 
136 PAPD1 Q9HA74 NP_060579.2  Poly(A) RNA polymerase (PAP) associated 
domain containing 1  
0 0.350314038 
137 SFXN1 Q9H9B4 NP_073591.2  sideroflexin 1  6.08E-02 0.343399333 
138 DHX30 Q7L2E3-2 NP_619519.1  DEAH (Asp-Glu-Ala-His) box polypeptide 30 
isoform 3  
0 0.341712835 
139 CLPX O76031 NP_006651.2  ClpX caseinolytic protease X homolog  0 0.333521432 
140 NSUN4 Q96CB9 NP_950245.2  NOL1/NOP2/Sun domain family 4 protein  0 0.333521432 
141 METT11D1 Q9H7H0 NP_073571.1  methyltransferase 11 domain containing 1 isoform 
2  
0 0.325711366 
142 TFB1M Q9Y384 NP_057104.1  transcription factor B1, mitochondrial  0 0.324192792 
143 DLD B2R5X0 NP_000099.2  dihydrolipoamide dehydrogenase precursor  9.65E-02 0.318256739 
144 MTERFD1 Q96E29 NP_057026.3  MTERF domain containing 1  0 0.30701048 
145 PMPCA Q10713 NP_055975.1  peptidase (mitochondrial processing) alpha  3.85E-02 0.302429122 
146 PCCB P05166 NP_000523.2  propionyl Coenzyme A carboxylase, beta 0 0.296890252 
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polypeptide  
147 SHMT2 P34897 NP_005403.2  serine hydroxymethyltransferase 2 (mitochondrial)  3.78E-02 0.296890252 
148 PTCD1 O75127 NP_056360.2  pentatricopeptide repeat domain 1  0 0.291549665 
149 OXA1L Q15070  NP_005006.1  oxidase (cytochrome c) assembly 1-like, 
mitochondrial inner membrane protein  
0 0.282649831 
150 VARS2 Q5ST30 NP_065175.3  valyl-tRNA synthetase 2-like  0 0.277011153 
151 AARS2 A2RRN5 NP_065796.1  alanyl-tRNA synthetase like  0 0.275760733 
152 SLC25A40 Q8TBP6 NP_061331.2  mitochondrial carrier family protein  0 0.274274986 
153 MRS2 Q9HD23 NP_065713.1  MRS2-like, magnesium homeostasis factor  0 0.264855217 
154 HK1 P19367 NP_000179.1  hexokinase 1 isoform HKI  0 0.261856883 
155 DDX28 Q9NUL7 NP_060850.1  DEAD (Asp-Glu-Ala-Asp) box polypeptide 28  3.85E-02 0.254182266 
156 ECSIT Q9BQ95 NP_057665.2  evolutionarily conserved signaling intermediate in 
Toll pathway  
0 0.253254336 
157 C7orf30 Q96EH3 NP_612455.1  hypothetical protein LOC115416  0 0.249609141 
158 LONP1 P36776 NP_004784.2  mitochondrial lon peptidase 1  7.71E-02 0.249609141 
159 NDUFS2 O75306 NP_004541.1  NADH dehydrogenase (ubiquinone) Fe-S protein 
2, 49kDa  
0 0.242623672 
160 RARS2 Q96FU5 NP_064716.1  arginyl-tRNA synthetase-like  0 0.236247035 
161 NDUFA13 Q9P0J0  NP_057049.3  cell death-regulatory protein GRIM19  0 0.232846739 
162 ECHS1 P30084 NP_004083.2  mitochondrial short-chain enoyl-coenzyme A 
hydratase 1 precursor  
0 0.232846739 
163 LOC648605   XP_944686.1  PREDICTED: similar to Trimethyllysine 
dioxygenase, mitochondrial precursor  
0 0.232846739 
164 IMMT   NP_006830.1  inner membrane protein, mitochondrial  2.62E-02 0.22995052 
165 DBT Q5VVL8 NP_001909.2  dihydrolipoamide branched chain transacylase 
precursor  
4.20E-02 0.228247006 
166 RNMTL1 Q9HC36 NP_060616.1  RNA methyltransferase like 1  0 0.225279857 
167 RHOT2 Q8IXI1 NP_620124.1  ras homolog gene family, member T2  0 0.223824937 
168 FASTKD2 Q9NYY8 NP_055744.2  FAST kinase domains 2  0 0.216483949 
169 C3orf58 Q8NDZ4 NP_775823.1  hypothetical protein LOC205428  0 0.216483949 
170 AGK Q53H12 NP_060708.1  multiple substrate lipid kinase  5.02E-02 0.216483949 
171 TARS2 Q9BW92 NP_079426.2  threonyl-tRNA synthetase-like 1  0 0.216483949 
172 AASS Q9UDR5 NP_005754.2  aminoadipate-semialdehyde synthase  0 0.209133425 
173 NDUFS1 P28331 NP_004997.4  NADH dehydrogenase (ubiquinone) Fe-S protein 
1, 75kDa precursor  
0 0.208795797 
174 SLC30A9 Q6PML9 NP_006336.3  solute carrier family 30 (zinc transporter), member 
9  
0 0.206792641 
175 SLC25A18 Q9H1K4 NP_113669.1  solute carrier  0 0.205260937 
176 SLC25A21 Q9BQT8 NP_085134.1  solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21  
0 0.205260937 
177 ERLIN2 O94905 NP_009106.1  SPFH domain family, member 2 isoform 1  0 0.205260937 
178 EFHA1 Q8IYU8 NP_689939.1  EF hand domain family, member A1  0 0.202264435 
179 MTERF Q99551 NP_008911.1  mitochondrial transcription termination factor 
precursor  
0 0.197929811 
180 ECH1 Q13011 NP_001389.2  peroxisomal enoyl-coenzyme A hydratase-like 
protein  
0 0.193776642 
181 CLPB Q9H078 NP_110440.1  suppressor of potassium transport defect 3  0 0.193776642 
182 ACSS1 Q9NUB1 NP_115890.2  acyl-CoA synthetase short-chain family member 1  0 0.190577239 
183 ALDH1B1 Q8WX76 NP_000683.3  aldehyde dehydrogenase 1B1 precursor  4.44E-02 0.189793791 
184 RPUSD3 Q6P087 NP_775930.1  RNA pseudouridylate synthase domain containing 
3  
0 0.188502227 
185 GRSF1 Q12849-2 NP_002083.2  G-rich RNA sequence binding factor 1  0 0.185971012 
186 FLAD1 Q8NFF5 NP_079483.3  flavin adenine dinucleotide synthetase isoform 1  0 0.181581733 
187 PCCA Q8WXQ7 NP_000273.2  propionyl-Coenzyme A carboxylase, alpha 
polypeptide precursor  
0 0.180769016 
188 CABC1 Q8NI60 NP_064632.2  chaperone, ABC1 activity of bc1 complex like 
precursor  
0 0.178768635 
189 LETM1 O95202 NP_036450.1  leucine zipper-EF-hand containing transmembrane 
protein 1  
2.75E-02 0.176489987 
190 KIAA0564 A3KMH1 NP_055873.1  hypothetical protein LOC23078 isoform a  5.95E-02 0.166663489 
191 PUS1 Q9Y606 NP_079491.2  pseudouridylate synthase 1 isoform 1  0 0.165914401 
192 PCK2 Q6IB91  NP_004554.2  mitochondrial phosphoenolpyruvate carboxykinase 
2 isoform 1 precursor  
0.030355309 0.161274969 
193 DDOST B2RDQ4 NP_005207.2  dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase precursor  
0 0.151395399 
194 TBRG4 Q969Z0 NP_004740.2  cell cycle progression 2 protein isoform 1  0 0.147364722 
195 AP2M1 Q96CW1 NP_004059.2  adaptor-related protein complex 2, mu 1 subunit 
isoform a  
0 0.142068906 
196 ALDH2 P05091 NP_000681.2  mitochondrial aldehyde dehydrogenase 2 
precursor  
0 0.139209961 
197 GLDC Q2M2F8 NP_000161.2  glycine dehydrogenase (decarboxylating)  0 0.137823152 
198 RHOT1 Q8IXI2-3 NP_001028740.1  ras homolog gene family, member T1 isoform 1  0 0.132541315 
199 PITRM1   NP_055704.2  metalloprotease 1  0 0.126481692 
200 DNAJC11 Q9NVH1 NP_060668.1  DnaJ (Hsp40) homolog, subfamily C, member 11  0 0.124210035 
201 MTIF2   NP_002444.2  mitochondrial translational initiation factor 2 
precursor  
0 0.122018454 
202 MRPP3 O15091 NP_055487.2  Mitochondrial ribonuclease P protein 3, KIAA0391 0 0.110336318 
203 LARS2 Q15031 NP_056155.1  leucyl-tRNA synthetase 2, mitochondrial precursor  0 0.106511785 
204 FASTKD5 Q7L8L6 NP_068598.1  FAST kinase domains 5  0 0.100694171 
205 FASTKD1 Q8TEA9 NP_078898.2  FAST kinase domains 1  0 0.099606032 
206 NLRX1 Q86UT6 NP_078894.2  NLR family member X1 isoform 1  0 9.26E-02 
207 SUPV3L1 Q8IYB8 NP_003162.2  suppressor of var1, 3-like 1  0 8.90E-02 
208 GARS   NP_002038.2  glycyl-tRNA synthetase  0 8.68E-02 
209 GCS1 Q13724 NP_006293.1  mannosyl-oligosaccharide glucosidase  0 7.89E-02 
210 ALDH1L2 Q3SY69 NP_001029345.1  aldehyde dehydrogenase 1 family, member L2  0 7.58E-02 
211 ELAC2 Q6IA94 NP_060597.3  elaC homolog 2  0 7.30E-02 
 
 
205 
Publications arising: 
 
Mateusz Kolanczyk*, Markus Pech*, Tomasz Zemojte, Hiroshi Yamamoto, Ivan Mikula, 
Maria-Antonietta Calvaruso, Ricarda Richter
 
, Björn Fischer, Anita Ritz, Nadine Kossler, 
Boris Thurisch, Ralf Spörle, Jan Smeitnik, Uwe Kornak, Danny Chan, Martin Vingron, 
Pawel Martasek, Robert N. Lightowlers, Leo Nijtmans, Markus Schülke-Gerstenfeld, 
Knud H. Nierhaus, Stefan Mundlos. (2011) NOA1 is an essential GTPase required for 
mitochondrial protein synthesis and apoptosis. Molecular Biology of the Cell, 22(1):1-11 
(*These authors contributed equally to this work.)  
Ricarda Richter
 
, Aleksandra Pajak, Sven Dennerlein, Agata Rozanska, Robert N. 
Lightowlers, and Zofia M. A. Chrzanowska-Lightowlers. (2010) Translation Termination 
in human mitochondrial ribosomes. Biochem Soc Trans, 38(6):1523-1526 
Ricarda Richter
**This publication was selected as the subject for "Did you see...?" commentary: Md 
Emdadul Haque, Linda L. Spremulli (2010) ICT1 comes to the rescue of mitochondrial 
ribosomes. The EMBO Journal 29(6): 1019-1020 
, Joanna Rorbach, Aleksandra Pajak, Hans J. Wessels, Martijn A. 
Huynen, Jan A. Smeitink, Robert N. Lightowlers, Zofia M. Chrzanowska-Lightowlers. 
(2010) A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human 
mitochondrial ribosome. The EMBO Journal 29(6):1116-25** 
 
Richard Temperley*, Ricarda Richter
 
*, Sven Dennerlein, Robert N. Lightowlers, Zofia 
M. Chrzanowska-Lightowlers. (2010) Hungry Codons Promote Frameshifting in Human 
Mitochondrial Ribosomes. Science 327, p. 301 (* These authors contributed equally to 
this work.) 
Joanna Rorbach, Ricarda Richter
Nucleic Acids 
Research
, Hans J. Wessels, Mateusz Wydro, Marcin Pekalski, 
Murtada Farhoud, Inge Kühl, Mauricette Gaisne, Nathalie Bonnefoy, Jan A. Smeitink, 
Robert N. Lightowlers, Zofia M.A. Chrzanowska-Lightowlers. (2008) The human 
mitochondrial ribosome recycling factor is essential for cell viability. 
  36, 5787-99.  
 
Volume 22 January 1, 2011 1 
 NOA1 is an essential GTPase required for 
mitochondrial protein synthesis 
 Mateusz  Kolanczyk a, b,* ,  Markus  Pech c,* ,  Tomasz  Zemojtel d ,  Hiroshi  Yamamoto c ,  Ivan  Mikula e , 
 Maria-Antonietta  Calvaruso f ,  Mariël  van den Brand f ,  Ricarda  Richter g ,  Bjoern  Fischer a, b , 
 Anita Ritz a, b ,  Nadine  Kossler a , b ,  Boris  Thurisch a, b ,  Ralf  Spoerle h ,  Jan  Smeitink  f ,  Uwe  Kornak a , b , 
 Danny  Chan i ,  Martin  Vingron d ,  Pavel  Martasek  e ,  Robert N.  Lightowlers g ,  Leo  Nijtmans  f , 
 Markus  Schuelke j ,  Knud H.  Nierhaus c ,  and  Stefan  Mundlos a , b 
 a Development & Disease Group, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany;  b Institute for 
Medical Genetics, Charité University Medical Center, 13353 Berlin, Germany;  c AG Ribosomen, Max Planck Institute for 
Molecular Genetics, 14195 Berlin, Germany;  d Department of Computational Molecular Biology, Max Planck Institute 
for Molecular Genetics, 14195 Berlin, Germany;  e Department of Pediatrics and Center for Applied Genomics, I st 
Faculty of Medicine, Charles University, 12109 Prague, Czech Republic;  f Nijmegen Centre for Mitochondrial Disorders 
at the Department of Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 
 g Mitochondrial Research Group, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, 
United Kingdom NE2 4HH;  h Department of Developmental Genetics, Max Planck Institute for Molecular Genetics, 
14195 Berlin, Germany;  i Department of Biochemistry, the University of Hong Kong, Hong Kong, China;  j Department of 
Neuropediatrics and NeuroCure Clinical Research Center, Charité University Medical Center, 13353 Berlin, Germany 
 This article was published online ahead of print in MBoC in Press (http://www
.molbiolcell.org/cgi/doi/10.1091/mbc.E10-07-0643) on November 30, 2010.
*These authors contributed equally to this paper.
The authors declare no competing fi nancial interests.
 Address correspondence to: Mateusz Kolanczyk ( kolanshy@molgen.mpg.de ) or 
Tomasz Zemojtel ( zemojtel@molgen.mpg.de ).
 Abbreviations used: 3D, three dimensions; DAP3, death-associated protein 3; 
DAPI, 4′,6-diamidino-2-phenylindole; DNP, 2,4-dinitrophenol;  dsRNA, double-
stranded RNA; FBS, fetal bovine serum; GTP, guanosine triphosphate; MEF, 
mouse embryonic fi broblast; mtDNA, mitochondrial DNA; MuLV, murine leuke-
mia virus; nDNA, nuclear DNA; NOA, nitric oxide associated; OPT, optical to-
mography; OXPHOS, oxidative phosphorylation; PBS, phosphate-buffered sa-
line; PFA, paraformaldehyde; PMSF, phenylmethylsulfonyl fl uoride; PVDF, 
polyvinylidene fl uoride; qPCR, quantitative PCR; RIPA, radioimmunoprecipita-
tion assay; siRNA, small interfering RNA; TCA, trichloroacetic acid; TEM, trans-
mission electron microscopy; TGC, trophoblast giant cell; TRAFAC, translation 
factors.
 ABSTRACT Nitric oxide associated -1 (NOA1) is an evolutionarily conserved guanosine triphos-
phate (GTP) binding protein that localizes predominantly to mitochondria in mammalian cells. 
On the basis of bioinformatic analysis, we predicted its possible involvement in ribosomal 
biogenesis, although this had not been supported by any experimental evidence. Here we 
determine NOA1 function through generation of knockout mice and in vitro assays. NOA1-
defi cient mice exhibit midgestation lethality associated with a severe developmental defect 
of the embryo and trophoblast. Primary embryonic fi broblasts isolated from NOA1 knockout 
embryos show defi cient mitochondrial protein synthesis and a global defect of oxidative 
phosphorylation (OXPHOS). Additionally,  Noa1–/– cells are impaired in staurosporine-induced 
apoptosis. The analysis of mitochondrial ribosomal subunits from  Noa1–/– cells by sucrose 
gradient centrifugation and Western blotting showed anomalous sedimentation, consistent 
with a defect in mitochondrial ribosome assembly. Furthermore, in vitro experiments revealed 
that intrinsic NOA1 GTPase activity was stimulated by bacterial ribosomal constituents. Taken 
together, our data show that NOA1 is required for mitochondrial protein synthesis, likely due 
to its yet unidentifi ed role in mitoribosomal biogenesis. Thus, NOA1 is required for such basal 
mitochondrial functions as adenosine triphosphate (ATP) synthesis and apoptosis. 
 INTRODUCTION 
 Mitochondria are the principal energy-producing organelles be-
lieved to have evolved from eubacteria that were engulfed by 
primordial eukaryotic cells ( Gray  et al. , 2001 ). In the course of evo-
lution mitochondria retained rudimentary genomes, whereas most 
of the other necessary genetic information was relocated to the 
nucleus of the host cell. As a result, in mammalian cells only 
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13 proteins (all of which are translated by mitochondrial and not 
cytosolic ribosomes) are encoded by mitochondrial DNA (mtDNA). 
Mitochondrial ribosomes (mitoribosomes) are assembled from 
more than 70 nuclearly encoded proteins (at least 29 in the 28S 
small subunit and 48 in the 39S large subunit) and 2 species of 
mitochondrially encoded rRNA  (Koc  et al. , 2001 ). Relatively little is 
known about how these multiple components assemble into a 
catalytically active complex and what factors are required for com-
pletion of this process. We identifi ed nitric oxide-associated -1 
(NOA1) as a predominantly mitochondrially localized guanosine 
triphosphate (GTP) binding protein, homologous to the essential 
 Bacillus subtilis GTPase, YqeH ( Zemojtel  et al. , 2006b ). YqeH de-
fi nes a subfamily of circularly permutated GTPases conserved in 
some species of bacteria and all known eukaryotic organisms ( Leipe 
 et al. , 2002 ). The protein belongs to a larger family of YlqF/YawG 
translation factors (TRAFAC), whose members, such as YlqF, have 
been implicated in ribosomal assembly in  B. subtilis ( Kim do  et al. , 
2008 ). Independent of homology to bacterial YqeH, a possible in-
volvement of NOA1 in mitoribosome function has been implicated 
by data from the yeast protein interactome ( Zemojtel  et al. , 2006a ). 
Here the NOA1 yeast homologue YOR205C was shown to be a 
part of a protein complex associated with the S5 protein of the 
small mitoribosomal subunit. YqeH has been suggested to partici-
pate in the biogenesis of the 30S ribosomal subunit and to assist in 
50S ribosomal subunit assembly ( Loh  et al. , 2007 ;  Uicker  et al. , 
2007 ). In a recent study, human NOA1 was shown to interact with 
complex I of the electron transport chain and with three mitoribo-
somal proteins, MRPL12, MRPS27, and MRPS29 (also known as 
death-associated protein 3 [DAP3]), indicating that NOA1 may in-
teract with the mitoribosome ( Tang  et al. , 2009 ). To date, however, 
no experimental data were available to support a role for NOA1 in 
mitochondrial protein synthesis. Similarly, a physiological role of 
the protein in mammalian development was also unknown. Here 
we present a comprehensive analysis of the cellular and develop-
mental role of mammalian NOA1. We show that NOA1 inactivation 
impairs mitochondrial protein synthesis and causes global defect 
of oxidative phosphorylation (OXPHOS), defective apoptosis, and 
midgestation lethality of knockout mice. 
 RESULTS 
 Noa1 gene inactivation results in midgestation lethality 
 To experimentally address the function of NOA1 in a physiological 
in vivo context, we generated mice in which  Noa1 was inactivated 
( Figure 1 ). Mutant embryos appeared growth retarded and at E9.5 a 
maximum of nine somites was observed ( Figure 1, E–G , and 
 Figure 2A ). At E10.5 many embryos were necrotic, and no viable 
 Noa1–/– embryos were detected thereafter, indicating midgestation 
lethality ( Table 1 ). Cell proliferation as measured by bromodeoxyuri-
dine (BrdU) incorporation was drastically reduced in E9.5  Noa1 –/– 
embryos ( Figure 2A ), and few areas of apoptotic cell death were 
observed ( Figure 2, B and C ), indicating that cell proliferation as well 
as apoptosis was severely impaired. Transmission electron micros-
copy (TEM) of  Noa1 –/– embryos revealed abnormal mitochondria 
with characteristically swollen cristae ( Figure 2D ) but no abnormali-
ties in other organelles. In addition, we observed severe defects of 
the placenta with a reduction of all three trophoblast layers, includ-
ing the trophoblast giant cell (TGC) layer ( Figure 3 , Supplemental 
Figure S1). This fi nding was in line with  Noa1 being expressed in the 
trophoblast but not in the maternal part of the placenta ( Figure 3A ). 
Together these results indicated that  Noa1 is indispensable for nor-
mal development of the embryo and the placenta possibly due to 
an important function in mitochondria. 
 FIGURE 1:  Generation of the  Noa1 knockout mice. (A) Strategy of 
 Noa1 gene targeting. The top bar indicates the enzymatic cleavage 
sites at the  Noa1 genomic locus ( BamH I), K ( Kpn I), N ( Not I), and 
C ( Cla I). GTPase domain encoding Exon1 (dark grey segment) was 
targeted. Homologous recombination using this construct (middle 
bar) resulted in a targeted allele (bottom bar) where a large part of 
exon1 was replaced by the  loxP fl anked, PGK-gb2 promoter driven, 
neomycin/kanamycin resistance cassette (white segment – Neo/Kan; 
yellow triangles –  loxP sites). Insertion of the selection cassette 
introduced a  Not I endonuclease recognition site enabling Southern 
blot–based detection of homologous recombination with the internal 
and external probes (black boxes above the panels). Red rulers 
indicate expected  Bam HI/ Not I fragment sizes for the wild-type locus 
as well as the altered fragment size in the homologously targeted 
locus. Black rulers indicate lengths of the long-range PCR products 
obtained from the wild type and homologously targeted locus. 
(B) Southern blot and long-range-PCR–based detection of the 
homologous recombination. (C) PCR-based genotyping strategy. 
(D) Western blot analyses of E9.5 wild type,  Noa+/– , and  Noa1–/– 
embryo lysates with β-actin as loading control. (E) Appearance of 
 Noa1 knockout embryos at E7.5. (F) A comparison of the intact 
embryos at E9.5 is shown to illustrate the difference in size. (G)  Noa1 
knockout embryo development is arrested at prerotation stage 
(inset). E9.5 wild-type embryo displays 21 somites whereas NOA1-
defi cient littermate (magnifi ed) reaches maximally a 9-somite stage. 
See also Supplemental Movies S1 and S2 available online. 
Volume 22 January 1, 2011 Targeted inactivation of Noa1 gene in mouse | 3 
Stage Litters Noa1+/+ Noa1+/− Noa1−/− Total
E7.5 2 2 (10%) 13 (65%) 5 (25%) 20
E8.5 7 14 (25%) 32 (58%) 9 (16%) 55
E9.5 16 21 (17%) 80 (66%) 20 (17.0%) 121
E10.5 5 6 (17%) 22 (61%) 8 (22%) 36
E14.5 1 2 (33.3%) 4 (66.6%) 0 6
E15.5 6 16 (31%) 36 (69%) 0 52
E16.5 2 5 (33.3%) 10 (66.6%) 0 15
P1 5 9 (25%) 27 (75%) 0 36
P28 11 32 (38%) 52 (62%) 0 84
 TABLE 1:  Intercross of  Noa1+/ − mice – offspring genotype distribution.  Knockout embryos could not be detected 
beyond E10.5, indicating midgestation lethality. Heterozygous animals were born in the expected Mendelian ratio. No 
overt lethality of heterozygotes was observed in the postnatal period. 
from E9.5  Noa1 –/– embryos.  Noa1- defi cient cells grew in a me-
dium known to compensate for mitochondrial respiratory defi -
ciency and showed no overt abnormalities in the mitochondrial 
network (Supplemental Figure S3A). To test mitochondrial func-
tion we measured cellular respiration by polarographic assays in 
digitonin-permeabilized cells. Complex I–, III–, and IV–dependent 
oxygen consumption was severely reduced in mutant cells 
( Figure 4A ), indicating a global OXPHOS defect. Consequently, 
 Noa1 knockout cells showed reduced viability and cellular ATP 
content when grown under nutrient restriction ( Figure 4, B and C ). 
Similar results were obtained after  NOA1 depletion in HeLa cells 
(Supplemental Figure S2). 
 Because the results of polarographic measurements are 
infl uenced by mitochondrial substrate import, we further ad-
dressed OXPHOS complex function in direct biochemical as-
says. Spectroscopic assays revealed that the activity of complexes 
I, III, IV, and V was strongly reduced in  Noa1–/– cells, whereas the 
activity of complex II was increased ( Figure 4D ). Blue-native electro-
phoresis of isolated mitochondria showed a decreased amount of 
assembled complex I, III, IV, and V ( Figure 4E ) and an accumulation 
of the unassembled complex V (F1), whereas no free F1 subunit was 
detected in wild-type cells. Confi rmatory to this, in-gel activity of 
complex I measured by the colorimetric enzymatic assay (immuno-
globulin E [IgE] ) was also strongly reduced ( Figure 4E , top stripe). 
These fi ndings suggested a general defect of mitochondrial protein 
synthesis in  Noa1–/– cells, as complex I, III, IV, and V all include pro-
teins encoded by the mtDNA, whereas all proteins of complex II are 
encoded in the nucleus and imported into the mitochondrium. 
 Compromised mitochondrial protein synthesis 
in Noa1–/– cells 
 To test this possibility,  Noa1–/– cells were assayed for mitochondrial 
protein synthesis. Radioactive methionine labeling showed a defi -
ciency in de novo mitochondrial protein synthesis ( Figure 5A ). 
Normal copy number and integrity of mtDNA were confi rmed by 
quantitative PCR (qPCR) and long-range PCR, excluding defects of 
replication and/or mtDNA repair as a cause of compromised protein 
synthesis (Supplemental Figure S3, B and C). Expression of genes 
encoding proteins of the electron transport chain or mitoribosomal 
function was increased in the mutant cells, indicating that mtDNA 
transcription in the knockout cells was maintained, increased ex-
pression likely being compensatory to the protein synthesis defect 
( Figure 5B ). Interestingly, 16S rRNA transcript level from the large 
ribosomal subunit was increased twofold in mutant cells whereas 
12S rRNA remained at the control level indicative of a possible de-
fect of mitoribosome biogenesis ( Uicker  et al. , 2007 ). These results 
are consistent with NOA1 being required for mitochondrial protein 
synthesis. 
 FIGURE 2:  Phenotype of  Noa1 knockout mice. (A) BrdU in-vivo label-
ing reveals arrest of proliferation in the E9.5  Noa–/– embryos. (B and C) 
Apoptosis in the E9.5  Noa1–/– embryos visualized by anti-activated 
caspase-3 immunolabeling in the whole mount preparations (B) and 
TUNEL staining on paraffi n sections (C). Data are representative of at 
least three embryos analyzed for each genotype. (D) Electron micro-
scopic analysis of the  Noa1–/– embryos. Many mitochondria show ab-
errant morphology characterized by swollen intracristal spaces (single-
headed arrows). Some appear collapsed into electron dense, shrunken 
remnants (double-headed arrow). Endoplasmic reticulum and other or-
ganelles appear normal in  Noa1–/– embryos (data not shown). ba – 
branchial arche, h – heart, nt – neural tube. 
 Global OXPHOS defect in the  Noa1–/– cells 
 To gain further information on the biochemical consequences 
of  Noa1 inactivation we isolated primary embryonic fi broblasts 
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more, although  Noa1 defi ciency had only 
a minimal effect on the position or band 
intensity of the small subunit in the su-
crose gradient ( Figure 4C , bottom pan-
els), the large subunits showed a marked 
shift to the slower migrating particles 
(lane 5, NOA1–/–  cf. NOA1+/+); these ef-
fects were rescued by adding  Noa1 in 
trans (NOA1–/– comp. in  Figure 5C ). 
Additionally, NOA1 complementation led 
to increased abundance of L12 protein in 
fractions 9 and 10. In line with the ob-
served partial rescue of mitoribosomal 
assembly, retroviral complementation re-
sulted in reactivation of mitochondrial 
protein synthesis, normalization of respi-
ratory chain complex assembly, and im-
proved viability of the knockout cells 
(Supplemental Figure S4). These data 
strongly suggest that inactivation of  Noa1 
resulted in an impaired assembly of the 
55S mitoribosome. 
 The GTPase activities of mammalian 
NOA1 and its bacterial homologue 
YqeH are stimulated by ribosomal 
components from  Escherichia coli 
 To gain further insight into NOA1 func-
tion, we purifi ed mammalian NOA1 as 
well as its bacterial homologue YqeH from 
 B. subtilis . Both mitochondrial NOA1 and 
bacterial YqeH showed a high and com-
parably strong intrinsic GTPase activity 
( Figure 6A ). This observation was not 
made with other G-factors involved in 
translation, such as elongation factor G 
(EF-G), which can be stimulated exclu-
sively by 70S ribosomes during protein 
synthesis and is boosted by empty 
70S uncoupled from protein synthesis 
(Gordon,  1970 ;  Qin  et al. , 2006 ). In line 
with a previously proposed role in 30S as-
sembly, YqeH GTPase activity could be 
stimulated by  E. coli 16S rRNA, more than 
twofold, whereas the addition of 23S 
rRNA had no effect ( Figure 6B ), similar to poly(U) addition (data 
not shown). 
 In addition, 21S precursor particles of the 30S subunit stimu-
lated the YqeH GTPase activity rather than mature 30S and 50S 
subunits or 70S ribosomes ( Figure 6C ). In contrast, NOA1 activity 
was stimulated by rRNAs of the small and large ribosomal subunits 
from both mammalian (human) mitochondria (12S and 16S rRNAs) 
and  E. coli (16S and 23S rRNAs) by 40% ( Figure 6D ). Precursor of 
the 30S  E. coli ribosome, the 21S particle prepared by total recon-
stitution (Nierhaus,  1990 ), stimulated NOA1 activity with approxi-
mately the same intensity ( Figure 6E ). Total reconstituted 30S par-
ticles as well as native 30S subunits induced a striking twofold 
increase of GTPase activity. Interestingly, the strongest effect was 
observed with 50S particles, whereas 70S ribosomes showed four 
times less stimulation underlining the specifi city of the observed 
effects. These results suggest an involvement of both bacterial 
YqeH and mammalian NOA1 in ribosomal biogenesis. 
 Altered mitoribosomal profi le in the  Noa1–/– cells 
 Protein synthesis within mitochondria is performed by 55S mito-
ribosomes, each of which consists of a small 28S subunit and a 
large 39S subunit. To determine whether the observed mito-
chondrial protein synthesis defect was due to a ribosomal dys-
function, we compared the mitoribosome sucrose density pro-
fi les of wild type or rescued cells and those lacking  Noa1 . The 
small subunit was traced with antibodies against the mitochon-
drial protein S18b (MRPS18b), which consistently revealed a 
similar profi le between wild type (NOA1+/+) and knockout cells 
(NOA1–/–). Similar levels of the 28S small subunit were found in 
fractions 4 and 5 in the wild type, knockout (NOA1–/–), and com-
plemented cells (NOA1–/– Comp.), but no 55S ribosomes could 
be visualized ( Figure 5C , fractions 8–10). Antibodies against the 
mitochondrial protein L12 (MRPL12), which reacted with the 
large 39S subunit (fractions 6 and 7), revealed the decrease in 
55S ribosomes in the NOA1–/– cell line (fractions 8–10). Further-
 FIGURE 3:  Noa1 is indispensable for placental trophoblast development. In situ hybridization 
on the sections of E8.5, E9.5, and E10.5 wild type and mutant littermate embryos at the 
implantation sites. Boxed areas in the top panels are enlarged in bottom panels. (A)  Noa1 
expression is restricted to the placental trophoblast at E9.5 (arrow). Intense expression in the 
labyrinth and spongiotrophoblast (arrowheads – magnifi cation 1×) and in the trophoblast giant 
cells (arrows – magnifi cation 2×).  Noa1 expression could not be detected in the maternal part of 
the placenta (star) or in the knockout embryos (data not shown). (B) Defect of the trophoblast 
progenitor cell differentiation in the  Noa1–/– mice. 4311/Tbpb is expressed in the trophoblast 
progenitor cells which give rise to glycogen cells and secondary giant trophoblast cells. 
Diminished 4311/Tbpb expression in the E8.5, E9.5 ectoplacental cone. (C) Defect of 
trophoblast giant cell differentiation in E9.5 and 10.5  Noa1–/– embryos visualized by diminished 
expression of placental lactogen I (PLI ). 
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restored caspase-3 activation in  Noa1–/– 
cells (Supplemental Figure S4E). Addition-
ally, mitochondrial membrane potential de-
termined with JC-1 staining was increased in 
knockout cells corroborating the observed 
apoptosis defect (Supplemental Figure S4F). 
Thus, NOA1 is necessary for activation of 
caspase-dependent apoptosis. 
 DISCUSSION 
 In the current study we address both the 
cellular and the developmental function of 
NOA1 by inactivating the gene in mice. The 
vital role of  Noa1 was underlined by a mas-
sively restricted growth and arrested prolif-
eration at ∼E9.5 followed by the death of 
 Noa1–/– mice at ∼E10.5 ( Table 1 and 
 Figures 1 and  2A ). The mitochondria in 
these developing embryos showed aberra-
tions of cristae morphology, whereas other 
organelles appeared not to be affected 
( Figure 2D ). Thus, both the timing of the 
lethality as well as the results of electron mi-
croscopic analysis refl ect the important mi-
tochondrial function of NOA1. Interestingly, 
the developmental defect extended to the 
placental trophoblast, which constitutes 
the interface between maternal and em-
bryonic circulation ( Figure 3B , Supplemen-
tal Figure 1)  (Red-Horse  et al. , 2004 ). The 
defect occurs at a relatively early stage of 
trophoblast differentiation as revealed by 
the diminished expression of 4311/Tbpb, 
demarcating the population of trophoblast 
progenitor cells at E8.5. The dependence of 
trophoblast development on NOA1 func-
tion exposes a crucial role of mitochondria 
in the development of the maternal–fetal 
interface. The importance of mitochondrial 
function in this process is further supported 
by the observation that knockouts of mito-
chondrial fusion factor Mtf2 as well as of 
mito-division factor Drp1 result in a defi -
ciency of trophoblast giant cells ( Chen  et al. , 
2003 ;  Wakabayashi  et al. , 2009 ). 
 The nature of NOA1 mitochondrial func-
tion was investigated in primary knockout 
mouse embryonic fi broblast (MEF) cells. 
 Noa1–/– cells were shown to have impaired 
activities of the electron transfer chain com-
plexes I, III, IV, and V but not of complex II, 
which lends strong support to NOA1 being 
required for expression of the mitochondrial genome. We therefore 
analyzed all stages of mtDNA expression and determined that 
NOA1 defi ciency impairs protein synthesis but does not cause loss 
of mtDNA and/or transcription. Thus, NOA1 appears to be specifi -
cally required for mitochondrial protein synthesis. Sucrose gradient 
centrifugation and Western blot experiments revealed that knock-
out cells exhibit an aberrant migration of the large mitoribosomal 
subunit, indicating that NOA1 is required for correct mitoribosome 
assembly ( Figure 5D ). Involvement of NOA1 in the biogenesis of 
the small mitoribosomal subunit cannot be ruled out at present, 
 Noa1–/– cells are resistant to staurosporine-induced 
apoptosis 
 NOA1 was previously reported to be involved in regulation of apop-
tosis in HeLa cells ( Tang  et al. , 2009 ). To verify whether the mitochon-
drial defects in NOA1-defi cient cells would also be accompanied by 
the impairment of apoptosis, embryonic fi broblasts were treated with 
staurosporine and apoptosis was monitored by accumulation of the 
cleaved caspase-3. A robust caspase-3 activation was detected 24 h 
postinduction in the control cells but was entirely absent in the mutant 
cells ( Figure 7 ). Retroviral reconstitution of NOA1 expression partially 
 FIGURE 4:  OXPHOS defi ciency in  Noa1–/– cells. (A) Cells were permeabilized with digitonin, and 
oxygen consumption was monitored polarographically in the presence of respiratory chain 
substrates and inhibitors. Note a marked decrease of the complex I–, III–, and IV–dependent 
oxygen consumption but not complex II–dependent oxygen consumption. Results represent 
mean ± SD of three independent experiments. (B) Reduced viability of the NOA1-defi cient cells 
was determined with Alamarblue. (C)  Noa1–/– cells show reduced ATP levels upon glucose 
deprivation. See also Supplemental Figure S6 for genetic complementation data. (D) Reduced 
enzymatic activities of the mitochondrial complexes I, III, IV, and V in the knockout cells. In 
contrast, complex II activity was increased. The enzymatic assay values are shown standardized to 
CS E3 activity. Results represent mean ± SD of three independent experiments. (E) In-gel activity 
(IGA) of complex I is decreased in knockout cells. Blue native electrophoresis (BN) showing 
reduction in quantities of the assembled complexes I, III, IV, and V and accumulation of the 
unassembled complex V intermediate (F1) in the homozygous  Noa1 mutant cells. 
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reconstitution intermediate of the small subunit, which is highly 
similar to the native 21S precursor particle (for a review, see 
Nierhaus,  1991 ). The strong stimulation contrasts with the effects of 
23S rRNA and the mature ribosomal subunits, which did not stimu-
late the intrinsic activity of YqeH. This fi nding supports the notion 
that the major activity of the bacterial YqeH is related to the early 
assembly phase of the small subunit. Interestingly, mammalian 
NOA1 was stimulated both by the bacterial 50S large ribosomal 
subunit and by the 30S small subunit. To a lesser degree, NOA1 
was also stimulated by naked rRNAs and precursor 21S particles, 
whereas only residual stimulation was observed with full 70S ribo-
somes. These data show that NOA1, like its bacterial homologue 
YqeH, has GTPase activity that is stimulated by the bacterial ribo-
somal constituents. The apparent difference in NOA1 and YqeH 
specifi city likely refl ects their evolutionary divergence. Indeed, 
NOA1 contains an ∼100-amino-acid insertion in the GTP-binding 
domain, which is absent from bacterial YqeH and  Arabidopsis 
NOA1 proteins. The latter could explain the differences in protein 
however. In this study our choice of antibodies against mouse small 
mitoribosomal subunit was limited to anti-MRPS18b, which did not 
show any defect. Several other commercially available anti-MRP an-
tibodies were tested, but none were capable of cross-reactivity with 
murine MRPs (data not shown). 
 Our knowledge about mitochondrial ribosome biogenesis and 
function is essentially based on the studies of bacterial and yeast 
model systems. Ribosome assembly comprises the processing and 
folding of pre-RNA and its concomitant assembly with ribosomal 
proteins. A large number of ribosomal constituents as well as non-
ribosomal factors are involved. Among these factors, the GTPases 
(a family of energy-consuming enzymes characterized by the so-
called G-domain) have been shown to play key roles in the assem-
bly of ribosomes in bacteria (Karbstein,  2007 ; Britton,  2009 ). As 
shown here, mitochondrial NOA1, similarly to its bacterial homo-
logue YqeH, has GTPase activity. The intrinsic GTPase activity of 
the  B. subtilis YqeH is strongly and specifi cally stimulated by 
16S rRNA of the small subunit from  E. coli as well as by the 21S 
 FIGURE 5:  NOA1 defi ciency impairs mitochondrial protein synthesis. (A) [ 35 S]methionine labeling of mitochondrial 
protein synthesis in primary embryonic fi broblasts reveals defi cient translation in NOA1 knockout cells. Concentrations 
of protein lysates were calculated by the bicinchoninic acid (BCA) method, and equal loading was confi rmed by 
Coomassie staining following exposure (data not shown). (B) Real-time PCR quantifi cation of the mitochondrial gene 
transcript levels. RNA species encoded by mitochondrial (underlined red) and nuclear (underlined blue) DNA were 
quantifi ed. Data were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and actin expression. 
(C) Cell lysates were fractionated in the 10–30% (vol/vol) isokinetic sucrose gradients and analyzed by Western blots 
with antibodies against MRPL12 (39S mitoribosomal subunit) or MRPS18b (28S mitoribosomal subunit). Representative 
blots were analyzed densitometrically (bottom panel). See also Supplemental Figure S4 for genetic complementation 
data. comp. – knockout cells with retroviral complementation of NOA1 expression. 
Volume 22 January 1, 2011 Targeted inactivation of Noa1 gene in mouse | 7 
lated from the knockout embryos were impaired in staurosporine-
induced apoptosis ( Figure 7A ), and retroviral complementation 
partially reversed this phenotype (Supplemental Figure S4E). 
Importantly, NOA1 inactivation results in hyperpolarization of mito-
chondria, which likely contributes to the phenotype of defective 
apoptosis (Supplemental Figure S4F). In line with that, NOA1 knock-
down in neuroblastoma cells was reported to result in mitochondrial 
hyperpolarization, preventing cytochrome  c release ( Parihar  et al. , 
2008 ). Thus, although the exact molecular mechanism remains to 
be discovered, it is increasingly clear that a group of mitoribosome-
associated proteins, including NOA1, is required for the execution 
of programmed cell death. 
 Interestingly, NOA1 appears to play a similar role in plants, as 
 Arabidopsis NOA1 (formerly atNOS1 [Arabidopsis thaliana nitric 
oxide synthase 1] ) was shown to localize to plastids, where it is 
necessary for protein synthesis ( Flores-Perez  et al. , 2008 ). Simi-
larly, plastidial NOA1 localization was shown in the phytoplank-
ton diatom  Phaeodactylum tricornutum ( Vardi  et al. , 2008 ). Re-
markably, defi cient growth and the greening phenotype of 
atNOA1-defi cient plants could be complemented by  B. subtilis 
YqeH fused to the  Arabidopsis NOA1 organelle localization se-
quence ( Flores-Perez  et al. , 2008 ), clearly demonstrating that 
YqeH is a functional orthologue of plastid-localizing atNOA1. 
Like mitochondria, plastids are believed to have originated from 
target recognition ( Zemojtel  et al. , 2004 ). These data, together with 
the observed aberrant migration of the large ribosomal subunit in 
the  Noa1 knockout cells, further suggest a possible involvement of 
NOA1 in the mitoribosome biogenesis. 
 Several proteins involved in mitochondrial protein synthesis have 
been shown to be involved in the process of apoptosis. Among 
them were mitoribosomal GTP-binding protein MRPS29/DAP3 
(death-associated protein 3), MRPS30/PDCD9 or p52 (programmed 
cell death protein 9), and a protein with an apparent dual cell 
protective as well as pro-apoptotic function PDCD8/AIF (apoptosis-
inducing factor)  (Cavdar Koc  et al. , 2001 ; O’Brien,  2002 ;  Cheung 
 et al. , 2006 ). Interestingly, DAP3 was among several ribosomal pro-
teins recently shown to interact with NOA1 ( Tang  et al. , 2009 ). 
 Similarly to DAP3, NOA1 appears to be necessary for 
mitochondria-dependent apoptosis. The primary fi broblasts iso-
 FIGURE 7:  Noa1 -defi cient cells are resistant to staurosporine -induced 
apoptosis. Embryonic fi broblasts were cultured on coverslips in the 
presence of increasing concentrations of staurosporine. Apoptosis 
was monitored by measuring activation of the caspase-3. (A) The 
caspase-3–positive area was quantifi ed using ImageJ software and 
corrected for the cell number. Representative microscopic pictures are 
shown (data represent mean of at least 10 evaluated images with SEM 
as error bars). (B) Western blot with anti-activated caspase-3 
antibodies. Blots were stripped and probed with the antibody against 
GAPDH for loading control. 
 FIGURE 6:  GTPase activities of NOA1 and YqeH are differently 
stimulated by ribosomal components from  E. coli . (A) Intrinsic GTPase 
activities of NOA1 and YqeH at 30°C. (B) Specifi c stimulation of YqeH 
GTPase activity by  E. coli 16S rRNA at 30°C. (C) Specifi c stimulation of 
YqeH GTPase by equimolar amounts of  E. coli 30S precursors (21S) in 
comparison to total reconstituted 30S subunits (21S+TP30), ribosomal 
subunits (30S, 50S), and 70S ribosomes at 20°C. (D) Stimulation of 
NOA1 GTPase by equimolar amounts of mitochondrial rRNA (mt12S, 
mt16S) and  E. coli rRNA (Ec16S, Ec23S) at 20°C. (E) Stimulation of 
NOA1 GTPase by equimolar amounts of  E. coli 30S precursors before 
(21S) and after total reconstitution of 30S particles (21S+TP30), 
ribosomal subunits (30S, 50S), and 70S ribosomes at 20°C. 
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(Sigma). Cells were processed 18 h later for immunofl uorescence by 
fi xing in 4% PFA and 1× PBS for 10 min and permeabilizing with 
0.4% Triton X-100, 3% BSA, and 1× PBS for 10 min at 4°C. Incuba-
tion with an antibody against activated caspase-3 (Cell Signaling 
Technology) 1:400 was performed overnight in 3% BSA at 4°C. For 
visualization, an anti–rabbit immunoglobulin G (IgG) Alexa Fluor 488 
(Invitrogen, Molecular Probes) conjugate was applied. Nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI), and cells were 
mounted in Fluoromount (Scientifi c Services, Sparrow Bush, NY). 
Cells were photographed using a fl uorescence microscope (BX60; 
Olympus, Center Valley, PA) or scanning microscope (LSM510meta; 
Zeiss, Jena, Germany ). For each treatment, at least 10 images were 
evaluated with ImageJ software. Experiments were repeated at 
least three times, and more than 1,000 cells per sample were 
counted. 
 Immunocytochemistry 
 Cells grown on gelatin-coated coverslips were fi xed with 4% PFA 
and permeabilized in PBS/0.1% Triton X-100. Nonspecifi c binding 
was reduced by blocking with 5% bovine calf serum in PBS, and the 
cells were incubated with primary antibody in 1% BSA/PBS. 
 In situ hybridization 
 Embryos in deciduas were fi xed overnight at 4°C in 4% PFA, dehy-
drated through an ethanol and xylene series, and embedded in par-
affi n blocks. Sections (6 µm) were cut in a transverse plane with re-
spect to the placenta. Slides were processed for hematoxylin–eosin 
staining and in situ hybridization as previously described ( Vortkamp 
 et al. , 1996 ). Riboprobe template vectors were provided by 
Malgorzata Gasperowicz and James Cross, University of Calgary, 
Canada. For genotyping, embryonic tissue was scraped off 
unstained slides. DNA was recovered and genotyped by PCR. 
 HeLa cell culture and small interfering RNA (siRNA) 
transfections 
 HeLa human cervical carcinoma cells were maintained in DMEM 
medium (4.5 g/l glucose) supplemented with 10% fetal calf serum 
(FCS), penicillin G at 100 IU/ml, streptomycin at 100 g/ml, and 2 mM 
L-glutamate and cultured at 37°C in a humidifi ed atmosphere con-
taining 5% CO 2 and 95% air. The sequence of the sense strand of 
the NOA1 targeting siRNA was (GGUCAUACGUUACUCCAGA) 
dTdT. siRNA was transfected using DreamFect (Oz Biosciences, 
Marseille, France). 60% confl uent cells were transfected with 1 µM 
siRNA (20 nmol of double-stranded RNA [dsRNA]) according to sup-
plied protocol. Following transfection, cells were cultured in DMEM 
containing 10% FCS for 3 days. Cells were harvested 72 h post-
transfection for analysis. HeLa cells transfected with scrambled 
siRNA were used as control. 
 Western blotting 
 Protein lysates were prepared in SDS radioimmunoprecipitation 
assay (SDS RIPA) buffer supplemented with a complete protei-
nase tablet (Roche), 1 mM phenylmethylsulfonyl fl uoride (PMSF), 
1 mM sodium vanadate, and 1 mM sodium fl uoride. The lysate 
concentrations were determined using the Bradford assay (Bio-
Rad, Hercules, CA). Lysates (40 µg of protein per well) were re-
solved in 10% SDS–PAGE and subsequently transferred to poly-
vinylidene fl uoride (PVDF) membranes. The blots were probed 
with the rabbit anti-NOA1 polyclonal antibody generated against 
peptide: CVNVKGQRMKKSVAYK (1:100). Other antibodies used 
were: rabbit anti-actin (1:1,000; Sigma). Blots were developed 
with the Western Lightning® Plus–ECL system (PerkinElmer) . 
eubacterial endosymbionts. Thus mammalian NOA1 is an evolu-
tionarily extremely conserved GTPase, required for protein syn-
thesis in prokaryote -derived organelles. Further investigation 
into NOA1 structure and function is needed to unravel the exact 
mechanisms of its function in relation to mitoribosome and apop-
totic action. The  Noa1 inactivation in mouse, however, demon-
strates that this gene product plays a vital role in mitochondrial 
homeostasis and mammalian development. 
 MATERIALS AND METHODS 
 Tissue isolation and processing 
 BrdU solution (10 µl of 10 mM solution/1 g of mouse body weight) 
was injected intraperitoneally into pregnant mice 1 h before the 
mice were killed. Embryos were dissected from deciduas using an 
inverted microscope (Leica, Wetzlar,  Germany). Whole embryos 
were photographed in phosphate-buffered saline (PBS) using a 
microscope-mounted digital camera (Leica, Germany). Embryonic 
stages were estimated by timed pregnancies and somite counts. 
The embryos were fi xed in 4% paraformaldehyde (PFA) pH 7.4, de-
hydrated in ethanol, and paraffi n embedded. The specimens were 
sectioned at 6 µm, stained with hematoxylin–eosin or processed for 
immunohistochemical staining. 
 MEF culture 
 Eviscerated embryos were collected in U-bottomed 96-well plates, 
cut into small fragments with dissection forceps, and digested in 
25-µl of cell culture grade, 0.5% wt/vol trypsin at 37°C for 20 min. 
Subsequently, they were dispersed by pipetting and plated into 
one well of the 96-well, fl at-bottomed plate in 200 µl of fresh DMEM 
containing glucose at 1 g/l, 10% fetal bovine serum (FBS), 2% pen-
icillin/streptomycin, L-uridine at 50 µg/ml (Sigma, St. Louis, MO), 
0.1 mM nonessential amino acids (Invitrogen, Carlsbad, CA), 1 mM 
sodium pyruvate (Sigma), and 10% Amniomax C-100 supplement 
(Invitrogen). The medium was changed every second day until cells 
reached confl uence. Cells were subsequently expanded and con-
tinuously passaged until spontaneously immortalized colonies were 
derived. Cells were cultured at 37°C in 95% air / 5% CO 2 . 
 Retroviral infection 
 BOSC23 packaging cells were transiently transfected with a retro-
viral vector expressing mouse  Noa1 (pQCXIP-mNOA1) using the 
CalPhos Mammalian Transfection Kit (Clontech Laboratories, 
Mountain View, CA ). Retroviral stocks were collected 48 h post-
transfection.  Noa1- defi cient MEFs were infected with the retrovi-
rus in the presence of 6 µg of polybrene and selected for 4 days 
with puromycin at 2.5 µg/ml . 
 Immunofl uorescence 
 For BrdU detection, sections were pretreated by 2N HCl treatment 
and incubated with a monoclonal antibody against BrdU (1:50; 
Roche Diagnostics, Indianapolis, IN ). Apoptotic cell death was visu-
alized in the whole mount specimens with antibodies against acti-
vated caspase-3 (Cell Signaling Technology, Danvers, MA). Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) as-
says on the paraffi n sections were performed using the In Situ Cell 
Death Detection Kit (Roche Diagnostics ) following the manufactur-
er’s protocol. Alexa-568 and/or Alexa-488 conjugated goat anti–
rabbit secondary antibodies were used in all experiments. 
 Quantifi cation of immunofl uorescence staining 
 Embryonic fi broblasts were seeded on coverslips. After 12 h, the 
cells were treated with increasing concentrations of staurosporine 
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 Analysis of mitochondrial protein synthesis 
 In vitro pulse labeling of mitochondrial translation products was 
performed as described elsewhere ( Boulet  et al. , 1992 ), with a 
few adaptations. In brief, cells were labeled for 60 min at 37°C in 
L-methionine–free and L-cysteine–free DMEM with 10% dialyzed 
FCS, [ 35 S]methionine and [ 35 S]cysteine at 200 µCi/ml (Tran35S-
Label; MP Biomedicals, Eindhoven, The Netherlands), and 
emetine at 100 µg/ml, and were subsequently chased for 10 min 
in regular DMEM with 10% FCS. Total cellular protein was resus-
pended and incubated for 10 min in PBS containing 2% lauryl 
maltoside. Unsolubilized material was removed by centrifugation 
at 10,000 ×  g for 10 min. The protein concentration was deter-
mined (Micro BSA Protein Assay Kit; Pierce ) and loading buffer 
was added to the supernatant 1:1 (Tricine Sample Buffer; Thermo 
Fisher Scientifi c, Rockford, IL). The samples were separated 
through 16% polyacrylamide gels and subsequently scanned on 
a FLA5100 (Fujifi lm Life Science, Düsseldorf, Germany). Equal 
protein loading was confi rmed using colloidal Coomassie Blue 
staining (data not shown). 
 Isokinetic sucrose gradient analysis of mitochondrial 
ribosomes 
 Cell lysis was performed in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
1 mM EDTA, 1% Triton X-100, + PI-Mix, 1 mM PMSF, and 10 mM 
MgCl 2 for 30 min at 4˚C. After a 10-min incubation, lysate was 
clarifi ed by centrifugation at 12,000 ×  g at 4˚C. Approximately 
0.9 mg of supernatant was loaded onto a linear sucrose gradient 
(10–30% [vol/vol], 1 ml) in 50 mM Tris-HCl, pH 7.2, 10 mM 
Mg(OAc) 2 , 40 mM NH 4 Cl, 100 mM KCl, 1 mM PMSF, and chloram-
phenicol at 50 µg/ml and centrifuged for 2 h 15 min at 100,000 × 
 g at 4˚C. Fractions of 100 µl were collected, and 10 µl of each frac-
tion was analyzed by Western blot. Antibodies used were anti-
MRPS18b (ProteinTech Group, Chicago, IL) and anti-MRPL12 
(Abcam, Cambridge, MA). 
 Quantitative RT–PCR 
 cDNAs were synthesized from 1 µg total RNAs with murine leuke-
mia virus (MuLV) reverse transcriptase (Applied Biosystems, 
Carlsbad, CA). TaqMan universal PCR was then performed on an 
ABI PRISMs 7900 cycler (Applied Biosystems), using the SYBR 
green method according to the manufacturer’s instructions. Tran-
scripts of the following genes were monitored: NOA – NOA1, 16S 
RNA, 12S RNA, ND1 – NADH dehydrogenase subunit 1; ND6 – 
NADH dehydrogenase subunit 6, CytOx1 – Cyt  c oxidase subunit 
1, CytOx2 – Cyt  c oxidase subunit 2, cytB – cytochrome  b , ATP6 – 
ATP synthase F0 subunit 6, EF-Tu – Elongation Factor Tu, L20 – 
mitochondrial ribosomal protein L20, AIF – apoptosis inducing 
factor (see also supplemental primer list). 
 mtDNA analysis 
 The mtDNA/nuclear DNA (mtDNA/nDNA) ratio was estimated us-
ing qPCR with primers specifi c for mtDNA-encoded  Cox1 gene 
(subunit 1 of cytochrome  c oxidase) and nuclearly encoded  Ndufv1 
gene (NADH:ubiquinone oxidoreductase) (see supplemental primer 
list). DNA quantifi cation was repeated fi ve times in independent 
qPCR reactions, and an average mtDNA/nDNA ratio was calculated. 
All values were expressed as means ± SD. 
 Mitochondrial genome integrity was tested using primers listed 
in the supplement and the Expand Long Template PCR System 
(Roche) according to the manufacturer’s protocol. PCR conditions 
were: 94°C for 3 min; 10 cycles: 94°C for 10 s, 65°C for 30 s, 68°C 
for 16 min; 20 cycles: 94°C for 10 s, 65°C for 30 s, 68°C for 16 min 
 TEM 
 Whole E9.5 embryos were fi xed with 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer solution (pH 7.3) at 4°C, washed, and postfi xed in 
2% osmium tetroxide in the same buffer. Samples were dehydrated 
in ethanol, then embedded in Eponate 12 epoxy resin (Serva, 
Heidelberg, Germany) and sectioned on a Reichert-Jung Ultracut 
microtome (Leica, Wetzlar, Germany) . Semithin sagittal sections of 
whole embryos were stained with methylene blue-azure to locate 
and mark the somite regions. The ultrathin sections were prepared, 
stained with uranyl acetate followed by lead citrate, and imaged 
using an EM906 Zeiss (Oberkochen, Germany) electron microscope 
at 80 kV. 
 Optical tomography (OPT ) 
 The OPT method was used to visualize embryos in three dimensions 
(3D). The method accumulates projection images of an entire speci-
men from many different angles, and recalculates the original 3D 
structure by using a “back-projection” reconstruction algorithm 
( Sharpe  et al. , 2002 ). OPT scans were performed in UV light using a 
GFP1 fi lter for detection of the embryos’ autofl uorescence using 
IPLab software from Scanalytics (Rockville, MD). Results were 
exported to QuickTime movies. 
 Polarography 
 MEFs and siRNA-treated HeLa cells were trypsinized, washed 
twice with PBS, and permeabilized with digitonin at 50 µg/ml. The 
optimum incubation time for permeabilization (50 s for MEFs; 
120 s for HeLa) was determined in separate time series for each 
cell line and defi ned as the shortest duration after which 99% of 
the cells were trypan blue positive. Additionally, we verifi ed ade-
quate mitochondrial coupling by measuring the increase of respi-
ration after decoupling with DNP (2,4-dinitrophenol) in compari-
son to the state IV respiration without ADP. The DNP / state IV 
respiration rates were 1.7 ± 0.1 in wild-type cells and 1.8 ± 0.2 in 
the knockout MEF cells. The cells (1 × 10 7 ) were resuspended in 
reaction buffer and introduced into the reaction chamber of a 
Clark-type electrode (Hansatech Instruments, Norfolk, England), 
and oxygen concentrations were measured in 1-ml volumes at 
37°C with substrates and inhibitors according to standard proto-
cols ( Hofhaus  et al. , 1996 ). After completion of the polarographic 
measurement, cells were collected and DNA quantifi ed using a 
Quant-iT PicoGreen DNA kit (Invitrogen) according to the supplied 
protocol. Oxygen consumption was given as mean ± SD nmol O 2 
per minute per µg of DNA ( n ≥ 4). 
 Blue-native PAGE and complex I in-gel activity assay 
 Blue-native PAGE was used for separation of the OXPHOS com-
plexes on 5–15% polyacrylamide-gradient gels as described before 
( Calvaruso  et al. , 2008 ). After electrophoresis of 40 µg of protein 
from MEFs, gels were further processed for in-gel activity assays and 
Western blotting. Assembly of the OXPHOS complexes was ana-
lyzed using monoclonal antibodies against subunits of complex I 
(NDUFA9, NDUFS3), complex III (Core2), complex V (α-ATPase) 
(Molecular Probes, Leiden, The Netherlands), and complexes II 
(SDHA) and IV (CoxVa) (MitoSciences, Eugene, OR). 
 OXPHOS enzyme complex measurements 
 The activities of the OXPHOS enzyme complexes were measured in 
MEFs as described previously (Lazarov and Cooperstein,  1951 ; 
 Smeitink  et al. , 2001 ;  Janssen  et al. , 2003 ,  2007 ). Citrate synthase 
(CS) activities were determined in cultured fi broblast as previously 
described (Srere,  1969 ). 
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subunit (TP30) for 30 min at 40°C in 15 ml of Rec20 buffer: 20 mM 
HEPES-KOH (pH 7.6 at 0°C), 20 mM Mg(acetate) 2 , 400 mM 
NH 4 (acetate), and 4 mM β-mercaptoethanol (for details, see 
Nierhaus,  1990 ). Subsequently, poly(U)-dependent poly(Phe) syn-
thesis was performed with 6 pmol of reconstituted particles, which 
were incubated at 37°C for 1 h in 40 µl with 6 pmol of 50S subunits, 
13.4 µg of bulk transfer RNA (tRNA bulk ), 33.4 µg of poly(U), 10 nmol 
of phenylalanine (23 dpm/pmol), 3.33 µl of S100 enzymes in the 
presence of 20 mM HEPES-KOH (pH 7.6 at 0°C), 6 mM Mg(acetate) 2 , 
150 mM NH 4 (acetate), 4 mM β-mercaptoethanol, 2 mM spermidine, 
0.05 mM spermine, 3 mM ATP, 1.5 mM GTP, and 5 mM acetyl 
phosphate. The reaction mix (35 µl) was subjected to hot trichloro-
acetic acid (TCA) precipitation and fi ltered through glass fi lters. 
Control reconstitutions were performed at 20°C for 1 h, but other-
wise under identical conditions in the presence and absence of 
9 pmol of YqeH. The  B. subtilis YqeH factor did not accelerate the 
 E. coli reconstitution process of the 30S subunit. 
 Preparation of 21S particle 
 600 A 260 units of 16S rRNA and 240 e.u. of TP30 were reconstituted 
for 30 min in ice water. The incubated sample was centrifuged 
through a 10–30% sucrose gradient containing Rec20 in a Beckman 
Zonal rotor at 24,000 rpm for 19 h at 4°C. Fractions containing the 
heavy shoulder of the 21S peak were collected and the particles 
were pelleted and resuspended in Rec20 buffer. Protein content of 
the 21S particles was determined by two-dimensional electrophore-
sis, and the following proteins were detected: S4, S5, S7, S8, S9, 
S13, S14, S15, S16, and S18. The proteins S1 and S20 could not be 
resolved on the 30S control. The intactness of the rRNA was con-
fi rmed by RNA electrophoresis. Controls containing the 21S parti-
cles were subjected to a reconstitution incubation in the presence of 
TP30 and checked for poly(Phe) synthesis in the presence of mature 
50S subunits. The results confi rmed that the 21S particles were 
authentic intermediates, which could be processed to active 30S 
subunits. 
 GTPase assay 
 The assay was performed in a 50-µl reaction volume under opti-
mized ion conditions (20 mM HEPES-KOH [pH 8.0 at 0°C], 4.5 mM 
Mg(acetate) 2 , 150 mM K(acetate), 2 mM spermidine, 0.05 mM sper-
mine, and 4 mM β-mercaptoethanol). The incubation mixture con-
tained 10 pmol of YqeH or NOA1, 2.5 nmol of [γ 32 P]GTP (20 dpm/
pmol), and the indicated amounts of rRNA, 21S particles, or ribo-
somal subunits. Samples were incubated either 1 h at 30°C or 6 h at 
20°C, and the reaction was stopped by the addition of 120 µl of 
0.5 M H 2 SO 4 and 1.5 mM NaH 2 PO 4 . The released γ-phosphate was 
extracted by mixing the samples with 30 µl of 200 mM MoNaO 4 and 
800 µl of water-saturated 2-butanol. Samples were vortexed for 
1 min followed by centrifugation at 16,000 ×  g for 10 min at 4°C. 
The radioactivity obtained in the butanol phase was measured in a 
Wallac 1409 Liquid Scintillation Counter . 
 All animal experimental procedures were approved by the local 
animal ethics commission, State Offi ce of Health and Welfare Berlin 
(LAGeSo). 
(+20 s/cycle). For detection of shorter products, elongation time was 
reduced to 8 min. 
 ATP assay 
 ATP levels were measured with the ATPlite Bioluminescence Assay 
kitSystem (Roche). Cells were trypsinized after a 36-h incubation 
time in culture medium with (4.5 g/l) or without glucose. The cells 
were washed once in PBS and resuspended in the kit’s dilution 
buffer. 
 Viability assay 
 Viability was measured with an alamarBlue assay according to sup-
plied protocol (Invitrogen ). Defi ned cell numbers were plated in 96-
well formats, and the resazurin substrate reduction was monitored in 
the cell culture medium by measuring the accumulation of the fl uo-
rescent resorufi n (excitation at 530 nm, emission at 590 nm). 
 Preparation of rRNA 
 16S rRNA and 23S+5S rRNA of  E. coli were prepared by phenol 
extraction followed by ethanol precipitation starting with purifi ed 
30S and 50S ribosomal subunits, respectively (Lietzke and Nierhaus, 
 1988 ). The genes coding for the mitochondrial 12S and 16S rRNA 
were amplifi ed from human mtDNA using the primers mt12S fw and 
mt12S rev or mt16S fw and mt16S rev, leading to the fusion of a T7 
promoter sequence at the 5′-end of the genes. PCR fragments were 
digested with  Hind III and  Eco RI and cloned into pSP65 cleaved 
with the same enzymes. Transcription of the genes was performed 
in vitro using T7 RiboMAX Express (Promega, Madison, WI) 
with the new constructed plasmids (linearized with  Eco RI) as tem-
plate. Transcribed RNA was purifi ed by gel fi ltration and ethanol 
precipitation. 
 Cloning, expression, and purifi cation of  B. subtilis YqeH and 
human NOA1 
 The gene coding for  B. subtilis YqeH was amplifi ed from genomic 
DNA by PCR and cloned into pET28a (Novagen, Merck KGaA, 
Darmstadt, Germany ) via  Nde I and  Xho I, leading to an N-terminal 
His-tag fusion. The correct sequence was confi rmed by sequenc-
ing. The gene was expressed in BL21(DE3) and the protein purifi ed 
via Ni-NTA agarose (Qiagen, Valencia, CA, according to the manu-
facture’s manual) followed by anion exchange chromatography 
(MonoQ, GE Healthcare, Piscataway, NJ). The protein was fi nally 
dialyzed against 20 mM HEPES·KOH (pH 8.0 at 0°C), 6 mM 
Mg(acetate) 2 , 150 mM K(acetate), and 4 mM β-mercaptoethanol. 
 Full-length cDNAs for human NOA (IRALp962E057Q2) was ob-
tained from the German Resource Center for Genome Research 
(RZPD, Berlin). The gene coding for Δ 25a.a.-hNOA1 protein 
(hNOA1 without mitochondria targeting sequence – 25 amino acids 
of N terminus) was amplifi ed by PCR and cloned into pGEX-6P 
(Amersham Pharmacia Biotech, Buckinghamshire, UK) via  Eco RI and 
 Xho I leading to an N-terminal GST-tag fusion. The gene was 
expressed in BL21-CodonPlus (DE3)-RP (Stratagene, Santa Clara, 
CA ), and the protein was purifi ed via Glutathione Sepharose 4B 
(Amersham Pharmacia Biotech, Piscataway, NJ) using PBS buffer pH 
6.2 supplemented with 1% Triton X-100, according to the manufac-
ture’s manual. The protein was fi nally dialyzed against 50 mM Tris, 
pH 7.0, at 4°C, 150 mM NaCl and concentrated using Centriprep 
YM-10 (Amicon, Bedford, MA ). 
 30S reconstitution and poly(Phe) synthesis 
 0.125 A 260 unit of 16S  E. coli rRNA equivalent to 9 pmol was incu-
bated with 0.05 equivalent units (e.u.) of total proteins of the 30S 
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Translation termination in human mitochondrial
ribosomes
Ricarda Richter, Aleksandra Pajak, Sven Dennerlein, Agata Rozanska, Robert N. Lightowlers
and Zofia M.A. Chrzanowska-Lightowlers1
Mitochondrial Research Group, Institute for Ageing and Health, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, U.K.
Abstract
Mitochondria are ubiquitous and essential organelles for all nucleated cells of higher eukaryotes. They contain
their own genome [mtDNA (mitochondrial DNA)], and this autosomally replicating extranuclear DNA encodes
a complement of genes whose products are required to couple oxidative phosphorylation. Sequencing of
this human mtDNA more than 20 years ago revealed unusual features that included a modified codon
usage. Specific deviations from the standard genetic code include recoding of the conventional UGA stop to
tryptophan, and, strikingly, the apparent recoding of two arginine triplets (AGA and AGG) to termination
signals. This latter reassignment was made because of the absence of cognate mtDNA-encoded tRNAs, and
a lack of tRNAs imported from the cytosol. Each of these codons only occurs once and, in both cases, at the
very end of an open reading frame. The presence of both AGA and AGG is rarely found in other mammals,
and the molecular mechanism that has driven the change from encoding arginine to dictating a translational
stop has posed a challenging conundrum. Mitochondria from the majority of other organisms studied use
only UAA and UAG, leaving the intriguing question of why human organelles appear to have added the
complication of a further two stop codons, AGA and AGG, or have they? In the present review, we report
recent data to show that mammalian mitochondria can utilize a − 1 frameshift such that only the standard
UAA and UAG stop codons are required to terminate the synthesis of all 13 polypeptides.
Introduction
Mitochondria are vital organelles that are present in all
nucleated cells of higher eukaryotes. Theyplay critical roles in
many processes, including calcium homoeostasis, apoptosis,
Fe–S cluster formation and oxidative phosphorylation.
Mitochondria contain their own genome (mtDNA, where mt
is mitochondrial) encoding mt-mRNAs that are translated
within the organelle [1]. In humans, these transcripts
encode 13 proteins that are all components of the oxidative
phosphorylation machinery, in addition to the two mt-
rRNAs and 22 mt-tRNAs, which are required for the
intramitochondrial translation of the mt-mRNAs. The
remaining protein components required for intra-organellar
translation andmitochondrial biogenesis are nuclear-encoded
and need to be imported from the cytosol. Human mtDNA
is a relatively small genome (16569 bp) and is found in
many copies per mononucleate cell. A minimal non-coding
sequence is present, which contains regions that control the
initiation of mtDNA replication and transcription. From
these regions, this compact genome is almost fully transcribed
from both strands [2]. As a consequence, long polycistronic
transcriptional units are generated, which are subsequently
processed to separate the mt-rRNA, mt-tRNAs and mt-
mRNAs, and are then matured [2,3]. For the mt-tRNAs,
Key words: mitochondrion, protein synthesis, release factor, stop codon, translation termination.
Abbreviations used: IF, initiation factor; mt, mitochondrial; ORF, open reading frame; RF, release
factor; RRF, ribosome recycling factor; UTR, untranslated region.
1To whom correspondence should be addressed (email Z.Chrzanowska-Lightowlers@
ncl.ac.uk).
this involves the addition of -CCA to the 3′-teminus of
the precursor by the tRNA-nucleotidyltransferase, a protein
encoded by TRNT1 [4]. The 3′-termini of the mt-mRNAs
are also matured, but by the addition of a poly(A) tail. This
modification appears to be constitutive and is effected by
mtPAP, a nuclear-encoded poly(A) polymerase that is specific
to mitochondria [5]. In contrast with cytosolic mRNAs, their
mitochondrial counterparts lack any modification to the 5′-
termini and remain as a simple 5′-PO4. Another contrasting
feature is the relative lack of UTRs (untranslated regions),
leaving most ORFs (open reading frames) unflanked. Thus
initiation commences at or within three nucleotides of the
extreme 5′-termini for all except two of the ORFs, whereas
completion of the UAA stop codon is facilitated by the
addition of ‘A’ residues as a consequence of polyadenylation
of seven ORFs.
Protein synthesis in the human
mitochondrion
Initiation of protein synthesis occurs mainly at AUG codons,
but AUA and AUU can also be decoded as initiating
methionines [1]. Comparedwith translation in the eukaryotic
cytosol, where there are many IFs (initiation factors) that
come together to form the initiation complex, there appears
to be a much reduced system in mammalian mitochondria.
In the latter, the initiation complex appears to have retained
only two homologues: IF2 and IF3 [6,7]. It does appear,
however, that mtIF2 may have taken on the functions of
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bacterial IF1 [8]. Elongation proceeds along the mt-mRNA
facilitated by mtEF-Tu, mtEF-Ts and mtEF-G1 [9–12].
Another major difference lies in the general structure of the
mammalian mitochondrial ribosome when compared with
the more familiar bacterial 70S and eukaryotic cytosolic 80S
counterparts [13]. Rather than a predominance of rRNA,
mammalian mitochondrial ribosomes have reduced the
RNA component to two shorter rRNA species, 12S and
16S, while concomitantly increasing the number of protein
components, thus reversing the conventional ratio to ∼70%
protein and only ∼30% rRNA. As a consequence, the
structure is more open and porous with no conventional
E-site and with altered sedimentation values of 28S and 39S
for the small and large subunits respectively and 55S for the
complete monosome [13].
Termination of protein synthesis in human
mitochondria
The 55S particle continues protein synthesis until a
stop codon is reached and positioned within the A-site.
Sequencing of the human mtDNA almost 30 years ago
[1] revealed the features mentioned above. This included
the reassignment of the standard stop codon UGA as a
tryptophan, a not uncommon reassignment in mitochondrial
genetic codes. Strikingly, it also indicated the apparent
recoding of AGA and AGG as stop signals since each of
these triplets is found only once and, in both cases, only
at the very end of the ORFs of mitochondrial transcripts
MTCO1 orMTND6 respectively. The conclusion that these
were now stop signals was driven by the fact that the
mtDNAdoes not code for any tRNAthat could decode either
AGA/AGG triplets and no tRNA has been shown to be
imported physiologically into the human organelle [14]. The
remaining 11 mitochondrial ORFs terminate in either of
the two standard stops, UAA or UAG. The original dilemma
was therefore what form of the class I RF (release factor)
would be required to promote peptidyl-tRNA hydrolysis
at these stop codons? Do human mitochondria follow the
bacterial paradigm where two RFs are required to decode
the three stop codons (RF1 recognizing UAA/UAG, and
RF2 showing specificity for UGA/UAA [15,16]), or do they
utilize a single RFmore akin to eRF1 (eukaryotic RF1)/aRF1
(archaeal RF1) in the eukaryotic or archaeal cytosol respect-
ively [17,18]? A single mitochondrial RF, however, would
have to recognize an unusual and expanded repertoire of four
triplets.
Over 12 years ago, bioinformatic mining identified an
encouraging candidate for the role of human mtRF1. This
protein contained a predicted decoding tripeptide motif
(comprising proline and threonine with a variable amino acid
between the two and thus designated the ‘PXT’motif) which,
althoughdivergent, alignedmore closelywith that of bacterial
RF1 than RF2 [19]. The PXT motif in mtRF1 is made up of
six amino acids, PEVGLS, rather than just the three, thus
differing from the accepted RF1 type PXT consensus in both
length and sequence. It was considered that these differences,
when taken with a second sequence variation at the tip of
the α-5 helix, could have evolved to allow recognition of this
extended repertoire of stop triplets. Subsequent biochemical
analysis with mtRF1, however, failed to identify any release
activity with any codons. A more recent search for a further
candidate identified a protein, mtRF1a, with high overall
identity with mtRF1 [20]. Analysis of the codon recognition
domains revealed greater similarity to that of the bacterial
RF1 homologue and consensus sequences, with PKT as the
sequence constituting the tripeptide motif. Activity assays
demonstrated that mtRF1a has a specificity for the standard
UAA and UAG codons, but fails to recognize AGA/AGG
or any other codon tested [20]. Since the in vitro assays
are performed with 70S bacterial ribosomes, the lack of
recognition of AGA/AGG by mtRF1 or mtRF1a could
have been the consequence of using a heterologous system,
especially in the light of the significant differences between
55S and 70S particles described above. Further bioinformatic
searches have now revealed a family of four predicted
mitochondrial RFs, with ICT1 and C12orf65 adding to the
previously described mtRF1 and mtRF1a. Intriguingly, these
two new members, ICT1 and C12orf65, both lack the two
regions involved in codon recognition and are therefore
unlikely candidates for AGA/AGG recognition [21].
Reanalysis of the two transcripts containing the AGA or
AGG codons indicated that each of these triplets is directly
preceded by a ‘U’ nucleotide, which, following procession of
the mitochondrial ribosome to the end of the reading frame,
would be placed immediately adjacent, in the P-site [1]. Thus,
by invoking a single nucleotide shift, a conventional UAG
stop signal would be positioned in the A-site. In support
of this hypothesis, although 3′-UTRs are unusual in human
mt-mRNAs, these are present in both of the transcripts
containing in-frame AGA or AGG, and are predicted to
form stable secondary structures [22]. Frameshifting on
mitochondrial mRNAs is not common and no examples
have been identified previously in mammalian mitochondria.
Indeed there are only very few examples in mitochondria,
all of which thus far are in the +1 direction and occur
within the mt-ORFs [23–25]. The frameshifting proposed
in human mitochondria would contrast not only with these
other mitochondrial examples (as it is in the − 1 direction),
but also with all standard frameshifts, as it would occur after
protein synthesis has been completed. Furthermore, many
frameshifts offer an inefficient alternative to readthrough
[26], which can be regulated by changes in physiological
conditions [27]. In the instance of this human mitochondrial
example, there would be no possibility for readthrough, as
there is no cognate mt-tRNA for the AGA/AGG triplets.
We have been able to test this hypothesis by combining the
use of a mitochondrially targeted bacterial A-site-specific
endonuclease, mtRelE, together with sequence analysis of the
resultant cleavedRNA [22]. These finemapping data revealed
the A-site codon at termination and confirmed that a − 1
frameshift does indeed occur. Thus the human mitochondrial
translation system only requires the more standardUAG and
UAA codons for termination. Moreover, as a consequence,
C©The Authors Journal compilation C©2010 Biochemical Society
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only a single RF is required, mtRF1a, which has already been
characterized to show selectivity and specificity for these two
termination signals [20].
Recycling of the human mitochondrial
ribosome following translation
termination
No orthologue of a class II RF has been identified in
human mitochondria, leaving the question of how mtRF1a is
removed from the mitoribosome after translation. Recycling
of the post-termination complex to release the deacylated
mt-tRNA, mt-mRNA and separation of the monosome into
the two subunits is effected by the mitochondrial ribosome
recycling factor, mtRRF, in conjunction with mt-EF-G2
and mt-IF3 [28–31]. This second elongation factor mt-EF-
G2 was characterized recently and appears to play no role
in elongation, but co-operates exclusively with mtRRF in
the recycling process [29]. The eukaryotic 80S and bacterial
70S ribosomes were believed to employ only a single EF-
G for both processes. However, bioinformatic, in vitro and
in vivo data now show that in fact it is not uncommon
for bacteria to have separated the elongation and recycling
activities and have two EF-G paralogues, as is the case in
humanmitochondria [32]. HumanmtRRF has anN-terminal
presequence that targets the protein to the mitochondrion,
but this is not cleaved after successful import into the
matrix of the organelle, as is the case for many of the
nuclear-encoded but mitochondrially destined proteins [28].
Alignment with numerous RRF sequences suggests that the
human mtRRF has a 79-amino-acid N-terminal extension
that lacks homology with other proteins [28]. Since this is
retained in the mature protein, it is tempting to speculate that
it may contain as yet uncharacterized functional domains.
Investigations are ongoing in our group to determine
whether such domains are present and, if so, what their
contribution might be to the process of mitoribosomal
recycling.
In conclusion, mitochondrial translation and termination,
particularly in humans, shares a number of similarities, but
also differs inmanyways from these processes in bacteria and
the eukaryotic cytosol. This is perhaps not surprising, as it
has become clear over the last 30 years that the mitochondrial
protein synthesis machinery has an essential association with
the membrane, reflecting the highly hydrophobic nature
of its translation products, exclusively so in mammals. A
greater understanding of this process is hampered by a lack
of two important factors. First, our inability to manipulate
the mitochondrial genome, which means that it is currently
not possible to investigate the role of any cis-acting elements
in mitochondrial translation. Second, although impressive
reconstituted protein synthesis systems have been reported,
these are essentially hybrid systems and we therefore lack
a faithful reconstituted mitochondrial translation system. If
either of these two issues can be resolved in the near future,
our in-depth understanding of these processes will increase
rapidly.
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A functional peptidyl-tRNA hydrolase, ICT1, has
been recruited into the human mitochondrial
ribosome
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Bioinformatic analysis classifies the human protein en-
coded by immature colon carcinoma transcript-1 (ICT1) as
one of a family of four putative mitochondrial translation
release factors. However, this has not been supported by
any experimental evidence. As only a single member of
this family, mtRF1a, is required to terminate the synthesis
of all 13 mitochondrially encoded polypeptides, the true
physiological function of ICT1 was unclear. Here, we
report that ICT1 is an essential mitochondrial protein,
but unlike the other family members that are matrix-
soluble, ICT1 has become an integral component of the
human mitoribosome. Release-factor assays show that
although ICT1 has retained its ribosome-dependent PTH
activity, this is codon-independent; consistent with its
loss of both domains that promote codon recognition
in class-I release factors. Mutation of the GGQ domain
common to ribosome-dependent PTHs causes a loss of
activity in vitro and, crucially, a loss of cell viability,
in vivo. We suggest that ICT1 may be essential for hydro-
lysis of prematurely terminated peptidyl-tRNA moieties in
stalled mitoribosomes.
The EMBO Journal (2010) 29, 1116–1125. doi:10.1038/
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Introduction
Human mitochondria are ubiquitous organelles that are es-
sential for cell viability. Among many crucial functions,
mitochondria couple the process of oxidative phosphoryla-
tion, where cellular respiration is harnessed to generate ATP.
This demanding mechanism requires the synthesis and import
of many nucleus-encoded proteins as well as the intramito-
chondrial production of 13 polypeptides that are encoded
by the mitochondrial genome, mtDNA. Consequently, correct
maintenance and expression of mtDNA is essential for cell
viability. Although we are gradually learning more about the
principal factors and mechanisms underlying the mainte-
nance and transcription of mtDNA, the process of mitochon-
drial translation has proven extremely difficult to be
characterised in detail. This is in part because isolated mito-
chondria lose their capacity to synthesise proteins after solu-
bilisation of the inner membrane, consistent with loss of
crucial membrane-associated factors. Furthermore, despite
impressive efforts to reconstitute in vitro mitochondrial trans-
lation systems (Yasukawa et al, 2001; Takemoto et al, 2009),
results have been limited. Invaluable contributions from the
laboratories of Spremulli, Watanabe and O’Brien have identi-
fied or characterised constituents of both the bovine small
28S (mt-SSU) (Suzuki et al, 2001) and large 39S (mt-LSU)
(Koc et al, 2001) mitoribosomal subunits and many proteins
involved in translational initiation and elongation (Spremulli
et al, 2004), but important factors remain to be unearthed.
To improve our understanding of this process, we have
started to identify other principal components in mitochon-
drial protein synthesis. We have focused our efforts on a
previous report where tagged mitochondrial ribosome recy-
cling factor (mtRRF) was shown to immunoprecipitate mitor-
ibosomes and associated proteins from mitochondrial lysates
(Rorbach et al, 2008). Proteomic analysis uncovered a large
number (73) of mitoribosomal proteins (MRPs). In addi-
tion, another 94 polypeptides were identified, a number of
which have been tentatively identified as nucleoid proteins.
Immature colon carcinoma transcript-1 (ICT1) was consis-
tently associated with immunoprecipitation (IP), but it was
neither known to be mitochondrial nor have an experimen-
tally verified function, although it is predicted to be a member
of the prokaryote/mitochondrial release factor family (uni-
prot Q14197). This family is intriguing. We have recently
been able to show that of the four family members,
only mtRF1a is necessary and sufficient to terminate the
translation of all 13 mitochondrially encoded polypeptides
(Soleimanpour-Lichaei et al, 2007; Temperley et al, 2010).
What, therefore, is the function, if any, of the three remaining
family members? We report here that a second member of
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this family, ICT1, is a component of the 39S mt-LSU. It has
retained its ribosome-dependent peptidyl-tRNA hydrolase
(PTH) activity that is essential for cell viability.
Furthermore, this ribosome-dependent PTH activity is
codon-non-specific. We speculate that this ribosome-asso-
ciated activity may be involved in the hydrolysis of pepti-
dyl-tRNAs that have been prematurely terminated and thus in
the recycling of stalled mitoribosomes.
Results
ICT1 is an essential mitochondrial protein
To determine the subcellular location of ICT1, western blot
analysis was performed using cell lysate and enriched mito-
chondria. As shown in Figure 1A, a 3- to 5-fold enrichment
was seen for the mitochondrial matrix protein mtRF1a along
with concomitant increase in ICT1. Crucially, ICT1 was
resistant to addition of proteinase-K to intact mitochondria,
but was lost on solubilisation of the organelle. To assess
whether ICT1 is processed on import into mitochondria, full-
length ICT1 (FL) or a truncated form lacking the N-terminal
29 residues (D29) were prepared. Both proteins were ex-
pressed in Escherichia coli as N-terminal glutathione-S-trans-
ferase (GST)-fusion proteins before cleavage and purification
as detailed under Materials and methods. Migration of en-
dogenous ICT1 in comparison with recombinant proteins
(FL/D29) is consistent with cleavage on mitochondrial im-
port, with the loss of B30 residues.
To assess whether ICT1 serves an essential function in
mitochondria, siRNAs were designed to target the transcript.
Two siRNAs were highly efficient in depleting ICT1 from cells
(Figure 1B), causing a morphological alteration and a reduc-
Figure 1 ICT1 is an essential protein necessary for mitochondrial protein synthesis. (A) Human ICT1 is a mitochondrial protein. Cell lysate (CL
50mg, lanes 1, 5) or mitochondria (10mg, lanes 2–4, 6–8) were isolated from HeLa and HEK293T cells and subjected to western blot analysis
either immediately (lanes 1, 2; 5, 6) or after treatment with proteinase-K (lanes 3, 7). Mitochondria were lysed with Triton X-100 to confirm the
sensitivity of marker proteins to the protease (lanes 4, 8). Mitochondrial release factor-1a (mtRF1a) was used as a mitochondrial matrix marker
and ribosomal protein-S6 (S6-RP) as a cytosolic marker. Purified FL (lane 9) and an ICT1 deleted of N-terminal 29 residues (D29, lane 10) are
shown in comparison with the endogenous protein. (B–E) Depletion of ICT1 inhibits cell growth, impairs mitochondrial protein synthesis and
decreases mitochondrial respiratory chain complexes. HeLa cells in standard glucose media were transfected with either of two siRNAs directed
to ICT1 transcript (si-ICT1A or B) or a non-targeting control (si-NT), and cell numbers were counted at 3-day intervals. Standard errors were
derived from three independent experiments (C). Cell lysates were isolated from non-targeting and ICT1-depleted cells (3 days) and subjected
to western blotting for ICT1 (B) and various markers (D). The relative levels for the MRP MRPL3 and respiratory components NDUFB8 or COX2
were quantified (lower panel) with standard errors derived from three independent repeats. (E) After 3-day siRNA-mediated depletion, cells
were subjected to metabolic labelling of mitochondrial proteins for 15 min after inhibition of cytosolic protein synthesis. Aliquots (50 mg) were
separated by 15% SDS–PAGE and exposed to a PhosphorImager. Proteins are identified by comparison against those reported by Chomyn
(1996). A section of the gel stained with Coomassie blue (CBB) following exposure is shown to indicate even loading of cell lysate.
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tion in cell number even when grown on standard, mainly
glycolytic media (Figure 1C). To confirm that effects were
specific and not off-target, cells lacking mtDNA (rho0 cells)
were also transfected with ICT1-specific siRNA and control
siRNAs. The rationale being, as rho0 cells lack mitochondrial
gene expression and are still able to grow on glucose media
supplemented with uridine and pyruvate, depletion of any
protein involved solely in mitochondrial gene expression
should have minimal effect. Accordingly, siRNA-mediated
depletion of b-actin or HSP70 severely compromised the
growth of rho0 cells, whereas growth was unaffected by
depletion of ICT1 or the mitochondrial translation factor
mtEF-Tu (Supplementary Figure S1). These data are
strongly indicative that ICT1 functions in mitochondrial
gene expression.
After only 3 days of ICT1 depletion, a decrease in the
markers of the highly stable mitochondrial respiratory chain
complex-I (NDUFB8) and IV (COX2) was confirmed by
western blotting of HeLa lysates (Figure 1D). Interestingly,
a similar decrease was also noted for the MRP MRPL3,
indicating that levels of mitoribosome and possibly rates of
mitochondrial protein synthesis may be compromised.
Therefore, de novo synthesis of mitochondrial translation
products was assessed by in vivo metabolic labelling.
Figure 1E shows that in the ICT1-depleted cells 35S-met
incorporation is indeed reduced.
ICT1 is a member of the large mitoribosomal subunit
Why does loss of ICT1 lead to reduction in mitochondrial
protein synthesis? To investigate this question and to deter-
mine what components of the mitochondrial matrix asso-
ciated with ICT1, a FLAG-tagged ICT1 was inducibly
expressed in human HEK293T cells, facilitating IP. As
shown in Figure 2A, silver staining uncovered a large number
of proteins, similar to a previous profile where tagged mtRRF
had immunoprecipitated the mitoribosome and associated
proteins (Rorbach et al, 2008). Western blot analysis
(Figure 2B) confirmed the presence of numerous MRPs and
the predicted trace amounts of mtRRF. From proteomic data
of the complete eluate, more than 200 mitochondrial proteins
were identified (Supplementary Table S1), the MRPs being
the most abundant (Supplementary Table S2); consistent with
ICT1 interacting with entire mitoribosomes. As a second
method to determine whether ICT1 was a component of the
mitoribosome, complexes from untransfected cells were se-
parated by isokinetic sucrose density gradients and fractions
were subjected to blotting (Figure 2C). ICT1 co-sediments
with MRPL3 and MRPL12, both components of the 39S mt-
LSU. As has been found in other reports (Nolden et al, 2005;
Williams et al, 2005), the mitochondrial monosome is not
easily identified in cell or mitochondrial lysates by western
blot after density-gradient centrifugation. This was also
evidenced here by the lack of detectable small subunit marker
DAP3 in the more dense fractions (Figure 2C, fractions 7–10).
Therefore, to resolve this issue, we pre-concentrated samples
by first immunoprecipitating mt-LSU and monosomes from
mitochondrial lysates using FLAG-ICT1 and subjected the
entire eluate to an identical gradient centrifugation.
Fractions were then assessed by silver staining and western
blotting. A similar distribution profile is still seen for ICT1
and MRPL3 (excluding free ICT1 caused by overexpression)
(Figure 2D). Crucially, however, DAP3 is now visible in
fractions 7–9, defining the monosomal fractions. Therefore,
ICT1 behaves as an integral member of the 39S mt-LSU and a
component of the intact 55S monosome.
Further support for ICT1 being an integral component of
the 39S mt-LSU, was obtained from ICT1-depleted HeLa cells.
Lysate was subjected to a similar isokinetic gradient, showing
that the mt-LSU marker MRPL3, although present, was
shifted into less dense fractions as compared with that in
cells treated with non-targeting control siRNA (si-NT;
Figure 2E). By contrast, the profile of the 28S mt-SSU protein
DAP3 was unchanged, implying that only assembly of the mt-
LSU and not the mt-SSU is affected on ICT1 depletion.
To confirm that the decrease in mt-LSU assembly observed
in ICT1-depleted cells caused a concomitant decrease in the
level of intact monosome, we used a cell line that expresses a
FLAG-tagged component of the mt-SSU, MRPS27, that was able
to IP both mt-SSU and entire monosome. After 3 days of ICT1
depletion and MRPS27-FLAG induction, FLAG-IP was per-
formed and eluates were blotted (Figure 2F). Levels of DAP3
were unaffected by ICT1 depletion. However, anti-MRPL3 and
MRPL12 antibodies showed a 60% reduction of each of these
proteins in the ICT1-depleted cells, consistent with a decrease
in the monosome formation, presumably due to decreased mt-
LSU assembly. This was also consistent with the decreased 35S
metabolic labelling of mitochondrial proteins as shown in
Figure 1E. Finally, to show that mitoribosomal association of
ICT1 was not simply mediated by the FLAG tag, similar
isokinetic gradients were used to separate the immunoprecipi-
tated eluate from cells expressing MRPL20-FLAG. When
correctly assembled, this FLAG-tagged protein was able to IP
mt-LSU, assembly intermediates and intact monosome. As
show in Figure 2G, ICT1 was clearly associated with mt-LSU
and monosome. These data confirm that ICT1 is an important
component of the complete monosome.
ICT1 is a ribosome-bound, codon-independent PTH
ICT1 is an integral component of the mitoribosome, but on
the basis of homology it is predicted to be a ribosome-
dependent PTH/translation release factor. This is surprising,
as to our knowledge, no other PTH has been shown to be an
integral ribosomal component. There are now four proteins
classified as members of the mitochondrial release factor
family, namely mtRF1a, mtRF1, ICT1 and another unchar-
acterised protein C12orf65 (Figure 3B). Curiously, both ICT1
and C12orf 65 have lost the two domains involved in codon
recognition (a5 and PXT/SPF domain), potentially resulting
in the dangerous situation of release factors that lack codon
specificity. However, none of our previous IPs identified
C12orf65 as a co-precipitant with mitoribosome components
(data not shown). To determine whether ICT1 could promote
hydrolysis of the ester bond between the growing peptide and
the P-site tRNA, we used a well-established assay using
isolated E. coli ribosomes, tritiated fmet-tRNAMet, synthetic
codons and purified ICT1 (Caskey et al, 1971; Tate and
Caskey, 1990; Soleimanpour-Lichaei et al, 2007). In compar-
ison to the exquisite codon selectivity of mtRF1a, ICT1
promiscuously promoted the release of formylmethionine
from its P-site tRNA irrespective of the codon sequence
used to programme the assay and indeed even in the absence
of codons in the A-site (Figure 3C). To determine whether
ICT1 possessed a direct ribosome-independent PTH activity,
or whether it functioned specifically to promote ribosome-
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dependent hydrolysis, purified ICT1 was incubated with
f[3H]met tRNAmet in the absence of ribosomes before extrac-
tion and estimation of standard release factor activity.
No significant increase in counts was noted over background,
confirming that no significant hydrolysis of the substrate
occurred in the absence of the ribosome (Figure 3C).
Figure 2 ICT1 is an integral component of the mitoribosome. (A, B) FLAG-tagged ICT1 immunoprecipitates mitoribosomes. HEK293T cells
expressing FLAG-tagged ICT1 or mitochondrially localised luciferase (mtLuc-FLAG) were induced for 3 days; mitochondria were isolated, lysed
and subjected to IP as detailed. The eluate and mitochondrial lysate before IP (IP-input) were separated by 15% SDS–PAGE and visualised by
silver staining. * designates the FLAG protein. (B) Aliquots of the eluates were also subjected to western blot analysis with the indicated
antibodies: MRPL3, MRPL12, MRPS6 and DAP3 as mitoribosomal markers; mtRRF, mitoribosome recycling factor; SDH, 70-kDa component of
complex-II. (C) ICT1 co-sediments with the large mitoribosomal subunit. HeLa cells were lysed (600 mg), separated through a 10–30% sucrose
gradient and fractionated as detailed (HeLa and HEK293T lysates gave identical separations). Components of the 39S mt-LSU (MRPL3,
MRPL12) and 28S mt-SSU (DAP3) mitoribosomal subunits were visualised by western blotting. On immediate lysis, mtRRF is used as a matrix-
soluble marker. (D) ICT1 also co-sediments with the intact monosome. Mitochondria (3 mg) of ICT1-FLAG-expressing HEK293T cells were
subjected to FLAG IP; the entire eluate was separated by isokinetic density gradients and fractions were blotted as detailed above or visualised
by silver staining (lower panel). Mitochondrial SSU (DAP3) and mt-LSU (MRPL3) MRPs are visualised. The approximate indicators for 28S mt-
SSU, 39S mt-LSU and 55S monosome are shown and were determined as described under Materials and methods. (E) ICT1 is an integral
member of 39S mt-LSU. Cell lysates (600 mg) from ICT1-depleted (si-ICT1B) or non-targeted control cells (si-NT) were separated by isokinetic
gradients and proteins were visualised in the fractions by western blotting as described. Sedimentation markers were identified as above.
(F) Loss of ICT1 causes depletion of the monosome. Cells expressing MRPS27-FLAG were treated with si-NT or si-ICT1B, after which IP was
performed. To assess monosome formation, levels of MRPL3 and MRPL12 were quantified by western blotting of three individual experiments
(right panel; MRPL3 P¼ 0.001, MRPL12 Po0.001, MRPS27 P¼ 0.3). (G) ICT1’s association with mitoribosomes is not FLAG-dependent.
Mitochondria from cells expressing MRPL20-FLAG were subjected to FLAG IP and the eluate was analysed by western blotting after isokinetic
density gradients as described in panel D.
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A mutation of the GGQ domain of ICT1 causes loss
of cell viability
ICT1 is an essential MRP with a ribosome-dependent yet
codon-independent PTH activity, in vitro. Is it possible that
ICT1 needs to maintain this activity when it is assembled into
the mitoribosome, in vivo?
PTH activity of release factors is mediated by the domain
containing the tripeptide motif GGQ (Frolova et al, 1999;
Figure 3A and B). It has been shown that mutations in
either of the two glycine residues completely abolishes in
vitro PTH activity while retaining the structural integrity of
the protein (Frolova et al, 1999). To determine whether the
GGQ domain is critical for ICT1’s function, we reproduced
two of these GGQ mutants by site-directed mutagenesis.
First, recombinant ICT1GSQ and ICT1AGQ were purified,
monodispersion was confirmed by dynamic light scattering,
and then they were subjected to the release assay described
above (Figure 4A). Each retained B1% of peptide-
release activity (GSQ 1.1%, AGQ 0.8% residual activity).
Having confirmed the requirement of the GGQ domain for
the PTH activity of ICT1, it was then possible to assess the
importance of the PTH activity in vivo. If PTH activity is
crucial then replacement of wild-type ICT1 with ICT1GSQ
would be predicted to compromise mitochondrial gene ex-
pression, leading to reduced growth on galactose.
Consequently, an HEK293T cell line was engineered to
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express a FLAG-tagged version of ICT1GSQ and compared
with the wild-type ICT1-FLAG expressor. On induction,
the ICT1 mutant was incorporated into mitoribosomes,
which were assembled at levels similar to that in the
wild-type transfected control (Figure 4B and C), but induction
resulted in a substantial overexpression of ICT1GSQ such
that the majority of the protein remained free and not
mitoribosome-bound (Figure 4C). A similar overexpression
was also noted on induction of wild-type ICT1-FLAG
(Figure 4C, upper panels), which in itself produced a mild
growth phenotype. To reduce the levels of the overexpressed
protein to that of the endogenous untransfected controls and
concomitantly deplete the endogenous ICT1, serial dilutions
of si-ICT1B were used. A concentration of siRNA was
achieved that resulted in levels of FLAG-tagged ICT1 equiva-
lent to that of the untransfected controls (10 nM; Supple-
mentary Figure S2). Using this strategy, growth rates of these
various cell lines were compared, uncovering a slower dou-
bling time in the ICT1GSQ mutant, confirming that ICT1
requires a functional GGQ domain to maintain cell viability
(Figure 4D, 3 cf. 4).
Discussion
Following stringent purification methods, isolation of bovine
mt-SSU, mt-LSU and the 55S monosome has allowed char-
acterisation of many constituents and a low-resolution struc-
ture (Sharma et al, 2003). These data are in agreement that
the mammalian mitoribosome differs substantially from
other ribosomes that have been characterised. In particular,
the 30:70 (w:w) protein-to-RNA ratio is reversed, with only
one reduced rRNA component for each subunit and an
increased number of protein factors, as determined by initial
LCMS, resulting in a larger, more porous structure (O’Brien,
2002). Were some MRPs missed in this original screen? Our
data indicates that ICT1 is indeed one such protein.
ICT1 is classified bioinformatically as one of four members
of the prokaryotic/mitochondrial release factor family. It is
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now known that all 13 mitochondrial encoded polypeptides
terminate translation with the aid of mtRF1a (Soleimanpour-
Lichaei et al, 2007; Temperley et al, 2010). A third member,
mtRF1, has yet to be shown to have release-factor activity,
but, similar to ICT1 and mtRF1a, is an essential mitochon-
drial protein. The final member, C12orf65 currently has an
unknown function, although with a mitochondrial location
(unpublished observation). ICT1 and C12orf65 are signifi-
cantly smaller than the RF1 and RF2 types of class-I bacterial
release factors. Alignments highlight that this loss occurs in
three main regions: the N-terminus and the two sections
(tripeptide motif and the tip of the a-5 helix) that come into
close contact with the mRNA in the ribosomal A-site and
determine the STOP codon specificity (Figure 3). Lack of
these domains is consistent with the loss of codon specificity
noted for ICT1 in this study. By contrast, there is striking
sequence conservation of the GGQ motif. By superimposing
the available structure of the mouse ICT1 on RF1
(Thermotoga maritima) and RF2 (Thermus thermophilus),
it is clear that in all three proteins the GGQ motif reside in
a flexible loop (Figure 3A). Furthermore, although there is
reduced sequence identity in this domain, the structural
features surrounding this motif are highly conserved and
important in positioning the GGQ at the surface of the RF
(Frolova et al, 1999). This suggests that maintaining the way
in which the GGQ motif is presented to the substrate is
important. Curiously, ICT1 contains a stretch of 25 residues
that has no sequence similarity to C12orf65 or the other RFs
(Figure 3B, bold, italics). In the structural superimpositions,
this feature can also be distinguished, primarily in the
unmatched horizontal helix in ICT1. As this feature is lacking
in release factors that interact transiently with the ribosome
and also from C12orf65 that does not IP with the mitoribo-
some, it is possible that this feature is involved in the
integration of ICT1 into the mt-LSU.
What could be the function of a ribosome-bound, codon-
independent PTH and how could its capacity for indiscrimi-
nate peptide release be controlled and positively harnessed?
There are several possibilities. First, if mitoribosomes initiate
translation on 30 truncated or mutated mt-mRNA that lack
termination codons, the terminus of the mRNA will even-
tually reach the P-site and be retained by the anchoring
peptidyl-tRNA but will leave an A-site devoid of mRNA or
release factors to trigger recycling. In the absence of a
mitochondrial analogue to the bacterial tmRNA system that
rescues stalled ribosomes (Keiler et al, 1996), PTH activity
will be needed to liberate the peptide from the peptidyl-tRNA,
forming a substrate that can be recycled. A similar activity
would be necessary to help recycle mitoribosomes that have
prematurely stalled. Alternatively, many genetic studies
have highlighted the necessity of salvaging tRNA species
from prematurely released peptidyl-tRNAs generated
through abortive elongation events during protein synthesis,
a function normally provided by a freely soluble PTH (re-
viewed by Das and Varshney, 2006). To date no human
mitochondrial protein is known to show this activity
(although candidates exist). Our data are consistent with
mammalian mitoribosomes streamlining this process by in-
corporation of a codon-independent PTH activity that can
recognise and hydrolyse peptidyl-tRNAs caught during their
premature release from the mitoribosome (or even from the
mt-LSU if the stalled ribosome dissociates, as has been
suggested for E. coli ribosomes by Varshney and co-workers
(Singh et al, 2008)).
Cryo-EM data of mammalian mitoribosomes uncovers a
feature absent in the bacterial ribosomes. This is a surface
cavity in the mt-LSU near the exit tunnel, described as the
polypeptide-accessible site (PAS) that prematurely exposes
the nascent peptide to the solvent (Sharma et al, 2003;
Figure 5A). It is created by loss of rRNA regions and proteins
orthologous to bacterial components (O’Brien, 2002).
Integration of ICT1 at this mitoribosomal site could allow
access to peptidyl-tRNAs caught on release from the mitor-
ibosome after aborted elongation (Figure 5C). Ribosomes use
substrate-induced fit mechanisms to promote conformation
changes that facilitate either peptide bond formation or
hydrolysis (Schmeing et al, 2005). Premature release of a
peptidyl-tRNA may cause ribosomal distortion, resulting in
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Figure 5 A schematic representation of the putative position and
function of ICT1 in the human mitochondrial ribosome. (A) A
simplified cartoon of the 55S mitochondrial ribosome indicating
the polypeptide exit tunnel and site (PES) and the PAS in the large
subunit as defined by Sharma et al (2003). No orthologues of the
proteins that would occupy the PAS have been found in mammalian
mitochondria, and we postulate that is where ICT1 is positioned
with the GGQ domain inserted deep into the pocket. Sites for the
aminoacyl (A) and peptidyl (P) tRNAs are shown. The mt-mRNA is
depicted between the large and small mt-ribosomal subunits.
(B) Under conditions of normal termination, the ester bond of the
peptidyl-tRNA is positioned close to the peptidyl-transferase centre
(PTC); the release factor, mtRF1a, enters through the A-site, recog-
nising the stop codon (UAA) and aligning the GGQ domain at the
PTC to promote hydrolysis of the ester bond and release of the
nascent peptide. (C) Where abortive elongation occurs, the pepti-
dyl-tRNA may drop away from the P-site towards the PES, aligning
the ester bond close to the GGQ domain of ICT1, promoting
cleavage of the tRNA, which allows both mt-tRNA and truncated
peptide to be released from the mitochondrial monosome (or
potentially from dissociated 39S mt-LSU).
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the juxtaposition of the GGQ motif and peptidyl-tRNA, pro-
moting ester bond hydrolysis in a codon-independent man-
ner. Crucially, this would release the tRNA for recharging.
Clearly, to support any of these hypotheses, it would be of
enormous benefit to generate high-resolution structural data
to identify exactly where in the mitoribosome ICT1 is found.
To date, there are only very limited structural data concerning
the mammalian mitoribosome and producing such structural
data is beyond the scope of this paper. Further experiments
will be necessary to elucidate the exact role of this PTH
activity; however, it is interesting to note that ICT1 is mito-
chondrial, has become incorporated into the mitoribosome,
lost all stop codon specificity, but has acquired another
function of equal importance to mitochondrial translation.
Contrastingly, mtRF1a has retained its RF activity. It is
tempting to speculate on what diverging fates may also
have befallen the other two members of this family.
Materials and methods
Cell culture
Human HeLa cells were cultured (371C, humidified 5% CO2) in
Eagle’s MEM (Sigma) supplemented with 10% (v/v) foetal calf
serum (FCS), 1 non-essential amino acids (NEAA) and 2 mM
L-glutamine. 143B.206 rho0 osteosarcoma cells (provided by R
Wiesner, University of Koeln) were propagated in Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) FCS,
50mg/ml uridine and 1 NEAA. Flp-InT-Rex-293 cells (HEK293T;
Invitrogen) were grown in identical media supplemented with
10 mg/ml BlasticidinS and 100mg/ml Zeocin (Invitrogen). Post-
transfection selection was performed with HygromycinB (100 mg/
ml). For growth on respiratory substrates, the medium contained
glucose-free DMEM (Gibco), 0.9 mg/ml galactose, 1 mM sodium
pyruvate, 10% (v/v) FCS, NEAA and 2 mM L-glutamine. For growth
curve analyses, the galactose medium included 50mg/ml uridine.
Subcellular localisation
Human mitochondria or cell lysates were prepared in a homo-
genisation buffer (10 mM Tris–HCl (pH 7.4), 0.6 M mannitol, 1 mM
EGTA) by differential centrifugation. Aliquots of mitochondria were
treated with proteinase-K (4mg/100mg protein) for 30 min at 41C
and either lysed (1% final v/v Triton X-100) or treated with 1 mM
PMSF before separation through 15% PAG and transfer to a PVDF
membrane. Western blots were performed and developed as
described by Soleimanpour-Lichaei et al (2007).
siRNA constructs and transfection
Three sequences targeting ICT1 were tested for efficiency of protein
depletion. The nucleotide positions are relative to the reference
sequence NM_001545.1; sense strands were as follows:
si-ICT1A 50 CUAGAUCGCUUGACAAUAU dTdT 30 (nt 222–240);
si-ICT1B 50 GCCGCUAUCAGUUCCGGAA dTdT 30 (nt 421–439)
and
si-ICT1C 50GGGUCCCGAAUGGUGCAAA dTdT 30 (nt 181–199).
Experiments were performed with si-ICT1B unless otherwise
specified. si-ICT1C was found to be ineffective. Transfections were
performed with 20% confluent HeLa cells using Oligofectamine
(Invitrogen) in Optimem-I medium (Gibco) with 0.2mM siRNA.
Reverse transfections were performed as described by Ovcharenko
et al (2005) using approximately 12 000 HEK293Tcell per cm2 using
Lipofectamine RNAiMAX (Invitrogen) in Optimem-I medium
(10–33 nM siRNA). Custom and control non-targeting (NT; ref.:
OR-0030-neg05) duplex siRNAs were purchased pre-annealed from
Eurogentec.
In vivo mitochondrial protein synthesis
Mitochondrial protein synthesis in cultured cells was performed as
described by Chomyn (1996) after addition of emetine and pulsed
with [35S]-methionine for 15 min. Aliquots (50 mg) of total cell
protein were separated by 15% (w/v) SDS–PAGE. The gels were
exposed to PhosphorImage cassettes and visualised using the
ImageQuant software.
Production of FLAG- and GST-fusion constructs, transfection,
expression and purification
The original human ICT1 clone was obtained from MGC
(MGC:21251; accession no. BC015335) and encodes the only
isoform to be described. All constructs were prepared by PCR
using the MGC clone as template. Constructs to facilitate inducible
expression of C-terminal FLAG-tagged ICT1 were prepared by
generating an amplicon from nt 2 to 620 using the following
primers: 50-CTTTCTTAAGCTTCCACCATGGCGGCCACCAGGTG-30
and 50-CTCTCCGATATCCTACTTATCGTCGTCATCCTTGTAATCGTCC
ATGTCGACCCTC-30. The amplicon and pcDNA5/FRT/TO (Invitro-
gen) were digested with HindIII/EcoRV and ligated. C-terminal
FLAG-tagged MRPS27 and MRPL20 were constructed by PCR
amplification from MGC clones 6009616 and 3542715 (accession
nos. BC064902 and BC009515), respectively, using primers 50-CTTT
CTTGGATCCCCACCATGGCTGCCTCCATAGTGCG-30 and 50-CTCTCT
CTCGAGCTACTTATCGTCGTCATCCTTGTAATCGGCAGATGCCTTTGC
TGCTT-30 (MRPS27 Forward and Reverse) or 5-TACTATAAGCTTAC
CATGGTCTTCCTCACCG-3 and 5-ATACTACTCGAGCTACTTATCGTC
GTCATCCTTGTAATCGTGGTACTGCACCACTC-3 (MRPL20 Forward
and Reverse). The amplicons were digested with BamHI/XhoI or
HindIII/XhoI, respectively, and ligated into similarly digested
pcDNA5/FRT/TO. The GST-fusion constructs were made of the FL
or N-terminal-deleted (D29) ICT1. These were generated by
amplifying nt 2 or 90–623, respectively. The forward primers
incorporated a BamHI site (FL Forward 50-CTTTCTTGGATCCAT
GGCGGCCACCAGGTG-30; D29 Forward 50-CTTTCTTGGATCCCTG
CACAAGCAGAAAGACG-30) and the same reverse primer was used
for both amplification reactions (Reverse 50-CTCTCCCTCGAGT
CAGTCCATGTCGACCCTC-30 containing an XhoI site). The ampli-
cons and vectors were digested to allow in-frame downstream
fusion of ICT1-GST in pGEX-6P-1 (GE Healthcare). The constructs
derived from pGEX-6P-1 or pcDNA5/FRT/TO were used for
transfection of E. coli Rosetta pLysS (Merck Biosciences) or
HEK293T cells, respectively. Bacteria were induced, and protein
was purified and cleaved from GST using PreScission Protease
exactly as previously described for mtRRF (Rorbach et al, 2008).
Bacterial expression of both FL GST-ICT1-fusion protein and D29
was deleterious to growth, but was not lethal. Human HEK293T
cells were transfected atB50% confluence with the vectors pOG44
and pcDNA5/FRT/TO containing sequences of the genes to be
expressed (FLAG-tagged ICT1, mtLuc and derivatives) as previously
described (Soleimanpour-Lichaei et al, 2007).
Dynamic light scattering
Dynamic light scattering measurements were performed using a
commercial Zetasizer 1600 (Malvern Instruments) equipped with a
He–Ne laser (633 nm, 5 mW). Aliquots (20ml) of protein samples
(concentrations of 0.1–1 mg/ml) were pipetted into low-volume
glass cuvettes and equilibrated for 3 min in the apparatus before
measurement. All samples were measured a minimum of five times
at 251C for 70 s.
Affinity purification and elution of FLAG peptides
Mitochondria were isolated from HEK293T cells expressing FLAG
derivatives and treated with DNase-I (0.5 U/mg mitochondria;
15 min RT) and proteinase-K (5mg/mg mitochondria; 30 min 41C)
followed by 1 mM PMSF inhibition. The pelleted mitochondria were
washed in a homogenisation buffer, treated with digitonin to
remove the outer membrane (400mg/mg mitochondria), washed
and resuspended in a lysis buffer (50 mM Tris–HCl (pH 7.4),
150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1% (v/v) TX-100, 1
protease inhibitor cocktail (Roche), 1 mM PMSF). IP was performed
using an anti-FLAG M2-agarose affinity gel following manufac-
turer’s recommendations (Sigma Aldrich, St Louis, MO, USA).
Elution was performed using 5 mg of 3 FLAG peptide per 100ml of
an elution buffer.
LC MS/MS analysis of negative control and ICT1 IP
The immunopurification of ICT1 and negative control (IP eluate
from the lysate of untransfected HEK293T cells subjected to the
identical IP protocol with anti-FLAG M2-agarose) were separated
using SDS–PAGE. Individual gel lanes were cut into three bands and
were in-gel digested as described elsewhere (Wilm et al, 1996). The
resulting peptide solutions were desalted and concentrated offline
using STAGE tips (Rappsilber et al, 2003). Measurements were
performed using an Agilent 1100 nanoflow system connected
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through a nano-electrospray ion source to a 7T linear ion-trap
Fourier transform ion cyclotron resonance mass spectrometer (LTQ
FT ULTRA; Thermo Scientific). Peptide separations were performed
using a 15-cm fused silica emitter (New Objective, PicoTip Emitter;
tip: 8±1mm, ID: 100mm, FS360-100-8-N-5-C15) packed with
reversed-phase ReproSil-Pur C18AQ 3-mm resin purchased from
Dr Maisch GmbH. Samples were loaded directly onto the analytical
column at a flow of 600 nl/min eluent-A (3% acetonitrile, 0.5%
acetic acid). Bound peptides were eluted from the column at a rate
of 300 nl/min using an LC gradient of 10–40% eluent-B (80% v/v
acetonitrile, 0.5% acetic acid) in 60 min, followed by a steep
gradient of 40–100% eluent-B in 5 min. The mass spectrometer was
programmed to select the top four most abundant ions from each
survey scan in the ICR cell for subsequent fragmentation analysis
using collision-induced dissociation (CID) in the linear ion trap.
Only double and triple charged ions were selected for CID analysis,
and dynamic exclusion with early expiration was enabled to prevent
re-selection of previously fragmented ions.
MRP identification and data analysis
Precursor and fragment ions were extracted from raw data files using
ExtractMSn (Thermo Scientific). Individual LC MS/MS data files of all
three gel slices were combined for each sample before database
search. Peptides were identified by automated database searches
using Mascot (Matrix Science Mascot version 2.2) against the Refseq
database (release 29) and a Refseq reverse database for automated
validation using false-discovery rate calculations. Database searches
were performed with a 20-p.p.m. precursor ion tolerance and 0.8-Da
tolerance for MS/MS fragment ions using the following specifications:
tryptic cleavage allowing one missed cleavage, carbamidomethylation
(C) as fixed modification, and allowing deamidation (NQ) and
oxidation (M) as variable modifications. Subsequent peptide identi-
fications were blasted against the Refseq database and validated by
false-discovery rate calculation using the PROVALT software (Weath-
erly et al, 2005). PROVALTwas set to calculate peptide score cut-offs to
achieve a calculated o1% false-discovery rate. Protein abundances
were calculated as exponentially modified Protein Abundance Index
(emPAI) values according to Ishihama et al (2005). MRPs were
marked as enriched if (i) they were identified with at least three
unique peptides and (ii) when emPAI values were at least twofold
higher in the ICT1 IP sample as compared with that in the negative
control. The table represents only identified human MRPs that appear
in the Refseq database.
Isokinetic sucrose-gradient analysis of mitochondrial
ribosomes
Total cell lysates (0.5–0.7 mg in lysis buffer) or eluted immunopre-
cipitates were loaded on a linear sucrose gradient (1 ml 10–30%
(v/v)) along with 50 mM Tris–HCl (pH 7.2), 10 mM Mg(OAc)2,
40 mM NH4Cl, 0.1 M KCl, 1 mM PMSF, and 50mg/ml chloramphe-
nicol, and centrifuged for 2 h 15 min at 100 000 g at 41C. Fractions
(100ml) were collected and 10-ml aliquots were analysed directly by
western blotting or silver staining as follows: PAG were fixed in
50% methanol for 1 h, followed by 15-min incubation in staining
solution (0.8% (w/v) AgNO3; 1.4% (v/v) NH4OH; 0.075% (w/v)
NaOH), three washes of 5 min each in nanopure dH2O, and then
developed in 0.055% (v/v) formaldehyde/0.005% (w/v) citric acid
and fixed in 45% methanol/10% acetic acid.
Northern blot analysis for mitoribosomal subunit markers
in gradient gel fractions
To identify the 28S mt-SSU and 39S mt-LSU in gradient fractions, the
12S and 16S mt-rRNA were visualised by northern blotting. RNA
was prepared by phenol extraction from half of each gradient
fraction. Northern blots were performed as described by Chrza-
nowska-Lightowlers et al (1994). Briefly, aliquots of RNA (5mg)
were electrophoresed through 1.2% agarose under denaturing
conditions and transferred to GenescreenPlus membrane (NEN
duPont) following the manufacturer’s protocol. Probes were
generated using random hexamers on PCR-generated templates
corresponding to the internal regions of the 12S and 16S mt-rRNA.
An estimate of 55S monosome was made from the position of the
cytosolic 28S rRNA (representing the 60S cytosolic LSU) visualised
on ethidium bromide staining of the agarose gel.
Mutagenesis of ICT1
Mutations in the GGQ tripeptide were introduced into the bacterial
(AGQ, GSQ) and human (GSQ) ICT1 expression constructs
following the QuikChange II site-directed mutagenesis protocol
(Stratagene). The following primers and their complements were
used; base changes from wild type are underlined: AGQ, 50-GTA
GTGGTCCTGCGGGGCAGAATG-30; GSQ, 50-GTGGTCCTGGGTCGCA
GAATGTGAAC-30.
In vitro release-factor assay
E. coli ribosomes were purified and assays were performed essentially
as described by Tate and Caskey (1990) with modifications as detailed
in reference Soleimanpour-Lichaei et al (2007). Briefly, an f[3H]met-
tRNAmet substrate was made by combining 3.8 nmol L-[methyl-3H]-
methionine (GE Healthcare) and cold methionine up to a concentra-
tion of 21.8 nmol, 3.5 mM leucovorin (Sigma) as the formyl donor,
20mM amino acids (Promega), 0.3 mg N-formylmethionine-specific
tRNA (Sigma), 1.2 mM ATP, 1 mM DTT, 10 mM MgCl2, in cacodylate
buffer (100 mM, pH 6.8), and incubating for 30 min at 371C. The
ribosomal substrate (amounts given are per 50ml of assay) was
prepared by incubation of 70S ribosomes (5 pmol) with AUG
(250 pmol) and f[3H]met-tRNAmet (2.5 pmol) in 20 mM Tris–HCl (pH
7.4), 10 mM Mg(OAc)2 and 150 mM NH4Cl at 301C for 20 min. This
‘activated’ ribosomal substrate was stored on ice before interrogation
with release factors for activities with selected codons. Reactions that
lacked the 70S were otherwise identical.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Hungry Codons Promote Frameshifting
in Human Mitochondrial Ribosomes
Richard Temperley,* Ricarda Richter,* Sven Dennerlein, Robert N. Lightowlers,
Zofia M. Chrzanowska-Lightowlers†
Ribosome frameshifting, although rare,must occur in mitochondrial (mt) trans-lation systems with interrupted open
reading frames (ORFs) (1), but all human mt-
ORFs are unbroken. However, we show that
human mitoribosomes do invoke
–1 frameshift at the AGA and
AGG codons predicted to termi-
nate the two ORFs inMTCO1 and
MTND6, respectively. As a conse-
quence, both ORFs terminate in
the standard UAG codon, neces-
sitating the use of only a single
mitochondrial release factor (2).
Frameshifting could be pro-
moted by (i) paused mitoribosomes
on AGA or AGG triplets, because
no mt-tRNAs exist that recognize
these codons; (ii) upstream “slip-
pery” sequences that are poorly de-
fined in human mt-mRNA; or (iii)
a downstream stable secondary
structure predicted for bothMTCO1
andMTND6 (fig. S1) (3). To dem-
onstrate that –1 frameshifting oc-
curs in human mitochondria, we
targetedRelE, a bacterial endoribo-
nuclease that specifically cleaves
mRNA in the ribosomal A site,
to the mitochondrion [mtRelE
(4, 5), fig. S2]. This enzyme shows
marked sequence preference for
standard termination codons UAG
andUAAwith negligible predicted
recognition of AGA and AGG
(4). On induction, the majority of
MTCO1 (68 T 1.73%, n = 3) and
MTCO2 (70 T 1.4%, n = 3) were
intact (Fig. 1A, lanes 1 and 3),
ruling out nonspecific transcript
degradation by mtRelE. How-
ever, mitochondrial translation
was reduced for most mt-proteins,
including COX1 and ND6 (Fig.
1B).Depletion of themitochondri-
al release factor mtRF1a stabilizes transcripts
through extended association with the mitori-
bosome,whereasRelEpromotesreleaseofcleaved
mRNAfrom bacterial ribosomes (4). Therefore,
mtRelEexpressionwouldbepredicted toabrogate
mitoribosome-mediated protection. mtRF1a de-
pletion in tandem with mtRelE expression does
reduce the amounts of full-length mt-transcripts
and markedly so for MTCO1 (Fig. 1A, lanes 2
and4), indicating both recognition and cleavage
by mtRelE.
Northern analysis could not resolve whether
the short 3′ untranslated regions (3′UTRs)
present in MTCO1 [72 nucleotides (nt)] had
been lost post–mtRelE cleavage. MTND5,
however, possesses a longer 3′UTR (568 nt).
On mtRelE induction, a species was detected
that is consistent with cleavage at the stop codon
and loss of this 3′UTR (Fig. 1A, lanes 3 and 4
indicated by asterisks). Human mtDNA encodes
two transcripts with overlapping ORFs, one
containing MTATP8/6 (RNA14) and one
MTND4L/4 (RNA7). Cleavage at the stop codon
of the upstream ORF would release an RNAwith
a 5′-truncated downstream ORF. As with
MTND5, novel species were detected on mtRelE
expression. This was particularly apparent for
RNA14, where MTATP8 terminates in UAG, a
preferred stop codon for RelE (Fig. 1A).
Fine mapping was performed on MTCO2
and the 5′ truncated site of MTATP6 in the
bicistronic RNA14 (fig. S3). This revealed
mtRelE cleavage in the UAG termination codon
uniquely between nucleotides 2 and 3 before reade-
nylation. This result therefore allowed us to
determine unequivocally whether termination of
MTCO1 occurred at the AGA or UAG codon;
AGA termination codon would result
in –AAAAUCUAGAn, whereasUAG
would produce –AAAAUCUAAn. On
sequencing, 10 clones from control
cells reflected full-length 3′UTR
containing MTCO1 transcripts; two
were truncations in the antisense
tRNASer, a commonly identified
expressed sequence tag. This species
was also found in two of the mtRelE
samples. However, all the remain-
ing 33 mtRelE clones terminated in
–AAAAUCUA followed by read-
enylation (Fig. 1C), signifying that
MTCO1 terminates at UAG rather
than AGA. These data suggest that
mtRF1a is sufficient to terminate all
13 human mt-ORFs.
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Fig. 1. Expression of mtRelE results in specific cleavage of mt-mRNA stop
codons. Cells expressing mtRelE show (A) specific cleavage of mt-mRNA,
generating novel products indicated by asterisks in both wild-type (WT) cells
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mtDNA encoded gene products; and (C) cleavage of MTCO1 transcripts specific
at the UAG codon (33/35 clones, 2 were common truncated WT sequences)
whereas WT cells retained the 3′UTR.
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ABSTRACT
The molecular mechanism of human mitochondrial
translation has yet to be fully described. We are par-
ticularly interested in understanding the process of
translational termination and ribosome recycling in
the mitochondrion. Several candidates have been
implicated, for which subcellular localization and
characterization have not been reported. Here,
we show that the putative mitochondrial recycling
factor, mtRRF, is indeed a mitochondrial protein.
Expression of human mtRRF in fission yeast
devoid of endogenous mitochondrial recycling
factor suppresses the respiratory phenotype. Fur-
ther, human mtRRF is able to associate with Escher-
ichia coli ribosomes in vitro and can associate with
mitoribosomes in vivo. Depletion of mtRRF in
human cell lines is lethal, initially causing profound
mitochondrial dysmorphism, aggregation of mitori-
bosomes, elevated mitochondrial superoxide pro-
duction and eventual loss of OXPHOS complexes.
Finally, mtRRF was shown to co-immunoprecipitate
a large number of mitoribosomal proteins attached
to other mitochondrial proteins, including putative
members of the mitochondrial nucleoid.
INTRODUCTION
Mitochondria play a vital role in a wide variety of cellular
processes in eukaryotic cells. They possess their own geno-
mic DNA (mtDNA) that encodes 13 proteins, along with
22 tRNA and 2 ribosomal RNA (1). All protein products
of the mitochondrial genome are part of the multi-subunit
complexes involved in oxidative phosphorylation.
Synthesis of these proteins is carried out on a specialized
translational apparatus located within the organelle. The
components of the mitochondrial translational machin-
ery—translational factors and mitoribosomes—are dis-
tinct from those in the cytosol and generally resemble
bacterial counterparts (2).
Our understanding of the mechanisms of mitochondrial
translation is far from complete. A limited number of
factors involved in mitochondrial translation initiation,
elongation and termination have been identified and char-
acterized (3–7). The mechanism of the last step of protein
synthesis, the disassembly of the post-termination com-
plex, has not yet been explored in human mitochondria.
Due to the monophyletic a-proteobacterial origin of
mitochondria, our knowledge of ribosome recycling in
prokaryotes can serve as a rough model for mitochondrial
processes, although it is highly likely that they will prove
to be important variations. In the bacterial system, when a
ribosome reaches a stop codon, the nascent polypeptide is
released by the coordinated actions of a sequence-specific
class I release factor (RF1 or RF2) and a sequence-
independent class II release factor [RF3, (8)]. The resulting
post-termination complex containing mRNA and deacy-
lated tRNA in the P/E site (9), has to be disassembled and
ribosomal subunits need to be recycled to initiate a new
round of protein synthesis. This process is catalysed by the
ribosome recycling factor (RRF). RRF is universally con-
served in eubacteria and deletion of the gene-encoding
RRF (frr) has been shown to be lethal for Escherichia
coli (10). Mycoplasma genitalium, with one of the smallest
genomes reported to date, retains RRF despite losing RF2
and RF3, further supporting a key role for this factor in
prokaryotic translation (11).
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The mechanism of bacterial ribosome recycling
has been addressed by several independent laboratories
[for example, (12–14)]. Conformational changes mediated
by RRF bound to the 70S ribosome can disrupt the inter-
subunit bridges leading to separation of the monosome.
This process requires GTP hydrolysis that is triggered by
elongation factor G (EFG). Subsequently, initiation factor
3 (IF3) binds to the 30S subunit preventing re-association
of the free subunits. More recently, emphasis has been
placed on the exact role played by bacterial RRF in this
process. Cryoelectron microscopy data on E. coli RRF
binding to 70S post-termination complexes is consistent
with a spontaneous movement of RRF from around the
peptidyltransferase centre in the monosome to a site on
the 50S subunit, resulting in the cleavage of intersubunit
bridges and subunit dissociation (15). However, no such
structural reorganization was found on X-ray crystallog-
raphy of a similar but not identical Thermus thermophilus
system (16).
To date, no human mitochondrial ribosome recycling
factor has been characterized. A candidate, mtRRF, was
proposed several years ago from bioinformatic analyses of
several overlapping EST sequences (7) but with no sup-
portive functional studies or investigation of subcellular
localization. In this article, we report that this putative
mitochondrial recycling factor is indeed a mitochondrial
protein. Furthermore, we show a direct interaction of pur-
ified mtRRF with ribosomes of both bacterial and mam-
malian mitochondrial origin in vitro and in vivo. To assess
the physiological function of mtRRF, we have examined
the ability of human mtRRF to rescue yeast strains
deleted of their endogenous factor and the effect of
mtRRF depletion in cultured human cells. We observed
aggregation of mitoribosomes, increased ROS and pro-
found changes in mitochondrial morphology. Our results
imply that analogous to the bacterial situation, this pro-
tein is essential for mitochondrial function and viability of
human cells.
METHODS
Tissue culture manipulations
Human HeLa cells were cultured (378C, humidified 5%
CO2) in Eagle’s modified essential medium (Sigma-
Aldrich Co.Ltd, Dorset, UK) supplemented with 10%
(v/v) fetal calf serum (FCS), 1non-essential amino
acids and 2mM L-glutamine. Flp-InTMT-RexTM-293 cells
(HEK293T, Invitrogen Ltd, Paisley, UK) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FCS, 50 mg/ml uridine and 1 non-
essential amino acids in the presence of 10 mg/ml
Blasticidin S and 100 mg/ml Zeocin (Invitrogen). Post-
transfection selection was effected with Hygromycin B
(100mg/ml). For growth on respiratory substrates,
medium was glucose-free DMEM (Gibco, UK), 0.9mg/
ml galactose, 1mM sodium pyruvate, 10% (v/v) FCS,
non-essential amino acids and 2mM L-glutamine. For
growth-curve analyses, galactose medium included 50 mg/
ml uridine.
Production of GFP-, FLAG- and GST-fusion constructs
and cloning into yeast expression vectors
The original human mtRRF clone was obtained from
MGC (MGC:17776; Acc No BC013049), but primer posi-
tions described below are relative to the reference
sequence NM_138777.2.
To generate a fusion construct that would allow expres-
sion of mtRRF with GFP at the C-terminus, nucleotides
102–894 of the mtRRF cDNA were amplified using pri-
mers for 50-CACACATGATCAGATTGTCTTCAGTCA
TGG-30 and Rev 50-CACACATGATCAAGTTCTTTGG
TCTTCACTGC-30 (BclI sites underlined). This was
digested and cloned in-frame upstream of GFP in
pGFP3 (pcDNA3.1 Invitrogen, containing the GFP
open reading frame (ORF) and multiple cloning site
kindly donated by Dr D Elliott, Newcastle University).
The glutathione-S-transferase (GST)-fusion constructs
were made of the full-length (FL) or N-terminal deleted
(NDel) mtRRF. These were generated by amplifying
nucleotide 116 or nucleotides 324–940, respectively. The
FL forward primer incorporated a BclI site, whilst the
NDel included an EcoR1 site (FL for 50-CACACCTG
ATCAATGGCCTTGGGATTAAAG-30; NDel for 50-C
ACACCGAATTCCCAGAGTGAATATTAATGCT-30)
and the same reverse primer was used for both amplifica-
tion reactions (Rev 50-AATTATGCGGCCGCACTGGG
CTCTGGAGTATT-30 containing a NotI site). Amplicons
and vectors were digested to allow in-frame downstream
fusion of mtRRF-GST in pGEX-6P-1 or pGEX-6P-2,
respectively (GE Healthcare, Amersham, UK).
To generate a FLAG-tagged mtRRF construct, the fol-
lowing primers were used to amplify nucleotides 115–900.
The region corresponding to the FLAG tag is italicized
and EcoRV sites are underlined for 50-CTTTCTTGATAT
CCCACCATGGCCTTGGGATTAAAGTGCTTCCGC
ATGGTCCA-30 and Rev 50-CTCTCCGATATCCTACT
TATCGTCGTCATCCTTGTAATCTCCAAGGAGTT
CTTTGG-30.
A FL mtRRF PCR product (nucleotides 101–980) was
generated using primers for 50-CACACCTGATCAGGA
UUGUCUUCAGUCAUG-30 and Rev 50-CACACCTGA
TCAGAGAGAAGTCCCAATGTGC-30 (BclI site under-
lined). This product was cloned into pGEM-Teasy
(Promega, Southampton,UK), excised by NotI digestion
and subcloned into NotI-digested Saccharomyces cerevi-
siae URA3 expression vector pFL61 (17) or the
Schizosaccharomyces pombe ura4 expression vector
pTG1754 [a gift from Transgene, (18)], which both con-
tain a strong constitutive promoter.
Transient transfection of HeLa cells, microscopy
and image capture
HeLa cells were grown on coverslips to 50% confluency,
transfected with GFP fusion vector (1mg) using SuperFect
(Qiagen, Sussex, UK) as recommended and cultured for a
further 24 h prior to incubation with Mitotracker Red
CM-H2XRos (1mM final, Invitrogen). After brief fixation
(4% paraformaldehyde/PBS, 15min at room tempera-
ture), cells were mounted in Vectashield (H-1200 Vector
Laboratories Ltd, Peterborough, UK) and visualized by
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fluorescence microscopy using a Leica (Nussloch,
Germany) DMRA. Images were recorded as a Z-series
(0.5 mm slices) using a cooled CCD camera and imaging
system (Spot–II Diagnostics Instruments, Sterling
Heights, MI, USA).
Immunocytochemistry
HeLa cells (3 105) plated on coverslips were incubated
with Mitotracker Red CMH2XRos, as described above,
fixed in 3% paraformaldehyde, incubated with anti-
mtRRF polyclonal antibodies (1/300) for 4 h, washed,
and then incubated with AlexaFluor-488 conjugated
anti-rabbit antibodies (Molecular Probes, Invitrogen,
Paisley, UK) for 1 h. Signals were visualized by micro-
scopy as described above.
Mitochondrial import assays
Assays were performed and assessed using isolated rat
liver mitochondria following the methods described in
ref. (6) but with reticulocyte lysates programmed with
the relevant RNA species.
Over-expression and purification of mtRRF–GST
Escherichia coli strain Rosetta(DE3)pLysS (Novagen,
Merck Biosciences Ltd, Nottingham, UK)
was transformed with constructs for the over-expression
of the human mitochondrial RRF. Bacteria were induced
at 0.5 A600 with 1mM IPTG, overnight at 168C. Pelleted
cells were resuspended in 50mM Tris–HCl pH7.4,
150mM NaCl, 1mM lysozyme, 1mM EDTA, 1mM
PMSF and sonicated on ice 10 10 s (Soniprep 150).
Post-centrifugation (30 000g for 20min, 48C), the super-
natant was filtered (0.45 mm Corning) and incubated
for 3 h at 48C with glutathione Sepharose 4B beads
(GE Healthcare). Beads were extensively washed prior to
elution in 50mM Tris–HCl pH 7.8, 150mM NaCl, 20mM
reduced glutathione, 1mM PMSF.
For cleavage and removal of the GST on the Sepharose,
beads were incubated at 48C overnight in 50mM Tris–
HCl pH 7.8, 150mM NaCl, 1mM PMSF supplemented
with 1mM EDTA, 1mM DTT and 24 ml/ml PreScission
Protease (GE Healthcare). Eluted recombinant protein
was stored at 48C.
Production of anti-mtRRF antibodies
Recombinant human mtRRF purified as described above
was used as an antigen to raise rabbit antisera. Antibody
generation and affinity purification was performed by
Eurogentec, Belgium.
In vitro ribosome binding assay
Escherichia coli ribosomes were prepared as described in
ref. (6). Reactions (50ml) combined purified recombinant
mtRRF69 and 70S ribosomes (1 mM) in 10mM Tris–
HCl pH 7.2, 10mM Mg(OAc)2, 80mM NH4Cl, 1mM
DTT at room temperature for 30min. The mixture was
centrifuged through 10% (v:v) sucrose (150 ml in binding
buffer) for 1 h in Beckman–Coulter air-driven
ultracentrifuge (30 p.s.i.). Fractions (4 50 ml) were col-
lected and analysed by western blot.
Stable transfection of HEK293T cells with FLAG-tagged
mitochondrially targeted proteins
Cells were transfected at 30% confluency using
Superfect (Qiagen). The vectors, pOG44 expressing FRT
recombinase, and pcDNA5/FRT/TO containing
sequences of the genes to be expressed (FLAG-tagged
mtRRF or mitochondrially targeted luciferase) were com-
bined to give a total of 2 mg DNA in a 9:1 ratio, and mixed
with Superfect prior to a 3-h incubation with the cells.
Selection with Hygromycin B (100mg/ml) commenced 2
days later. Independent colonies were isolated, propagated
and analysed for induction (1 mg/ml tetracycline) by wes-
tern analysis using anti-FLAG antibodies (Sigma).
Isokinetic sucrose-gradient analysis of mitochondrial
ribosomes
Total cell lysates (0.5mg) were loaded on a linear sucrose
gradient [10–30% (v:v), 1ml] in 10mM Tris–HCl pH 7.2,
10mM Mg(OAc)2, 80mM NH4Cl, 1mM PMSF and cen-
trifuged for 2 h at 100 000g at 48C. Fractions of 100 ml
were collected and analysed by western blot.
Affinity purification and elution of FLAG peptides
Mitochondria were isolated from HEK293T cells over-
expressing FLAG-mtRRF or -mtLUC essentially as
described in ref. (6) and treated with proteinase K (5mg/
1mg of mitochondria; 30min 48C) followed by PMSF
(1mM) inhibition. Pelleted mitochondria were resus-
pended in lysis buffer (supplemented with 10mM
Mg(OAC)2 as indicated, although no difference in the
composition of protein precipitate could be measured
without supplement). Immunoprecipitation was per-
formed with a-FLAG-Gel following manufacturer’s
recommendations (Sigma Aldrich, St Louis, MO, USA).
Elution was effected with FLAG peptide. RNase A (5mg/
ml) and EDTA (50mM) were added as indicated.
Mass spectrometry analysis and protein identification
Mass spectrometric analysis of immunoprecipitated com-
plexes was performed as described in Supplementary
Material.
Yeast growth conditions, plasmid and general strain
constructions and complementation assays
All yeast strains used in this study are detailed in Table S2.
General yeast media and genetic techniques/transforma-
tion protocols were as described in ref. (18). In brief, fer-
mentable media contained 2% glucose, non-fermentable
conditions were 3% (v:v) glycerol/ethanol or 2% (v:v)
glycerol with 0.1% glucose or for S. pombe only 2%
(w:v) galactose/0.1% (w:v) glucose.
Production of S. pombe "rrf1 strain
A single S. pombe protein, encoded by the gene
SPBC1709.09, was found to have significant similarities
to both S. cerevisiae Rrf1 (Figure S4) and E. coli RRF.
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The ORF was PCR amplified from genomic DNA and
cloned into the NotI site of the pTG1754 and pFL61
expression plasmids for S. pombe and S. cerevisiae, respec-
tively. An S. pombe Drrf1::KanR strain (NB331) was con-
structed in the wild-type recipient strain NB205-6A by
using a PCR disruption strategy with hybrid rrf1-KanR
oligonucleotides as described in ref. (19), removing
629 bp encompassing the 735 bp rrf1Sp ORF (starting
8 bp before the ATG). Of 50, 22 clones showed delayed
growth on glycerol medium and were proved to contain
the correct insertion by PCR. Crossing to wild-type fol-
lowed by sporulation and tetrad analysis showed a 2:2
cosegregation of the geneticin resistance and slow glycerol
growth. Transformation with the Rrf1pSp-encoding plas-
mid restored growth on galactose, confirming that the
mitochondrial DNA was intact in this strain.
Spectroscopic analyses
Cells from Drrf1Sp transformants were dried, mixed
with sodium dithionite to fully reduce the cytochromes
and frozen in liquid nitrogen before recording the
absorbance of the samples at wavelengths from 630 nm
to 490 nm (spectrophotometer Cary 400O`, Varian, San
Fernando, CA). Peaks were the following: cytochrome c
(548 nm), cytochrome c1 (554 nm), cytochrome b (560 nm)
and cytochrome aa3 (603 nm).
siRNA constructs, transfection and RT–PCR analysis
The following sequences targeting mtRRF were tested for
efficiency of mRNA and protein depletion. Nucleotide
positions are relative to reference sequence NM_
138777.2, siRNA ORF1 50 GGACACCAUUAGGCUA
AUA dTdT 30 (nucleotides 211–229); siRNA ORF2 50
GAGAAAUGCUGGUGAAACU dTdT 30 (nucleotides
684–702); siRNA ORF3 50 GACAGUGCAUGAAAGA
CAA dTdT 30 (nucleotides 799–817). Experiments were
performed with siRNA ORF2 unless otherwise specified.
Treatment of stably transfected and induced HEK293T
cells was performed with siRNA UTR1 50 GUAUUC
UUGUUGCACUUAA dTdT 30 (nucleotides 1633–1651)
targeting the 30-UTR region that was absent in the indu-
cibly expressed form of mtRRF. Transfections were per-
formed on 20% confluent cells with Oligofectamine
(Invitrogen) in Optimem-I medium (Gibco) with final con-
centrations of 0.2 mM siRNA. Control non-targetting
siRNA and custom siRNA duplexes were purchased, pur-
ified and pre-annealed from Eurogentec. Quantification
of mtRRF mRNA was performed with TaqMan
Gene Expression Assay (Applied Biosystems,
Warrington, UK) using ABI Prism sequence detector
system. Data were normalized to GAPDH as an endogen-
ous control. Probe kits were ordered from Applied
Biosystems—HS01067555_g1 (mtRRF) and
HS999999905_m1 (GAPDH).
Cell preparations, western analysis and Blue Native-PAGE
Schizosaccharomyces pombe mitochondria was purified
from cells grown either in complete glucose medium or
in minimal glucose medium lacking uracil as described
in ref. (19) with Roche protease inhibitors present at all
stages. Yeast proteins were separated by 12% SDS–PAGE
and immobilized on nitrocellulose (Schleicher & Schuell,
London, UK) by wet transfer in 25mM Tris, 192mM
glycine, 0.02% (w/v) SDS and 20% (v/v) ethanol. Blots
were hybridized with mouse (anti-human Hsp60, Sigma
H-3525; anti-FLAG, Sigma H-1804) or rabbit antibodies
[anti-mtRRFHs (this work); -Cox2Sp, (20) -Arg8Sc (21); -
EFTuSp (18)].
Human cell lysates were prepared, separated by
SDS–PAGE and immobilized by wet transfer as
described (6). Proteins of interest were bound by overnight
incubation (48C) with antibodies [mtRRF, GDH
(Lightowlers Group, Newcastle); Porin, COX I, COX II,
SDH 70K and ND6 (MitoSciences, Eugene, OR); b-actin
(Sigma); DAP3, MRLP3 (Abcam, Cambridge, UK)] fol-
lowed by HRP-conjugated secondary antibodies (DAKO)
and visualized by ECL-plus (GE Healthcare).
Blue native gel electrophoresis was performed as
described in ref. (22) with 30 mg protein loaded per lane
and wet transfer as above.
Free radicals and mitochondrial mass measurements
MitoSOX (Molecular Probes) prepared in DMSO,
diluted to 5 mM in DMEM medium-lacking serum was
added to cells for 10min at 378C. Cells were washed
before re-suspension in 2ml DMEM-lacking serum and
passed through a FACScan flow cytometer (Becton
Dickinson Ltd, Oxford, UK, equipped with 488 nm
Argon laser). Data were collected for forward and side
scatter together with autofluorescence of unstained cells,
gating eliminated debris and apoptotic cells from the ana-
lyses. After acquisition, data were analysed by WinMDI
software (version 2.8). Experiments were performed on
four independent occasions with triplicate measurements
based on 10 000 events. Dihydrorhodamine 123 (DHR,
Molecular Probes) and nonyl acridine orange (NAO,
Molecular Probes) were resuspended in DMSO, diluted
to 30mM (DHR) or 10mM (NAO) in DMEM-lacking
serum and incubated with cells at 378C for 30 (DHR)
min or 10 (NAO) min. Cells were then washed before
resuspension in 2ml DMEM-lacking serum and green
fluorescence emission analysed as above.
Electron microscopy studies
Cells were grown as detailed above, pelleted and fixed in
2% glutaraldehyde in Sorensen’s phosphate buffer.
Samples were than post-fixed in 1% osmium tetroxide in
the same buffer, dehydrated in alcohol and embedded in
Epoxy resin (TAAB). Ultrathin sections were stained with
2% aqueous uranyl acetate and lead citrate and examined
using a Philips CM100 transmission electron microscope
(EM Research Services, Newcastle University).
In vivomitochondrial protein synthesis
Protein translation in HeLa cells was performed essen-
tially as described (23). Cells were incubated with radiola-
belled methionine for 15min.
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Respirometry
High-resolution respirometry was performed at 378C with
an Oroboros Oxygraph-2K (Oroboros Instruments,
Austria) essentially as detailed in ref. (6).
Statistical analysis
Students unpaired t-tests were used to determine the
significance of values as indicated in the figure legends.
Values of P< 0.05 were recorded as statistically
significant.
RESULTS
MtRRF, the human homologue of bacterial RRF,
is a mitochondrial protein
To confirm mitochondrial localization of the putative
human mtRRF predicted by in silico studies (7), a
mtRRF–GFP fusion construct was used to transfect
HeLa cells. This chimera included all but the terminal 2
residues of mtRRF fused N-terminal to GFP. Cells were
cultured for 24 h prior to staining with Mitotracker CM-
H2XRos, to visualize mitochondria. Fluorescence micro-
scopy images and line scan analysis (Figure 1A, left
panels) of transfected cells demonstrated co-localization
of mtRRF–GFP with Mitotracker Red. In contrast to
the well-defined, discrete pattern produced by mtRRF–
GFP, expression of the GFP protein alone produced a
diffuse stain (data not shown).
To verify, if localization of the mtRRF–GFP fusion
protein reflects the behaviour of the endogenous protein,
immunocytochemistry was performed. Polyclonal antisera
against FL recombinant protein were raised and anti-
mtRRF antibodies affinity were purified. Immunocyto-
chemistry (Figure 1A, right panels) indicated similar mito-
chondrial localization of both the endogenous and
mtRRF–GFP.
To confirm that mtRRF is indeed imported into the
mitochondrial matrix and not merely localized to the
organelle, import assays were performed with isolated
Figure 1. mtRRF is a mitochondrial protein with an extended N-terminal pre-sequence. (A) Human mtRRF is targeted to mitochondria. Left panels
show HeLa cells transiently transfected (24 h) with a mtRRF–GFP fusion construct. Cells were stained to visualize nuclei (DAPI blue) and
mitochondria (Mitotracker red). Fluorescence images and linescans confirmed mitochondrial localization of mtRRF–GFP by superimposition of
green and red signals (lower left). The image reflects three-independent transfections. Endogenous mtRRF in HeLa cells was visualized by immu-
nocytochemistry (upper right) using affinity purified anti-mtRRF and FITC secondary. DAPI-stained nuclei (blue) and Mitotracker the mitochondria
(red). Mitochondrial localization of mtRRF was confirmed by superimposition of linescan green and red fluorescence (lower right). The image
reflects three-independent transfections. (B) Human mtRRF is imported into mitochondria. FL 35S-radiolabelled mtRRF was in vitro synthesized and
incubated with rat liver mitochondria (lane 1). Under import conditions a single product is visible (lane 2) that is protected from proteinase K
(lane 3), but degraded by treatment with proteinase K and FCCP uncoupler (lane 4). Control import reactions contained DHFR with a mitochon-
drial pre-sequence (Su9) showing the FL pre-protein and the matured form under import conditions. (C) Sequence alignment (CLUSTALW)
indicates an extensive N-terminal pre-sequence when compared with E. coli or Thermotoga maritima. Identity to these RRFs is indicated in blue
and by , high levels of similarity by a colon ‘:’ and lower levels by a fullstop ‘.’.
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mitochondria and in vitro translated 35S-labelled mtRRF
(Figure 1B). Resistance of the radiolabelled protein to
proteinase K (lane 2) confirmed successful mitochondrial
uptake. Import resulted in cleavage of the mitochondrial
targeting pre-sequence of Su9-DHFR but interestingly not
of mtRRF. This is consistent with bioinformatic predic-
tions (www.cbs.dtu.dk/services/TargetP) being unable to
identify a clear cleavage signal in the mtRRF sequence
(7). Alignment of the mtRRF sequence with bacterial
counterparts indicates that optimal alignment begins at
position 80 of the FL mtRRF (Figure 1C). Since our
results show that this long N-terminal extension is not
a cleavable import signal but an integral part of the
mature protein, it suggests that it may be of functional
importance specific to mitochondria.
mtRRF binds E. coli ribosomes in vitro and can associate
with human mitoribosomes
Direct interaction of prokaryotic RRF with ribosomes in
the absence of other translation factors has been demon-
strated (16,24). Binding experiments were therefore per-
formed to determine if human mtRRF could play a
similar role to its bacterial homologues. Isolation of FL
over-expressed mtRRF showed that the protein tended
to aggregate (Figure S1). Therefore, a short N-terminal
truncation mtRRF69 was used as this deletion signifi-
cantly increased solubility of the recombinant protein.
Comparative circular dichroism analysis of both the FL
and truncated mtRRF confirmed that removal of the
N-terminus did not cause any major structural changes
(data not shown). In vitro binding assays showed that
mtRRF localized to the rapidly sedimenting ribosomal
fraction only in the presence of E. coli ribosomes
(Figure 2A), indicating a direct interaction.
To determine whether mtRRF could interact with
mitoribosomes in isolated organelles, FLAG epitope-
tagged mtRRF was inducibly expressed in human
Flip-In T-REx HEK293 cells (HEK293T) as described
in procedures. Subsequently, complexes containing the
fusion protein were isolated from solubilized mitochon-
dria by anti-FLAG affinity purification and FLAG pep-
tide elution. To control for non-specific binding, FLAG-
tagged mitochondrially targeted luciferase (mtluc) was
expressed in cells and immunoprecipitated by the same
procedure. Western analysis revealed a specific interaction
of mtRRF and mitoribosomal proteins (Figure 2B).
Mitoribosomes were very efficiently precipitated with
FLAG-mtRRF. Taken together these data show that
mtRRF can tightly associate with mitoribosomes.
Bacterial RRF is only transiently associated with ribo-
somes in vivo, partially occluding the P and A sites on
binding to the post-termination complex (9,15) so it was
surprising to find that the majority of mtRRF was bound
to mitoribosomes. To investigate this further, HEK293T
cells were induced as above and lysates were immediately
subjected to isokinetic sucrose-gradient centrifugation.
This mtRRF over-expression was not deleterious to cell
growth (data not shown) but led to a slight decrease in
mitoribosome formation (Figure 2C cf. Figure 5A). No
association of mtRRF with mitoribosomes at steady
state was detectable. However, binding became evident
on incubation (3 h) of the lysate prior to centrifugation
(mimicking the IP procedure) potentially due to dissocia-
tion or hydrolysis of charged tRNAs that would naturally
occupy most A/P sites. This dependence on pre-incubation
was not a consequence of mtRRF over-expression, as a
similar effect was noted with HeLa cell lysate (Figure 5A,
data not shown). Further, association was not due to non-
specific interactions promoted by the pre-incubation step
as interactions were lost either on RNase or EDTA treat-
ment (Figure 2E, lanes 1 and 2).
Mitoribosomes associated with numerous mitochondrial
proteins are co-immunoprecipitated with mtRRF
Immunoprecipitation (IP) experiments using mtRRF as
bait revealed an association with two mitoribosomal pro-
teins, presumably indicating the presence of the large (39S)
and small (28S) ribosomal subunits (MRPs) (Figure 2B).
To confirm the presence of other MRPs and determine
which if any additional proteins were present, IP experi-
ments were performed on lysates from a protease/DNase-
treated HEK293T mitoplast fraction. After elution of spe-
cifically bound proteins with FLAG peptide, the eluant
was separated by gel electrophoresis and gel slices sub-
jected to LC-MS/MS as detailed in Supplementary
Material. The mitoplast enrichment procedure yielded a
total of 167 identified mitochondrial proteins (Tables 1
and S1), 73 of which were indeed MRPs. Although
MRPs constituted most of the purified immunoprecipi-
tated proteins, detailed LC-MS/MS analysis revealed
some remaining cytosolic contaminants (data available
on request) but also allowed us to identify other mito-
chondrial proteins that co-immunoprecipitated with
mtRRF (Table 1). The second largest group were proteins
that had been previously reported as components of
human mitochondrial nucleoids (25–27). Among other
proteins interacting with mitoribosomes were factors
involved in intra-organellar translation, nucleic acid bind-
ing proteins and chaperones/proteases, all proteins that
might be expected to associate with ribosomal compo-
nents or nascent peptides. Several polypeptides known
to be involved in metabolism were also identified.
Human mtRRF improves the respiratory competence of
S. pombe "rrf1
To gain insight into the in vivo function of human mtRRF,
we first examined whether it could replace the endogenous
mtRRF of the budding yeast S. cerevisiae. Respiratory
deficiency due to loss of S. cerevisiae mtRRF (rrf1Sc)
was reportedly associated with depletion of cytochrome c
oxidase activity (28) or total loss of mtDNA (29). Thus,
for complementation analysis we used rrf1Sc strains
with different nuclear and mitochondrial backgrounds
(Supplementary Material). In the W303 background,
rrf1Sc cells showed a mild to pronounced respiratory
deficiency depending on the mitochondrial intron content
(Figure S2), but retained wild-type mtDNA. This allowed
direct complementation tests by transformation with
expression plasmids carrying either the natural S. cerevi-
siae gene, or human or S. pombe (fission yeast)
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homologues. However, neither the S. pombe nor the
human homologue complemented the S. cerevisiae
mutant (Figure 3A, data not shown).
As the fission yeast S. pombe is regarded as a closer
evolutionary relative to human than S. cerevisiae,
particularly in mitochondrial physiology (19), we inacti-
vated the gene coding the S. pombe mtRRF homologue
(rrf1Sp) to test if it could be replaced by human mtRRF.
Deletion of rrf1Sp slightly but significantly impaired
growth on non-fermentable carbon sources (Figure 3B),
Figure 2. Human mtRRF associates with bacterial ribosomes in vitro and mitoribosomes in vivo. (A) Human mtRRF binds E. coli ribosomes.
Recombinant mtRRF (mtRRF69) was incubated with or without 70S ribosomes prior to sedimentation through 10% (w:v) sucrose. Fractions were
subjected to western analysis. (B) mtRRF associates with mitoribosomes. FLAG-mtRRF and mtLuc HEK293T cells were induced, mitochondria
isolated. Lysate was prepared (lane 1) from which proteins were immunoprecipitated via the FLAG epitope (lanes 2–3). Western blot analysis used
antibodies to mtRRF, large 39S and small 28S mitoribosomal subunits (MRPL3, DAP3), mitochondrial chaperone (mtHSP70), complex IV (COX 2)
and a matrix protein (glutamate dehydrogenase -GDH). (C) Pre-incubation of mitochondria allows detection of mtRRF binding to mitoribosomes.
Lysate was prepared from HEK293T cells after induction of FLAG-mtRRF and was either separated immediately or post 3 h incubation on a
10–30% (v:v) isokinetic sucrose gradient. Fractions were analysed by western blot with antibodies to mtRRF, MRPL3 (39S mitoribosomal subunit)
or DAP3 (28S mitoribosomal subunit). A similar time-dependent mitoribosomal association in HeLa cell lysate was noted for the endogenous
mtRRF (data not shown). (D) HEK293T cells were induced (Tet) for FLAG-mtRRF (lanes 1–2) or control mtluc (lane 3) expression and
mitochondria isolated. Co-immunoprecipitating proteins were separated through a 12% SDS–PAG and visualized by silver stain. mtRRF, mtluc
and anti-FLAG IgG are indicated. (E) Preparations of the mtRRF IP were also treated with EDTA (lane 1) or RNase A (lane 2). Mitochondrial
lysate is shown in lane 3.
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lowered overall content of mt-encoded cytochromes
(Figure 3C) and decreased steady-state levels of mt-
encoded Cox2 protein (Figure 3D), consistent with a
role in mitochondrial translation. In addition, western
analysis of S. pombe mtRRF protein confirmed mitochon-
drial location (Figure S3). Transfectants of this strain
expressing FL human mtRRF were able to fully restore
normal growth on non-fermentable medium, levels of mt-
encoded cytochromes and Cox2 protein, correlating with
weak but reproducibly detectable mtRRFHs in only the
mitochondrial fraction (Figure 3B–D). Thus, human
mtRRF clearly performs the same function as S. pombe
mtRRF consistent with interaction with the S. pombe
mitochondrial translation machinery.
Loss of mtRRF in human cells results in reduced growth rate
and cell death
To determine the function of mtRRF in human mitochon-
dria, three siRNA specific to the human mtRRF mRNA
were designed and used to transfect HeLa and HEK293T
cells. A non-targeting siRNA (NT) was used to confirm
specificity. A reduction of 80–90% of mtRRF mRNA
levels were observed 2 days post-transfection with a con-
sequent dramatic reduction in mtRRF protein by day 3
(Figure 4A). To investigate the long-term effect of mtRRF
depletion, HeLa cells were retransfected with siRNA on
the third day of the experiment. Interestingly, the cells
transfected with mtRRF siRNA(ORF2) showed a signifi-
cant reduction in growth compared to NT controls
(Figure 4B). After 3 days of mtRRF siRNA treatment,
cells developed morphological changes and depletion for
more than 6 days was lethal. If cells were cultured in
glucose-free media supplemented with galactose to force
dependence on oxidative phosphorylation, the effect of
mtRRF depletion was even more profound (Figure 4B).
These observations suggest that mtRRF is an essential
protein and its loss affects mitochondrial functions.
To further ensure that the growth phenotype was spe-
cific to mtRRF depletion, an siRNA designed against the
30-UTR of mtRRF was introduced to HEK293T cells,
concomitant with inducible expression of the exogenous
FLAG-mtRRF lacking this 30-UTR. Expression of mtRRF
after transfection of the cells with 30-UTR-specific mtRRF
siRNA restored normal growth (Figure 4B) consistent
with the growth phenotype being solely due to depletion
of mtRRF.
Depletion of mtRRF partially affects mitochondrial
translation and inhibits mitoribosomal disassembly
What is the mechanism causing the growth phenotype? It
has been shown that in bacteria and yeast mitochondria,
inactivation of RRF inhibits protein synthesis (12,29). To
determine if the same is true for the mtRRF, we investi-
gated the effect of protein depletion on an in vivo mito-
chondrial protein synthesis. In the presence of mtRRF
siRNA, there was partial inhibition of mitochondrial pro-
tein translation (Figure 4C). Although the effect was not
as dramatic as in S. cerevisiae Drrf1 (29), it must be recog-
nized that even partial translation defects result in instabil-
ity and loss of mtDNA, which in turn produce a greater
impairment of mitochondrial protein synthesis. The rela-
tive synthesis of most of the components was significantly
altered (Figure 4C, data not shown). Consequently, the
steady-state levels of mtDNA-encoded proteins were pro-
gressively affected as detected by western blot (Figure 4D).
Although we did not observe significant reduction of the
protein levels after short siRNA treatment (2–3 days),
longer treatment resulted in decreased steady-state levels
of mitochondrially encoded proteins of up to 40% when
compared to non-targeting controls (day 6). These results
were consistent with the decreased levels of fully
assembled OXPHOS complexes after 6 days siRNA treat-
ment, as revealed by Blue Native gel electrophoresis
(Figure 4E). Moreover, polarographic measurements
showed that respiration rates of the siRNA-treated cells
decreased, consistent with affected function of OXPHOS
complexes (Figure 4F).
To further decipher the exact mechanism of mtRRF
function in mitochondrial translation, we looked at the
sedimentation profile of HeLa cell mitoribosomes in iso-
kinetic sucrose density gradients following mtRRF deple-
tion. Western analysis of mitoribosomes from cells treated
for 4 days with NT or mtRRF siRNA (Figure 5A) showed
a striking contrast in distribution of DAP3 representing
the small ribosomal subunit. mtRRF siRNA caused a shift
from fractions 5–8 to mainly 7. This fraction has proteins
Table 1. Predicted function of the mitochondrial proteins identified
after anti-FLAG mtRRF affinity precipitation
Protein typea Immunoprecipitation
mtRRFb mtRRF+EDTAc mtRRF+RNased
Mitoribosomal
proteinse
73 1 0
Nucleoidf
Class I 25 (31) 2 0
Class II 6 (10) 0 0
Class III 6 (16) 0 0
Nucleoidg 5 (6) 1 0
Translation
associated
6 1h 1h
Nucleic acid
binding/modifying
13 0 0
Metabolic 23 0 0
Chaperone/protease 5 0 0
Transporter 4 0 0
Unknown function 6 0 0
TOTAL 167j 7i 1
aKnown or predicted function of identified mitochondrial proteins.
bImmunoprecipitation from mitoplasts after protease and DNase
shaving.
cEDTA-washed immunoprecipitant from crude mitochondria.
dRNase-treated immunoprecipitant from crude mitochondria.
eMitoribosomal subunits identified by Koc et al. 2001 (39) and Cavdar
Koc et al. (40).
fPutative nucleoid proteins as recently classified by Bogenhagen et al.
(25) (of total proteins).
gPutative nucleoid proteins as identified by He et al. (26) (of total
proteins).
hMitochondrial ribosomal recycling factor, mtRRF.
iThree cytosolic ribosomal proteins were identified in the precipitation
following EDTA treatment.
jDoes not include any non-mitochondrial, hypothetical or predicted
proteins that were found.
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from both mitochondrial ribosomal subunits and repre-
sents monosome accumulation. Moreover, only after
mtRRF depletion where both ribosomal subunits detected
in the heaviest fraction (F11), suggesting aggregation of
the ribosomal proteins. We conclude that on depletion of
mtRRF, monosomes are poorly dissociated into single
subunits and non-functional monosomes accumulate, pro-
ducing aggregates. These data are consistent with mtRRF
functioning as a factor responsible for disassembly of ribo-
somes in human mitochondria.
Depletion of mtRRF causes increased mitochondrial
ROS and changes in mitochondrial morphology
The observed aggregation of mitoribosomes may have a
direct influence on mitochondrial function and may be a
primary cause of cell death. Stress conditions in mitochon-
dria are frequently associated with elevated levels of reac-
tive oxygen species (ROS). To assess stress due to ROS
accumulation in siRNA-treated cells, superoxide and
peroxide/peroxynitrite levels were measured by mitoSOX
and DHR, respectively. A statistically significant increase
of ROS levels over the NT control was seen at day 3, a
difference that was maintained through to day 6
(Figure 5B).
Increased ROS is often paralleled by augmented mito-
chondrial biogenesis and mtRRF depletion also resulted
in a significant increase of mitochondrial mass as mea-
sured by NAO fluorescence, a dye that binds selectively
to cardiolipin in the mitochondrial inner membrane
(Figure 5B).
These abnormalities were reflected in the progressive
morphological changes of mitochondria revealed by EM
(Figure 5C 3 days and 6 days mtRRF siRNA) where the
longer treatment resulted in a dramatic increase in mito-
chondrial density. Many more tightly packed membra-
nous sheets were observed, which was consistent with
increased mitochondrial biogenesis, whereas the numerous
‘black spots’ detected in the matrix compartment are con-
sistent with mitoribosome aggregates.
Figure 3. Human mtRRF suppresses a partial respiratory deficiency in Drrf1 fission yeast. (A) Human mtRRF cannot rescue the rrf respiratory
defect in budding yeast. Saccharomyces cerevisiae transformants of Drrf1 strain MG38 carrying the control vector pFL44L or URA3 plasmids
producing the S. cerevisiae, S. pombe or human mtRRF were replica-plated on non-fermentable media (eth/gly + glycerol 0.1% glucose) and
incubated at 288C. (B–D) Human mtRRF restores respiratory capacity in rrf1 fission yeast. Schizosaccharomyces pombe lacking endogenous RRF
(rrf1Sp, NB331) was transformed with vector alone (vector) or expressing human (RRFHs) or S. pombe (RRFSp) mtRRF (B). Serial dilutions of
three rrf1Sp transformants were spotted on complete glucose, uracil-free minimal or complete gly/eth media and grown at 28 8C for the times
indicated. (C) rrf1Sp transformants were grown on 2% glycerol/0.1% glucose (vector) or ethanol/glycerol medium (RRFSp or RRFHs) before
recording whole-cell cytochrome spectra. Cytochrome b+ c1 and aa3 correspond to Complex III and Complex IV, respectively. (D) Mitochondria
and post-mitochondrial supernatants from transformants grown in glucose medium minus uracil were separated by 12% PAGE and analysed by
western blot with antibodies recognizing human mtRRF, S. pombe mtEF-Tu and mt-encoded Cox2, human mt-Hsp60 and S. cerevisiae mtArg8 (this
also recognizes S. pombe Arg1 in mitochondria and an unknown protein in the supernatant).
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Figure 4. Depletion of human mtRRF severely affects cell viability and compromises mitochondrial translation. (A) siRNA-mediated depletion of
human mtRRF. HeLa cells were exposed to three different siRNA molecules all in the mtRRF-coding sequence or an control siRNA for 6 days and
RNA or cell lysates were prepared. Levels of mtRRF transcript compared to control siRNA transfected cells were quantified by real-time PCR
(upper graph, mean  SEM from four-independent transfections). Western blots (30 mg lysate/lane) in the lower panel were performed with
antibodies against mtRRF to confirm depletion and b-actin as a loading. The blot accurately reflects three experiments. (B) Depletion of mtRRF
causes a severe growth defect. Multiple aliquots of HeLa cells (left and centre panels) were exposed to targeted (mtRRF, open triangles) or non-
targeted (NT, black squares) siRNA for 6 days in glucose (left) or galactose (centre) media, cells counted and presented in a semi-log plot. Counts
were made of HEK293T transfectants (right panel) treated with non-targeted siRNA (NT, black squares) or siRNA directed against the endogenous
mtRRF 30-UTR with (open circles) or without (open triangles) concomitant inducible expression of FLAG-mtRRF. Numbers are a mean  SEM of
four independent wells. (C) In vivo mitochondrial proteins synthesis is partially affected by mtRRF depletion. HeLa cells were grown in the presence
of control (NT) or targeted (mtRRF) siRNA. Cytosolic protein synthesis was inhibited with emetine prior to labelling mitochondrial proteins with
35S-methionine (15min). Equal amounts of lysate (20 mg) were separated by 15% SDS–PAGE and gels analysed by PhosphorImager. Polypeptides
designation is as described in ref. (23). (D) Steady-state levels of mtDNA-encoded proteins are affected by depletion of mtRRF. Western blots show
analysis of cell lysates after 3 or 6 days siRNA treatment (mtRRF or NT) with antibodies against mitochondrial translation products or proteins
sensitive to mitochondrial translation inhibition (cytochrome c oxidase subunits I and II—COX I and 2; complex I subunit NDUFB8) or nuclear-
encoded complex II SDH 70kDa protein and b-actin as a loading control. The blot accurately reflects three repeat experiments. (E) OXPHOS
complexes are reduced at steady-state levels after mtRRF depletion. HeLa cells were exposed (6 days) to mtRRF- or NT-targeted siRNA prior to
BN–PAGE. Complexes were visualized with antisera to complex I, anti-39 kDa; complex II, anti-SDH 70 kDa; complex III, anti-core 2, complex IV,
anti-COII. The blot accurately reflects three experiments. SDH is a complex only comprising proteins encoded in the cytosol. (F) Respiratory
coupling is modestly affected in cells depleted of human mtRRF. HeLa cells were exposed (3 days) to mtRRF-or NT-targeted siRNA prior to high
resolution respirometry (as in Methods), three measures of respiratory control and capacity were made.
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DISCUSSION
Our studies presented here provide the first evidence that
this candidate functions as the human mitochondrial ribo-
some recycling factor: (i) mtRRF is a mitochondrial pro-
tein, (ii) mtRRF is able to bind bacterial ribosomes in vitro
and can tightly associate with human mitoribosomes
in vivo, (iii) expression of human mtRRF suppresses the
partial rrf1 respiratory deficiency in fission yeast in vivo
and (iv) upon depletion of mtRRF, the relative level of
mitochondrial monosomes increases whereas the free ribo-
somal subunits are reduced, indicating a defect in ribo-
some disassembly as has previously been reported on
depletion of the bacterial counterpart (12).
Our results show that although mtRRF can associate
tightly with mitoribosomes, the amount of interaction is
enormously increased by pre-incubation. There are many
possible hypotheses to explain this observation, but it is
interesting to note that high resolution studies have shown
Figure 5. Reduction of mtRRF results in redistribution of ribosomal proteins, increased ROS and mitochondrial dysmorphism. (A). HeLa lysates
were prepared from cells treated with mtRRF or non-targeted (NT) siRNA (3 days). After separation through 10–30% sucrose gradients, fractions
were analysed by western blot using antibodies against the small (DAP3) and large (MRPL3) mitochondrial ribosomal subunits, mtRRF, porin as a
mitochondrial membrane marker and glutamate dehydrogenase (GDH, matrix). (B) Superoxide levels are increased after mtRRF depletion. HeLa
cells were exposed to mtRRF (white) or non-targeted (NT, black) siRNA over 6 days and superoxide and peroxide levels were measured with
mitoSOX (superoxide) or DHR (peroxide) and compared to untreated controls. The fold increase is shown as a mean  SEM from minimally three
repeat experiments. Mitochondrial mass per cell was also measured using the cardiolipin selective dye NAO. (C) HeLa cells depleted of mtRRF show
altered morphology. EM micrographs show HeLa cells treated with mtRRF (3 and 6 days) or non-targeted (NT, 3 days) siRNA. The images reflect
mitochondria from two preparations.
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that RRF binds bacterial ribosomes that have adopted a
ratchet conformation at a site spanning both P and A site
(15). Therefore, it may be speculated that tRNA bound to
these sites may prevent interaction with mtRRF allowing
occupancy only when these sites become vacant.
Why does expression of human mtRRF restore the
respiratory function of an rrf1 mutant only in S. pombe
and not in S. cerevisiae? Human mtRRF shows a stronger
identity to S. pombe than the S. cerevisiae orthologue (EBI
tools 21.1% versus 16.8%; Figure S4). There is an overall
greater similarity between fission yeast and human
mtRNAs (30) and these two species share a highly con-
served set of general translation factors (18). In bacterial
systems, functional studies with heterologous RRF
and EFG proteins showed poor activity on the post-
termination ribosomal complex compared to assays
using RRF and EFG from the same species, underlining
the importance of interplay between RRF and EFG [for
example, (31,32)]. In light of these findings, it is also pos-
sible that human mtRRF was unable to rescue the growth
phenotype of S. cerevisiae rrf1 due to a weak interaction
with the budding yeast 70S mitoribosome or mtEFG that
also has only limited similarity with the human mtEFG.
Depletion experiments revealed that mtRRF is essential
for cell viability, with depletion causing gross mitochon-
drial dysmorphology and dysfunction. One of the primary
effects of mtRRF depletion, which seemed to precede
measurable translation abnormalities, was elevated ROS
production (evident by day two post-transfection). The
mechanisms that lead to mitochondrial ROS overproduc-
tion, although often associated with mitochondrial dys-
function are not always clear. Our recent work on
depletion of the mitochondrial release factor mtRF1a
also resulted in a profound increase in mitochondrial
ROS without any measurable effect on mitochondrial
translation (6). It is possible that increased ROS produc-
tion could be a direct result of mitoribosome aggregation,
but other subtle indirect effects cannot be ruled out. Our
results are another example that even a small disruption of
interplay between mitochondrial translation, respiration
and ROS production may lead to profound cellular
dysfunction.
In this study, lack of ribosome recycling led to a variety
of deleterious downstream consequences. Shortage of
available functionally active mitoribosomes eventually
affected translation, and subsequently resulted in
decreased steady-state levels of mitochondrially encoded
proteins, hence reduced amounts of fully assembled com-
plexes (6 days post-transfection). It was surprising, how-
ever, that a measurable decrease in mitochondrial protein
synthesis took so long to manifest. It is possible that
mitoribosomes are in excess in human organelles (33)
with translation being initiated by mitoribosomes that
had spontaneously disassembled. A similar process could
explain the partial growth defect in yeasts lacking RRF.
Another intriguing explanation could be that translation
may be able to initiate from monosomes that have termi-
nated translation, processed back along the mt-mRNA in
a 30 to 50manner to reach the 50-terminus and then scanned
to locate the closest initiation codon, all without the
monosome being dissociated. Although controversial, it
must be considered that there is currently no model to
explain how the mitoribosome naturally locates to the
mt-mRNA initiation codon in the absence of a 50-cap or
Shine–Dalgarno sequence.
Finally, proteomic analysis of the factors that were
eluted from immunoprecipitated mtRRF-FLAG, revealed
73 MRPs, several translation-associated factors and puta-
tive nucleoid proteins on the production and protease/
DNase treatment of mitoplasts (Table 1). Nucleoids are
dynamic structures containing mtDNA and proteins
involved in maintenance, replication and transcription of
the mitochondrial genome [reviewed in (34)]. These struc-
tures are well described in bacteria and close association
between nucleoids and ribosomes has been previously
measured in the Gram positive bacteria Bacillus subtilis,
with this association being dependent on active transcrip-
tion (35). Coupling of transcription and translation in
human mitochondria has been frequently suggested
(36,37), but there has been only one report showing inter-
action of mtRNA polymerase with a mitoribosomal pro-
tein, MRPL12, an interaction that was shown in vitro to
stimulate transcription (38). In a recent report on proteins
associated with nucleoids, 15 mitoribosomal proteins were
identified, along with assorted factors that also function in
protein synthesis (25). This observation is consistent with
our data, but the authors were concerned that MRPs may
have been present due to adventitious co-purification.
Such a criticism could also be levelled at our observation,
particularly as we were unable to completely remove cyto-
solic contamination, even in the mitoplasting experiments.
Without further experimentation, this remains only tenta-
tive evidence of a direct physical link between mitoribo-
some and nucleoid. However, these proteomic studies also
revealed several other candidate proteins that may be
associated with the translational machinery and/or
nucleoids. These findings open exciting avenues for further
investigations.
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